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Abstract 
 
 
The present work aimed to study the big potential of chromone derivatives and 1-(2-
fluorophenyl)prop-2-yn-1-ones for the synthesis of purine-like fused pyridines and 4-
quinolone derivatives. This includes a facile [3+3] domino cleavage of the chromone ring 
(that can be considered as masked 1,3-dicarbonyl compound) by electron-excessive 
aminoheterocycles (which can be considered as an interesting class of 1,3-CCN-
binucleophiles). In this regard, a wide range of substituents and substitution patterns are 
tolerated in the reaction. Consequently the synthesis of a wide range of fused pyridines and 
their further modifications were successfully performed. In addition a new and easy way for 
synthesis of 4-quinolone derivatives and other fused systems via domino cycloaddition 
reactions of ortho-fluorine-substituted benzoylchromones, 1-(2-fluorophenyl)prop-2-yn-1-
ones and aliphatic or aromatic amines were developed. The scope and limitations of all 
reactions were well studied. Some mechanistic explanations of developed transformations, in 
addition to detailed spectroscopic characterisation of synthesised compounds are presented. 
 
 
Kurzbeschreibung 
 
 
Die vorliegende Arbeit untersucht das Potential neuartiger Chromonderivate und 1-(2-
Fluorophenyl)prop-2-in-1-one für die Synthese purinanaloger polycyclischer Pyridine und 4-
Chinolone. Dies beinhaltet formale [3+3] Cyclisierungen mit elektronenreichen 
Aminoheterocyclen, einer interessanten Klasse von 1,3-CCN-Binucleophilen. Die 
Umsetzungen verlaufen unter Spaltung des Chromonringes. Das Chromon kann als maskierte 
1,3-Dicarbonylverbindung aufgefasst werden. Eine große Bandbreite unterschiedlicher 
Substitutionsmuster wurde in der Reaktion toleriert. Weiterhin wurde eine neue Synthese von 
4-Chinolonen und ähnlichen Verbindungen durch Cyclisierungen von ortho-
Fluorbenzoylchromonen, 1-(2-Fluorphenyl)prop-2-in-1-onen mit aliphatischen oder 
aromatischen Aminen entwickelt. Potential und Grenzen aller Reaktionen wurden im Detail 
untersucht. Basierend auf einigen Untersuchungen konnten auch mechanistische Vorschläge 
gemacht werden. 
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1.1. General Introduction 
 
Heterocyclic chemistry is one of the important areas of natural sciences and an inseparable 
part of modern life. Every year the demand of different representatives of the heterocyclic 
compounds (drugs, dyes, fluorescent compounds, macromolecules etc.) in daily life is getting 
bigger and the natural sources are not enough to suffice these needs. This became a 
motivation for chemists to find new and easy synthetic methods toward wide range of new 
synthetic heterocycles which can be used in different aspects of our everyday life. 
In family of natural and synthetic heterocycles nitrogen containing representatives stands out. 
The simplest representative of this class is pyridine, which is used as a precursor to 
agrochemicals, pharmaceuticals and in chemical industry as an important solvent and/or 
base.
1
 It is noteworthy that pyridine derivatives
2
 are widely used in the medicinal chemistry. 
For instance, niacin, also known as vitamin B3,
3
 being the precursor of nicotinamide adenine 
dinucleotide (NAD), and nicotinamide adenine dinucleotide phosphate (NADP) has a great 
impact on livelihood of live cells. Another example is isoniazid, which was synthesis about 
hundred years ago and is an important antitubercular drug
4
 (Figure 1.1.1). 
 
 
Figure 1.1.1. Biologically active simple pyridine derivatives. 
 
Additionally, from nitrogen-containing heterocycles the pyrimidine derivatives represent 
another important class of compounds which can be found in structures of different natural 
products, such as antibiotics (bacimethrin,
5
 sparsomycin,
6
 bleomycin
7
 etc), vitamins 
(thiamine
8
), anticancer agents (heteromine,
9
 variolin,
10
 meridianine,
11
 etc.), toxins 
(hepatotoxine, ptilocauline
12
) etc. Moreover, all bases from nucleic acids contain a pyrimidine 
core (Figure 1.1.2). 
 2 
 
 
Figure 1.1.2. Biologically active pyrimidine derivatives. 
 
More complex molecules like heteroannulated pyridines and pyrimidines, which can be 
classified as purines, and their deaza analogues also have a great importance, as they are lead 
structures for drug discovery. They can be found in a variety of medicaments and potential 
drugs. Purines and purine isosteres show a wide range of biological activities, for instance 
antiarrhythmic, antihistamine, anticancer, fungicidal, antiviral, anti-inflammatory activities,
13
 
inhibition of DNA-dependent protein kinesis etc.
14
 Some examples are represented in Figure 
1.1.3. Valacyclovir is an antiviral drug against herpes simplex, herpes zoster and herpes B,
15
 
abacavir is a nucleoside which is used against HIV and AIDS,
16
 another well known 
medicament is sildenafil citrate with a trade name Viagra, which is used to treat erectile 
dysfunction and pulmonary arterial hypertension,
17
 thiazolo[5,4-b]pyridine derivative, which 
is an anticoagulant.
18
 This list can be continued. 
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Figure 1.1.3. Biologically active heteroannulated pyridines and pyrimidines. 
 
1.2. General methods for the synthesis of fused pyridines 
 
It is obvious that the growing demands of chemical industry dramatically stimulate the 
development of new synthetic methods for the synthesis of different fused pyridines and/or 
modifications of existing building blocks. These movements in the field continue to be an 
urgent area of research that in principle can solve all actual synthetic tasks in the future. My 
present work is dedicated to development and studying of new and efficient synthetic 
methods, that will provide an easy way to a wide range of hetero-condensed pyridines. So that 
for the comparison in the following context some of well known methods for synthesis of 
heteroannulated pyridines will be discussed. 
The first system of choice are quinoline derivatives. Analysis of chemical literature shows 
that from existing methods for quinoline ring construction the oldest and most frequently used 
method is the reaction of anilines with 1,3-dicarbonyl compounds. This approach was 
developed by Combe in 1888 for the first time,
19
 then this method was modified in order to 
increase the substrate scope.
20
 Noteworthy the commercial synthesis of chloroquine (synthetic 
antimalarial drug) is based on this method (Scheme 1.2.1).
21
 
 
 
 4 
 
NH2
Me
O
MeO
N
H
Me N Me
Me
Me
O
c.H2SO4, r.t.

2,4-dimethylquinoline  
Scheme 1.2.1. Synthesis of quinolines by method of Combe. 
 
The next considered heterocyclic systems are 7-azaindole derivatives, also known as 
pyrrolo[2,3-b]pyridines. The prominent synthetic methods for construction of these 
heterocycles are mostly based on the chemistry of pyridine derivatives. However several 
synthetic pathways starting from pyrrole derivatives are also known. For instance, it was 
shown that 2-phenyl-1H-pyrrolo[2,3-b]pyridines 1.2.1 are easily available from 2-amino-3-
methylpyridine and benzoic anhydride in two steps. On the other hand, the same system can 
be prepared from 2-amino-3-(phenylethynyl)pyridine 1.2.2 in basic media (Scheme 1.2.2).
22
 
 
N NH2
Me
Ph O Ph
O Et3N
CH2Cl2, r.t. N N
H
Me
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O n-BuLi, THF
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H
Ph
N NH2
Ph
n-BuOK
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+
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O
  
Scheme 1.2.2. Synthesis of pyrrolo[2,3-b]pyridines 1.2.1 starting from pyridine derivatives. 
 
As was mentioned there are few approaches for the synthesis of 7-azaindoles starting from 
pyrrole derivatives. Though, recently a method based on three-component cyclocondensation 
of N-substituted 2-amino-4-cyanopyrroles, various aldehydes, and active methylene 
compounds in ethanol or acetic acid at reflux was reported (Scheme 1.2.3).23 
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Scheme 1.2.3. Synthesis of pyrrolo[2,3-b]pyridine starting from 5-aminopyroles. 
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Pyrazolo[3,4-b]pyridines are also an object of interest, so in the following schemes some 
approaches towards the synthesis of such systems will be presented. In this field the most 
applied methods are based on construction of pyridine core starting from pyrazole derivatives. 
For example, the reaction of 5-amino-3-methyl-1-phenylpyrazole with 2-cyano-3-
ethoxyacrylate leads to intermediate ethyl 3-(3-methyl-1-phenyl-1H-pyrazol-5-ylamino)-2-
cyanoacrylate 1.2.3, that in the presence of POCl3 subsequently turns to desired heterocyclic 
system by cyclization (Scheme 1.2.4).
24
 
 
 
Scheme 1.2.4. Synthesis of pyrazolo[3,4-b]pyridine starting from 5-aminopyrazole. 
 
On the other hand, Al-Isa et al. proposed an approach that involves pyrazole ring construction 
on pyridine core. Namely they have found that the synthesis of pyrazolo[3,4-b]pyridines can 
be accomplished by heating 6-hydrazido-4-methyl-2-phenyl-5-pyridinecarbonitrile in acetic 
acid or DMF (Scheme 1.2.5).
25 
 
 
Scheme 1.2.5. Synthesis of 4-methyl-6-phenyl-1H-pyrazolo[3,4-b]pyridin-3-amine. 
 
Almost all methods known to date for the synthesis of imidazo[4,5-b]pyridines are based on 
imidazole ring closure on pyridine core. The earliest report in this field appeared in 1927, 
which represents a reflux of 2,3-diaminopyridine in acetic acid anhydride that was followed 
by the formation of 2-methylimidiazolo[4,5-b]pyridine system. After the initial report this 
methodology was further developed using other anhydrides. As a result, a number of 
imidazo[4,5-b]pyridine derivatives with different substituents were synthesized (Scheme 
1.2.6).
26
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 Scheme 1.2.6. Synthesis of imidiazolo[4,5-b]pyridine starting from 2,3-diaminopyridine. 
 
Another approach was proposed by Soto et al. In order to prepare an imidazo[4,5-b]pyridine 
core 1.2.5, thay applied the reaction of 5-amino-1-methylimidazol-4-carbaldehydes 1.2.4 with 
malononitrile or ethyl cyanoacetate in ethanol at basic media under reflux (Scheme 1.2.7).
27 
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Scheme 1.2.7. Synthesis of 5-aminoimidazo[4,5-b]pyridine 1.2.5. 
 
Aiming to prepare thio-derivatives of imidazo[4,5-b]pyridines, Koga et al. showed that the 
heating of 5-amino-1-methylimidazol-2(3H)-thion with diethyl ethoxymethylenmalonate in 
10% NaOH water solution leads to corresponding imidazo[4,5-b]pyridine-2(3H)-thiones 1.2.6 
(Scheme 1.2.8).
28 
 
 
Scheme 1.2.8. Synthesis of imidazo[4,5-b]pyridine-2(3H)-thion 1.2.6. 
 
Additionally a two-step procedure towards thiazolo[4,5-b]pyridines was presented by 
Bergman et al. starting from aminopyridine and appropriate isothiocyanate, following by 
 7 
 
cyclization in presence of bromine in acetic acid or chloroform.
29
 
Despite the fact, that a number of synthetic approaches for the synthesis of heterocyclic fused 
pyridine derivatives appear in the literature, however, the overall interest in the chemistry of 
purine isosters is still very high. Moreover, analysis of the literature shows that the synthesis 
of fused pyridines bearing a carboxylic, formyl, amino and heteroaryl substituents still 
remains an actual synthetic task. Having in mind the deficiency, multiple steps and a number 
of other restrictions of the methods proposed before, the goal of this work was to design and 
develop new and efficient synthetic methods toward the wide range of fused pyridines starting 
from simple commercially available building blocks by non-demanding synthetic protocols. 
 
2. Synthesis of structurally diverse fused pyridines starting from 
chromones and electron-excessive aminoheterocycles 
 
As it was discussed in the introduction, our main goal was to develop a new, easy and 
universal synthetic pathway, which will allow us to build up different purine isosteres starting 
from low-cost starting materials. In order to construct the desired systems, different 
approaches were used. Specifically, in this part of work the domino reaction was investigated 
between chromones and electron-excessive aminoheterocycles. 
In current study the retrosynthetic analysis was based on the pathway that includes an 
enamine-like framework as 1,3-CCN-binucleophiles and set of different 1,3-CCC-
dielectrophiles (Figure 2.1). In following chapters we will use different electron-excessive 
aminoheterocycles as 1,3-CCN-binucleophiles and different chromen-4-ones as 1,3-CCC-
dielectrophiles. However, more relevant chemical application of electron-excessive 
aminoheterocycles and chromen-4-ones will be discussed at advance. 
 
 
Figure 2.1. Retrosynthetic analysis of fused pyridines. 
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2.1. Chemistry of electron-excessive aminoheterocycles 
 
Electron-excessive aminoheterocycles can be considered to act as enamines. Due to some 
contribution of enamine resonance structure, these systems usually have more C-nucleophile 
rather than N-nucleophile character (Figure 2.1.1). Consequently these systems are an 
interesting class of 1,3-CCN-binucleophiles, which initially react with electrophiles via β-
carbon atom. 
 
NH2
Electron-excessive
aminoheterocycles
NH2 NH2


 
Figure 2.1.1. Electron-excessive aminoheterocycles as enamines. 
 
1,3-CCN-binucleophiles are widely used in organic chemistry for construction of simple 
heterocyclic systems, such as pyridines, quinolines, purines and their isosters. In current 
chapter we would like to summarise previously known methods of the pyridine/pyrimidine 
syntheses, via enamine functionalization by the means of 1,3-CCC- and 1,3-CNC-
bielectrophiles. Simple systems, like pyridine derivatives, can be formed from 1,3-dicarbonyl 
compounds and 3-aminoacrylate. This approach with its variations is one of the most useful 
procedures towards the synthesis of unsymmetrically substituted pyridine derivatives.
30
 For 
instance, aminocrotonoethylat and aminoacrylonitriles were applied for the construction of 4-
CF3-pyridines. The reaction was carried out in ethanol under reflux, after 2 hours the desired 
products were isolated with moderate yields (Scheme 2.1.1).
30 
 
 
Scheme 2.1.1. Synthesis of 4-CF3-pyridines. 
 
Push-pull enamines appeared to be out of any general regularity: it was shown by authors, that 
the reaction of 1,1,1,5,5,5-hexafluoroacetylacetone with push-pull enamines (Alk2N = 
 9 
 
pyrrolidino, piperidino, morpholino) having a methyl group at the α-position, is sensitive both 
to the structure of enamines and to reaction conditions. As a result, a set of 
bis(trifluoromethyl)dialkylanilines and ethyl bis(trifluoromethyl)salicylate were prepared 
(Scheme 2.1.2).
31
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Scheme 2.1.2. Synthesis of bis(trifluoromethyl)dialkylanilines and ethyl 
bis(trifluoromethyl)salicylate. 
 
Kirollos et al. presented the synthesis of 2-CF3-quinolines starting from TFA-vinyls or TFA-
acetylene. The latter were reacted with electron-excessive anilines in neat trifluoroacetic 
acid.
32
 This method was suitable for synthesis of 2-CF3-benzo[h]quinolines 2.1.1
33
 and 
dihydrobenzo[c]acridine
34
 using various enaminoketones (Scheme 2.1.3). 
 
 
Scheme 2.1.3. Synthesis of 2-CF3-benzo[h]quinolines 2.1.1. 
 
In this context, electron-excessive anilines, possessing an electron donating group (EDG) in 
the aromatic ring can behave as enamines and react under mild conditions forming the 4-
trifluoromethylquinolines in good yields. Using this concept some androgen receptor 
modulators and a row of antitumor drugs were synthesised (Figure 2.1.2).
35
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Figure 2.1.2. Some examples of antitumor drugs with 4-trifluoromethylquinolines moiety. 
 
Afterwards, it was shown that this approach can be applied also for electron-excessive 
aminoheterocycles. This approach opened new horizons in the chemistry of fused 
pyrimidines, hence the reactions of numerous aminoheterocycles with 1,3-dielectrophiles 
were studied. By this synthetic road the pyridine ring was annulated to the pyrazole, furan, 
thiophene and uracil. The distinguishing features of this synthetic procedure are almost 
quantitative yields and the mild reaction conditions (Scheme 2.1.4).
36 
 
 
Scheme 2.1.4. Synthesis of 4-CF3-substituted fused pyridines. 
 
Meanwhile, Japanese authors have demonstrated the synthesis of pyrido[2,3-d]pyrimidines 
2.1.2 and pyrazolo[3,4-b]pyridines 2.1.3 by cyclocondensation of corresponding 6-
aminouracil or 5-aminopyrazole with CF3-enones (Scheme 2.1.5).
37 
 
 11 
 
 
Scheme 2.1.5. Synthesis of pyrido[2,3-d]pyrimidines 2.1.2 and pyrazolo[3,4-b]pyridines 
2.1.3. 
 
Another group used 5-formyl-1,3-dimethyluracil as 1,3-dielectrophile. The cyclization 
reactions of the latter, with various electron-excessive aminoheterocycles, lead to the 
formation of a serie of fused heterocycles containing a unit of nicotinic acid (Scheme 2.1.6).
38 
 
 
Scheme 2.1.6. Synthesis of nicotinic acid substituted fused pyridines. 
 
Furthermore, by our colleagues a cyclocondensation reaction of 3-acyl- and 3-formylindoles 
with aminoheterocycles was presented in order to prepare new heteroannulated 3-(2-
aminophenyl)-pyridines 2.1.4. The reaction starts with opening of indole ring that is followed 
by subsequent cyclocondensation. The reported transformation represents a rare example of 
domino reaction, which includes the cleavage of indole moiety (Scheme 2.1.7).
39
 
 
 
Scheme 2.1.7. Synthesis of heteroannulated 3-(2-aminophenyl)-pyridines 2.1.4. 
 
Recently, a variety of 1,3-fluorine-containing dielectrophiles were used for the annulation of 
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CNC-triade to an electron-excessive systems. The most utilized systems among these 1,3-
CNC-dielectrophiles are functionalized heterocumulenes. For instance, N-(1-chloro-2,2,2-
triflouroethylidene)urethane 2.1.5 was coupled with some electron-excessive 
aminoheterocycles in a two-step process: the first attack was directed by more hard 
nucleophilic centre; for aminoheterocyles it is the amino function. Formed amidines can 
undergo a cyclization reaction under harsh conditions (usually in toluene or o-xylene) leading 
to heteroannulated pyrimidines (Scheme 2.1.8).
40
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Scheme 2.1.8. Synthesis of heteroannulated pyrimidines in two steps starting from 2.1.5. 
 
Very recently was reported an interesting method for the assembly of fluorine-containing 
purines and thiazolo[4,5-d]pyridimines (7-thiopurines). The method involves cyclization of 5-
aminoimidazoles or 4-aminothiazoles with aryl isocyanates as 1,3-CNC-dielectrophiles 
(Scheme 2.1.9). 
 
 
Scheme 2.1.9. Synthesis of 2-(dialkylamino)-7-(trifluoromethyl)-6,7-dihydro[1,3]thiazolo[4,5-
d]pyrimidones 2.1.9 6-(trifluoromethyl)-1,3,6,9-tetrahydro-2H-purin-2-one 2.1.10. 
 
Reactions of 2-dialkylamino-thiazole-4-amines 2.1.6 generated in situ from their salts and 
1,2-dimethyl-imidazole-5-amine 2.1.7 with α-chloro-α-phenyl-β,β,β-trifluoroethyl-
isocyanates 2.1.8 leads to 2-(dialkylamino)-7-(trifluoromethyl)-6,7-dihydro[1,3]thiazolo[4,5-
 13 
 
d]pyrimidones 2.1.9 and 6-(trifluoromethyl)-1,3,6,9-tetrahydro-2H-purin-2-one 2.1.10 
respectively. Moreover, it was found that the reactions of 2.1.8 with 5-aminopyrazole, 5-
aminoisoxazole, 2-methoxy-5-aminofuran and 2-methoxy-5-aminothiophene result to a 
complex mixture of unidentified products. Furthermore, the use of less reactive urethanes 
leads to trifluoromethyl-containing heteroarylamines.
41
 
All discussed methods presented above prompted us to develop the chemistry of fused 
pyridine derivatives taking advantage of unique properties of electron-excessive 
aminoheterocyclic (Figure 2.1.3). 
 
 
Figure 2.1.3. List of used electron-excessive aminoheterocycles and anilines. 
 
Based on the literature data, we chose a library of diverse electron-excessive 
aminoheterocycles and anilines as main starting binucleophiles for our further study (Figure 
2.1.3). In the upcoming chapters the reactions of these enamine-like species with different 
bielectrophiles will be discussed. 
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2.2. Chemistry of Chromones 
 
The 2H-pyran-2-one ring systems are potential aromatic species, due to the contribution of the 
pyrylium-2-olate structure, but facile cleavage of the ring by nucleophiles makes it most 
likely a lactone rather than an aromatic system (Figure 2.2.1). 4H-pyran-4-one and its benzo 
derivatives (chromones) show chemical properties in agreement with substantial π-electron 
delocalization and consistent with a betaine structure (Figure 2.2.1). Earlier studies suggested 
that chemical shifts and coupling constants in these systems indicate the presence of a 
diamagnetic ring current, comparable to the one in benzene. Interestingly, replacement of the 
oxygen heteroatom with sulfur and/or nitrogen induces downfield shifts of the ring protons, 
suggesting increased ring currents and therefore increased aromaticity in thiopyrones and 
quinolones. 
 
O O O O
O O
O O
O
O
O
O
2H-pyran-2-one 4H-pyran-4-one
4H-chromen-4-one
pyrylium-2-olate pyrylium-4-olate
chromenylium-4-olate  
Figure 2.2.1. π-Electron delocalization and consistent with a betaine structure of pyranones. 
 
The fact, that chromone ring is also prone to undergo a facile domino cleavage of the ring by 
nucleophiles makes it most likely a conjugate push-pull system rather than an aromatic system 
(Figure 2.2.2). Hence, the aromaticity of the heterocyclic ring in pyrones and chromones is 
still under scrutiny. 
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Figure 2.2.2. Chromones likely a conjugate push-pull system. 
 
According to our retrosynthetic analysis, the second reaction component to be used are 1,3-
dielectrophiles. Particularly 4H-chromen-4-ones or simply chromones are prone to react with 
nucleophiles as 1,3-dielectrophiles (Figure 2.2.3). They can be considered as 1,3-dicarbonyl 
compounds with masked salicyloyl fragment at the position 2. In addition to their unique 
chemical properties, chromones are one of the significant classes of oxygen containing 
compounds, and many natural and synthetic derivatives of chromones possess a variety of 
biological activities.
42
 
 
 
Figure 2.2.3. 3-Substituted chromones as masked 1,3-dielectrophiles. 
 
The main synthetic interest of these clusters is their ability to react with different nucleophiles 
leading to assortment of new rearranged heterocyclic systems potentially relevant for drug 
discovery.
43
 Moreover, the reactivity of chromones is well documented in the literature, 
thereby in this chapter will be discussed readily available derivatives of chromones and their 
chemistry. In the family of chromone derivatives the most popular one is 3-formylchromone, 
which was for the first time synthesized on early 1970s. The reason of increased interest is 
that these types of molecules have three electrophilic centers: the aldehyde moiety, the C-4 
atom and the C-2 atom; the latter can be considered as a hidden aldehyde function (Figure 
 16 
 
2.2.4). Additionally, it was shown that the reactivity of C-4 atom toward nucleophiles is much 
lower compared to the formyl group and the C-2 atom. 
 
O
2
3
4
O
O
OH
3
4
O
O
2
O
R R
2.2.1 2.2.1'  
Figure 2.2.4. 3-Substituted chromones 2.2.1 as masked 1,3-dielectrophiles. 
 
According to detailed analysis of literature concerning the chemistry of 3-formylchromones 
2.2.1, the pathways of transformation of such molecules can be divided on three groups. 
Seldom, the chromone ring stays intact during the reaction, thus only formyl group 
participates in the reaction, similar to simple aromatic formyl group (Mode I, Scheme 2.2.1). 
For instance, the reaction of 3-formylchromones with alanine or phenylglycine ethyl ester 
(1,2-CN-binucleophile) in toluene in the presence of TsOH leads to pyrrole ring formation 
(Pathway A, Scheme 2.2.1).
44
 Another case represents the reaction of 3-formylchromone 2.2.1 
with aminocrotonate (1,3-CCN-binucleophile) in acetic acid, that delivers to a mixture of 
dihydropyridines (Pathway B, Scheme 2.2.1).
45
 Additionally, the authors found that 3-(5-
phenyl-3H-[1,2,4]-dithiazol-3-yl-chromen-4-ones are formed when 2.2.1 reacts with 
thiobenzamide (Pathway C, Scheme 2.2.1).
46
 
 
Scheme 2.2.1. The reactivity of the exocyclic formyl moiety of 3-formylchromone 2.2.1. 
 
Very often the reaction of 2.2.1 with binucleophiles proceeds via aldehyde moiety and C-2 
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atom of chromone ring, which is usually followed by recyclization and in some cases with 
various ring annulations (Mode II, Scheme 2.2.2). For example the reaction of 2.2.1 with 1,2-
N,N-binucleophiles, such as hydrazine derivatives provides a new pyrazoles ring formation 
(Pathway A, Scheme 2.2.2).
47
 Furthermore, a wide range of reactions with different 1,3-
binucleophiles were reported to date. An obvious example is the reaction of 2.2.1 with 1,3-
CCN-binucleophiles, such as cyanoacetamides or malonodiamides, which provides an 
interesting pathway to different pyridine derivatives (Pathway B, Scheme 2.2.2).
48
 
Interestingly, heterocyclic 1,3-CCN-binucleophiles like 1H-benzimidazole derivatives were 
considered as well. The cyclization takes place in ethylene glycol at 200-210 
o
C, or in 
TMSCl/DMF system resulting pyrido[1,2-a]benzimidazoles (Pathway C, Scheme 2.2.2).
49
 
Besides, a convenient synthesis of pyrimidine derivatives was proposed by the reaction of 3-
formylchromones 2.2.1 with 1,3-NCN-binucleophiles (for instance amidines, guanidines and 
ureas) (Pathway D, Scheme 2.2.2).
50
 Finally, by Langer’s group the reaction with 1,3-CCC-
binucleophiles, namely bissylil enol ethers were deeply investigated. According the 
methodology described by Langer et al., a broad number of benzophenone derivatives were 
obtained (Pathway E, Scheme 2.2.2).
51 
 
 
Scheme 2.2.2. Cyclizations trough formyl moiety and C-2 carbon atom. 
 
In some transformations of 3-formylchromone 2.2.1 with binucleophiles instead of pyrone 
ring opening a sort of ring annulation can take place (Mode III, Scheme 2.2.3). This type of 
annulation was observed in the reaction of 3-formylchromone 2.2.1 with heterocyclic amines 
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(1,3-CCN-binucleophiles) that leaded to the formation of fused pyridines (Pathway A, 
Scheme 2.2.3).
52
 An interesting results were disclosed with p-cresol, that behave as 1,3-CCO-
binucleophile, namely a subsequent ring annulation product 2.2.2 was obtained (Pathway B, 
Scheme 2.2.3).
53
 An annulation product was prepared also, when 3-formylchromone 2.2.1 
was treated with 1,4-binucleophiles (for instance N-substituted o-phenylendiamines) 
delivering to corresponding chromeno[2,3-b][1,5]benzoxazepin-13-ones 2.2.3 from moderate 
to good yields (Pathway C, Scheme 2.2.3).
54 
 
 
Scheme 2.2.3. Reactivity of exo-formyl moiety of 2.2.1 without pyrone ring opening. 
 
Nevertheless, except 3-formylchromone there are some other examples of chromone 
derivatives which were investigated to date. Recently a reaction of 3-(polyfluoroacyl)-4H-
chromen-4-ones 2.2.4 with different binucleophiles was performed. This approach provided a 
new and versatile pathway toward polyfluoroalkyl-substituted fluorinated molecules. For 
instance the reaction of fluorinated chromones 2.2.4 with aliphatic and aromatic amines in 
methanol at room temperature for two days afforded 3-(alkyl/arylaminomethylene)-2-
hydroxy-2-(polyfluoroalkyl)chroman-4-ones in good yields (Pathway A, Scheme 2.2.4).
55
 The 
reactions of 3-CORF-chromone with amidines or guanidines in the DMF delivers new 
derivatives of polyfluoroalkyl-pyrimidines (Pathway B, Scheme 2.2.4).
56
 Interestingly, the 
cycloaddition of 3-(polyfluoroacyl)-chromones (heterodiene) with 3,4-dihydro-2H-pyran and 
2,3-dihydrofuran under mild conditions produced novel fused pyrones in moderate yields 
(Pathway C, Scheme 2.2.4).
57 
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Scheme 2.2.4. Reactivity of 3-(polyfluororacyl)-chromones 2.2.4. 
 
The following chromone derivatives, which were intensively studied, are 4-oxo-4H-
chromene-3-carbonitriles 2.2.5. Not surprisingly, introduction of reactive and electron-
withdrawing CN group to the position 3 of chromone system initiates crucial changes of 
reactivity in the pyrone ring towards nucleophiles, that broadens the synthetic potential of 3-
cyano chromones. For example, remarkably was found that depending from the solvent the 
reaction of 3-cyanaochromones and phenyl hydrazine can give different products (Pathway A, 
B, Scheme 2.2.5).
58
 Moreover, the reaction of cyanochromone 2.2.5 with anilines under reflux 
in benzene, suddenly leaded to the formation of 2-amino-3-(aryliminomethyl)chromones 
(Pathway C, Scheme 2.2.5).
59
 Besides, the mixture of 3-cyanochromone 2.2.5 with different 
o-phenylenediamines in two steps can be converted to benzimidazole-substituted chromones 
(Pathway D, Scheme 2.2.5).
60 
 
 
Scheme 2.2.5. Reactivity of 3-cyanaochromones 2.2.5.  
 
Eventually, it should be noticed, that among the examples of binucleophiles discussed above 
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recently were published some samples of the reaction between electron-excessive 
aminoheterocycles 2.1 and 3-formyl 2.2.1 or 3-CORF-chromones 2.2.4. In the first case the 
reaction proceeds via pyrone ring opening - other ring closure (Mode II, Scheme 2.2.2), so 
corresponding pyridine derivatives were formed.
61
 In contrast to this, the products formed by 
the reaction of 3-(polyfluoroacyl)chromenones 2.2.4 with aminoheterocycles 2.1 are strongly 
dependent from the reaction conditions (Scheme 2.2.6).
62
 
 
 
Scheme 2.2.6. Electron-excessive aminoheterocycles 2.1 as binucleophiles in the reaction 
with chromones 2.2.1, 2.2.4.  
 
It is obvious that chromone derivatives with electron withdrawing groups (EWG) at the 
position 3 represent important and flexible starting materials and are intended for cyclization 
reaction with aminoheterocycles. Being inspired by the great chemical potential of the 
reaction between chromones and various binucleophiles, we started the present work, in order 
to develop new and efficient synthetic methods toward the wide range of purine-like 
compounds. So in the next few chapters the development of convenient procedures for 
preparation of diverse pyridine derivatives starting from chromones will be discussed. 
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2.3. 3-(Dichloroacetyl)chromone – a new building block for the synthesis of 
formylated purine isosteres. Design and synthesis of fused -
(formyl)pyridines 
 
2.3.1. Introduction 
 
As it was discussed in previous chapters, purine isosteres and purine-like scaffolds are of 
substantial attention in medicinal chemistry and drug design.
63
 In recent years functionalized 
derivatives of purine isosteres appear to be of high pharmacological importance as guide 
structures and synthetic building blocks in medicinal and agricultural chemistry.
64-70
 At the 
same time these building blocks, bearing a carbonyl group, are of special interest because of 
the potential capability in design of inosine 5'-monophosphate dehydrogenase (IMPDH) 
inhibitors.
71
 
IMPDH is a potential target in antitumor chemotherapy.
72
 The reason of extreme popularity of 
this enzyme among medicinal chemists is the fact, that IMPDH is a NAD-dependent enzyme, 
which controls de novo synthesis of purine nucleotides,
73
 namely it catalyzes the oxidation of 
inosine-5'-monophosphate (IMP) to xanthosine-5'-monophosphate (XMP) that is followed by 
transformation into guanosine-5'-monophosphate (GMP) (Scheme 2.3.1). 
 
 
Scheme 2.3.1. Action of IMPDH. 
 
The concentration of IMPDH is increased in tumour cells and activated lymphocytes, that is, 
in the cells with increased activity of synthetic pathways leading to concentration of nucleic 
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acids. Thus, inhibition of IMPDH should result in anticancer and immunosuppressive 
activities. Hence IMPDH has received considerable attention in recent years as an important 
target enzyme, not only for the discovery of anticancer drugs, but also for antiviral, 
antiparasitic and immunosuppressive chemotherapy (Figure 2.3.1).
74 
 
 
Figure 2.3.1. Active IMPDH inhibitors. 
 
Some of IMPDH inhibitors are currently used in the clinic and are released on the market, e.g. 
ribavirin,
75
 mizoribine,
76
 tiazofurin TR
77
 and mycophenolic acid MPA.
78
 However, 
development of new structures with potential inhibitor activity towards IMPDH continue to 
be of considerable interest. In this chapter we will discuss a versatile preparative approach for 
synthesis of purine isosteres bearing a formyl functionality located at the α-position of the 
purine/pseudo purine core. We consider these scaffolds to be mechanism-based inhibitors of 
IMPDH. 
 
2.3.2. Synthesis of starting materials 
 
In order to synthesis desired products, as a starting material was chosen 3-
(dichloroacetyl)chromone 2.3.2, which can be considered as a new polydentate electrophilic 
substrate for the synthesis of dichloromethylated fused pyridines. It is known from the 
literature, that 3-substituted chromones can be prepared by the reaction of 3-(dimethylamino)-
1-(2-hydroxyphenyl)-propen-1-one 2.3.1 with diverse electrophiles.
79
 According to the known 
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general procedure, we were able to prepare 3-(dichloroacetyl)chromone 2.3.2 in 75% yield by 
reaction of 3-(dimethylamino)-1-(2-hydroxyphenyl)-propen-1-one 2.3.1 with dichloroacetyl 
chloride in pyridine (Scheme 2.3.2). The product is stable at room temperature (r.t.) for 
several years. 
 
OH O
NMe2
Cl CHCl2
O
O
O
CHCl2
O
+
Py (3 equiv.), CH2Cl2
2.3.1
2.3.2 (75%)
(1.1 equiv.)
r.t., 8h
 
Scheme 2.3.2. Preparation of 3-(dichloroacetyl)chromone 2.3.2. 
  
It should be noticed, that despite the huge chemical potential of 3-(dichloroacetyl)chromone 
2.3.2 as a building block in organic synthesis, no data on the preparation and/or chemical 
properties of this molecule was reported before us. Another aspect that motivated us to choose 
3-(dichloroacetyl)chromone 2.3.2, is the possibility to have dichloromethyl group in purine 
isosteres, that can be easily converted into formyl
80
 and trichloromethyl
81
 groups. 
Noteworthy, it is difficult to prepare dichloromethylazines by direct chlorination of the 
corresponding derivatives, since this reaction usually affords a mixture of mono-, di- and 
trichloromethylazines.
82
 
 
2.3.3. Results and discussion 
 
According to the properties of 3-carbonyl-substituted chromones described in the Chapter 2.2, 
3-(dichloroacetyl) chromone 2.3.2 have three electron-deficient centres, namely carbon atoms 
C-2 and C-4 of the chromone moiety and the carbonyl C atom of COCCl2H group, in addition 
to electron deficient dichloromethyl group (Figure 2.3.2). 
 
 
Figure 2.3.2. Electron-deficient centres of 3-(dichloroacetyl)chromone 2.3.2. 
 
Due to several potentially reactive electrophilic centres, the reaction with binucleophiles in 
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principle can lead to several isomer products (Scheme 2.3.3). Therefore the development of 
chemo- and regioselective synthetic method towards the preparation of purine isosteres 
bearing a dichloromethyl group in position 2 was challenging. Based on the results from the 
literature, in acidic media the first attack of binucleophile is expecting to be on the position C-
2 with following intramoleculare cyclization via another electrophilic center. In order to 
examine the reactivity of 2.3.2, we started our investigation using electron-excessive 
aminoheterocycles E1-E8 described in the Chapter 2.1. The reaction of 3-
(dichloroacetyl)chromone 2.3.2 with E1 (Figure 2.1.2) was performed in acetic acid under 
reflux. Surprisingly, from a vast number of possible regioisomers 6-(dichloromethyl)-1,2-
dihydro-2-phenylpyrazolo[3,4-b]pyridin-3-one 2.3.3a was the only detected product. It was 
quite easy to control the end of the reaction by TLC, since the starting chromone was totally 
converted to the product. Having first promising results in hand, the rest of electron-excessive 
aminoheterocycles E2-E8 (Figure 2.1.2) were scanned with 3-(dichloroacetyl)chromone 2.3.2 
(Scheme 2.3.3). Gratifyingly, corresponding heteroannulated pyridines 2.3.3 were isolated in 
good to excellent yields (60-93%) (Table 2.3.1). 
 
 
Scheme 2.3.3. Preparation of α-CHCl2-substituted fused pyridines 2.3.3. 
 
Noteworthy, that in case of 4-amino-1H-imidazole-2(3H)-thione E2, the standard reaction 
condition in acetic acid was inapplicable, since the starting electron-excessive 
aminoheterocycle E2 was not stabile in acidic media. Therefore in this case an alternative 
TMSCl/DMF system was applied. This system have proved to be a water scavenger; 
accordingly in recent years it has found numerous applications in synthetic organic chemistry 
(Scheme 2.3.4).
83
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Scheme 2.3.4. Preparation of α-CHCl2-substituted imidazopyridine 2.3.3d by alternative 
procedure. 
Table 2.3.1. List of synthesised α-CHCl2-substituted fused pyridines 2.3.3. 
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As it was mentioned above, these conditions were successfully applied in the chemistry of 3-
formyl 2.2.1 and 3-CORF 2.2.4 chromones. Namely they were reacted with 
aminoheterocycles such as aminooxazoles, aminothiazoles, aminouracils etc (see Chapter 
2.2). In contrast to 3-CORF-chromones 2.2.4, the reaction of 3-(dichloroacetyl)chromone 
2.3.2 with electron-excessive aminoheterocycles is more regioselective (see scheme 2.2.6), 
since in all cases only one regioisomer of fused pyridines was detected. Besides, in most of 
the cases a simple recrystallisation was enough to purify obtained compounds. Exceptions 
were few, only in some cases there was a need to purify the crude by column 
chromatography. 
 
2.3.4. Unsuccessful results 
 
Unfortunately reactions with pyrimidine-2,4,6-triamine E9, 5-aminopyrimidine-2,4(1H,3H)-
dione E10, as well as with aniline derivatives E11, 12 were not successful. Using the both 
reaction conditions described above resulted in inseparable mixture of compounds. 
 
2.3.5. Mechanistic explanation 
 
We consider that the regioselective formation of annulated pyridines 2.3.3 starts with the 
attack of internal enamine-like -carbon at C-2 atom of 3-(dichloroacetyl)chromone 2.3.2. 
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Scheme 2.3.5. Putative mechanism of the reaction of 2.3.2 with electron-excessive 
aminoheterocycles. 
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The reason for this is that the -carbon atom in the enamine-like moiety is more nucleophilic 
than the primary amino group, thus it behaves more like C-nucleophile. Following pyrone 
ring opening delivers the intermediate B. Following subsequent intramolecular attack of 
amino group at the dichloroacetyl group form intermediate C. Finally, aromatization of 
intermediate C by fission of H2O molecule leads to the expected fused pyridines (Scheme 
2.3.5). 
Neither in AcOH, nor in TMSCl/DMF system no other alternative cyclization product was 
detected (see Scheme 2.3.3). 
 
2.3.6 Structure identification 
 
All structures obtained during the study were confirmed by 
1
H and 
13
C NMR, IR and mass-
spectrometry, in addition they are in good correspondence with earlier synthesized 
heterocyclic compounds. In 
1
H NMR spectra a typical singlet of the pyridine proton was 
observed at  8.17-8.53 ppm in DMSO-d6 (7.80-8.00 ppm in CDCl3). The singlet of CHCl2 
proton appears at  7.51-7.71 ppm in DMSO-d6 (7.01-7.50 ppm in CDCl3), additionally the 
singlet of OH was detected at  10.51-10.81 ppm in DMSO-d6 (11.03-11.79 ppm in CDCl3). 
The peak of OH was shifted to 10.50-11.00 ppm, which can be explained by formation of 
intramolecular hydrogen bond with the neighbouring keto-group. Moreover, all protons of 
benzene ring are shifted to higher field, which proofs the opening of the pyrone ring. In the 
13
C NMR spectra the peak of CHCl2 appears at  68.8-69.7 ppm. IR spectra show the 
stretchings of OH group at 3040-3061 cm
-1 
which confirmed the presence of hydrogen 
bonding. 
 
Table 2.3.2. Crystal structure of 2.3.3e. 
Compound Crystal Structure 
2.3.3e 
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Furthermore, the structure of 6-(dichloromethyl)-3-methyl-1-phenyl-5-salicyloyl-1H-
pyrazolo[3,4-b]pyridine 2.3.3e was established by X-ray single crystal analysis. The presence 
of hydrogen bond between OH and carbonyl O-atom was confirmed by crystal structure 
(Table 2.3.2). It was possible to see the planar core of heterocyclic fragment. The carbonyl 
group was slightly twisted out of the pyrazolopyridine plane, probably to minimize the 
electronic repulsion with the chlorine atoms of dichlomethyl group. The torsion angle for C5-
C4-C8-O1 was 45.3°. 
 
2.3.7. Further investigations 
 
Above already was mentioned that the fused pyridines - purine isosteres bearing formyl group 
at α-position of pyridine core are of special interest for the development of IMPDH 
inhibitors.
84
 Therefore as the next step of the work conversion of CHCl2 group (a masked 
formyl group) into formyl moiety was performed (Scheme 2.3.6). In overall six examples 
(one from each type of fused pyridines) 2.3.5 were prepared. The reaction was carried out in 
the MeOH using 4 equivalents of KOH. After completion of the reaction (TLC control), 
reaction mixture was worked up with 10 M HCl solution (Table 2.3.3).
85
 Proposed method 
delivers α-formyl-substituted imidazolo-, pyrazolo-, pyrrolo-, thiazolopyridine, and quinoline 
derivatives 2.3.5a-h in good yields. 
 
 
Scheme 2.3.6. Conversion of CHCl2 group to the CHO 2.3.5. 
 
The conversion of CHCl2 group to formyl was proved by NMR spectroscopy. In 
1
H NMR 
spectra the singlet of CHCl2 moiety at  7.51-7.71 ppm disappeared, and a new singlet 
corresponding to COH appeared at  10.55-11.81 ppm (DMSO-d6). Moreover, in the 
13
C 
NMR at 191.6-192.7 ppm (DMSO-d6) a peak for formyl carbon atom was detected. 
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Table 2.3.3. List of prepared 2-formyl fused pyridine derivatives 2.3.5. 
 
 
2.3.8 Conclusion 
 
In summary of presented chapter, for the first time was reported the synthesis of 3-
(dichloroacetyl)chromone 2.3.2. An efficient cyclocondensation reaction of 3-
(dichloroacetyl)chromone 2.3.2 as a new building block with diversity of electron-excessive 
aminoheterocycles E1-E8 was reported. The reflux in acidic condition was applied for most 
cases, or alternatively TMSCl/DMF system was used. The proposed methods were easy and 
simple ensuring good regioselectivity. Corresponding fused pyridines were formed in good 
yields. The dichlormethyl group was easily transferred into formyl group leading to formation 
of α-formyl-substituted fused pyridines 2.3.5. This approach gives a possibility to prepare 
new fused pyridines which could be IMPDH inhibitors. 
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2.4. 3-Methoxyalylchromone – a new building block for the synthesis of 
carboxylated purine isosteres. Design and synthesis of fused -
carboxymethyl pyridines 
 
2.4.1. Introduction 
 
Having initial successful results in preparation of -formyl-substituted purine isosteres, we 
continued the study on synthetic utility of 2-unsubstituted 3-acylchromones as starting 
materials towards -substituted fused pyridines. As it was previously mentioned, purine 
derivatives bearing carbonyl or carboxyl functional groups are of special interest in the design 
of IMPDH inhibitors. Moreover, fused pyridines with a carboxyl functional group in the -
position can be considered as derivatives of picolinic acid, an isomer of nicotinic acid. 
Picolinic acid acts as a chelating agent for some biogene metals, such as chromium, zinc, 
manganese etc in human body. It is involved in biological synthetic pathways of 
phenylalanine, tryptophan and number of alkaloids (Figure 2.4.1).
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Figure 2.4.1. Biologically active pyridines with carboxyl substituent. 
 
In order to prepare -carboxyl-substituted fused pyridines 3-methoxyalyl chromone was set 
as the main subject for the following study. We believed that it can have similar reactivity 
toward electron-excessive aminoheterocycles like other 3-carbonyl-substituted chromones, 
thereby giving an opportunity to construct a list of fused pyridines with carboxyl 
functionality. 
 
2.4.2. Synthesis of starting materials 
  
3-Methoxyalyl chromone 2.4.1 can be prepared from 3-(dimethylamino)-1-(2-
hydroxyphenyl)-propen-1-one 2.3.1 using
 
the same procedure proposed for 3-
(dichloroacetyl)chromone 2.3.2.
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r.t., 8h
 
Scheme 2.4.1. Preparation of 3-methoxyalyl chromone 2.4.1. 
 
That is, treatment of 1 equivalent of enaminone 2.3.1 with 1.1 equivalents of methoxyoxalyl 
chloride in diclormethane in the presence of pyridine as a base delivered desired 3-
methoxyalyl chromone in 79 % yield (Scheme 2.4.1). 
To the best of our knowledge so far exists only a single report related to the synthesis of such 
molecules. In the beginning of 1950s by Whalley et al. was presented the synthesis of 6,7-
dimethoxy-3-ethoxalyl-2-methylchromone, which was prepared from 2-
hydroxyacetophenone, diethyl oxalate and acetic anhydride.
88
 The chemistry of this molecule 
was not previously studied. Additionally, the structure of our starting chromone 2.4.1 was also 
confirmed by X-ray crystal structure analysis (Table 2.4.1). 
 
Table 2.4.1. Crystal structure of 3-methoxyalyl chromone 2.4.1. 
Compound Crystal Structure 
2.4.1 
 
 
 
2.4.3. Results and discussions 
 
Obviously, 3-methoxyalyl chromone 2.4.1 has analogous properties with 3-
(dichloroacetyl)chromone 2.3.2. Therefore the regioselectivity of reaction between this 
chromone as dielectrophile and aminoheterocycles as binucleophiles is interesting in its own 
right. 
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Figure 2.4.2. Possible reaction centers of 3-methoxyalyl chromone 2.4.1. 
 
Starting chromone 2.4.1 has four electron-deficient centres, i.e. carbon atoms C-2 and C-4 of 
chromone moiety and two carbonyl groups of COCO2Me moiety attached to carbon C-3 
(Figure 2.4.2). From the analysis of literature it is evident that the majority of previously 
described reactions of these compounds are nucleophilic additions with concomitant opening 
of pyrone ring, leading to various heterocyclic compounds. Our goal was to develop a 
convenient reaction condition for the reaction of 2.4.1 with different electron-excessive 
aminoheterocycles, with succeeding study of regioselectivity of the method. The sufficient 
results, which were obtained by the domino cyclocondensation reactions of 3-
(dichloroacetyl)chromone 2.3.2 with set of amioheterocycles, have motivated us to use similar 
conditions also for present investigation. Therefore, a test reaction of 2.4.1 with E1a was 
performed in acetic acid under reflux for 3 h (Scheme 2.4.2). Gratifyingly, starting from 
initial trials we were successful to obtain the desired fused pyrazolopyridine 2.4.2a in 57% 
yield. It is noteworthy that the product was formed with excellent regioselectivity. 
 
 
Scheme 2.4.2. Preparation of α-CO2Me-substituted fused pyridines 2.4.2. 
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Scheme 2.4.3. Preparation of α-CO2Me-substituted imidazo[4,5-b]pyridine-2(3H)-thiones 
2.4.2d-g. 
Table 2.4.2. Synthesised α-CO2Me-substituted fused pyridines 2.4.2. 
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Encouraged by these findings, on the next step of our work we tested the scope and 
limitations of proposed methodology towards various electron-excessive aminoheterocycles 
and anilines E2-E8. Gratifyingly, almost in all cases corresponding fused pyridines 2.4.2 with 
carboxymethyl group in -position of pyridine core were prepared in good yields and 
exclusive regioselectivity (Scheme 2.4.2, Table 2.4.2). However, as it was observed 
previously (see scheme 2.3.4), the reaction of 3-methoxyalyl chromone 2.4.1 with 4-amino-
1H-imidazole-2(3H)-thione E2 was not successful in acetic acid. Nevertheless, the alternative 
reaction condition, namely TMSCl/DMF system was successfully applied for this reaction 
leading to corresponding imidazo[4,5-b]pyridine-2(3H)-thiones 2.4.2d-g with good yields 
(Table 2.4.2). 
Interestingly, the reactivity of 3-methoxyalyl chromone 2.4.1 toward electron-excessive 
aminoheterocycles is comparable to those for 3-(dichloroacetyl)chromone 2.3.2, however the 
yields of compounds obtained from methoxyalyl chromone were in general lower (see Table 
2.4.2). 
 
2.4.4. Unsuccessful results 
 
Unfortunately the reactions of 3-methoxyalyl chromone 2.4.1 with anilines E7-8, 11, 12 as 
well as with pyrimidine-2,4,6-triamine E9 and 5-aminopyrimidine-2,4(1H,3H)-dione E10 
were not successful. In all cases a complex mixture of many unidentified products in addition 
to low quantities of two possible regioisomers were formed (detected by HPLC). Our 
numerous attempts to isolate and separate mentioned products experienced a failure. The 
reactions were repeated also in DMF/TMSCl system, though without any success. 
 
2.4.5. Mechanistic explanation 
 
Since the structure of 2.4.2 is in good correspondence with 2.3.3, this prompted us to consider 
that the regioselective formation of annulated α-CO2Me pyridines 2.4.2 starts with attack of 
internal enamine-like -carbon at C-2 atom of the chromone forming intermediate A (Scheme 
2.4.4). Following pyrone ring opening leads to formation of intermediate B (1,4-addition). 
Afterwards subsequent intramolecular attack of amino group to the first carbonyl group 
attached at position 3 of pyrone ring, leads to intermediate C. Finally, the cleavage of water 
molecule delivers desired fused pyridine. 
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Scheme 2.4.4. Putative mechanism of the reaction. 
 
During the reaction other products of alternative cyclization of intermediate A, involving an 
attack of amino group to the carbonyl group connected to the benzene ring, were not detected 
(for some possible by-products see Scheme 2.4.2). All reactions were repeated also in 
TMSCl/DMF system in order to detect alternative cyclization products. Nevertheless, only 
expected products were formed similar to those obtained in acetic acid. It is important 
mentioning, that the product, which could have been formed via alternative N-nucleophilic 
attack, was not detected either (Scheme 2.4.5). This was established based on the crystal 
structure analysis and 2D NMR (see below). 
 
 
Scheme 2.4.5. Mechanism of N-nucleophile attack. 
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2.4.6. Structure identification 
 
Structures of all obtained compounds were confirmed by 
1
H and 
13
C NMR, 2D NMR 
spectroscopy, IR and mass-spectrometry. Not surprisingly they were similar to earlier 
synthesized heterocyclic compounds. In 
1
H NMR spectra a typical singlet of the pyridine γ-
position proton was observed at  7.88-8.65 ppm in DMSO-d6. The singlet of COOMe moiety 
was at  3.60-3.81 ppm in DMSO-d6, additionally OH singlet appeared at  10.66-11.82 ppm 
in DMSO-d6. Moreover, all protons of the benzene ring were shifted to higher field. This may 
be accepted as an evidence for the opening of pyrone ring. In 
13
C NMR spectra was possible 
to see the peak of OMe at  52.1-53.0 ppm. The presence of hydrogen bonding was seen in the 
IR spectrums as well (OH-strech at 3049-3113 cm
-1
). 
 
Table 2.4.3. Crystal structure of 2.4.2i,l. 
Compound Crystal Structure 
2.4.2i 
  
2.4.2l 
 
 
 
The structures of 2.4.2i and 2.4.2l were independently confirmed by X-ray crystal structure 
analysis (Table 2.4.3). The spectral similarities of α-CO2Me-substituted fused pyridines 2.4.2 
with the products obtained in Chapter 2.3 can be considered as an evidence for similar 
regioselectivity. In the molecule 2.4.2i was seen the planner structure of indolopyridine 
system. Obviously, the carbonyl group was perpendicular to the plane of pyridine core, 
probably to minimise the energy of molecule (the torsion angle for C5-C6-C19-O4 was 
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91.8°). In contrast to this thiazolo[4,5-b]pyridin 2.4.2l does not have an excellent plannar 
form, since the sulfur atom was slightly out of the plane of pyridine. Moreover, in this 
structure the CO2Me group and the carbonyl group are both out of the plane of pyridine 
(torsion angles for C6-C5-C9-O3 and C5-C6-C7-O2 are -126.8° and 28.3° respectively). 
Furthermore, hydrogen bonds between OH group and carbonyl moiety is present in both 
structures. 
We measured also a NOESY spectra for 2.4.2h in order to examine the possibility of 
alternative regioselectivity via N-nucleophilic attack (Figure 2.4.3). Not surprisingly, only a 
week correlation between γ-proton of pyridine ring and -proton of benzoyl moiety with the 
methyl group of pyrazole ring was detected. The correlation between methyl group and OMe 
of the ester group was not observed. In case of second possible regioisomer corresponding 
correlation of methyl group from pyrazole ring with the ester moiety in γ-position of pyridine 
ring would be detected. However no correlation of this type was seen. This can be considered 
as an additional verification of regioselectivity of the product formed by C-nuclophilic attack. 
 
 
Figure 2.4.3. The correlations observed in NOESY spectra of compound 2.4.2h. 
 
2.4.7. Further investigations 
 
The next step of our study was the preparation of corresponding carboxylic derivatives of 
fused pyridines 2.4.6. As it was mentioned, -carboxyl-substituted pyridines are of 
considerable interest.
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The treatment of corresponding ester derivatives 2.4.2 with KOH in methanol under reflux 
delivered to desired products 2.4.6a-d in excellent yields (Scheme 2.4.6). 
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Scheme 2.4.6. The hydrolysis reaction α-CO2Me fused pyridines 2.4.6. 
 
By this method four examples of α-CO2H-substituted fused pyridines 2.4.6 were prepared 
(Table 2.4.4). The structures of all compounds were identified by NMR spectroscopy. 
Particularly for all four examples in 
1
H NMR spectra the singlet of OMe group disappeared, 
instead respective broad peak of COOH emerged on 13.71-13.98 ppm in DMSO-d6. 
 
Table 2.4.4. List of synthesised α-CO2H-substituted fused pyridines 2.4.6. 
OH
O
N CO2H
N
N
H
O
Ph
OH
O
N CO2H
N
N
Me OH
O
N CO2H
S
N
N
Me
Me
OH
O
N CO2H
N
N
O
O
Me
Me
2.4.6a, 80% 2.4.6b, 82% 2.4.6c, 79%
2.4.6d, 81%
 
2.4.8. Conclusion 
 
As the conclusion of this chapter should be noted that the synthesis and further 
transformations of 3-methoxyalylchromone 2.4.1 as masked dielectrophile was reported. We 
have showcased that 3-methoxyalylchromone 2.4.1 is a novel versatile reagent for the 
synthesis of fused pyridines - purine isosters bearing α-CO2H substituent. The scope and 
limitations of the method was examined. Namely cyclocondensation reaction of 3-
methoxyalylchromone 2.4.1 with different electron-excessive aminoheterocycles was 
performed. Corresponding fused pyridines 2.4.2 were prepared in good yields with excellent 
regioselectivity. For some exemples of 2.4.2 was possible to hydrolyse the ester group to 
appropriate α-CO2H-substituted fused pyridines 2.4.6. The possible biological relevance of 
new compounds is under investigation. 
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2.5. Synthesis of heteroannulated 3-nitro- and 3-aminopyridines by 
cyclocondensation of electron-excessive aminoheterocycles with 3-
nitrochromone 
 
2.5.1. Introduction 
 
Going on with our study towards the development of new and simple methods for the 
synthesis of diverse fused pyridines, we switched our attention on purine-like scaffolds 
containing an electron withdrawing group (EWG) at the β-position of the fused pyridine core 
(Scheme 2.5.1). It is known from the literature that 3-nitropyridines can form a stable 
Meisenheimer type hydrate II at the 4-position.
89
 Structures of this type represent promising 
patterns for the development of potential inhibitors for Adenosine Deaminase (ADA) 
(Scheme 2.5.1). 
 
in vivo
N
H
EWG
N R
EWG
R
OHH
H2O
II
Het
Het
I: EWG = NO2  
Scheme 2.5.1. The hydrate formation of 3-nitropyridines I. 
 
Adenosine Deaminase (ADA) is a cytosolic enzyme. ADA is an object of considerable 
interest; first of all, due to the fact that congenital defects of the enzyme in human cells causes 
severe combined immunodeficiency disease (SCID).
90
 Additionally, human ADAR 
(Adenosine Deaminase that acts on RNA) was specified as one of few unambiguously up-
regulated genes in solid tumours and liver cancer.
91
 The dysfunction of ADAR was related to 
cancer progression in mammals. ADA participates in the purine metabolism, particularly it 
degrades adenosine to produce inosine (Scheme 2.5.2). 
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Scheme 2.5.2. Action of ADA. 
 
Because of its importance for drug design, the mechanism of deamination reaction catalysed 
by ADAs and ADARs was recently studied in details.
92
 Notably, it was found that transition 
state of inosine production proceeds with a complete pro-S-face hydroxyl addition to 
adenosine in SNAr transition state (Figure 2.5.1). The formation of tetrahedral Meisenheimer 
intermediate during deamination reaction was well established and proved (Figure 2.5.1).
92
 
 
 
Figure 2.5.1. Formation of tetrahedral Meisenheimer intermediate. 
 
Moreover, known potent ADA inhibitors could be summarised into two big groups: 1) purine 
ribosides or 2'-deoxyribosides, containing the hydrated heterobase, which resembles the 
putative transition state (e.g. well known commercially available anticancer drugs 
conformicin and pentostatin);
93
 2) (+)-EHNA (erythro-9-(2-hydroxy-3-nonyl)adenine) and 
related compounds.
94
 The main disadvantage of these compounds is the fact that they are 
prone to be rapidly metabolized,
95
 which results in shorter duration of the action allowing 
faster recovery of enzymatic activity. Noteworthy, recently were reported some other highly 
potent non-nucleoside ADA inhibitors
96
, for instance 6-aminocarbovir
97
 (Figure 2.5.2). 
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Figure 2.5.2. Potential ADA inhibitors. 
 
According to the importance of ADA inhibitors in cancer research, we were interested in 
elaboration of principally new synthetic strategy giving possibility to prepare diverse libraries 
of bicyclic fused pyridines with nitro or amino group at the β-position. In principle they can 
also form a hydrate intermediate being a promising scaffolds towards the development of 
ADA transition state mimetics. 
 
2.5.2. Synthesis of starting materials 
 
Based on the retrosynthetic analysis and our previous results on development of new 
cyclocondensation reactions of chromones, we envisaged that 3-nitro(thio)chromones can be 
suitable starting dielectrophiles for the synthesis of heteroannulated 3-nitropyridines. 
 
O
OH
O
HNO3, AcOH (glacial)
NaNO2 (cat.)
60 oC, 15 min O
OH
O
NO2
KOH in H2O
55 oC, 1.5h
O
NO2
OH
H2SO4 (cat.)
reflux, 6h
O
O
NO2
R
2.5.1a-e
87% 81%
R-C(OMe)3
(8 equiv.)
 
Scheme 2.5.3. Preparation of 3-nitrochromones 2.5.1 from 4-hydroxycumarin; for R see 
Table 2.5.1. 
 
There are only two methods available in the literature describing the synthesis of 2-
unsubstituted 3-nitrochromones. The simplest represents a four step process, starting from 4-
hydroxycoumarin.
98
 Notably, in some cases it was possible to prepare 3-nitrochromone by 
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direct nitration of corresponding 3-hydroxymethyl- or 3-formylchromones.
99
 However, in this 
work the first method was used with some alternations in order to prepare 2-unsubstituted and 
2-substituted 3-nitrochomones. 
The nitration of 4-hydroxycoumarin was carried out in the mixture of glacial acetic acid and 
65% nitric acid, using catalytic amounts of sodium nitrite (Scheme 2.5.3). The following 
hydrolysis of 4-hydroxy-3-nitrocoumarin proceeds in aqueous solution of KOH at 55 °C for 
90 min. Subsequently the neutralization was done with 1.3 equivalents of acetic acid in ice 
bath (instead of HCl used in initial report). In this conditions 2'-hydroxy-2-nitroacetophenone 
was formed with up to 81% yield. Noteworthy, in strong acidic conditions the nitro group can 
be hydrolyzed to an aldehyde. Another optimization was the use of orthoesters (previously 
carboxylic acid anhydrides were used in the reaction) in the presence of sulphuric acid in 
order to obtain 3-nitrochromones 2.5.1 with improved yields. Applied changes were 
especially useful for R = H, since in this case formic anhydride was necessary as substrate. 
Thus we were able to prepare five different 3-nitrochromones 2.5.1 in 82-88 % yields (Table 
2.5.1). 
 
Table 2.5.1. List of synthesised 3-nitrochromones 2.5.1. 
2.5.1 R Reaction time of last step (h) Yields (%) 
a H 6 82 
b Me 3 84 
c Et 4 83 
d Ph 5 88 
e p-Tol 5 85 
 
It should be noticed that compounds 2.5.1d and 2.5.1e were also possible to synthesise by 
nitration of appropriate flavones, using ammonium nitrate and trifluoroacetic anhydride.
100
 In 
order to study the scope and limitations of the method 3-nitrothiochromone 2.5.2 was 
prepared as well, as a thio- analogue of nitrochromones 2.5.1. The later can be obtained by 
nitration of thiochroman-4-one with 65% nitric acid in acetic acid (Scheme 2.5.4).
101 
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Scheme 2.5.4. Preparation of 3-nitrothiochromone 2.5.2. 
 
Finally, it was not possible to prepare 3-nitro-2-(trifluoromethyl)chromone and methyl 3-
nitrochromone-2-carboxylate using the reaction of 2'-hydroxy-2-nitroacetophenone with 
trifluoroacetic anhydride and methyl 2-chloro-2-oxoacetate respectively. 
 
2.4.3. Results and discussions 
 
3-Nitrochromone 2.5.1 is a type of masked 1,3-dielectrophile as well, so it can be an 
interesting starting material toward binucleophiles (Figure 2.5.3). To date only few works are 
known in the literature describing the reaction of 3-nitrochromone 2.5.1 with amines, 
benzamidine, phenylhydrazine,
102
 amidines, guanidine, acid hydrazides, S-methylisothiourea 
and hydroxylamine.
103
 In addition, recently one of our colleagues have prepared a range of 1-
substituted 6-nitro-3H-imidazo[4,5-b]pyridines starting from 1-substituted 5-amino-1H-
imidazoles generated in situ.
104
 
 
 
Figure 2.5.3. 3-Nitrochromone 2.5.1 as 1,3-dielectrophile. 
 
Analogically to other chromones described above the domino reaction should be started with 
nucleophilic attack onto the position 2 with subsequent pyrone ring opening that can be 
followed by a cyclization with the second electrophilic centre. Using the general procedures 
developed in the last two chapters (see Chapter 2.2, 2.3), the test reaction of the 2-
unsubstituted chromone 2.5.1a with E1 proved to be successful, corresponding fused pyridine 
2.5.3a was isolated in 98% yields. We got the product with excellent regioselectivity; the 
other possible isomer that can be formed by nucleophilic substitution of nitro group was not 
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detected. 
 
 
Scheme 2.5.5. Preparation of library of 3-nitro-substituted fused pyridines 2.5.3. 
 
Table 2.5.2. List of obtained compounds 2.5.3 (see the yields in Table 2.5.3). 
 
 
Following the initial sufficient results, a set of other aminoheterocycles E1-E9 were tested. 
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Fortunately, corresponding 3-nitro-substituted fused pyridines 2.5.3a-p were successfully 
prepared in 62-98% yields (Scheme 2.5.5). It is worth mentioning that all reactions proceed 
with an excellent regioselectivity, in all cases only one product was formed. Besides, since 3-
nitrochromone 2.5.1a has only two electrophilic carbonyl centres, the regioselectivity in this 
case is different from the regioselectivity of two previously discussed chromones (see Chapter 
2.5.6). Additionally, the isolation of products was quite easy, as long as in most cases after 
completion of the reaction (TLC control) precipitation of the product occurred, therefore a 
simple filtration and washing was enough to get pure products (Table 2.5.2). 
Like encountered in previous chapters the 4-amino-1H-imidazole-2(3H)-thione E2 as well as 
6-amino-2,3-dihydro-2-thioxopyrimidin-4(1H)-one E9 were not stable in acetic acid, 
therefore corresponding products were prepared using the alternative reaction conditions 
(TMSCl/DMF), the yields were 95% and 65% respectively. In this context we were interested 
in comparison of 3-nitrochromones reactivity 2.5.1a towards aminoheterocycles E1-E9 in 
both conditions. For this reason the same reaction was runned in both conditions for majority 
of aminoheterocycles. One can see that in acetic acid reaction yields are higher, although in 
some cases the starting materials were not stable (E2, E9, Entry d,p, Table 2.5.3), or mixture 
of inseparable compounds (for instance in case of anilines) were formed (Entry m-o, Table 
2.5.3). Alternative methodology (TMSCl/DMF) was effective for all aminoheterocycles, 
though in some cases the duration of reactions was increased. For more active 
aminoheterocycles (Entry a,b,e, Table 2.5.3) the yields were comparable to those for Method 
A. Additionally, in TMSCl/DMF system the reaction with anilines emerged with good 62-
91% yields (Entry m-p, Table 2.5.3). Thereby these methods are complement to each other, 
thus together they offer an easy and comfortable route for preparing various types of 
hetero(carbo)annulated pyridines with NO2 group located at the -position of pyridine core. 
 
Table 2.5.3. Method A (Acetic acid, reflux), Method B (TMSCl/DMF, 100 
o
C, 140
 o
C for 
2.5.3n). 
2.5.3 Method A T (h) Method B T (h) 2.5.3 Method A T (h) Method B T (h) 
a 98 5 77 5 i 84 2 40 2 
b 87 2 63 2 j 97 4 44 4 
c 78 4 54 4 k 73 6 32 6 
d Mix 2 95 10 l 79 3 35 3 
e 97 1 88 1 m Mix 2 62 18 
f 65 4 43 4 n Mix 2 83 2 
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g 90 1 44 1 o Mix 2 91 10 
h 71 15 32 15 p Mix 2 65 4 
 
2.5.4 Unsuccessful results 
 
Having successful results with the range of aminoheterocycles E1-E9, next we tried to apply 
this methodology for 2-methyl-, 2-ethyl-3-nitrochromones 2.5.1b,c and 3-nitroflavones 
2.5.1d,e. Unfortunately, all trials to perform a domino cyclocondensation between 2-
substituted chromones and aminoheterocycles failed, only starting materials were recovered 
(by Method A and B). For some examples the reaction gave multicomponent mixtures, from 
which we could not isolated any fused pyridines. We supposed that cyclocondensation 
reaction of 3-nitrochromones 2.5.1 with electron-excessive aminoherecycles is rather sensitive 
to the nature of the substituent at the C-2 atom, hereby in order to obtain pyridines it is 
necessary to use chromones without any substitution at position 2. This can be a result of 
steric and conjugation factors. Furthermore, the reaction of 3-nitrothiochromone 2.5.2 with 
amines was also ineffective and only starting thiochromone was recovered from the reaction 
mixture. The reaction was carried out in standard conditions developed as well as under 
harsher conditions (dimethylacetamide, TMSCl, 170 °C), however no product was observed. 
This can be explained with the thought that 3-nitrothiochromone 2.5.2 is much less reactive 
than 3-nitrochromone 2.5.1. The differences in reactivity between 2.5.1 and 2.5.2 may be 
connected with the difficulties met by the nucleophile in attacking position 2 of thiopyrone, 
since the sulphur atom is less electronegative therefore the electrophilicity of the C-2 is 
strongly reduces. Therewith, it was shown before that the aromaticity of thiochromone system 
is much higher than in simple chromones.
105
 
 
2.4.5 Mechanistic explanation 
 
Likely the condensation reaction proceeds very similar two previous chromones. We believe 
that the reaction starts by conjugate addition of enamine-like carbon atom of E onto the 2
nd
 
position of 2.5.1a to give intermediate A. Afterwards the pyrone ring opening takes place 
delivering intermediate B (Scheme 2.5.6). 
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Scheme 2.5.6. Putative mechanism of the cyclocondensation reation. 
 
Following intramolecular attack of amino group onto the carbonyl group affords intermediate 
C, later on the elimination of water molecule gives corresponding fused pyridines 2.5.3 with 
nitro group at the β-position. 
 
 
Scheme 2.5.7. Putative formation of the product by N-nucleophile attack. 
 
In fact we conducted all reactions using both methods (Method A and B); interestingly in all 
cases we got the same regioisomer so we were interested to detect any type of intermediate or 
alternative product, for instance product of N-nucleophile attack of the enamine-like moiety 
2.5.4 (Scheme 2.5.7). However, product of this type or any others were not detected (see next 
chapter). This fact makes our proposed method a versatile approach towards the regioselective 
synthesis of 3-nitro-substituted fused pyridines. 
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2.5.6. Structure identification 
 
All structures were confirmed by 
1
H and 
13
C NMR spectroscopy, as well as IR and mass-
spectrometry. In all cases obtained products were similar to the formerly prepared fused 
pyridines. In 
1
H NMR spectra the typical singlet of pyridine proton was observed at  8.15-
9.13 ppm in DMSO-d6 (7.93-8.82 ppm in CDCl3). In addition a broad OH singlet appeared at 
 9.84-10.41 ppm in DMSO-d6 (8.50-11.7 ppm in CDCl3). A slight interaction (hydrogen 
bond) was detected between OH and the nitrogen of pyridine, although not for all cases. 
Moreover, the protons of benzene appear in higher field proving the opening of pyrone ring. 
 
Table 2.5.4. Crystal structure of 2.5.3d,e,j,m. 
Compound Crystal Structure 
2.5.3d 
 
 
2.5.3e 
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2.5.3j 
 
 
2.5.3m 
 
 
 
The structures of 2.5.3d,e,j,m were independently confirmed by X-ray crystal structure 
analysis (Table 2.5.4). In all structures appears planar structure of fused pyridine core. 
Moreover, in all cases the N-atom of NO2 group is almost in the same plane with fused 
pyridine core, though oxygens were perpendicular to the pyridine surface (in d the torsion 
angle H4-C4-C5-N4 is 38.76
o
). Since the α-hydroxyphenyl group in the fused pyridine is in 
free rotation, in some cases the OH group can be on the side of nitrogen atom (2.5.3d and m), 
in other cases the OH group is turned towards the opposite side (2.5.3e and j). Furthermore, 
the hydrogen bonds were observed in the first type of structures (2.5.3d and m). 
The structural identification of the rest of fused pyridines was based on the date obtained from 
crystal structures. It is worth mentioning that all structures are in correspondence to the mode 
of proposed general mechanism. The product of N-nucleophile cyclocondensation was not 
observed. 
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Figure 2.5.4. NOESY analysis of compounds 2.5.3l and p. 
 
In addition to this argument the NOESY analysis shows a week interaction between pyridine 
γ-H with OH and NH2 in the structures of 2.5.3l and 2.5.3p respectively. This is an additional 
evidence for proposed regioselectivity (Figure 2.5.4). 
 
2.4.7. Further investigations 
 
Having access to the fused 3-nitropyridines 2.5.3 and due to the biological importance of 3-
aminopyridine derivatives, we studied their synthesis by hydrogenation of fused 3-
nitropyridines 2.5.3 using Pd/C (10 mol%) in MeOH. We found that the reaction proceeds 
with excellent yields leading to appropriate 3-amino-substituted fused pyridines 2.5.5 
(Scheme 2.5.8). 
 
N
HO
NO2 H2 (1 atm.) 
Pd/C (10 mol%)
MeOH, r.t., 24h N
HO
NH2
2.5.3 2.5.5 a-n  
Scheme 2.5.8. Hydration of the 3-nitropyridines 2.5.3. 
 
The structures of corresponding products were established by 
1
H NMR spectroscopy. In all 
spectras a large singlet of NH2 appears at  4.00-6.00 ppm in DMSO-d6. Furthermore, in IR 
spectrums appears a broad signal at 3392-3226 cm
-1
 that also corresponds to NH2 group 
(Table 2.5.5). 
The reduction of compounds 2.5.3d and 2.5.3l was not effective, this can be explained by the 
property of sulphur atom to poison the Pd-catalyst. Obtained products can be used further to 
prepare novel 3-unsubstituted pyridines by using of synthetic combinatorial means. 
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Table 2.5.5. Prepared 3-aminopyridines 2.5.5. 
 
 
2.5.8. Conclusion 
 
In conclusion of this chapter should be mentioned that the regioselective cyclocondensation 
reaction of 3-nitrochromone 2.5.1a and electron-excessive aminoheterocycles 2.1 was studied 
in detail. Corresponding fused 3-nitropyrdines 2.5.3 and 3-aminopyridines 2.5.5 were 
prepared in good to excellent yields. The scope and limitations of the method towards 2-
substituted 3-nitrochromones 2.5.1b-e and aminoheterocycles 2.1 was well investigated. The 
presence of NO2 group gave a possibility to perform further operations, namely appropriate 
aminopyridines were synthesised by simple hydration. All prepared compounds can be 
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biologically active, thus the biological evaluation of these compounds is currently in study. 
 
2.6. 2,3-Unsubstituted chromones as versatile reagents for the synthesis of 
fused pyridines 
 
2.6.1. Introduction 
 
The proposed methods in Chapters 2.3, 2.4, 2.5 allowed us to synthesise a variety of fused 
pyridines and quinolines bearing different functional groups such as CHCl2 and CHO 
(Chapter 2.3), COOMe and COOH (Chapter 2.4), NO2 and NH2 (Chapter 2.5). In described 
procedures were applied cheap and easily available starting materials. The next step of the 
present work was the preparation of α-aryl and/or hetreoaryl-substituted fused pyridine 
derivatives. This type of compounds is of special interest, since they can be considered as 
purine isosteres. Such compounds are widely used in medicinal chemistry, in the engineering 
of drug-like scaffolds.
106
 
According to the retrosynthetic analysis and our previous experience we have assumed that 
2,3-unsubstituted chromones could be an ideal starting materials for preparation of β,γ-
unsubstituted fused pyridines. It is worth mentioning that to date there are only few papers 
presenting the reactivity of 2,3-unsubstituted chromones towards binucleophiles. This can be 
explained by the low reactivity of this type of chromones in comparison to similar structures 
having an EWG at the position 3. In this chapter the properties of different 2,3-unsubstituted 
chromones towards electron-excessive aminoheterocycles and aromatic amines will be 
discussed. 
 
2.6.2. Synthesis of starting materials 
 
According to the literature data 2,3-unsubstituted chromones 2.6.2a-h can be prepared in 2 
steps starting from o-hydroxyacetophenone. The first step is the preparation of (E)-3-
(dimethylamino)-1-(2-hydroxyaryl)prop-2-en-1-ones 2.6.1 by reaction of o-
hydroxyacetophenones with DMFDMA (N,N-dimethylformamide dimethyl acetal).
107
 On the 
second step subsequent treatment of (E)-3-(dimethylamino)-1-(2-hydroxyaryl)prop-2-en-1-
ones 2.6.1 with perchloric acid leads to chromone ring formation. Nevertheless, we have 
found that corresponding chromones can be easily prepared starting from 2.6.1 in 
TMSCl/DMF system at 100 
o
C under argon atmosphere (Scheme 2.6.1). 
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Scheme 2.6.1. Preparation of 2,3-unsubstituted chromones 2.6.2. 
 
Proposed methodology allowed us to prepare desired 2,3-unsubstituted chromone derivatives 
in almost quantitative yields (90-97%). Following this procedure eight examples of different 
2,3-unsubstituted chromones 2.6.2 were synthesized, however only first five chromones were 
tested during the next studies (Table 2.6.1). 
 
Table 2.6.1. List of prepared chromones 2.6.2. 
2.6.2 R Yields (%) 
a H 93 
b 6-Me 97 
c 6-Br 94 
d 6-Cl 97 
e 7,8-Benzo 90 
f 6-OMe 95 
g 6-Cl-7-Me 95 
h 7-OMe 94 
 
2.6.3. Results and discussions 
 
2,3-Unsubstituted chromones can be considered as 1,3-CCC-dielecrophiles possessing a 
masked 1,3-dicarbonyl fragment in the structure (Scheme 2.6.2). Actually 2,3-unsubstituted 
chromones appeared to be less reactive in comparison to the other representatives. So far only 
few reactiones with pyrone ring opening of 2,3-unsubstituted chromones are known, for 
instance, the reaction with dimethyl acetonedicarboxylate
108
 or N-iminopyrimidine ylide.
109
 
Recently, in our laboratory TMSOTf mediated reaction of 2,3-unsubstituted chromones with 
1,3-bissilyl enol ethers were investigated, as a result number of functionalized 6H-
benzo[c]chromen-6-one derivatives were synthesized.
110
 In all cases the reaction proceeded 
by nucleophilic 1,4-addition, that was accompanied by pyrone ring opening. 
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Scheme 2.6.2. 2,3-Unsubstituted chromones as 1,3-dielectrophile. 
 
Continuing our research program dedicated to the design and synthesis of novel fused 
pyridines, the reaction of 2,3-unsubstituted chromones with set of electron-excessive 
aminoheterocycles was examined. The initial experiments of 2.6.2a with E1 were carried out 
in AcOH under reflux, but unfortunately the desired product was not detected. However, 
when the alternative reaction condition was used (TMSCl/DMF system), luckily we could 
isolate corresponding 2-phenylpyrazolo[3,4-b]pyridin-3-one 2.6.3a in 90% yield (Scheme 
2.6.3). 
 
 
Scheme 2.6.3. Synthesis of β,γ-unsubstituted fused pyridines 2.6.3-2.6.12. 
 
Having primary successful results in hand the scope and limitations of the reaction was 
studied. Initial chromones 2.6.2a-e were reacted with a set of electron-excessive 
aminoheterocycles and anilines E1-E10. As a result a number of β,γ-unsubstituted fused 
pyridines 2.6.3-2.6.12 were prepared in good yields (Table 2.6.2). 
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Table 2.6.2. List of synthesised β,γ-unsubstituted fused pyridines 2.6.3-2.6.12. 
 
Encouraged with successful results we have considered (E)-3-(dimethylamino)-1-(2-
hydroxyaryl)prop-2-en-1-one 2.6.1 to be a starting material for the synthesis of β,γ-
unsubstituted fused pyridines. As it was shown in the chapter preparation of 2,3-unsubstituted 
chromones 2.6.2 and further cyclocondensation with aminheterocycles runs at similar 
conditions (Scheme 2.6.1, 2.6.2). In this context we were interested in shortening the process 
by skipping one step. Therefore, we tried to start the cyclization reaction from enaminones 
2.6.1, keeping in mind the possibility to synthesize corresponding chromone in situ. As a 
model the reaction of enaminone 2.6.1a with electron-excessive aminoheterocycle E1a was 
chosen (Figure 2.6.1). The state and direction of the reaction in the period of full conversion 
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of reactants was controlled by TLC (Heptane : Ethyl acetate 1:2). In the first TLC one can see 
starting materials (2.6.1a and E1a), corresponding chromone 2.6.2a along with the reaction 
mixture in the beginning of reaction (Figure 2.6.1). Half an hour later the second TLC showed 
an interesting picture, namely the spot of 2.6.1a vanished and a spot similar to chromone 
2.6.2a in addition to a spot corresponding to fused pyridine appeared. After 3 hours third TLC 
showed full conversion of staring materials with a spot corresponding to the product 2.6.3a. 
 
 
Figure 2.6.1. TLC control of the reaction (2.6.2a-Chromone (Rf = 0.4), 2.6.1a- Enamine (Rf = 
0.26), RM-Reaction mixture (Rf = 0.62), E1a- enaminone (Rf = 0.16)). 
 
Once the reaction successfully delivered the corresponding products (2.6.3a, Figure 2.6.1), the 
same set of electron-excessive aminoheterocycles were tested in the reaction. In addition 
yields of prepared β,γ-unsubstituted fused pyridines were compared to those, which were 
synthesized using 2,3-unsubstituted chromones (Scheme 2.6.4, Table 2.6.3). 
The data of Table 2.6.3 indicates that the yields are resemble for both starting materials. 
However, the privilege of enones is that it gives an opportunity to reach desired fused 
pyridines in one step, skipping the synthesis of chromones. It can be concluded that the 
starting enaminones 2.6.1a-e can also be versatile starting compounds toward synthesis of 
diverse fused pyridines. This can represent an interesting approach for synthesis of other 
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heterocyclic systems in the future. 
 
 
Scheme 2.6.4. Synthesis of β,γ-unsubstituted fused pyridines 2.6.3-2.6.5, 2.6.7-2.6.8, 2.6.10-
2.6.11 starting from enones 2.6.1. 
 
Table 2.6.3. List of yields of prepared fused pyridine. 
Product  Yileds (%)
a
 Yileds (%)
b
 Product  Yileds (%)
a
 Yileds (%)
b
 
2.6.3a 90 86 2.6.7b 60 54 
2.6.3b 77 78 2.6.7c 62 60 
2.6.3c 92 90 2.6.7d 55 50 
2.6.4a 90 89 2.6.8a 88 87 
2.6.4b 90 86 2.6.8b 89 87 
2.6.4c 76 74 2.6.8c 85 85 
2.6.4d 61 60 2.6.8d 90 88 
2.6.4h 58 60 2.6.8e 65 66 
2.6.5a 97 93 2.6.8f 65 60 
2.6.5b 92 92 2.6.8g 97 90 
2.6.5c 75 74 2.6.10 72 77 
2.6.7a 61 61 2.6.11 84 82 
(a) Starting from 2.6.2, (b) starting from 2.6.1. 
 
2.6.4. Unsuccessful results 
 
Summarising unsuccessful results it must be noticed that the reaction of chromones 2.6.2 and 
corresponding enaminones 2.6.1 with anilines failed, more precisely no product was detected 
at all. Additionally, the reaction of enaminones 2.6.1 and E12 delivered to the formation of 
naphtho[2,3-f]quinolone framework (GC/MS data). However, due to low solubility in 
common solvents it was not possible to measure a 
1
H NMR spectra, in order to see which of 
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possible isomers were formed. Nevertheless, the mass-spectrometry as well as elemental 
analysis data confirm the formation of naphtho[2,3-f]quinolone skeleton (See Chapter 2.6.6). 
 
2.6.5. Mechanistic explanation 
 
2,3-Unsabtituted chromones in terms of active reaction centres are similar to 3-nitrochromone 
2.5.1. The only difference is that NO2 group being a strong EWG makes the position 2 more 
electron deficient, in other words they should react with binucleophiles following the same 
reaction pathway. Therefore, the proposed mechanism is similar to the one presented in 
Chapter 2.5.5 (Scheme 2.6.5). 
 
 
Scheme 2.6.5. Putative mechanism of the annulation reaction of 2.6.2. 
 
We suppose that the reaction starts with formation of benzopyrylium salt A by initial 
silylation. This makes position 2 of chromone framework more favourable for nucleophilic 
attack. Subsequent nucleophilic attack of β-carbon atom of aminoheterocycles to the position 
2 gives the first intermediate B in this cascade. The γ-pyrone ring opening delivers second 
intermediate C. Additionally, it should be noticed that such type intermediates (intermediate 
C) are quite stable, thus in some cases it can be isolated and characterized.
 111
 In the next step 
amino group attacks the carbonyl moiety forming silylated pyridine hydrate D. Further, the 
elimination of Me3SiOH forms desired product. 
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Concerning the reaction starting from enaminones 2.6.1, we assume that first corresponding 
chromone 2.6.2 formation takes place (based on the TLC study and structure identification, 
see next chapter), that is followed by cyclocondensation (Scheme 2.6.6). 
 
 
Scheme 2.6.6. Putative mechanism of the annulations reaction of 2.6.1 and electron-excessive 
aminoheterocycles. 
 
 
Scheme 2.6.7. Putative mechanism of the annulation reactions, where the aminoheteocycles 
behave as N-nucleophiles. 
 
The reaction starts with activation of C-2 atom of enamine fragment, that is followed by the 
attack of oxygen atom to the electrophilic centre. Subsequent cyclization leads to the 
formation of chromone, so further steps of the reaction proceeds as was shown in Scheme 
2.6.4. This mechanism is more reasonable, since obtained products are similar to the ones 
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obtained from corresponding chromones 2.6.3-2.6.12 (Scheme 2.6.6). 
It should be noticed that during the study of these reactions other regioisomers 2.6.13 were 
not detected. The latter would have been formed by initial N-nucleophile attack of electron-
excessive aminoheterocycle (Scheme 2.6.7). Herein we can affirm that proposed methodology 
is absolutely regioselective for the range of used starting materials (See Chapter 2.6.6). 
 
2.6.6. Structure identification 
 
Structures of all synthesised compounds were confirmed by 1D and 2D NMR, mass and IR 
spectroscopy. Despite the fact that we have different 5,6-bicyclic systems and different initial 
chromones, still was possible to follow some general peaks in 
1
H and 
13
C NMR spectra. In all 
cases the peak of OH group was observed in 
1
H NMR at 11.46-14.88 ppm (DMSO-d6). In a 
case of 6-methylchromone the singlet of methyl group was seen in 
1
H NMR at 2.25-2.35 ppm 
and in 
13
C NMR at 20.0-21.0 ppm (DMSO-d6) (Table 2.6.2, compounds 2.6.3a, 2.6.4b, 
2.6.5b, 2.6.6a, 2.6.8b,d,f,h, 2.6.9a). The presence of Br was easily detected by GC/MS 
spectromethry, since the mass peaks for both isotopes of Br were presented in almost equal 
intensity (Table 2.6.2, compounds 2.6.4b, 2.6.5b, 2.6.7c, 2.6.8i). The same was with 
compounds bearing Cl (Table 2.6.2, compounds 2.6.3c, 2.6.4g,i,h, 2.6.5c, 2.6.6b, 2.6.7a,d,j, 
2.6.8c,e, 2.6.9b), namely in all cases about 30% of M+2 peak was detected. In IR spectra a 
broad peak of OH group appears at 3140-2764 cm
-1 
indicate the hydrogen bonding between 
the pyridine nitrogen and OH group. 
In NOESY spectra of compound 2.6.4b we observed an interaction between N-Ph protons and 
OH of the α-aryl moiety, in addition to a very week correlation between methyl group of aryl 
and N-Ph protons (Figure 2.6.2). Another week correlation was detected between N-Me and 
γ-proton of the fused pyridine. However, there were no interaction between two methyl 
groups or N-Me and OH group of the aryl moiety. These interactions could have been 
observed if we would have another regioisomer. This could be taken as an evidence for the 
regioselectivity of the reaction. 
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Figure 2.6.2. Visible correlations in NOESY spectra for compound 2.6.4b. 
 
Furthermore, structures of 2.6.3a,b,c, 2.6.5a and 2.6.7d (Table 2.6.2) were identified also by 
X-ray single crystal analysis (Table 2.6.4). It should be noticed that all five structures exactly 
correspond to expected regioisomers. This is an additional confirmation for regioselectivity of 
the reaction. In all frameworks we observed a planar core of fused pyridine system. Moreover, 
the α-hydroxyphenyl group was almost at the same plane with fused pyridine core. This can 
be explained by a hydrogen bond between OH and N-atom of pyridine ring. The torsion angle 
between pyridine core and o-hydroxyphenyl moiety is 2.64
o
-14.39
o
. The length of hydrogen 
bonds in all structures is in the range of 1.639-1.781 Å. 
 
Table 2.6.4. X-ray crystal structures of compounds 2.6.3a-c, 2.6.5a, 2.6.7d. 
Compound Crystal Structure 
2.6.3a 
 
 
2.6.3b 
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2.6.3c 
 
 
2.6.5a 
 
 
2.6.7d 
 
 
 
2.6.7. Further investigations 
 
Encouraged by the results regarding enaminones 2.6.1 as starting materials for synthesis of 
fused pyridine, next the reactivity of similar enaminones without a hydroxyl group was 
exanimated. The study of regioselectivity of this reaction was relevant since the absence of 
hydroxyl group could influence on cyclization reaction mechanism (actually it can not go 
through in situ chromone ring formation). Furthermore, using this approach the synthesis of 
new derivatives of α-aryl-substituted fused pyridines would be possible. For this purpose the 
reaction of (E)-3-(dimethylamino)-1-(4-(trifluoromethyl)phenyl)prop-2-en-1-one 2.6.14 and 
E1a was tasted. Fortunately, the cyclocondensation product 2.6.15a was isolated in 70% yield 
(Scheme 2.6.8). According to initial study the structure of obtained product was in good 
correspondence with previously isolated products. 
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TMSCl (1 mL)/DMF
Ar, 100-120 oC, 3-11 h
Ar
O
N
Me
Me
NH2
E1-E6
N
+
Ar
2.6.14
2.6.16-2.6.19
a: 4-CF3-C6H4
b: 4-OMe-C6H4
c:2-F-C6H4
d: 3-Py
e: 4-Py
Ar =
(1.1 equiv.)  
Scheme 2.6.8. Preparation of α-aryl-substituted fused pyridine from 2.6.14. 
 
Being inspired by this finding a list of enaminones 2.6.14 were reacted with electron-
excessive aminoheterocycles E1-E6 as a result 16 examples of different α-aryl-substituted 
fused pyridines were successfully prepared in good yields (Table 2.6.5). 
 
Table 2.6.5. List of prepared fused pyridines 2.6.15-2.6.19. 
 
 
It is important mentioning that when pyridine-substituted enaminones 2.6.14d,e were used, 
corresponding fused pyridines were successfully formed. That is, among others preparation of 
α-heteroaryl-substituted fused pyridines by proposed methodology is equally effective. All 
structures of obtained products were established by 1D NMR. For example with p-OMe 
enaminones 2.6.14b the singlet of OMe appears at 3.81-3.88 ppm in 
1
H NMR and 55.2-55.4 
ppm in 
13
C NMR (DMSO-d6). In case of 2.6.14a CF3 group was detected in 
19
F NMR spectra 
as singlet at -60.9-61.4 ppm (DMSO-d6). Furthermore, in 
13
C NMR the characteristic quartet 
for CF3 at 117.2-124.1 ppm with (
1
JC-F ~ 280 Hz) and a quartet for CCF3 at 128.7-140.2 ppm 
(
2
JC-F ~ 30 Hz) were present (DMSO-d6). Another specific peak was for 2-F-aryl-substituted 
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product (Table 2.6.5, compounds 2.6.15c, 2.6.16b) in 
19
F NMR spectra a singlet in -115.9-
116.6 ppm emerged (DMSO-d6). Besides, a doublet located at 113.2-113.5 ppm in 
13
C NMR 
that belongs to the carbon atom bounded with fluorine atoms with a coupling constant of 
1
JC-F 
~ 240 Hz was typical for such compounds (DMSO-d6). The structure of 2.6.18b was 
independently confirmed by X-ray crystal structure analysis once more indicating proposed 
regioselectivity (Table 2.6.6). 
 
Table 2.6.6. X-ray crystal structures of compound 2.6.18b. 
Compound Crystal Structure 
2.6.18b 
 
 
 
Here again we could see a planar structure of thiazolo[4,5-b]pyridine core like was in earlier 
examples, in addition interestingly the aryl group is in the same plane with thiazolo[4,5-
b]pyridine. 
 
 
Scheme 2.6.9. Putative mechanism of the the annulation reactions starting from 2.6.14. 
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Considering the possible reaction mechanism, we suppose that the reaction starts with 
formation of iminium salt of corresponding enamine (intermediate A) by the reaction of 
enones with TMSCl. Further nucleophilic attack of electron-excessive aminoheterocycles to 
iminium fragment gives rise to second intermediate B. Following elimination of Me2NSiMe3 
and intramolecular attack of amino group to the carbonyl atom forms intermediate D which 
via elimination of Me3SiOH delivers desired product (Scheme 2.6.8). It should be mentioned 
that other regioisomer of initial N-nucleophilic attack of electron-excessive aminoheterocycle 
was not detected. 
 
2.6.8. Conclusion 
 
In summary the reaction of non-activated 2,3-unsubstituted chromones 2.6.2 and enaminones 
2.6.1, 2.6.14 with different electron-excessive aminoheterocycles was investigated. A wide 
range of different α-aryl and heteroaryl fused pyridines were successfully synthesised. The 
scope and limitations of method was illustrated as well. The proposed methodology is 
relevant since most of prepared α-aryl and heteroaryl fused pyridines are not available by 
other methods. Furthermore, the investigation of biological activity of these compounds is in 
progress. 
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3. [5+1] Synthesis of 4-quinolones 
3.1. General methods for the 4-quinolones synthesis  
 
The next topic of investigation was preparation of 4-quinolines, which are an important class 
of N-containing heterocycles.
112
 Functionalized 4-quinolones are attractive compounds 
playing an increasingly important role in drug discovery. This framework is structural unit 
found in a vast array of natural products
113
 and synthetic materials.
114
 Over the years, 4-
quinolone derivatives have attracted considerable attention from medicinal chemists due to 
their diverse biological activity. Starting with a serendipitous discovery about 50 years ago,
115
 
the story of 4-quinolone antibacterial agents started with introduction of nalidixic acid in 1963 
(Figure 3.1.1).
116
 
 
 
Figure 3.1.1. Biologicaly relevant 4-quinolone derivatives. 
 
Although the clinical use of nalidixic acid is limited only to urinary tract infections, the 
interest was stimulated by its gram-negative activity, uniqueness and relative simplicity of its 
chemical structure. Next big evaluation in this area was the discovery of Koga et al. showing 
that the 6-fluoroquinolones are not only an order of magnitude more active than the previous 
agents against gram-negative bacteria, but also have exceptionally broad-spectrum of 
biological action.
117
 Norfloxacin is the first member of modern fluoroquinolones (Figure 
3.1.1). Since then a number of other fluoroquinolones were introduced on the market, e.g. 
ciprofloxacin as an antibiotic against gram-positive bacteria.
118
 Fleroxacin has similar 
properties but in comparison to other fluoroquinolones has excellent bioavailability, high 
concentrations in plasma and other body fluids and long half-life (10-12 h) in addition to time 
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heavy side effects.
119
 Another example is moxifloxacin which is new antibacterial agent 
against respiratory diseases (Figure 3.1.1).
120
 
The major demand of these compounds has motivated many chemists to develop different 
pathways of the synthesis of 4-quinolone core. Numerous synthetic routes to 4-quinolones 
have been reported involving Camps cyclization (Scheme 3.1.1 A),
121
 reaction of isatoic 
anhydrides (Scheme 3.1.1 B),
122
 cyclization of N-substituted phenacyl or acetonyl 
anthranilates in polyphosphoric acid,
123
 cyclization of anthranilic acid derived ynone 
intermediates (Scheme 3.1.1 C),
124
 intramolecular coupling of aryl halides with β-enaminones 
(Scheme 3.1.1 D),
125
 acid-catalyzed cyclization (Scheme 3.1.1 E),
126
 cycloacylation of aniline 
derivatives (Scheme 3.1.1 F),
127
 palladium-catalyzed carbonylative Sonogashira coupling of 
2-iodoaniline with arylacetylene (Scheme 3.1.1 G),
128
 and metal free intramolecular 
amination (Scheme 3.1.1 H).
129
 
 
 
Scheme 3.1.1. Some synthetic routes for 4-quinolone ring construction. 
 
Meanwhile, Pd-mediated reactions nowadays have occupied a privilege position in modern 
organic and heterocyclic chemistry, since Pd-catalysed carbo- and heterocyclizations open 
new horizons for assembling of new carbo- and heterocyclic frameworks. For instance Pd-
catalyzed annulation of internal alkynes by aryl/vinylic halides bearing an oxygen or nitrogen 
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nucleophile is a versatile way to generate a wide variety of heterocycles.
130
 Thus, in 1995 
Larock and co-workers reported the reaction of aryl iodides with internal alkynes using 
Pd(OAc)2 as a catalyst in the presence of base in DMF leading to N-/O-heterocycles 3.1.1 in 
good yields (Scheme 3.1.2).
131
 Later from the same group was presented the synthesis of 3,4-
disubstituted isocoumarins 3.1.2 in good yields by treating the halogen-containing aromatic 
esters with internal alkynes in the presence of a Pd-catalyst (Scheme 3.1.2).
132
 
 
XH
I
R3
R2
X
R2
R3
+
 Pd(OAc)2, DMF, 
Bu4NCl or LiCl
base, 80-140 oC, 
1-5h , 57-90%
R1 = H, Ac; R2 = Me, t-Bu, Et, 
Ph; R3 = Ph, Me, COH, 
CO2Et, Si(i-Pr)3, SiMe3; 
X = O, NH2, t-BuOH, CO2Me; 
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Me2COH, Ph, Me3Si, i-Pr3Si; 
Y = I, Br.
+
3.1.1
3.1.2  
Scheme 3.1.2. Construction of benzofuran, indole and isocoumarine rings. 
 
Recently, Wu et al. have demonstrated that 2-(2-phenylethynyl)benzonitrile can be cyclised 
by aryl iodides in the presence of Pd(PPh3)4 and NaOMe, in MeOH to give 3-
diarylmethylideneisoindoles as sole product in moderate yields (Scheme 3.1.3).
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 When 2-(1-
hexynyl)benzonitrile was employed, isoindole derivatives were obtained together with 
isoquinolines. 
 
CN
R
N
Ar R
OMe
N
Ar
R
OMe
+
cat. Pd(PPh3)4/ MeOH
NaOMe, reflux, 24-28h,  12-56%
R = Ph, n-Bu; 
Ar = Ph, p-Tol, p-OMePh.
+ArI
 
Scheme 3.1.3. Synthesis of isoindole and isoquinoline derivatives from o-alkynyl benzonitriles 
and aryl iodides 
 
Another interesting structure, that is mostly used in the synthesis of different 4-quinoline 
derivatives, is N-arylenaminone 3.1.3 that was considered as a starting compound in the study 
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of Cacchi et al.. They have presented a CuI mediated construction of 4-quinolone moiety by 
intramolecular cyclization (Scheme 3.1.4).
134
 In other studies this structure was isolated as an 
intermediate in multistep construction of 4-quinolone structure starting from 4-bromo-2-
fluoroacetophenone
135
 or o-haloaryl acetylenic ketones.
136
 The latter was successfully 
converted to quinolone by catalytic
136
 and catalyst-free base mediated cyclization reaction 
(Scheme 3.1.4).
135,137
 
 
O HN
R2
R1
X
R3
R1
N
O
R3
R2
R4
R4
X=F, Cl, Br
R1 = Alk, halogen
R2 = Alkyl, Aryl, Heteroaryl, CF3
R3 = Alkyl, Aryl, Heteroaryl
R4 = H, CO2R
3.1.3  
Scheme 3.1.4. Synthesis of 4-quinolone derivatives starting from N-arylenaminone 3.1.3. 
 
Although all presented methods are interesting and offer variety routes for 4-quinolone 
synthesis, however the increasing demand of quinolone derivatives, due to their high 
importance in medical chemistry and drug discovery, motivated us to develop new methods 
for production of diverse 4-quinolones. 
 
3.2. Efficient [5+1] synthesis of 4-quinolones by domino amination and 
conjugate addition reactions of 1-(2-fluorophenyl)prop-2-yn-1-ones with 
amines 
 
3.2.1. Introduction 
 
Although the presented in Scheme 3.1.1, 3.1.4 methods are effective and give relatively high 
yields of 4-quinolones, most of them are incompatible with sensitive functionalities,
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includes numerous synthetic steps or need harsh reaction conditions,
121-125,127,139
 besides some 
starting materials are not readily available.
126,139
 On this basis we assume that the 
investigation of new and more general strategies for synthesis of 4-quinolones are essential. 
Based on retro-synthetic analysis (Scheme 3.2.1) and previous expertise in the chemistry of 
Pd-catalyzed cyclizations which were demonstrated above (Scheme 3.1.2, 3.1.3), we have 
supposed that a possible synthetic pathway towards heteroannulated 4-quinolones I can be the 
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catalyst-free reaction of phenylpropyn-1-ones II bearing a good leaving group in α-position to 
the carbonyl function with different amines. It should be noticed that previously by Xu et al. 
was presented a Pd-catalyzed cyclization of o-haloaryl acetylenic ketones with amines.
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Scheme 3.2.1. Retrosynthetic analysis of 4-quinolones. 
 
3.2.2. Synthesis of starting materials 
 
To start our investigation towards synthesis of 4-quinolone derivatives we needed to choose 
appropriate starting materials. The retrosynthetic analysis shows that initial 1-phenylalk-2-yn-
1-ones must bear a good leaving group. It is known from the literature that fluoro or nitro 
groups in the ortho-positions to an EWG substituent can be easily substituted by 
nucleophiles.
141
 Therefore a list of 1-(2-fluorophenyl)alk-2-yn-1-one derivatives 3.2.2 having 
good leaving groups in appropriate position were synthesis. They are easily available from 
commercially available fluorinated (or nitrated) benzoyl chlorides 3.2.1 and alkynes by 
Sonogashira cross-coupling reaction (Scheme 3.2.2).
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O
Cl
LG
R1
O
LG
R1
R2
R2
H
+
PdCl2(PPh3)2 (2 mol%)
CuI (4 mol%)
TEA (1.5equiv.), THF,
 Ar, r.t., 15h
3.2.1 3.2.2
(1.3 equiv.)  
Scheme 3.2.2. Synthesis of starting1-(2-fluorophenyl)prop-2yn-1-one 3.2.2 by Sonogashira 
reaction. 
 
Table 3.2.1. List of synthesised ynones 3.2.2. 
3.2.2 LG R1 R2 Yield (%) 
a F H Ph 88 
b F H 4-t-BuC6H4 78 
c F 5-F 4-t-BuC6H4 84 
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d F 5-F 4-MeC6H4 81 
e F 4-F 4-MeC6H4 97 
f F 6-F Ph 70 
g F 6-F 4-MeC6H4 73 
h F 6-F 4-t-BuC6H4 80 
i F 6-F (CH2)4Me 70 
j F 3,4,5,6-F 4-t-BuC6H4 75 
k NO2 H Ph 73 
 
In standard conditions for Sonogashira reaction this transformation runs smoothly leading to 
desired products with good to excellent yields. According to this methodology a number of 
mono- and multifluorine-substituted starting 1-phenylalk-2-yn-1-ones were synthesised 
(Table 3.2.1). Moreover, one example of ortho-nitro ynone 3.2.2k was prepared as well, 
which was used later on (see Chapter 3.2.3) to show the possibility of usage other leaving 
groups (LG) in this reaction (Table 3.2.1). All compounds were purified by column 
chromatography (Heptane : Ethyl acetate 30:1). The structure of all starting materials were 
corroborated by 
1
H, 
19
F and 
13
C NMR spectroscopy, moreover the structure of 3.2.2e was 
indepently characterised by X-ray crystal structure analysis (Table 3.2.2). 
 
Table 3.2.2. X-ray crystal structures of compound 3.2.2e. 
Compound Crystal Structure 
3.2.2e 
 
 
 
3.2.3. Results and discussions 
 
We started our investigation using as model reactants 3.2.2a and (2-phenylethyl)amine. In 
order to find optimal conditions for cyclization reaction a number of different reaction 
conditions were tested (Table 3.2.3). Initially we used 2 equivalents of amine in DMF as a 
solvent and K2CO3 as base. Unfortunately, in these conditions we could isolate the desired 
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product only in 18% yield. During further investigations turned out, that in this reaction 
combination of solvent, base and temperature is extremely important. Thus, we found that the 
yields can be increased by changing the solvent to DMA and increasing the temperature up to 
160 
o
C (35%). Furthermore, when the base was changed from K2CO3 to Li2CO3, the yields 
were dramatically increased (up to 89%, Entry 7), hence these conditions was taken as the 
optimal. Noteworthy, that when amount of amine was reduced to 1.2 equivalents, the yield 
was decreased to 71% (see Chapter 3.2.5). 
 
Table 3.2.3. Optimization of the synthesis of 4-quinolone 3.2.3a. 
 Amine Solvent Base Temp (
o
C) Time (h) Yield (%) of 3.2.3a 
1 2 equiv DMF K2CO3 140 10 18 
2 2 equiv DMF Li2CO3 140 10 25 
3 2 equiv DMA K2CO3 160 12 35 
4 2 equiv DMA Li2CO3 160 12 58 
5 2 equiv DMA Li2CO3 160 18 73 
6 2 equiv DMA K2CO3 160 24 51 
7 2 equiv DMA Li2CO3 160 24 89 
8 1.2 equiv DMA Li2CO3 160 24 75 
 
Having an optimized reaction conditions in hand, compounds 3.2.2a and 3.2.2b were reacted 
with the list of amines. Fortunately, a number of corresponding 4-quinolones 3.2.3a-h were 
prepared with good to excellent yields (Scheme 3.2.3, Table 3.2.4). Examining the scope of 
the reaction we observed, that aliphatic amines reacted much better than anilines, probably 
because of decreased nucleophilicity of anilines. 
 
 
Scheme 3.2.3. Synthesis of 4-quinolones 3.2.3a-f from appropriate 2-fluorophenylpropyn-1-
ones 3.2.2a,b and amines. 
 
On the next stage of our work the reactivity of nitro-substituted ynone 3.2.2k was tested and 
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compared to those for fluorine-substituted starting ynones. Since the nitro group is a good 
leaving group, we assumed that the reaction can be successful even under milder conditions 
(Scheme 3.2-4). When the reaction was performed in DMF using K2CO3 as a base at 130 
o
C, 
corresponding products were obtained in good yields. Interestingly any change of the reaction 
conditions did not increased the yields, moreover the use of other nitro-substituted starting 
ynones did not change the yields either (Table 3.2.4). 
 
 
Scheme 3.2.4. Synthesis of 4-quinolones 3.2.3a-f from 3.2.2k. 
 
Table 3.2.4. List of 4-quinolones 3.2.3. 
3.2.3 R1 R2 Yields (%) 3.2.2a,b Yields (%) 3.2.2k 
a Ph (CH2)2Ph 89 79 
b Ph (CH2)3Ph 86 80 
c Ph CH2-4-MeOC6H4 87 77 
d Ph (CH2)4Me 84 79 
e Ph (CH2)5Me 89 78 
f Ph 3,5-(MeO)2C6H3 74 70 
g 4-t-BuC6H4 4-ClC6H4 75 - 
h 4-t-BuC6H4 4-BrC6H4 73 - 
 
When ynones with two fluorine atoms in the core were examined, we observed an interesting 
phenomenon (Scheme 3.2.5). Namely, when the second fluorine atom was at ortho or para 
position to the carbonyl group (3.2.2e, g, h, i), following the cyclzation reaction the second 
fluorine atom was also substituted by amine, leading to corresponding amino-substituted 
quinolones 3.2.5, 3.2.6. However, in case of second fluorine atom located at meta-position to 
the carbonyl group, further substitution did not took place, that is simple 4-quinolones 3.2.4 
were formed with a fluorine atom in the molecule (Table 3.2.5 for the reaction with aliphatic 
amines). 
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Scheme 3.2-5. Synthesis of 4-quinolones 3.2.4a-c, 3.2.5, 3.2.6a-g. 
 
Table 3.2.5. List of amino-substituted and non-substituted 4-quinlones from aliphatic amines.  
 R1 R2 Yileds(%) 
3.2.4a 4-Tol (CH2)5Me 85 
3.2.4b 4-Tol (CH2)2Ph 88 
3.2.4c 4-Tol (CH2)3Ph 83 
3.2.5 4-Tol (R)-CH(Ph)Me 33
a
 
3.2.6a 4-t-BuC6H4 (CH2)3Ph 82 
3.2.6b 4-t-BuC6H4 CH2-4-MeOC6H4 85 
3.2.6c 4-t-BuC6H4 (CH2)2Ph 93 
3.2.6d 4-Tol (CH2)2-3,4-(MeO)2C6H3 85 
3.2.6e 4-Tol (R)-CH(Ph)Me 40
a
 
3.2.6f (CH2)4Me (CH2)2Ph 82 
3.2.6g (CH2)4Me (CH2)3Ph 75 
(a) Reaction took 60h. 
 
Interestingly when ynones with two fluorine atoms in the molecule 3.2.2 were reacted with 
anilines, the only product was simple quinolone with a fluorine atom in the molecule, the 
further nucleophilic substitution of second fluorine did not took place at all (Scheme 3.2.6, 
Table 3.2.6). 
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Scheme 3.2.6. Synthesis of 4-quinolones 3.2.7a-i from anilines. 
 
Table 3.2.6. List of 4-quinlones 3.2.7 obtained from anilines. 
3.2.7 3.2.2 F R1 R2 Yileds (%) 
a c 6-F 4-t-BuC6H4 3,5-(OMe)2C6H3 77 
b c 6-F 4-t-BuC6H4 4-MeOC6H4 78 
c e 7-F 4-Tol 4-t-BuC6H4 75 
d e 7-F 4-Tol 3,5-Me2C6H3 79 
e f 5-F Ph 3,5-Me2C6H3 77 
f g 5-F 4-Tol 3,5-Me2C6H3 71 
g g 5-F 4-Tol 4-EtC6H3 70 
h h 5-F 4-t-BuC6H4 3,5-(OMe)2C6H3 73 
i i 5-F (CH2)4Me 4-MeOC6H4 72 
 
3.2.4. Unsuccessful results 
 
It should be admitted that the reaction of ynones 3.2.2 with electron-deficient heteroaromatic 
amines, such as benzo[d]thiazol-2-amine, pyrimidin-2-amine, or pyridin-2-amine failed, 
moreover no conversion of starting materials took place. Additionally, the reaction of 3.2.2j 
with all types of amines failed, though a number of reaction conditions were tested. 
 
3.2.5. Mechanistic explanation 
 
In order to understand the mechanism of the reaction we did some test reactions aiming to 
isolate some intermediates. For this purpose the reaction of 3.2.2c with phenethylamine in 
DMF at 100 
o
C was performed for 10h. Unexpectedly, a spot different from our starting 
material and product was detected in TLC. Fortunately, we were able to isolated and 
determine the structure of product, that was a product of Michael type addition of amine to 
triple bond of alkyne 3.2.8 (Scheme 3.2.7). When the reaction was performed with 2 
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equivalents of Li2CO3, the similar product was obtained. Moreover, we found that it is 
possible to transfer the intermediate to corresponding quinolone 3.2.4d in the standard 
conditions using 1 equivalent of appropriate amine. However, it should be mentioned that in a 
case of bulky amines the further cyclization was not possible, even under harsh conditions, 
like treatment with potassium carbonate in N-methyl-2-pyrrolidone (NMP) at 190 °C or in 
diphenyl ether at 220 °C. 
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Me
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+
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DMF, Ar, 100 oC, 15h
O
F
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Me
Me
R1
O
N
F
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Me
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R R
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For b
adamantyl 
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O
N
adamantyl Me
Me
X
3.2.2 3.2.8
3.2.4d
3.2.9
Me
Me
Me
Me
Me
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Scheme 3.2.7. Synthesis of the intermediates 3.2.8 and conversion to 4-quinolones. 
 
Nevertheless, when intermediates 3.2.8 was reacted with 2 equivalents of other amines, 
corresponding 4-quinolones 3.2.10 were obtained (Scheme 3.2.8, Table 3.2.7), although the 
yields were lower in comparison to one-pot synthesis of corresponding 4-quinolones. 
 
 
Scheme 3.2.8. Conversion of intermediates 3.2.8 to the 4-quinolones 3.2.10. 
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Table 3.2.7. List of 4- quinlones 3.2.10 synthesised from intermediates 3.2.8. 
3.2.10 R R1 R2 Yileds (%) 
a 6-F (CH2)2Ph 3,5-(OMe)2C6H3 60 
b 6-F (CH2)2Ph 4-MeOC6H4 64 
c H adamantyl 4-ClC6H4 70 
d H adamantyl 4-BrC6H4 64 
 
With these positive results in hand we assumed that one-pot synthesis of 4-quinolones starts 
with formation of intermediates 3.2.8a,b by initial addition of appropriate amine to the 
alkynes 3.2.2 (Scheme 3.2.9). In the next step Li
+
 coordinates to the F forming intermediate 
A. The latter undergoes an aromatic nucleophilic substitution with second molecule of amine 
via intermediate B. The elimination of fluorine anion in form of salt LiF delivers the 
intermediate C. Finally an intramolecular Michael addition via intermediate D leads to 
corresponding 4-quinolones 3.2.3. In this step the reaction can go further, since the second 
fluorine atom may be substituted. 
 
 
Scheme 3.2.9. Putative mechanism for 4-quinolone 3.2.3 ring formation. 
 
Furthermore, in case of ynones, with two fluorine atoms in the molecule 3.2.2, we could 
obtain another intermediate. Namely, the reaction of 3.2.2e,g with 1 equivalent of a bulky 
amine, like (R)-(+)-(1-phenethyl)amine (the enantiomorically pure amine was chosen in order 
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to avoid diasteremeric pairs) leads to compound 3.2.11 (Scheme 3.2.10). These intermediates 
can also be easily transformed to corresponding quinolones 3.2.5, 3.2.6e using standard 
conditions. 
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NH2
F
O HN
Me
Ph
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F
HN
Me
Ph
3.2.5
3.2.6e
3.2.2e,g 3.2.11a,b
Li2CO3 (2 equiv.)
DMA, Ar, 160 oC,
10-15h
DMA, Ar, 160 oC,
10-15h
Li2CO3 (2 equiv.)
 
Scheme 3.2.10. Formation of the intermediates C (Scheme 3.2.9) and its conversion to the 4-
quinolones 3.2.5, 3.2.6e. 
 
The structures of all intermediates and final products were determinate by 
1
H, 
19
F and 
13
C 
NMR as well as with mass spectrometry (see Chapter 3.2.6). Moreover, in some cases the 
structures were also proved by X-Ray crystal structure analysis. 
 
3.2.6. Structure identification 
 
The structures of new synthesised compounds were corroborated by NMR methods, mass and 
IR spectroscopy. In 
13
C NMR spectras of starting materials the carbon atoms of triple bond 
appears in 88.1-89.2 and 93.2-94.2 ppm, additionally the peak of carbon from carbonyl group 
shows up at 171.1-173.5 ppm (CDCl3). In quinolones the β-CH was seen in 
1
H NMR at 6.10-
6.49 ppm, besides in 
13
C NMR peaks of triple bond were gone, instead the β-C of quinolone 
ring appears at 111.2-114.7 ppm (CDCl3). In 
19
F NMR spectra we could see the peaks of 
fluorine in mono- and 2,6-disubstituted compounds (3.2.2a,b and 3.2.2f-i respectively) at -
111.0 ppm (CDCl3). For 2,5- and 2,4-difluorine-substituted compounds (3.2.2c,d and 3.2.2e 
respectively) was seen typical doublets at -117.0-117.0 ppm and -106.0-99.7 ppm respectively 
(CDCl3). Moreover, the typical doublets were also seen in 
13
C NMR at 160.0-162.0 ppm with 
a coupling constant 248-258 Hz (CDCl3). Additionally, in case of products, where the second 
fluorine atom was substituted (3.2.5, 3.2.6e), the double peaks of corresponding amines were 
seen in addition to the broad singlet of NH at 10.4-10.76 ppm. In IR spectra peaks of C=O 
 79 
 
and NH were detected at 1600-1640 cm
-1
 and 3310-3286 cm
-1
 respectively. 
Independently a structure from each type of products was identified by X-ray crystal structure 
analysis. In the first three structures (Table 3.2.8) were seen the planar structure of quinolone 
core. In 3.2.6b a hydrogen bond was seen between NH and carbonyl group. In open chain 
intermediates 3.2.11 and 3.2.8 O=C-C=C-NH fragment was almost planner due to hydrogen 
bonds, in addition all substituents were maximum away from each other (Table 3.2.8). 
 
Table 3.2.8. Crystal structures of 3.2.3f, 3.2.6b, e, 3.2.7h, 3.2.8b. 
Compound Crystal Structure 
3.2.3f 
 
 
3.2.6b 
 
 
3.2.7h 
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3.2.8b 
 
 
3.2.11b 
 
 
 
3.2.7. Further investigations 
 
According to results obtained in the chemistry of ynones with two fluorine atoms, we were 
interested in preparation of some mixed substituted quinolones. As it was shown before, the 
second fluorine atom was not possible to substitute using anilines, consequently we tested the 
reaction of compounds 3.2.7d,f,g with aliphatic amines using the standard reaction conditions 
developed by us. Gratifyingly, we succeed to prepare three examples of quinolones 3.2.12a-c 
bearing an amino-substituent at fused benzene ring (Scheme 3.2.11, Table 3.2.9). 
 
Li2CO3 (2 equiv.)
DMA, Ar, 160 oC,
15-20h
(2 equiv.)
O
N
R2
R1
R R3 NH2+
O
N
R2
R1
HN
R3
3.2.7d,f,g 3.2.12a-c  
Scheme 3.2.11. Synthesis of 4-quinolones 3.2.12. 
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Table 3.2.9. List of synthesised 4-quinolones 3.2.12. 
3.2.12 R R1 R2 R3 Yields (%) 
a 5-F 4-Tol 3,5-Me2C6H3 (CH2)2Ph 97 
b 5-F 4-Tol 4-EtC6H3 (CH2)2Ph 84 
c 7-F 4-Tol 3,5-Me2C6H3 (CH2)5Me 79 
 
Unexpectedly, during careful examination of the reaction between ynones with two fluorine 
atoms and electron-rich anilines, we could detect appropriate aminated 4-quinolones, although 
the yields never overcome 3-5%. In this context the reactions of 3.2.2g,i as well as 3.2.7h,i 
with anilines were performed under harsher conditions, that is in N-methyl-2-pyrrolidone at 
185 
o
C for 30h. Luckily, these reactions gave desired aniline disubstituted quinolones 3.2.13 
in good yields (Scheme 3.2.12, Table 3.2.10). 
 
 
Scheme 3.2.12. Synthesis of amino-substituted quinolones 3.2.13. 
 
Table 3.2.10. List of synthesised dianiline-substituted quinolones 3.2.13. 
3.2.13 R1 R2 Yields (%) 
a 4-Tol 4-EtC6H4 97 
b (CH2)5Me 4-MeOC6H4 84 
 
Furthermore, we were interested in testing of our methodology towards more complex 
structures. Therefore the reaction of starting ynones 3.2.2 with diamines was carried out under 
standard reaction condition. The reaction was successful for both aliphatic and aromatic 
amines (Scheme 3.2.13). These results show that proposed methodology can be useful, for 
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instance, for construction of quinolin-4-one-containing dendrimers. 
 
 
Scheme 3.2.13. Synthesis of N,N'-linked 4-quinolones 3.2.14. 
 
3.2.8. Conclusion 
 
As a conclusion a very easy and practical route for synthesis of different substituted 4-
quinolones was developed starting from 1-(2-fluorophenyl)prop-2-yn-1-ones 3.2.2 and 
aliphatic or aromatic amines. It was possible to isolate some intermediates, which allowed us 
to explain the mechanism of the reaction in detail. The scope and limitations of the reaction 
was well studied. Proposed methodology gives a possibility to synthesize more complex 4-
quinolone derivatives. 
 
3.3. Amino group induced recyclization/ring formation of (ortho-fluoro)-3-
bezoylchromones: A new [5+1] domino strategy for syntheszing of 4-
quinolones 
 
3.3.1. Introduction 
 
Analysing the structures of pharmaceuticals based on 4-quinolone derivatives (see Figure 
3.1.1) one can see that in most of the structures a carboxylic moiety is presented in position 3 
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of 4-quinolone core. In course of our study on development of new and efficient methods for 
synthesis of 4-quinolones with potential bioactivity, on the next stage of our work we 
examined the possibilities for synthesis of 3-carbonyl-substituted 4-quinolones. 
As was mentioned before, a bunch of methods are known in the literature for construction of 
4-quinolones (Scheme 3.1.1). Among the methods discussed above perhaps the most versatile 
are methods based on [5+1] cyclizations due to the broad substrate scope allowing the 
synthesis of target systems with different substituents. In this context except the methodology 
described by us, worth mentioning the methodology based on the reaction of N-
arylenaminones and nucleophiles (see Scheme 3.1.4). Furthermore, in the work of Bouzard et 
al. was presented another three step synthesis of 3-CO2Et-substituted 4-quinolones, starting 
from 2-chlorobenzoyl chlorides which were first transformed to enol ether fragments that 
were treated with an amine to prepare corresponding 4-quinolone 3.3.1 (Scheme 3.3.1).
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Scheme 3.3.1. Synthesis of 3-CO2E-substituted 4-quinolone from ortho-haloaroyl halides. 
 
Additionally, a similar pathway was presented by Mitsos et al. The reaction of ester of N-
hydroxysuccinimide and anthranilic acid 3.3.2 with β-keto esters gives an intermediate which 
spontaneously cyclise to corresponding 4-quinolone 3.3.3 (Scheme 3.3.2).
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3-5 days
Scheme 3.3.2. Synthesis of 3-CO2Et-substituted 4-quinolone starting from 3.3.2. 
 
According to the literature data presented above and our previous experience we proposed a 
new approach for construction of 4-quinolones bearing a carbonyl substituent at position 3 
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based on the one step domino reaction (Scheme 3.3.3). The retrosynthetic analysis in principle 
is very much similar to what has been shown in Scheme 3.2.1. The main difference is that in 
this case instead of hydroamination of alkyne (Scheme 3.2.1 II) we have an intramolecular 
nucleophilic substitution on conjugate push-pull system (Scheme 3.3.3 B). 
 
 
Scheme 3.3.3. Retrosynthetic analysis of 3-carbonyl-4-quinolones A. 
 
As it was presented in previous chapters chromones having an EWG (nitro group, carbonyl 
group etc.) at the position 3 are rather labile toward nucleophiles which can promote some 
pyrone ring-opening reactions. Moreover, it was proposed to consider such systems as 
masked diketones that can be used as 1,3-CCC-dielectrophiles. Accordingly, summarizing our 
results on the chemistry of chromones and 4-quinolones, we assumed that 3-benzoyl 
chromones, bearing a good leaving group in the ortho-position of benzoyl moiety, can be 
considered as useful starting materials for the synthesis of 4-quinolones bearing a carbonyl 
substituent at position 3 (Scheme 3.3.4). 
 
 
Scheme 3.3.4. 3-Benzoyl chromones as masked dielectrophiles. 
 
3.3.2. Synthesis of starting materials 
 
In previous chapter we have demonstrated that fluorine atom can be a good leaving group in 
aromatic nucleophilic substitution reaction. Therefore we synthesized a number of ortho-
halogen-substituted 3-benzoyl-4H-chromen-4-ones 3.3.4 as starting materials for synthesis of 
4-quinolones. 3-Benzoyl-4H-chromen-4-ones 3.3.4 can be prepared from 3.3.5 and 
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corresponding halogenated benzoyl chlorides 3.3.6 under reflux in DCM using pyridine as 
base.
79
 According this procedure a list of different 3-benzoyl chromones 3.3.4 were 
successfully synthesised with good to excellent yields (Scheme 3.3.5, Table 3.3.1). 
 
O
OH
N
Me
Me
+
R1
R2
Cl
O X
R3
R4
Py (3 equiv.)
Ar, DCM, 
0 oC to r.t. to reflux, 8h
O
O O
R1
R2
X
R3
R43.3.5
3.3.6
3.3.4
R5R5
(1.1 equiv.)
Scheme 3.3.5. Synthesys of ortho-halogen-substituted 3-benzoyl-4H-chromen-4-ones 3.3.4. 
 
Table 3.3.1. List of synthesised ortho-halogen benzoyl chromones 3.3.4. 
3.3.4 X R1 R2 R3 R4 R5 Yileds (%) 
a  Br H  H  H  H  H  81 
b  Cl H  H  H  H  H  80 
c  F H  H  H  H  H  78 
d  F Me  H  H  H  H  80 
e  F H  OMe  H  H  H  88 
f  F Cl  H  H  H  H  71 
g  F Cl  Me H  H  H  58 
h F H  H  F  H  H  60 
i F H H H F H 95 
j F Br H H F H 75 
k F H  H  H  H  F  66 
 
All compounds were purified by column chromatography. Structures of starting materials 
were characterised by NMR spectroscopy (
1
H, 
13
C, 
19
F, see Chapter 3.3.5). Furthermore, the 
structure of 3.3.4e was also supported by X-ray crystal structure analysis (Table 3.3.2). 
 
Table 3.3.2. X-ray crystal structures of compound 3.3.4e. 
Compound Crystal Structure 
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3.3.4e 
 
 
 
3.3.3 Results and discussions 
 
With the list of starting materials in hand we started working on study and optimisation of 
desired cyclization reaction. For this purpose a test reaction of 3.3.4b (X = Cl) and 
phenethylamine was performed in DMF at 100 
o
C using K2CO3 as a base. Fortunately, 
starting from initial test reaction desired 4-quinolone ring formation was observed, though the 
yield was only 22%. The same reaction in similar conditions with chromone 3.3.4a (X = Br) 
did not work at all. Since earlier (see Chapter 3.1) with similar transformation we had an 
excellent results using aromatic nucleophilic substitution of fluorine, next the starting 
chromone with X = F was tested. Not surprisingly, from primary test reactions the yield was 
improved to 65%. Interestingly, the use of other bases like Na2CO3, Li2CO3, Cs2CO3, NEt3 
etc. did not increase the yield over 67%. The next tool for optimization of reaction conditions 
was the manipulation of the temperature. Luckily, performing the reaction in DMF using 
K2CO3 as base at increased up to 130 
o
C temperature, we could improve the yield to 82%. 
Additionally, the change of base and/or solvent (DMA, NMP) did not raise the yield. Having 
optimal reaction conditions in hand the scope of the reaction was examined with regard to 
different chromones 3.3.4c-k and aliphatic amines (Scheme 3.3.6, Table 3.3.3). 
Interestingly, we found that in most of the cases the reaction did not stop on quinolone ring 
formation 3.3.7, instead of this the formed product reacts with second molecule of amine 
leading to formation of the appropriate Schiff base 3.3.8. Notably, the only case when we 
could avoid the formation of Schiff base was the use of bulky t-butylamine 3.3.7a. In all other 
cases the formation of simple product 3.3.7 was not detected, even though the reaction was 
carried out with 1 equivalent of amine. Moreover, in case of chromone 3.3.4h-j with second 
fluorine atom located at meta or para position to carbonyl group, the substitution of second 
fluorine by appropriate amine in standard reaction conditions was not detected (Table 3.3.3). 
Nevertheless, in case of chromone 3.3.4k with second fluorine located in the ortho-position of 
carbonyl group, expectedly substitution of second fluorine with amine accrued (see also 
previous chapter) leading to single product 3.3.9 detected in 41% yield (Scheme 3.3.6). Thus 
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a number of aliphatic amines including cyclic amines can be successfully used in the reaction 
(Table 3.3.3). In addition, the purification of final products was quite easy, in most of the 
cases a simple recrystallization or washing was enough to get a clean product. 
 
 
Scheme 3.3.6. Synthesis of 3-ortho-hydroxybenzoyl-substituted 4-quinolones 3.3.7, 3.3.8, 
3.3.9. 
 
Table 3.3.3. List of synthesised 3-ortho-hydroxybenzoyl-substituted 4-quinolones 3.3.7, 3.3.8. 
 R1 R2 R3 3.3.7 (%) 3.3.8 (%) 
a H H t-Bu 55 - 
b H H Cyclohexyl - 46 
c H H Cyclopropyl - 48 
d H H (CH2)2C6H5 - 74 
e H H n-Hexyl - 65 
f 4-OMe H Cyclopentyl - 55 
g 5-Cl H (CH2)3C6H5 - 53 
h 4-Me-5-Cl H n-Hexyl - 70 
i H 6'-F (CH2)2C6H5 - 78 
j 5-Br 6'-F (CH2)2C6H5 - 40 
 
An interesting result was observed when anilines were used instead of aliphatic amines. 
Namely in the same reaction conditions depending on substituents of anilines two different 
products were observed that were condensed chromone derivatives 3.3.10 and small amount 
of quinoline 3.3.11 (Scheme 3.3.7, Table 3.3.4). Interestingly, so far no single product of 
quinolone ring formation was observed, although several anilines were examined. Structure of 
prepared products was determinate by 1D and 2D NMR. The structure of 3.3.11 was also 
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possible to characterise by X-ray crystal structure analysis (see Chapter 3.3.5). 
 
O
O O F
N
HO
R1
+
NH2
R3
K2CO3 (2 equiv.)
DMF, Ar, 130 oC
OR
R2
3.3.4
3.3.10
3.3.11
O
O
O
HN
R3
R2
R1
OMe
MeO
(2 equiv.)
O
OH
R3
5-10h
 
Scheme 3.3.7. Synthesis of 3.3.10, 3.3.11 using anilines. 
 
Table 3.3.4. List of synthesised 4-quinolones 3.3.10 and quinolines 3.3.11. 
 R1 R2 R3 Yields (3.3.10%) Yields (3.3.11%) 
a H H 4-F 84 - 
b H H 3-CF3 74 - 
c 5-Cl H 3-CF3 50 - 
d 4-Me-5-Cl H 3-CF3 54 - 
e H 6-F 3,5-Cl2 71 - 
f H H 3,4,5-(OMe)3 70 - 
g 5-Me H OMe 60 10 
h 5-Me H H 55 8 
 
To date the work on exploration of list of anilines is in progress. Besides, in order to clarify 
how the electronic effects of substituents in amines can influence on reaction pathway, we are 
planning to use some heterocyclic amines as well (see also Chapter 3.3.4). 
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3.3.4. Mechanistic explanation 
 
Before the prediction of anything putative concerning mechanism of the reaction we tried to 
detect some possible intermediates. For this purpose the reaction of chromone 3.3.4c with a 
secondary aliphatic amine was performed using standard reaction conditions. Interestingly, 
corresponding amino-substituted chromone 3.3.12 was isolated in almost quantitative yield 
(Scheme 3.3.8). That means that the reaction probably starts with aromatic nucleophilic 
substitution of fluorine, the usage of secondary amine locks the domino reaction in the first 
step. 
 
O
O O F
Me
H
N+
K2CO3 (2 equiv.)
Ar, DMF, 130 oC, 10 h
O
O O N
Me
3.3.4c 3.3.12, (91%)(2 equiv.)  
Scheme 3.3.7. Synthesis of possible intermediate 3.3.12. 
 
Having these results in hand we assume that the reaction of aliphatic amines with 
corresponding chromone starts with aromatic nucleophilic substitution of fluorine atom 
leading to formation of intermediate A. The following intramolecular attacks of amino group 
to 2
nd
 position of chromone moiety forms intermediate B. Finally the recyclization of pyrone 
ring delivers desired 4-quinolones 3.3.7 (Scheme 3.3.9). In most of the cases this is not the 
final step, the reaction runs further with second molecule of amine leading to the formation of 
corresponding Schiff bases 3.3.8. 
 
Scheme 3.3.9. Putative mechanism of 4-quinolone 3.3.7, 3.3.8 formation. 
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The formation of unexpected condensed chromone derivative 3.3.10 can be explained by 
admitting an unusual behavior of anilines. While the reaction of chromone 3.3.4 with aliphatic 
amines starts with aromatic nucleophilic substitution of fluorine, in case of anilines the 
reaction most probably initiates by water that can be presented in the base (K2CO3) in trace 
amounts. We assume that in this case the reaction starts with nucleophilic attack of water onto 
the position 2 of pyrone fragment, which gives rise to the intermediate B via intermediate A. 
Fortunately, we could isolate and characterize intermediate B (compound 3.3.13), including 
by X-ray analysis. Intermediate B in basic media can be presented in two tautomeric forms 
(intermediates B and C). Hence, in this stage corresponding aniline can attack the carbonyl 
group of intermediates C leading to the formation of Schiff base (intermediates D) through 
release of water that can initiate another cycle. Finally intermediate D in basic conditions can 
be transformed to appropriate hemiaminals 3.3.10, which most probably are more stable than 
corresponding hemiacetals (intermediates B). 
 
O
O O F
O
O
O
OH
O
O O F
HOH
O
O O F
OH2
3.3.4
A
NH2-Ar
O
O
O
HN
Ar
3.3.10
O
O
OH
O
O
O
OH
N
Ar
CD
- HOH
B (3.3.13)
Scheme 3.3.10. Putative formation of compound 3.3.10. 
 
The formation of unusual quinoline derivative 3.3.11 can be explained following the same 
considerations. Thus, the intermediate C (formed by nucleophilic attack of water to pyrone 
ring of 3.3.4) can be attacked by enamine-like carbon of electron-excessive aniline forming 
intermediate D. This can be followed by intramolecular nucleophilic attack of amino group to 
the 2
nd
 position of pyrone ring that will cause a pyrone ring opening via intermediate E. 
Finally, the 1,4-dihydroquinoline intermediate (F) can form corresponding quinoline 
derivative 3.3.11 through release of water that can initiate another cycle (Scheme 3.3.11). 
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3.3.4
O
O O NH2
D
E
F
3.3.11
O
O
O OH
+
O
O O F
HOH
OH
O
O
OH
HO
NH2
EDG
EDG
O
O
N
H2
OH
HO
EDG
N
OH
O
OH
H
HO
EDG
N
O
EDG
HO
OH
- HOH
B (3.3.13) C
Scheme 3.3.11. Putative mechanism of formation of quinoline derivative 3.3.11. 
 
3.3.5. Structure identification 
 
The structures of new synthesised compounds were corroborated by NMR, mass and IR 
spectroscopy. In all ortho-fluorine-substituted and 2,6-disubstituted 3-benzoyl-4H-chromen-
4-ones (3.3.4c-g and 3.2.2k respectively) the 
19
F NMR show the presence of fluorine atom at -
111.0 ppm (CDCl3). For 2,4- and 2,5-difluorine-substituted compounds (3.3.4h and 3.3.4i 
respectively) was seen typical doublets at -106.0 -102.0 ppm and -117.7 -117.0 ppm 
respectively (CDCl3). Moreover, the typical doublets were also seen in 
13
C NMR spectra at 
160.0 - 162.0 ppm with a coupling constant 248 - 258 Hz (CDCl3). In 
1
H NMR the typical 
singlet of quinolone ring in all prepared quinoline derivatives 3.3.7-3.3.9, 3.3.11 appears at 
7.2-7.8 ppm (CDCl3) and 7.7-8.3 ppm (DMSO-d6). Furthermore, the OH gives a broad singlet 
at 14.5-16.1 ppm (CDCl3) and 16.0 ppm (DMSO-d6). In 
13
C NMR corresponding quinolone 
CH occurs at 116.3-118.0 ppm (CDCl3) and 120.2-121.2 ppm (DMSO-d6). The structures of 
condensed chromone derivatives 3.3.10 were first studied by 2D NMR spectroscopy. 
Particularly, in HSQC spectra the proton at 7.02-7.10 ppm (DMSO-d6) turned to be NH group 
instead of CH. Accordingly, the chiral CH proton next to the NH group gives a doublet at 6.6-
6.9 ppm (DMSO-d6). Furthermore, in HMBC spectra of compound 3.3.10h the correlation 
between NH and carbons C-11 and C-12 as well as the correlation between CH and carbons 
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C-10, C-19, C-24 were seen (Figure 3.3.1). Additionally, in NOESY spectra the correlation 
between the chiral CH and the ortho-CH bonds of aniline moiety is well seen. The typical 
pick of chiral CH in 
13
C NMR spectra was detected at 76.4-77.8 ppm (DMSO-d6). In case of 
quinolines 3.3.11 the proton of pyridine ring gives a singlet at 8.15 ppm (CDCl3), moreover 
two OH groups are seen at 11.8 and 12.7 ppm (CDCl3). 
 
O
O
O
HN
H
OMe
OMe
HMBC spectra
O
O
O
HN
H
OMe
OMe
NOESY spectra
H
H
3.3.10h
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
Me Me
2
20
24
 
Figure 3.3.1. 2D NMR from 3.3.10h. 
 
At least a structure from each type of compounds was independently characterized by X-ray 
crystal structure analysis (Table 3.3.5). In the first three structures was detected the flat 
framework of quinolone core. Another general property was that in all three structures the 
fragment of Schiff base was almost perpendicular to the quinolone plane (the torsion angle 
was 60-90
o
). In addition, a hydrogen bond was present in all cases between OH of the benzoyl 
fragment and nitrogen atom of Schiff base moiety. Besides, the substituents of two nitrogen 
atoms were maximum away from each other which is probably energetically more favourable 
for the molecule. Furthermore, in the structure of compound 3.3.8i was presented the second 
fluorine atom in meta-position to carbonyl group. Similarly, in compound 3.3.11h the flat 
core of quinoline system was observed. The ortho-hydroxyphenyl and ortho-hydroxybenzoyl 
substituents were out of the quinoline plane (torsion angels were C2-C1-C10-C15 = -33.52
o 
and C1-C2-C16-C22 = -48.32
o
 respectively), though two hydrogen bonds between the OH of 
ortho-hydroxyphenyl group and quinoline nitrogen and carbonyl oxygen and OH of ortho-
hydroxybenzoyl group were detected. Finally, the structure of intermediate 3.3.13 was almost 
planer, only the C-10 was out from the polycyclic plane (torsion angels are C12-C9-C8-C10 = 
-7.94
o 
and C12-C11-O4-C10 = 27.47
o
). The identification of all other synthesised compounds 
was obtained by comparison of the X-ray crystallography and NMR data. 
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Table 3.3.5. X-ray crystal structures of 3.3.8b,d,i, 3.3.11h, 3.3.13. 
Compound Crystal Structure 
3.3.8b 
  
3.3.8d 
 
 
3.3.8i 
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3.3.11h 
 
 
3.3.13 
 
 
 
3.2.7. Further investigations 
 
In order to extend the substrate scope of proposed methodology initial chromone 3.3.4c was 
reacted with electron-excessive amioheterocycles (see Chapter 2.1, Figure 2.1.2). In this 
context the test reaction of 3.3.4c with 3-methyl-1-phenyl-1H-pyrazol-5-amine E3 in standard 
reaction conditions not surprisingly delivered to corresponding pyrazolopyridine fused system 
3.3.14 in 71% yield (Scheme 3.3.12). Interestingly, in this case among usual domino pyrone 
ring opening and pyridine ring closure, we observed an unexpected intramolecular 
substitution of fluorine by phenol OH that leads to formation of an eight membered ring. We 
suppose that the formation of pyrazolopyridine system proceeds with similar mechanistic 
pathway presented in previous chapters. The structure of 3.3.14 was determined by 1D NMR 
spectroscopy and by X-Ray crystal structure analysis (Table 3.3.6). 
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N
N
Ph
Me
NH2
+
K2CO3 (2 equiv.)
3.3.14, (71%)
DMF, Ar, 130 oC
3.3.4c E3
N
N
N
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O
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N
N
N
Ph
Me
O
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Scheme 3.3.12. Synthesis of pyrazolo[3,4-b]pyridine 3.3.14 from 5-aminopyrazole E3. 
 
Table 3.3.6. X-ray crystal structures of 3.3.14. 
Compound Crystal Structure 
3.3.14 
 
 
 
Finally, with an eye to extend the work of previous chapter (see Chapter 3.2, Scheme 3.2.13) 
we tried to perform the synthesis of linked quinolones using diamines. For this purpose the 
reaction of benzoyl chromone 3.3.4c with 4-(4-aminobenzyl)benzenamine was examined in 
standard reaction conditions. Fortunately, we were able to synthesize desired linked 4-
quinolone derivative 3.3.15 in moderated yield, thus once more demonstrating the huge 
synthetic potential of proposed methodology (Scheme 3.3.12). 
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N
O
O
HO
3.3.15, (66%)
O
O O F
+
H2N NH2
K2CO3 (4 equiv.)
DMF, Ar, 130 oC
10h
3.3.4c
N
O
O
OH
(2 equiv.)  
Scheme 3.3.12. Synthesis of linked 4-quinolone 3.3.15. 
 
3.3.8. Conclusion 
 
In summary we have demonstrated a new and easy way for synthesis of 4-quinolone 
derivatives via [5+1] domino cycloaddition reaction of ortho-fluorine-substituted 
benzoylchromones 3.3.4 and aliphatic amines. The method proved to be rather sensitive 
towards the nature of used amines. Particularly, in case of anilines different unexpected 
products were prepared. Hence, the observed properties made initial chromones an important 
tool for synthesis of new fused pyridine derivatives. The extension of scope and limitations of 
the methodology is under extensive study. 
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4. Summary 
 
The scope of this thesis is to show the chemical potential of chromones, other masked 
dielectrophiles and electron-excessive aminoheterocycles as building blocks for the synthesis 
of new fused pyridine derivatives. 
As described in Chapters 2.3 and 2.4 the [3+3] domino reaction of chromones bearing a 
carbonyl fragment at position 3 with electron-excessive aminoheterocycles in acidic media 
leads to the formation of fused pyridines bearing a β-benzoyl fragment with exceptional 
regioselectivity. The scope and limitations of the reaction along with some further 
transformations was studied (Scheme 4.1). 
 
+
O
O
R
O
H2N NR
O
HO
R = CHCl2, CO2Me.
NR1
O
HO
R1 = CHO, CO2H.  
Scheme 4.1. 
 
Further investigations described in Chapters 2.5 and 2.6 show that the [3+3] domino reaction 
of 2,3-unsubstituted chromones (generated in situ), enaminones and chromones bearing an 
electron withdrawing nitro group at position 3 with electron-excessive aminoheterocycles in 
acidic media leads to the formation of fused pyridines bearing an α-aryl fragment with 
exceptional regioselectivity. The scope and limitations of the methodology along with some 
further transformations was studied (Scheme 4.2). 
 
O
N
Me
Me
+
O
O
H2N
NAr
R1
R1 = H, NO2.
NAr
R2
R2 = H, NH2.
O
O
Ar
O
N
Me
Me
NO2
in situ
OH
 
Scheme 4.2. 
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Subsequently the domino reaction of (ortho-fluoro)-3-bezoylchromones with aliphatic 
amines, anilines and electron-excessive aminoheterocycles was studied (Chapter 3.3). 
According to applied nucleophile the reaction provided different final products, namely 
quinolones and other fused systems. The scope and limitations of the proposed concept was 
studied (Scheme 4.3). 
 
O
O O F
N
O N OH
Alk
Alk
R1
R1
R2
R2
O
O
O
HN
R3
R2
R1
NH2-Alk
H2N
R3
H2N
N
O
O
R2
R1  
Scheme 4.3. 
 
Finally inspired by the results of the domino reaction of (ortho-fluoro)-3-bezoylchromones 
with aliphatic amines described in Chapter 3.3, a new efficient [5+1] synthesis of 4-
quinolones by domino amination and conjugate addition reactions of 1-(2-fluorophenyl)prop-
2-yn-1-ones with amines was developed (Chapter 3.2). The scope and limitations of the 
method along with some further transformations was studied (Scheme 4.4). 
 
O
F
R1
+ R2H2N
O
N
R2
R1
F
F
O
N
R2
R1
HN
R3
 
Scheme 4.4. 
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Appendixed 
 
A.1. Experimental Section 
 
A.1.1. Equipment 
 
1
H NMR Spectroscopy: Bruker AM 250, Bruker ARX 300, Bruker ARX 500; δ = 0.00 ppm 
for tetramethylsilane; δ = 7.25 ppm for (CDCl3); δ = 2.50 ppm for DMSO-d6; 
Characterization of the signals: s = singlet, d = doublet, dd = doublet of doublets, ddd = 
doublet of doublet of doublets, t = triplet, dt = double of triplet, q = quartet, quint = quintet; m 
= multiplet, br = broad. Spectra were evaluated according to first order rules. All coupling 
constants are indicated as (J). 
 
13
C NMR Spectroscopy: Bruker AM 250, (62.9 MHz); Bruker: ARX 300, (75 MHz), Bruker: 
ARX 500, (125 MHz); Ref: δ = 77.00 ppm for CDCl3; δ = 39.7 ppm for DMSO-d6. The 
multiplicity of the carbon atoms was determined by the DEPT 135 and APT technique (APT 
= Attached Proton Test) and quoted as CH3, CH2, CH and C for primary, secondary, tertiary 
and quaternary carbon atoms, respectively. Characterization of the signal: q = quartet. The 
multiplicity of the signals was determined by the DEPT and/or the APT recording 
technologies. 
 
Mass Spectroscopy (MS): AMD MS40, AMD 402 (AMD Intectra), Varian MAT CH 7, 
MAT 731. 
 
High Resolution mass spectroscopy (HRMS): Finnigan MAT 95 or Varian MAT 311; 
Bruker FT CIR, AMD 402 (AMD Intectra). 
 
Infrared spectroscopy (IR): Bruker IFS 66 (FT IR), Nicolet 205 FT IR; Nicolet Protege 460, 
Nicolet 360 Smart rbit (ATR); KBr, KAP, Nujol, and ATR; Abbreviations for signal 
allocations: w = weak, m = medium, s = strong, br = broad. 
 
Elementary analysis: LECO CHNS-932, Thermoquest Flash EA 1112. 
 
X-ray crystal structure analysis: Bruker X8Apex Diffractometer with CCD-Kamera (Mo-
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Kα and graphite monochromator, λ = 0.71073 Å). 
 
Melting points: Micro heating table HMK 67/1825 Kuestner (Büchi apparatus); Melting 
points are uncorrected. 
 
Column chromatography: Chromatography was performed over Merck silica gel 60 (0,063 -
0,200 mm, 70 - 230 mesh) as normal and/or over silica gel 60 (0,040 - 0,063 mm, 200 -400 
mesh) as flash chromatography. All solvents were distilled before use. 
 
Thin layer chromatography: Merck DC finished aluminum foils silica gel 60 F254 and 
Macherey finished foils Alugram® Sil G/UV254. Detection under UV light at 254 nm and/or 
366 nm without dipping reagent, as well as with vanillin-sulfuric acid reagent (1 mL vanillin 
in 100 mL stock solution of 85% methanol, 14% acetic acid and 1% sulfuric acid). 
 
Chemicals and work technique: All solvents for using were distilled by standard methods.  
All of the chemicals are standard, commercially available from Merck
®
, Aldrich
®
, Arcos
®
 and 
others. 
 
A.2. General procedures and spectroscopic data 
 
A.2.1. General procedure for the synthesis of 3-(Dichloroacetyl)chromone 2.3.2: 
 
To a dry dichloromethane solution (100 mL) of 3-(dimethylamino)-1-(2-hydroxyphenyl)prop-
2-en-1-one 2.3.1 (20 g, 105 mmol), 27 mL of dry pyridine (345 mmol) was added. The 
solution was set on stirring on ice bath, and corresponding dichlor acetylchloride (11.1 mL, 
115.5 mmol) was added dropwise. The reaction mixture was stirred at r.t. for 8 h. Afterwords 
the solvent was removed in vacuo. The formed solid was well washed with water to give a 
black crude material, which was then purified by flash column chromatography. Chromone 
2.3.2 was obtained as light yellow crystals (19.3 g, 75%), mp 173-174 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 7.57 (s, 1H, CHCl2), 7.58-7.64 
(m, 1H, CHAr), 7.78 (dd, 1H, 
3
J = 8.4 Hz, 
4
J = 0.6 Hz, CHAr), 7.88-7.94 
(m, 1H, CHAr), 8.15-8.19 (m, 1H, CHAr), 9.16 (s, 1H, CHO). 
13
C NMR (75.5 MHz, DMSO-d6): δ = 70.5 (CHCl2), 118.2 (CH), 18.7, 
123.9 (C), 125.7, 127.0, 135.4 (CH), 155.2 (C), 165.1 (CHO), 173.5, 183.9 (C). 
O
O
CHCl2
O
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MS (GS, 70eV): m/z (%) = 255 (M
+
, 1), 257 (1), 221 (34), 173 (100), 121 (35). 
HRMS (EI): Calcd for C11H6O3Cl2 (M
+
) 255.96885. Found 255.968748. 
IR (ATR, cm
-1
): 
~  = 3005 (w), 1700 (m), 1643 (s), 1611 (s), 1591 (w), 1550 (s), 1463 (s), 
1388 (m), 1335 (w), 1309 (s), 1259 (w), 1230 (w), 1204 (w), 1176 (w), 1144 (m), 1033 (w), 
1006 (m), 951 (w), 902 (w), 880 (w), 854 (m), 799 (m), 778 (s), 759 (s), 746 (s), 729 (s), 690 
(s), 645 (m), 612 (m). 
 
A.2.2. General procedure for the synthesis of compounds 2.3.3a-c, e-p in acetic acid. 
 
In a round-bottom flask the mixture of 3-(dichloroacetyl)chromone 2.3.2 (1 equiv.) and 
appropriate aminoheterocycle E (1.1 equiv.) was dissolved in AcOH (10 mL/1.0 mmol of 
chromone 2.3.2) and heated under reflux in an inert atmosphere for 2-5 h (controlled by 
TLC). After completion of the reaction volatiles were evaporated under reduced pressure. The 
residue was treated with water, filtered, dried in air, and recrystallized from appropriate 
solvent or subjected to column chromatography (silica gel). 
 
A.2.3. General procedure for the synthesis of compounds 2.3.3d in TMSCl/DMF. 
 
The 3-(dichloroacetyl)chromone 2.3.2 (1 equiv.) and 4-amino-1H-imidazole-2(3H)-thione 
E2b (1.1 equiv.) were placed in a pressure tube under the flow of dry argon and dissolved in 
dry DMF (5 mL/1 mmol of chromone 2.3.2) containing 1 mL of TMSCl. The mixture was 
heated at 100-120 °C for 7 h (controlled by TLC). After the reaction was completed volatiles 
were evaporated under reduced pressure. The residue was treated with water, filtered, dried in 
air, and recrystallized from iPrOH:Heptane 2:1. 
 
6-(dichloromethyl)-5-(2-hydroxybenzoyl)-1,2-dihydro-2-phenylpyrazolo[3,4-b]pyridin-3-
one (2.3.3a). 
Starting from 3-(dichloroacetyl)chromone 2.3.2 (0.257 g, 1 mmol) 
and 5-amino-1,2-dihydro-2-phenylpyrazol-3-one E1a (0.193 g, 1.1 
mmol) in 10 mL AcOH. 2.3.3a was isolated as green solid (0.319 
g, 77%), mp = 199-200 
o
C.  
1
H NMR (300 MHz, DMSO-d6): δ = 6.96-7.02 (m, 2H, CHAr), 
7.32 (t, 1H, 
3
J = 7.1 Hz, CHAr), 7.48-7.57 (m, 4H, CHAr), 7.67 (s, 1H, CHCl2), 7.88 (d, 2H, 
3
J 
= 8.0 Hz, CHAr), 8.20 (s, 1H, Py), 10.62 (s, 1H, OH), 12.8 (br. s, 1H, NH).  
OH
O
N CHCl2
N
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13
C NMR (75.5 MHz, DMSO-d6): δ = 68.8 (CHCl2), 109.3 (C), 117.2, 119.5, 120.0 (CH), 
123.8, 124.8 (C), 126.0, 129.2, 131.6, 135.1 (CH), 136.3 (C), 137.0 (CH), 155.3, 156.8, 158.1, 
158.2 (C), 195.6 (C=O).  
MS (GS, 70eV): m/z (%) = 413 (M
+
, 5), 78 (96), 63 (100), 44 (12).  
HRMS (ESI): Calcd for C20H13Cl2N3O3 (M+H) 414.0407. Found 414.0409.  
IR (ATR, cm
-1
): 
~  = 3041 (w), 2915 (w), 2352 (w), 2143 (w), 2018 (w), 1962 (w), 1661 (m), 
1617 (s), 1597 (s), 1485 (m), 1450 (m), 1404 (w), 1358 (m), 1303 (m), 1242 (s), 1221 (m), 
1199 (m), 1156 (m), 1034 (w), 948 (w), 930 (m), 878 (w), 820 (m), 774 (m), 754 (s), 686 (s), 
650 (s), 611 (m), 578 (m), 530 (m).  
 
6-(dichloromethyl)-5-(2-hydroxybenzoyl)-1,2-dihydro-2-methylpyrazolo[3,4-b]pyridin-3-
one (2.3.3b). 
Starting from 3-(dichloroacetyl)chromone 2.3.2 (0.257 g, 1 mmol) 
and 5-amino-1,2-dihydro-2-methylpyrazol-3-one E1b (0.124 g, 1.1 
mmol) in 10 mL AcOH. 2.3.3b was isolated as white solid (0.310 
g, 88%), mp = 178-179 
o
C.  
1
H NMR (300 MHz, DMSO-d6): δ = 3.46 (s, 3H, NMe), 6.94-7.00 
(m, 2H, CHAr), 7.43-7.53 (m, 2H, CHAr) 7.67 (s, 1H, CHCl2), 8.10 (s, 1H, Py), 10.53 (s, 1H, 
OH), 12.53 (br. s, 1H, NH).  
13
C NMR (75.5 MHz, DMSO-d6): δ = 30.5 (NMe), 68.9 (CHCl2), 117.1, 119.4 (CH), 123.5, 
124.1 (C), 131.4, 134.9, 136.6 (CH), 153.4, 156.9, 157.3, 157.8, 172.0 (C), 195.8 (C=O).  
MS (GS, 70eV): m/z (%) = 351 (M
+
, 64), 316 (M
+
-Cl, 100), 281 (89), 268 (M
+
-CHCl2, 96), 
252 (26), 231 (11), 121 (88).  
HRMS (ESI): Calcd for C15H12Cl2N3O3 (M+H) 352.0250. Found 352.0249. 
IR (ATR, cm
-1
): 
~  = 3050 (w), 1706 (w), 1622 (m), 1477 (m), 1455 (w), 1361 (m), 1300 (m), 
1246 (s), 1205 (s), 1180 (s), 1155 (s), 1033 (m), 917 (s), 867 (w), 849 (w), 818 (s), 767 (s), 
754 (s), 707 (s), 693 (s), 680 (s), 649 (m). 
 
6-(dichloromethyl)-5-(2-hydroxybenzoyl)-1,2-dihydro-1-methylpyrazolo[3,4-b]pyridin-3-
one (2.3.3c). 
OH
O
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N
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Starting from 3-(dichloroacetyl)chromone 2.3.2 (0.257 g, 1 mmol) and 
5-amino-1,2-dihydro-2-methylpyrazol-3-one E1c (0.124 g, 1.1 mmol) in 
10 mL AcOH. 2.3.3c was isolated as white solid (0.275 g, 78%), mp = 
179-181 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 3.92 (s, 3H, NMe), 6.95-7.01 (m, 
2H, CHAr), 7.43-7.53 (m, 2H, CHAr), 7.74 (s, 1H, CHCl2), 8.28 (s, 1H, Py), 10.51 (s, 1H, OH), 
11.56 (br. s, 1H, NH).  
13
C NMR (75.5 MHz, DMSO-d6): δ = 33.2 (NMe), 69.3 (CHCl2), 117.2, 119.3 (CH), 122.7, 
124.4 (C), 131.4, 134.6, 134.9 (CH), 148.7, 153.6, 154.3, 157.8, 172.0 (C), 196.5 (C=O).  
MS (EI, 70eV): m/z (%) = 351 (M
+
, 29), 316 (M
+
-Cl, 100), 281 (74), 268 (M
+
-CHCl2, 57), 
252 (22), 196 (12), 121 (52).  
HRMS (ESI): Calcd for C15H12Cl2N3O3 (M+H) 352.0250. Found 352.0247.  
IR (ATR, cm
-1
): 
~  = 3050 (w), 1712 (w), 1599 (m), 1574 (m), 1495 (w), 1479 (w), 1286 (m), 
1201 (s), 994 (w), 919 (m), 808 (m), 769 (s), 707 (s), 649 (s). 
 
5-(dichloromethyl)-6-(2-hydroxybenzoyl)-1-methyl-3-phenyl-1H-imidazo[4,5-b]pyridine-
2(3H)-thione (2.3.3d). 
Starting from 3-(dichloroacetyl)chromone 2.3.2 (0.257 g, 1 mmol) and 
4-amino-1H-imidazole-2(3H)-thione E2b (0.226 g, 1.1 mmol) in 5mL 
DMF and 1 mL of TMSCl. 2.3.3d was isolated as yellow solid (0.382 
g, 86%), mp = 233-235 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 3.76 (s, 3H, Me), 6.94-7.06 (m, 
2H, CHAr), 7.32 (s, 1H, CHCl2), 7.47-7.64 (m, 7H, CHAr), 8.00 (s, 1 H, Py), 11.03 (s, 1 H, 
OH).  
13
C NMR (75.5 MHz, DMSO-d6): δ = 31.4 (Me), 69.2 (CHCl2), 116.4, 117.7, 119.4 (CH), 
122.2, 126.4, 127.8, 128.4 (C), 129.0, 129.1, 132.6 (CH), 134.2 (C), 136.5 (CH), 145.8, 146.7, 
160.1, 173.3 (C), 197.1 (C=O).  
MS (EI, 70eV): m/z (%) = 443 (M
+
, 7), 373 (59), 360 (M
+
-CHCl2, 100), 344 (24), 298 (10).  
HRMS (ESI): Calcd for C21H16Cl2N3O2S (M+H) 444.0335. Found 444.0334.  
IR (ATR, cm
-1
): 
~  = 1735 (w), 1624 (m), 1598 (m), 1500 (m), 1483 (w), 1422 (s), 1339 (s), 
1301 (s), 1202 (s), 1154 (s), 1065 (w), 967 (m), 818 (m), 750 (s), 690 (m), 651 (m). 
 
6-(dichloromethyl)-5-(2-hydroxybenzoyl)-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine 
(2.3.3e). 
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Starting from 3-(dichloroacetyl)chromone 2.3.2 (0.257 g, 1 mmol) and 4-
amino-1H-imidazole-2(3H)-thione E3 (0.190 g, 1.1 mmol) in 10 mL 
AcOH. 2.3.3e was isolated as light brown solid (0.284 g, 69%), mp = 
205-206 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 2.61 (s, 3H, Me), 6.96-7.03 (m, 2H, 
CHAr), 7.34-7.40 (m, 1H, CHAr), 7.51-7.64 (m, 5H, CHAr), 8.36 (dd, 2H, 
3
J = 8.7 Hz, 
4
J = 0.9 
Hz, CHAr), 8.53 (s, 1H, Py), 10.81 (s, 1H, OH). 
13
C NMR (75.5 MHz, DMSO-d6): δ = 12.2 (Me), 69.5 (CHCl2), 116.2 (C), 117.5, 119.4, 
119.9 (CH), 123.0 (C), 126.0, 128.3, 129.3, 132.1, 133.5, 135.8 (CH), 138.6, 144.5, 148.8, 
153.5, 159.2 (C), 196.8 (C=O). 
MS (GC, 70eV): m/z (%) = 411 (M
+
, 74), 376 (90), 341 (99), 328 (M
+
-CHCl2, 100), 312 (41), 
291 (32), 256 (21), 179 (12), 121 (25), 77 (43).  
HRMS (ESI): Calcd for C21H14Cl2N3O2 (M-H) 410.0469. Found 410.048.  
IR (ATR, cm
-1
): 
~  = 1620 (m), 1592 (m), 1559 (w), 1510 (w), 1497 (w), 1482 (w), 1293 (m), 
1209 (s), 1154 (m), 947 (w), 930 (m), 806 (m), 752 (s), 665 (s), 630 (s). 
 
1-(4-methoxybenzyl)-5-(2-hydroxybenzoyl)-6-(dichloromethyl)-1H-pyrrolo[2,3-
b]pyridine-3-carbonitrile (2.3.3f). 
Starting from 3-(dichloroacetyl)chromone 2.3.2 (0.257 g, 1 mmol) and 1-(4-
methoxybenzyl)-5-amino-1H-pyrrole-3-carbonitrile E4a (0.250 g, 1.1 
mmol) in 10 mL AcOH. 2.3.3f was isolated as white solid (0.383 g, 93%), 
mp = 238-240 
o
C. 
1
H NMR (300 MHz, CDCl3): δ = 3.80 (s, 3H, OMe), 5.54 (s, 2H, CH2), 
6.85-6.93 (m, 3H, CHAr), 7.12 (d, 1H, 
3
J = 8.3 Hz, CHAr), 7.21 (s, 1H, 
CHCl2), 7.31 (dd, 1H, 
3
J = 8.2 Hz, 
4
J = 1.5 Hz, CHAr), 7.39-7.43 (m, 2H, 
CHAr), 7.55-7.61 (m, 1H, CHAr), 7.88 (s, 1H, pyrrole), 8.08 (s, 1H, Py), 11.79 (s, 1H, OH). 
13
C NMR (75.5 MHz, CDCl3): δ = 49.1 (CH2), 55.3 (OMe), 68.6 (CHCl2), 86.1 (CN), 113.9 
(C), 114.6, 118.9 (CH), 119.1 (C), 119.4 (CH), 119.5, 125.7, 126.9 (C), 129.6, 130.3, 133.3, 
137.7, 137.8 (CH), 146.1, 150.6, 160.0, 163.7 (C), 200.2 (C=O). 
MS (EI, 70eV): m/z (%) = 465 (M
+
, 22), 430 (14), 395 (25), 382 (M
+
-CHCl2, 13), 121 (100), 
77 (19). 
HRMS (ESI): Calcd for C24H18Cl2N3O3 (M+H) 466.072. Found 466.0722.  
IR (ATR, cm
-1
): 
~  = 2223 (s), 1621 (m), 1603 (s), 1550 (w), 1513 (s), 1483 (w), 1350 (m), 
1305 (m), 1240 (s), 1154 (s), 1032 (m), 915 (m), 817 (m), 782 (s), 763 (s), 706 (s), 663 (s), 
OH
O
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605 (s). 
 
1-(4-methoxybenzyl)-5-(2-hydroxybenzoyl)-6-(dichloromethyl)-1H-pyrrolo[2,3-
b]pyridine-3-carbonitrile (2.3.3g). 
Starting from 3-(dichloroacetyl)chromone 2.3.2 (0.257 g, 1 mmol) and 5-
amino-1-cyclohexyl-1H-pyrrole-3-carbonitrile E4b (0.208 g, 1.1 mmol) 
in 10 mL AcOH. 2.3.3g was isolated as yellowish solid (0.360 g, 84%), 
mp 174-176 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 1.15–2.10 (m, 10H, cyclohexyl), 
4.71-4.86 (m, 1H, NCH), 6.95-7.02 (m, 2H, CHAr), 7.46 (dd, 1H, 
3
J = 7.8 
Hz, 
4
J = 1.7 Hz, CHAr), 7.53-7.58 (m, 1H, CHAr), 7.57 (s, 1H, CHCl2), 8.20 (s, 1H, pyrrole), 
8.90 (s, 1H, Py), 10.77 (s, 1H, OH).  
13
C NMR (75.5 MHz, DMSO-d6): δ = 24.8, 25.1, 32.0, 39.8 (CH2), 55.2 (NCH), 69.4 
(CHCl2), 84.0 (CN), 114.5 (C), 117.4, 119.1 (CH), 119.4, 123.2 (C), 126.5, 129.9, 132.1, 
135.7, 139.3 (CH), 145.2, 149.0, 159.0 (C), 197.2 (C=O).  
MS (GC, 70eV): m/z (%) = 427 (M
+
, 12), 392 (81), 357 (23), 344 (M
+
-CHCl2, 67), 309 (13), 
275 (41), 262 (100), 246 (43), 207 (27), 121 (16).  
HRMS (ESI): Calcd for C22H20Cl2N3O2 (M+H) 428.0927. Found 428.0924.  
IR (ATR, cm
-1
): 
~  = 2219 (m), 1621 (s), 1601 (m), 1553 (w), 1521 (w), 1480 (w), 1292 (s), 
1189 (s), 1153 (s), 1030 (w), 933 (w), 916 (m), 778 (m), 757 (s), 708 (s), 641 (s). 
 
1-tert-butyl-5-(2-hydroxybenzoyl)-6-(dichloromethyl)-1H-pyrrolo[2,3-b]pyridine-3-
carbonitrile (2.3.3h). 
Starting from 3-(dichloroacetyl)chromone 2.3.2 (0.257 g, 1 mmol) and 
1-tert-butyl-5-amino-1H-pyrrole-3-carbonitrile E4c (0.179 g, 1.1 mmol) 
in 10 mL AcOH. 2.3.3h was isolated as gray solid (0.317 g, 79%), mp 
200-202 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 1.85 (s, 9H, t-Bu), 6.95-7.02 (m, 
2H, CHAr), 7.48 (dd, 1H, 
3
J = 7.8 Hz, 
4
J = 1.6 Hz, CHAr), 7.52-7.58 (m, 1H, CHAr), 7.60 (s, 
1H, CHCl2), 8.17 (s, 1H, pyrrole), 8.80 (s, 1H, Py), 10.75 (s, 1H, OH).  
13
C NMR (75.5 MHz, DMSO-d6): δ = 28.5 (t-Bu), 59.3 (Ct-Bu), 69.5 (CHCl2), 83.1 (CN), 
114.7 (C), 117.4, 119.4 (CH), 120.2, 123.2, 125.8 (C), 129.7, 132.0, 135.6, 139.7 (CH), 145.8, 
148.3, 158.9 (C), 197.1 (C=O).  
MS (GC, 70eV): m/z (%) = 401 (M
+
, 10), 366 (36), 318 (40), 310 (28), 275 (32), 274 (32), 
OH
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262 (100), 246 (32), 218 (11), 121 (10).  
HRMS (EI): Calcd for C20H17Cl2N3O2 (M
+
) 401.0669. Found 401.0670.  
IR (ATR, cm
-1
): 
~  = 2229 (s), 1624 (m), 1601 (m), 1519 (w), 1483 (w), 1418 (m), 1370 (m), 
1190 (s), 1083 (w), 1034 (w), 910 (w), 864 (w), 758 (s), 706 (s), 646 (s), 607 (m). 
 
5-(dichloromethyl)-6-(2-hydroxybenzoyl)-N,N-dimethylthiazolo[4,5-b]pyridin-2-amine 
(2.3.3i). 
Starting from 3-(dichloroacetyl)chromone 2.3.2 (0.257 g, 1 mmol) 
and N
2
,N
2
-dimethylthiazole-2,4-diamine E5a (0.157 g, 1.1 mmol) 
in 10 mL AcOH. 2.3.3i was isolated as gray solid (0.318 g, 73%), 
mp 244-245 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 3.25 (s, 6H, NMe2), 6.93-7.00 
(m, 2H, CHAr), 7.42 (dd, 1H, 
3
J = 7.8 Hz, 
4
J = 1.6 Hz, CHAr), 7.51 (s, 1H, CHCl2), 7.48-7.54 
(m, 1H, CHAr), 8.29 (s, 1H, Py), 10.64 (s, 1H, OH).  
13
C NMR (75.5 MHz, DMSO-d6): δ = 39.8 (NMe2), 69.4 (CHCl2), 117.3, 119.3 (CH), 123.1, 
123.8, 125.9 (C), 131.5, 131.6, 135.0 (CH), 151.7, 158.3, 165.4, 172.6 (C), 196.6 (C=O).  
MS (EI, 70eV): m/z (%) = 381 (M
+
, 35), 346 (73), 311 (69), 298 (M
+
-CHCl2, 100), 282 (64), 
268 (12), 263 (14), 261 (21), 226 (15), 121 (11).  
HRMS (ESI): Calcd for C16H14Cl2N3O2S (M+H) 382.0178. Found 382.0181.  
IR (ATR, cm
-1
): 
~  = 1620 (w), 1602 (m), 1556 (s), 1505 (w), 1478 (w), 1403 (m), 1292 (s), 
1217 (s), 1158 (m), 931 (m), 793 (s), 744 (s), 702 (s), 664 (m). 
 
5-(dichloromethyl)-6-(2-hydroxybenzoyl)-2-morpholinothiazolo[4,5-b]pyridine (2.3.3j). 
Starting from 3-(dichloroacetyl)chromone 2.3.2 (0.257 g, 1 
mmol) and 2-morpholinothiazol-4-amine E5b (0.204 g, 1.1 
mmol) in 10 mL AcOH. 2.3.3j was isolated as yellow solid 
(0.297 g, 70%), mp 226-228 
o
C. 
1
H NMR (250 MHz, CDCl3): δ = 3.72-3.76 (m, 8H, morpholine), 6.93-7.00 (m, 2H, CHAr), 
7.43 (dd, 1H, 
3
J = 7.8 Hz,
 4
J = 1.6 Hz, CHAr), 7.49-7.52 (m, 2H, CHCl2, CHAr), 8.33 (s, 1H, 
Py), 10.64 (s, 1H, OH).  
13
C NMR (62.9 MHz, CDCl3): δ = 48.7, 66.2 (CH2 morpholine), 68.3 (CHCl2), 118.8, 119.3 
(CH), 119.6, 123.1, 125.2 (C), 129.7, 133.1, 137.6 (CH), 152.7, 163.4. 165.5, 172.0 (C), 199.8 
(C=O).  
MS (EI, 70eV): m/z (%) = 423 (M
+
, 33), 390 (25), 389 (21), 388 (70), 387 (20), 354 (11), 353 
(48), 352 (21), 342 (15), 341 (47), 340 (M
+
-CHCl2, 100), 324 (32), 303 (14), 296 (16), 266 
OH
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(12), 246 (11), 121 (14).  
HRMS (ESI): Calcd for C18H16Cl2N3O3S (M+H) 424.0827. Found 424.0286.  
IR (ATR, cm
-1
): 
~  = 1620 (w), 1599 (w), 1544 (m), 1505 (m), 1485 (m), 1424 (m), 1290 (s), 
1214 (s), 1111 (s), 1025 (m), 931 (m), 790 (m), 749 (s).  
 
5-(dichloromethyl)-6-(2-hydroxybenzoyl)-2-pyperidinothiazolo[4,5-b]pyridine (2.3.3k). 
Starting from 3-(dichloroacetyl)chromone 2.3.2 (0.257 g, 1 mmol) 
and 2-(piperidin-1-yl)thiazol-4-amine E5c (0.201 g, 1.1 mmol) in 
10 mL AcOH. 2.3.3k was isolated as yellow solid (0.312 g, 74%), 
mp 263-264 
o
C. 
1
H NMR (300 MHz, CDCl3): δ = 1.72  (m, 6H, piperidine), 3.73 (m, 4H, piperidine), 6.84 (td, 
1H, 
3
J = 8.1 Hz,
 4
J = 1.0 Hz, CHAr), 7.01 (s, 1H, CHCl2), 7.06 (dd, 1H, 
3
J = 8.4 Hz, 
4
J = 0.7 
Hz, CHAr), 7.32 (dd, 1H, 
3
J = 8.0 Hz,
 4
J = 1.1 Hz, CHAr), 7.49-7.54 (m, 1H, CHAr), 7.81 (s, 
1H, Py), 11.78 (s, 1H, OH).  
13
C NMR (75.5 MHz, CDCl3): δ = 24.0, 25.4, 50.0 (CH2 piperidine), 68.4 (CHCl2), 118.7, 
119.2 (CH), 119.6, 122.4, 125.4 (C), 129.2, 133.1, 137.4 (CH), 152.5, 163.3, 166.1, 171.5 (C), 
199.9 (C=O).  
MS (EI, 70eV): m/z (%) = 421 (M
+
, 16), 386 (22), 351 (81), 338 (M
+
-CHCl2, 100), 322 (47), 
295 (16), 268 (13), 121 (14), 84 (13), 69 (16).  
HRMS (ESI): Calcd for C19H18Cl2N3O2S (M+H) 422.0491. Found 422.0494. 
IR (ATR, cm
-1
): 
~  = 2938 (m), 1617 (m), 1594 (w), 1538 (s), 1503 (m), 1482 (w), 1316 (m), 
1291 (s), 1248 (m), 1213 (s), 1125 (m), 934 (m), 850 (w), 787 (m), 732 (s), 705 (s), 627 (m), 
604 (m). 
 
6-(2-hydroxybenzoyl)-7-(dichloromethyl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione 
(2.3.3l). 
Starting from 3-(dichloroacetyl)chromone 2.3.2 (0.257 g, 1 mmol) 
and 6-aminopyrimidine-2,4(1H,3H)-dione E6a (0.140 g, 1.1 mmol) 
in 10 mL AcOH. 2.3.3l was isolated as white solid (0.253 g, 69%), 
mp 237-238 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 6.96-7.01 (m, 2H, CHAr), 7.45-
7.54 (m, 2H, CHAr), 7.56 (s, 1H, CHCl2), 8.20 (s, 1H, Py), 10.59 (s, 1H, OH), 11.68 (s, 1H, 
NH), 12.28 (s, 1H, NH).  
13
C NMR (75.5 MHz, DMSO-d6): δ = 68.1 (CHCl2), 110.4 (C), 117.2, 119.5 (CH), 123.8, 
126.0 (C), 131.4, 135.3, 139.5 (C), 150.2, 153.6, 158.0, 158.1, 161.2 (C), 194.8 (C=O).  
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MS (EI, 70eV): m/z (%) = 366 (M
+
, 2), 330 (69), 295 (62), 282 (M
+
-CHCl2, 100), 266 (11), 
239 (11), 223 (7), 196 (8), 121 (22), 69 (14), 57 (10), 44 (15).  
HRMS (ESI): Calcd for C15H8Cl2N3O4 (M-H) 366.9897. Found 366.9914.  
IR (ATR, cm
-1
): 
~  = 3176 (w), 3051 (w), 1682 (s), 1603 (s), 1574 (s), 1504 (w), 1481 (m), 
1403 (m), 1294 (m), 1242 (s), 1155 (m), 921 (m), 754 (s), 650 (s). 
 
6-(2-hydroxybenzoyl)-7-(dichloromethyl)-1,3-dimethylpyrido[2,3-d]pyrimidine-
2,4(1H,3H)-dione (2.3.3m). 
Starting from 3-(dichloroacetyl)chromone 2.3.2 (0.257 g, 1 mmol) 
and 6-amino-1,3-dimethylpyrimidine-2,4(1H,3H)-dione E6b (0.171 g, 
1.1 mmol) in 10 mL AcOH. 2.3.3m was isolated as yellow solid 
(0.303 g, 77%), mp 196-197 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 3.28 (s, 3H, Me), 3.66 (s, 3H, 
Me), 6.96-7.01 (m, 2H, CHAr), 7.47 (dd, 1H, 
3
J = 8.2 Hz,
 4
J = 1.6 Hz, CHAr), 7.51-7.57 (m, 1 
H, CHAr), 7.61 (s, 1H, CHCl2), 8.25 (s, 1H, Py), 10.57 (s, 1H, OH).  
13
C NMR (62.9 MHz, DMSO-d6): δ = 28.5, 29.4 (Me), 68.4 (CHCl2), 110.6 (C), 117.2, 119.5 
(CH), 123.6, 125.9 (C), 131.4, 135.4, 140.1 (CH), 150.8, 151.4, 157.3, 158.0, 160.0 (C), 194.5 
(CH).  
MS (EI, 70eV): m/z (%) = 393 (M
+
, 3), 358 (99), 310 (M
+
-CHCl2, 100), 294 (21), 120 (44), 
69 (11).  
HRMS (EI): Calcd for C17H13Cl2N3O4 (M
+
) 393.0278. Found 393.0271.  
IR (ATR, cm
-1
): 
~  = 1712 (m), 1666 (m), 1656 (m), 1628 (m), 1601 (s), 1572 (m), 1485 (m), 
1357 (m), 1243 (s), 1156 (m), 1089 (w), 959 (w), 917 (m), 783 (s), 751 (s), 667 (m). 
 
6-(2-hydroxybenzoyl)-7-(dichloromethyl)-1-methylpyrido[2,3-d]pyrimidine-2,4(1H,3H)-
dione (2.3.3n). 
Starting from 3-(dichloroacetyl)chromone 2.3.2 (0.257 g, 1 mmol) 
and 6-amino-1-methylpyrimidine-2,4(1H,3H)-dione E6c (0.155 g, 
1.1 mmol) in 10 mL AcOH. 2.3.3n was isolated as yellow solid 
(0.270 g, 71%), mp 235-236 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 3.58 (s, 3H, Me), 6.97-7.01 
(m, 2H, CHAr), 7.46 (dd, 1H, 
3
J = 8.1 Hz,
 4
J = 1.7 Hz, CHAr), 7.51-
7.57 (m, 1H, CHAr), 7.62 (s, 1H, CHCl2), 8.32 (s, 1H, Py), 10.57 (s, 1H, OH), 11.94 (s, 1H, 
NH).  
13
C NMR (62.9 MHz, DMSO-d6): δ = 28.5 (Me), 68.4 (CHCl2), 111.5 (C), 117.2, 119.5 (CH), 
OH
O
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123.6, 125.6 (C), 131.4, 135.3, 139.6 (CH), 150.5, 152.8, 157.4, 157.9, 160.2 (C), 194.6 
(C=O).  
MS (EI, 70eV): m/z (%) = 380 (M
+
, 2), 344 (42), 309 (52), 296 (M
+
-CHCl2, 100), 280 (12), 
121 (21).  
HRMS (EI): Calcd for C16H11Cl2N3O4 (M
+
) 379.0121. Found 379.0115.  
IR (ATR, cm
-1
): 
~  = 3330 (w), 3035 (w), 1732 (m), 1699 (s), 1596 (s), 1567 (m), 1475 (m), 
1338 (m), 1279 (m), 1157 (s), 1100 (m), 900 (m), 755 (s), 597 (s). 
 
2-(dichloromethyl)-3-(2-hydroxybenzoyl)-5,7-dimethoxyquinoline (2.3.3o). 
Starting from 3-(dichloroacetyl)chromone 2.3.2 (0.257 g, 1 
mmol) and 3,5-dimethoxybenzenamine E7a (0.168 g, 1.1 mmol) 
in 10 mL AcOH. 2.3.3o was isolated as white solid (0.282 g, 
72%), mp 188-189 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 3.92 (s, 3H, OMe), 3.99 (s, 
3H, OMe), 6.80 (s, 1H, CHAr), 6.96-7.01 (m, 2H, CHAr), 7.16 (s, 1H, CHAr), 7.47-7.53 (m, 
2H, CHAr), 7.70 (s, 1H, CHCl2), 8.41 (s, 1H, Py), 10.55 (s, 1H, OH).  
13
C NMR (75.5 MHz, DMSO-d6): δ = 56.1, 56.4 (OMe), 69.3 (CHCl2), 93.7, 100.3 (CH), 
114.3 (C), 117.2, 119.4 (CH), 123.9, 125.5 (C), 131.5, 134.0, 135.0 (CH), 149.7, 154.1, 156.0, 
158.1, 163.9 (C), 196.5 (C=O).  
MS (EI, 70eV): m/z (%) = 391 (M
+
, 47), 356 (M
+
-Cl, 100), 339 (10), 321 (49), 292 (21), 271 
(42), 236 (22), 206 (12), 121 (23), 65 (13).  
HRMS (ESI): Calcd for C19H16Cl2NO4 (M+H) 392.0451. Found 392.0457.  
IR (ATR, cm
-1
): 
~  = 1620 (s), 1600 (s), 1571 (m), 1480 (w), 1291 (m), 1203 (s), 1043 (w), 
1033 (m), 915 (m), 815 (m), 760 (s), 630 (m). 
 
2-(dichloromethyl)-3-(2-hydroxybenzoyl)-N,N-dimethylquinolin-7-amine (2.3.3p). 
Starting from 3-(dichloroacetyl)chromone 2.3.2 (0.257 g, 1 mmol) 
and N
1
,N
1
-dimethylbenzene-1,3-diamine E8 (0.152 g, 1.1 mmol) in 
10 mL AcOH. 2.3.3p was isolated as yellow solid (0.255 g, 60%), 
mp 186-188 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 3.14 (s, 6H, NMe2), 6.94-7.02 
(m, 2H, CHAr), 7.05 (d, 1H, 
4
J = 2.4 Hz, CHAr), 7.37 (dd, 1H, 
3
J = 9.2 Hz,
 4
J = 2.5 Hz, CHAr), 
7.44-7.54 (m, 2H, CHAr), 7.71 (s, 1H, CHCl2), 7.89 (d, 1H, 
3
J = 9.2 Hz, CHAr), 8.25 (s, 1H, 
Py), 10.61 (s, 1H, OH).  
OH
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13
C NMR (75.5 MHz, DMSO-d6): δ = 39.9 (NMe2), 69.7 (CHCl2), 104.7, 117.2, 118.0, 118.2 
(CH), 119.3, 123.4, 124.0 (C), 129.8, 131.5, 134.7, 139.8 (CH), 149.4, 153.0, 153.7, 158.3 
(C), 197.0 (C=O). 
MS (EI, 70eV): m/z (%) = 374 (M
+
, 100), 339 (37), 322 (18), 291 (54), 207 (18), 137 (17). 
HRMS (EI): Calcd for C19H16Cl2N2O2 (M
+
) 374.0655. Found 374.0658. 
IR (ATR, cm
-1
): 
~  = 1614 (w), 1576 (m), 1505 (m), 1479 (w), 1330 (m), 1146 (m), 971 (w), 
914 (m), 810 (s), 752 (s), 704 (s), 631 (m). 
 
A.2.4. General procedure for the synthesis of compounds 2.3.5a-f. 
 
The fused pyridine derivative 2.3.3 (1 equiv.) and potassium hydroxide (4 equiv.) were 
dissolved in ethanol (10 mL/1 equiv. of 2.3.3) and heated under reflux for 2 h (under argon 
atmosphere). After completion of the reaction (TLC control), the reaction mixture was diluted 
with 10 M HCl (5 mL). The precipitate was filtered, washed with H2O, dried in vacuum at 60 
°C for 3 h. The residue was purified by recrystallization from appropriate solvent or by using 
column chromatography (silica gel). 
 
5-(formyl)-6-(2-hydroxybenzoyl)-1-methyl-3-phenyl-1H-imidazo[4,5-b]pyridine-2(3H)-
thione (2.3.5a). 
Starting from 2.3.3d (0.150 g, 0.33 mmol) and potassium hydroxide 
(0.074 g, 1.32 mmol) in 10 mL ethanol. 2.3.5a was isolated as white 
solid (0.09 g, 70%), mp 183-184 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 3.55 (s, 3H, Me), 6.93 (t, 1H, 
3
J 
= 9.2 Hz, CHAr), 7.00-7.07 (m, 2H, CHAr), 7.61 (d, 1H, 
3
J = 9.2 Hz, 
CHAr), 7.61-7.69 (m, 5H, CHAr), 8.22 (s, 1H, Py), 10.08 (s, 1H, OH), 11.03 (s, 1H, COH).  
13
C NMR (75.5 MHz, DMSO-d6): δ = 31.4 (Me), 116.9, 118.7, 119.3 (CH), 123.2, 126.4, 
129.0 (C), 129.4, 130.0, 131.1, 132.6 (CH), 134.2 (C), 137.5 (CH), 145.8, 146.7, 161.1, 173.3 
(C), 192.2 (CHO), 197.1 (C=O).  
MS (EI, 70eV): m/z (%) = 389 (M
+
, 5), 312 (39), 297 (100), 268 (10).  
HRMS (ESI): Calcd for C21H16N3O3S (M+H) 390.0688. Found 390.0689. 
IR (ATR, cm
-1
): 
~  = 2725 (m), 1633 (w), 1512 (m), 1500 (m), 1488 (w), 1453 (m), 1388 (m), 
1332 (m), 1153 (m), 969 (w), 909 (s), 815 (m), 744 (s), 701 (s), 608 (s). 
 
6-formyl-5-(2-hydroxybenzoyl)-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine (2.3.5b). 
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Starting from 2.3.3f (0.150 g, 0.32 mmol) and potassium hydroxide (0.071 g, 
1.28 mmol) in 10 mL ethanol. 2.3.5b was isolated as yellowish solid (0.095 
g, 72%), mp 155-157 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 2.63 (s, 3H, Me), 7.02-7.11 (m, 2H, 
CHAr), 7.40-7.48 (m, 1H, CHAr), 7.61-7.68 (m, 4H, CHAr), 8.51 (dd, 2H, 
3
J = 8.4 Hz,
 4
J = 1.0 
Hz, CHAr), 8.43 (s, 1H, Py), 10.09 (s, 1H, OH), 10.84 (s, 1H, COH).  
13
C NMR (75.5 MHz, DMSO-d6): δ = 12.2 (Me), 117.2, 118.5, 119.9 (CH), 120.1, 123.6, 
126.4 (C), 128.9, 130.2, 132.4, 133.9 (CH), 136.1 (C), 138.8 (CH), 145.5, 149.0, 153.5, 159.3 
(C), 191.8 (CHO), 196.8 (C=O).  
MS (EI, 70eV): m/z (%) = 357 (M
+
, 34), 342 (80), 325 (79), 296 (100), 312 (41), 219 (42), 
191 (21).  
HRMS (ESI): Calcd for C21H16N3O3 (M+H) 358.1161. Found 358.1162. 
IR (ATR, cm
-1
): 
~  = 2733 (m), 1632 (w), 1577 (m), 1532 (m), 1497 (w), 1462 (m), 1332 (m), 
1294 (m), 1211 (s), 1111 (s), 953 (m), 931 (m), 808 (m), 750 (s), 665 (s), 630 (s), 601 (m). 
 
1-(4-methoxybenzyl)-5-(2-hydroxybenzoyl)-6-(formyl)-1H-pyrrolo[2,3-b]pyridine-3-
carbonitrile (2.3.5c). 
Starting from 2.3.3f (0.150 g, 0.36 mmol) and potassium hydroxide (0.081 
g, 1.44 mmol) in 10 mL ethanol. 2.3.5c was isolated as white solid (0.104 
g, 81%), mp 169-171 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 3.82 (s, 3H, OMe), 5.51 (s, 2H, CH2), 
6.92-6.98 (m, 3H, CHAr), 7.23 (d, 1H, 
3
J = 8.0 Hz, CHAr), 7.39 (dd, 1H, 
3
J 
= 8.0 Hz,
 4
J = 1.4 Hz, CHAr), 7.42-7.48 (m, 2H, CHAr), 7.57-7.63 (m, 1H, 
CHAr), 7.93 (s, 1H, pirrole), 8.18 (s, 1H, Py), 10.09 (s, 1H, OH), 11.79 (s, 
1H, COH).  
13
C NMR (75.5 MHz, DMSO-d6): δ = 49.1 (CH2), 55.3 (OMe), 86.5 (CN), 114.6 (C), 114.9, 
119.2 (CH), 119.9 (C), 120.4, 120.6 (CH), 125.8, 127.0 (C), 129.9, 130.6, 133.7 (CH), 138.1 
(C), 138.4 (CH), 146.2, 150.6, 160.6, 164.0 (C), 192.0 (CHO), 200.2 (C=O).  
MS (EI, 70eV): m/z (%) = 411 (M
+
, 32), 380 (24), 354 (31), 325 (13), 248 (100).  
HRMS (ESI): Calcd for C24H18N3O4 (M+H) 412.1256. Found 412.1253. 
IR (ATR, cm
-1
): 
~  = 2782 (s), 1623 (m), 1600 (m), 1551 (w), 1510 (m), 1483 (w), 1355 (m), 
1303 (m), 1240 (s), 1155 (m), 1030 (m), 910 (s), 816 (m), 705 (s), 665 (m), 605 (s). 
 
5-formyl-6-(2-hydroxybenzoyl)-2-pyperidinothiazolo[4,5-b]pyridine (2.3.5d). 
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Starting from 2.3.3k (0.150 g, 0.35 mmol) and potassium hydroxide 
(0.078 g, 1.40 mmol) in 10 mL ethanol. 2.3.5d was isolated as white 
solid (0.083 g, 65%), mp 143-145 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 1.73 (m, 6H, piperidine), 3.75 (m, 
4H, piperidine), 6.79 (td, 1H, 
3
J = 8.0 Hz,
 4
J = 0.9 Hz, CHAr), 7.11 (dd, 1H, 
3
J = 8.3 Hz,
 4
J = 
0.8 Hz, CHAr), 7.42 (dd, 1H, 
3
J = 8.0 Hz,
 4
J = 1.6 Hz, CHAr), 7.51–7.57 (m, 1H, CHAr), 7.91 
(s, 1H, Py), 10.11 (s, 1H, OH), 11.70 (s, 1H, COH).  
13
C NMR (75.5 MHz, DMSO-d6): δ = 24.0, 25.4, 50.0 (CH2 piperidine), 119.7, 120.2 (CH), 
120.8, 122.9, 126.4 (C), 129.9, 134.1, 138.4 (CH), 152.6, 163.3, 166.9, 171.5 (C), 191.6 
(CHO), 199.9 (C=O).  
MS (EI, 70eV): m/z (%) = 367 (M
+
, 16), 338 (32), 321 (71), 244 (100), 216 (46).  
HRMS (ESI): Calcd for C19H18N3O3S (M+H) 368.1223. Found 368.1229. 
IR (ATR, cm
-1
): 
~  = 2845 (m), 1622 (m), 1582 (w), 1510 (m), 1482 (w), 1333 (m), 1290 (m), 
1213 (s), 1113 (m), 931 (m), 852 (w), 787 (s), 729 (s), 707 (s), 623 (m), 605 (m). 
 
6-(2-hydroxybenzoyl)-7-(formyl)-1,3-dimethylpyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione 
(2.3.5e). 
Starting from 2.3.3m (0.150 g, 0.38 mmol) and potassium hydroxide 
(0.085 g, 1.52 mmol) in 10 mL ethanol. 2.3.5e was isolated as yellow 
solid (0.103 g, 80%), mp 221-223 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 3.30 (s, 3H, Me), 3.70 (s, 3H, 
Me), 7.01-7.07 (m, 2H, CHAr), 7.51 (dd, 1H, 
3
J = 8.1 Hz,
 4
J = 1.5 Hz, 
CHAr), 7.54-7.59 (m, 1H, CHAr), 8.33 (s, 1H, Py), 10.02 (s, 1H, OH), 10.59 (s, 1H, COH).  
13
C NMR (75.5 MHz, DMSO-d6): δ = 28.5, 29.4 (Me), 110.6 (C), 117.4, 119.8 (CH), 124.2, 
126.2 (C), 131.6, 135.9, 141.2 (CH), 151.1, 152.1, 157.9, 158.1, 160.0 (C), 192.7 (CHO), 
194.5 (C=O).  
MS (EI, 70eV): m/z (%) = 339 (M
+
, 9), 324 (69), 309 (100), 292 (23), 263 (14).  
HRMS (EI): Calcd for C17H13N3O5 (M
+
) 339.0986. Found 339.0988. 
IR (ATR, cm
-1
): 
~  = 2779 (m), 1738 (m), 1656 (m), 1630 (m), 1607 (m), 1569 (m), 1485 (m), 
1359 (s), 1225 (s), 1162 (s), 1100 (w), 963 (w), 916 (m), 789 (s), 756 (s), 661 (m). 
 
2-formyl-3-(2-hydroxybenzoyl)-5,7-dimethoxyquinoline (2.3.5f). 
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Starting from 2.3.3o (0.150 g, 0.38 mmol) and potassium hydroxide 
(0.085 g, 1.52 mmol) in 10 mL ethanol. 2.3.5f was isolated as white 
solid (0.099 g, 77%), mp 223-225 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 3.98 (s, 3H, OMe), 4.00 (s, 3H, 
OMe), 6.87 (s, 1H, CHAr), 7.01-7.06 (m, 2H, CHAr), 7.25 (s, 1H, 
CHAr), 7.51-7.58 (m, 2H, CHAr), 8.36 (s, 1H, Py), 10.13 (s, 1H, OH), 10.55 (s, 1H, COH).  
13
C NMR (75.5 MHz, DMSO-d6): δ = 56.1, 56.4 (OMe), 94.7, 100.9 (CH), 114.7 (C), 117.6, 
119.7 (CH), 124.2, 125.9 (C), 132.1, 134.0, 135.6 (CH), 150.1, 154.1, 156.0, 158.2, 163.9 (C), 
191.6 (CHO), 196.5 (C=O).  
MS (EI, 70eV): m/z (%) = 337 (M
+
, 27), 306 (40), 370 (100), 253 (36), 224 (12), 196 (11).  
HRMS (EI): Calcd for C19H15NO5 (M
+
) 337.1229. Found 337.1227. 
IR (ATR, cm
-1
): 
~  = 2755 (m), 1623 (s), 1601 (m), 1589 (m), 1462 (m), 1301 (s), 1209 (m), 
1055 (w), 1003 (m), 921 (s), 817 (s), 760 (s), 608 (m). 
 
A.2.4. General procedure for the synthesis of 3-methoxalylchromone 2.4.1: 
 
To a dry dichloromethane solution (100 mL) of 3-(dimethylamino)-1-(2-hydroxyphenyl)prop-
2-en-1-one 2.3.1 (20 g, 105 mmol) was added 27 mL dry pyridine (345 mmol). The solution 
was set on stirring on ice bath, subsequently corresponding methyloxalylchloride (10.6 mL, 
115.5 mmol) was added dropwise. Afterwards the reaction mixture was stirred at r.t. for 8 h. 
Next the reaction mixture was stripped of solvents and liquid residues. The residue was 
washed with water. 3-Methoxalylchromone 2.4.1 was obtained as light pink crystals (19.1 g, 
79%), mp 133-135 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 3.88 (s, 3H, OMe), 7.61 (t, 1H, 
3
J 
= 7.3 Hz, CHAr), 7.78-7.81 (m, 1H, CHAr), 7.90-7.95 (m, 1H, CHAr), 
8.11 (dd, 1H, 
3
J = 7.9 Hz, 
4
J = 1.5 Hz, CHAr), 9.12 (s, 1H, Pyranone). 
13
C NMR (62.9 MHz, DMSO-d6): δ = 52.7 (OMe), 118.5 (C), 118.9 
(CH), 123.9 (C), 125.2, 127.0, 135.6 (CH), 155.6, 164.0 (C), 164.6 (CH), 174.1, 184.6 (C).   
MS (GC, 70 eV): m/z (%) = 232 (M
+
, 3), 204 (21), 189 (16), 173 (100), 121 (40). 
HRMS (ESI): Calcd for C12H9O5 (M+H) 233.0459. Found 233.0461. 
IR (ATR, cm
-1
): 
~  = 1728 (m), 1693 (m), 1645 (s), 1465 (m), 1395 (m), 1328 (s), 1231 (m), 
1171 (m), 1107 (m), 1016 (s), 854 (m), 800 (m), 763 (s), 705 (s). 
 
A.2.5. General procedure for the synthesis of compounds 2.4.2a-b, h-q in acetic acid. 
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In a round-bottom flask the mixture of 3-methoxalylchromone 2.4.1 (1 equiv.) and 
appropriate aminoheterocycle E (1.1 equiv.) was dissolved in AcOH (10 mL/1.0 mmol of 
chromone 2.4.1) and heated under reflux in an inert atmosphere for 2-5 h (controlled by 
TLC). After completion of the reaction volatiles were evaporated under reduced pressure. The 
residue was treated with water, filtered, dried in air, and recrystallized from appropriate 
solvent or subjected to column chromatography (silica gel). 
 
A.2.6. General procedure for the synthesis of compounds 2.4.2c-g in TMSCl/DMF. 
 
The 3-methoxalylchromone 2.4.1 (1 equiv.) and 4-amino-1H-imidazole-2(3H)-thione E2 (1.1 
equiv.) were placed in a pressure tube under the flow of dry argon and dissolved in dry DMF 
(5 mL/1 mmol of chromone 2.4.1) containing 1 mL of TMSCl. The mixture was heated at 
100-120 °C for 5-7 h (controlled by TLC). After the reaction was completed volatiles were 
evaporated under reduced pressure. The residue was treated with water, filtered, dried in air, 
and recrystallized from appropriate solvent or subjected to column chromatography (silica 
gel). 
 
Methyl 5-(2-hydroxybenzoyl)-2,3-dihydro-3-oxo-2-phenyl-1H-pyrazolo[3,4-b]pyridine-6-
carboxylate (2.4.2a). 
Starting from 3-methoxalylchromone 2.4.1 (0.232 g, 1 mmol) and 
5-amino-1,2-dihydro-2-phenylpyrazol-3-one E1a (0.193 g, 1.1 
mmol) in 10 mL AcOH. 2.4.2a was isolated as green solid (0.222 
g, 57%), mp 222-224 
o
C.  
1
H NMR (300 MHz, DMSO-d6): δ = 3.76 (s, 3H, OMe), 6.93-7.02 
(m, 2H, CHAr), 7.33 (t, 1H, 
3
J = 7.6 Hz, CHAr), 7.46-7.58 (m, 4H, CHAr), 7.88 (d, 2H, 
3
J = 8.1 
Hz, CHAr), 8.34 (s, 1H, Py), 10.77 (s, 1H, OH), 12.5 (br. S, 1H, NH). 
13
C NMR (62.9 MHz, DMSO-d6): δ = 52.8 (OMe), 110.0 (C), 117.2, 119.4, 120.1 (CH), 
122.6 (C), 126.0, 128.0, 129.2, 131.5, 135.2, 135.8 (CH), 136.4, 152.0, 155.2, 157.0, 158.5, 
165.6 (C), 195.2 (C=O).  
MS (EI, 70 eV): m/z (%) = 389 (M
+
, 14), 357 (28), 344 (11), 330 (M
+
-CO2Me, 100). 
HRMS (ESI): Calcd for C21H16O5N3 (M+H) 390.1084. Found 390.1083.  
IR (ATR, cm
-1
): 
~  = 3033 (w), 1720 (w), 1643 (s), 1482 (w), 1438 (w), 1356 (m), 1296 (m), 
1253 (m), 1201 (m), 1182 (m), 1147 (m), 1120 (m), 1088 (m), 1033 (w), 928 (w), 870 (w), 
OH
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828 (w), 752 (s), 684 (s), 662 (m). 
 
Methyl 5-(2-hydroxybenzoyl)-2,3-dihydro-2-methyl-3-oxo-1H-pyrazolo[3,4-b]pyridine-6-
carboxylate (2.4.2b). 
Starting from 3-methoxalylchromone 2.4.1 (0.232 g, 1 mmol) and 
5-amino-1,2-dihydro-2-methylpyrazol-3-one E1b (0.124 g, 1.1 
mmol) in 10 mL AcOH. 2.4.2b was isolated as white solid (0.262 
g, 80%), mp 245-247 
o
C.  
1
H NMR (300 MHz, DMSO-d6): δ = 3.49 (s, 3H, NMe), 3.73 (s, 
3H, OMe), 6.91-7.01 (m, 2H, CHAr), 7.41 (t, 1H, 
3
J = 7.8 Hz, CHAr), 7.50 (d, 1H, 
3
J = 7.5 Hz, 
CHAr), 8.22 (s, 1H, Py), 10.71 (s, 1H, OH), 12.37 (s, 1H, NH). 
13
C NMR (62.9 MHz, DMSO-d6): δ = 30.7 (Me), 52.7 (OMe), 108.4 (C), 117.2, 119.3 (CH), 
122.8, 126.5 (C), 131.4, 135.0, 135.3 (CH), 151.7, 153.4, 156.6, 158.3, 165.9 (C), 195.3 
(C=O).  
MS (EI, 70 eV): m/z (%) = 327 (M
+
, 9), 295 (10), 268 (100), 239 (12), 196 (10), 121 (18).  
HRMS (ESI): Calcd for C16H14O5N3 (M+H) 328.0928. Found 328.0927.  
IR (ATR, cm
-1
): 
~  = 3106 (w), 1715 (m), 1682 (s), 1614 (s), 1567 (w), 1480 (w), 1439 (m), 
1360 (w), 1310 (m), 1241 (s), 1148 (s), 1115 (w), 1031 (w), 973 (w), 918 (m), 850 (w), 803 
(w), 786 (m), 767 (s), 731 (s), 723 (s), 651 (s), 632 (m), 614 (s). 
 
Methyl 6-(2-hydroxybenzoyl)-2,3-dihydro-1,3-dimethyl-2-thioxo-1H-imidazo[4,5-
b]pyridine-5-carboxylate (2.4.2c). 
Starting from 3-methoxalylchromone 2.4.1 (0.232 g, 1 mmol) and 4-
amino-1,3-dimethyl-1H-imidazole-2(3H)-thione E2a (0.157 g, 1.1 
mmol) in 5 mL DMF and 1 mL of TMSCl. 2.4.2c was isolated as 
white solid (0.254 g, 71%), mp 273-275 
o
C. 
1
H NMR (250 MHz, DMSO-d6): δ = 3.35 (s, 6H, 2xNMe), 3.73 (s, 
3H, OMe), 6.88-7.01 (m, 2H, CHAr), 7.32-7.50 (m, 2H, CHAr), 8.07 (s, 1H, Py), 11.20 (s, 1H, 
OH). 
13
C NMR (62.9 MHz, DMSO-d6): δ = 29.9, 30.7 (Me), 52.5 (OMe), 115.5, 117.5, 119.3 (CH), 
121.3, 127.9 (C), 132.2 (CH), 136.2 (CH), 138.1, 144.7, 160.3, 164.9, 173.3 (C), 198.0 
(C=O). 
MS (GC, 70 eV): m/z (%) = 357 (M
+
, 9), 325 (100), 297 (22), 281 (15), 264 (24). 
HRMS (ESI): Calcd for C17H16O4N3S (M+H) 358.0856. Found 358.0857.  
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IR (ATR, cm
-1
): 
~  = 1715 (m), 1631 (m), 1480 (w), 1439 (m), 1404 (w), 1360 (w), 1310 (m), 
1196 (m), 1115 (w), 1031 (w), 973 (w), 918 (m), 850 (w), 803 (w), 786 (m), 731 (s), 723 (s), 
651 (s), 632 (m), 614 (s). 
 
Methyl 6-(2-hydroxybenzoyl)-2,3-dihydro-1-methyl-3-phenyl-2-thioxo-1H-imidazo[4,5-
b]pyridine-5-carboxylate (2.4.2d). 
Starting from 3-methoxalylchromone 2.4.1 (0.232 g, 1 mmol) and 4-
amino-1-methyl-3-phenyl-1H-imidazole-2(3H)-thione E2b (0.226 g, 
1.1 mmol) in 5 mL DMF and 1 mL of TMSCl. 2.4.2d was isolated as 
white solid (0.306 g, 73%), mp 291-292 
o
C. 
1
H NMR (250 MHz, DMSO-d6,80 
o
C): δ = 3.57 (s, 3H, NMe), 3.81 (s, 
3H, OMe), 6.88 (t, 1H, 
3
J = 7.2 Hz, CHAr), 7.02 (d, 1H, 
3
J = 8.0 Hz, CHAr), 7.34 (d, 1H, 
3
J = 
7.1 Hz, CHAr), 7.54-7.63 (m, 6H, CHAr), 8.04 (s, 1H, Py), 11.10 (s, 1H, OH). 
13
C NMR (125.7 MHz, DMSO-d6, 303K): δ = 31.3 (Me), 52.4 (OMe), 115.7, 117.4, 119.1 
(CH), 121.1, 128.0 (C), 128.5, 129.0, 129.1, 132.0 (CH), 133.3, 134.2 (C), 136.0 (CH), 138.3, 
145.1, 160.1, 164.7, 173.5 (C), 197.6 (C=O). 
MS (EI, 70 eV): m/z (%) = 419 (M
+
, 10), 387 (55), 360 (M
+
-CO2Me, 100), 342 (15), 121 (14), 
93 (10), 77 (33), 65 (18), 51 (11). 
HRMS (EI): Calcd for C22H17N3O4S (M
+
) 419.09343. Found 419.09360. 
IR (ATR, cm
-1
): 
~  = 3053 (w), 1710 (m), 1668 (w), 1621 (m), 1607 (s), 1469 (m), 1447 (s), 
1419 (s), 1387 (s), 1340 (s), 1267 (s), 1192 (m), 1148 (m), 1125 (s), 1109 (m), 1030 (m), 954 
(m), 924 (w), 904 (w), 879 (m), 816 (w), 798 (m), 760 (s), 704 (s), 689 (s), 672 (m), 631 (m), 
570 (m). 
 
Methyl 6-(2-hydroxybenzoyl)-3-cyclohexyl-2,3-dihydro-1-methyl-2-thioxo-1H-
imidazo[4,5-b]pyridine-5-carboxylate (2.4.2e). 
Starting from 3-methoxalylchromone 2.4.1 (0.232 g, 1 mmol) and 4-
amino-3-cyclohexyl-1-methyl-1H-imidazole-2(3H)-thione E2c (0.205 
g, 1.1 mmol) in 5 mL DMF and 1 mL of TMSCl. 2.4.2e was isolated as 
pink solid (0.272 g, 64%), mp 291-292 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 1.16-1.95 (m, 10H, cyclohexyl), 
3.37 (m, 1H, CHN), 3.70 (s, 3H, NMe), 3.75 (s, 3H, OMe), 6.89-6.94 
(m, 1H, CHAr), 7.03 (d, 1H, 
3
J = 7.7 Hz, CHAr), 7.46-7.56 (m, 2H, CHAr), 8.08 (s, 1H, Py), 
11.01 (s, 1H, OH). 
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13
C NMR (75.5 MHz, DMSO-d6): δ = 24.2, 24.7 (CH2 cyclohexyl), 30.7 (CHN), 31.8 (CH2 
cyclohexyl), 48.6 (Me), 53.0 (OMe), 112.4 (C), 117.6, 119.3 (CH), 120.2, 121.3 (C), 128.6, 
131.7 (CH), 134.2 (C), 136.2 (CH), 137.9, 138.1, 145.8, 160.0, 163.9 (C), 195.7 (C=O). 
MS (GC, 70 eV): m/z (%) = 425 (M
+
, 33), 382 (100), 366 (M
+
-CO2Me, 62), 310 (9), 284 (17). 
HRMS (EI): Calcd for C22H23N3O4S (M
+
) 425.14038. Found 425.14045. 
IR (ATR, cm
-1
): 
~  = 2929 (w), 2853 (w), 2139 (w), 1947 (w), 1737 (m), 1614 (s), 1574 (s), 
1438 (m), 1340 (m), 1297 (m), 1275 (w), 1241 (s), 1150 (m), 1069 (w), 1031 (w), 976 (w), 
887 (m), 822 (m), 758 (s), 712 (s), 679 (m), 559 (m). 
 
Methyl 6-(2-hydroxybenzoyl)-3-ethyl-2,3-dihydro-1-methyl-2-thioxo-1H-imidazo[4,5-
b]pyridine-5-carboxylate (2.4.2f). 
Starting from 3-methoxalylchromone 2.4.1 (0.232 g, 1 mmol) and 4-
amino-3-ethyl-1-methyl-1H-imidazole-2(3H)-thione E2d (0.173 g, 
1.1 mmol) in 5 mL DMF and 1 mL of TMSCl. 2.4.2f was isolated as 
yellow solid (0.260 g, 70%), mp 212-213 
o
C. 
1
H NMR (500 MHz, DMSO-d6, 70 
o
C): δ = 1.34 (t, 3H, 3J = 7.2 Hz, 
Me), 3.48 (q, 2H, 
3
J = 7.2 Hz, CH2), 3.69 (s, 6H, OMe, NMe), 6.90 (t, 1H, 
3
J = 8.0 Hz, CHAr), 
7.04 (d, 1H, 
3
J = 8.0 Hz, CHAr), 7.40-7.42 (m, 1H, CHAr), 7.52-7.55 (m, 1H, CHAr), 7.94 (s, 
1H, Py), 11.0 (s, 1H, OH). 
13
C NMR (125.8 MHz, DMSO-d6, 70 
o
C): δ = 13.8, 31.9 (Me), 46.0 (CH2), 52.1 (OMe), 
116.3, 117.4, 118.9 (CH), 120.9 (C), 131.5 (CH), 135.9 (C), 137.0 (CH), 137.7, 138.2, 141.6, 
145.8, 160.0, 163.6 (C), 196.1 (C=O). 
MS (GC, 70 eV): m/z (%) = 371 (M
+
, 11), 356 (23), 324 (18), 312 (100). 
HRMS (ESI): Calcd for C18H18N3O4S (M+H) 372.1013. Found 372.1015.  
IR (ATR, cm
-1
): 
~  = 2561 (w), 1719 (m), 1625 (s), 1575 (s), 1438 (m), 1369 (m), 1348 (m), 
1299 (s), 1261 (s), 1243 (s), 1216 (s), 1184 (s), 1126 (s), 1107 (m), 1032 (w), 910 (m), 887 
(m), 821 (m), 800 (m), 759 (s), 731 (s), 685 (s). 
 
Methyl 6-(2-hydroxybenzoyl)-3-(4-chlorophenyl)-2,3-dihydro-1-methyl-2-oxo-1H-
imidazo[4,5-b]pyridine-5-carboxylate (2.4.2g). 
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Starting from 3-methoxalylchromone 2.4.1 (0.232 g, 1 mmol) and 4-
amino-3-(4-chlorophenyl)-1-methyl-1H-imidazol-2(3H)-one E2e 
(0.246 g, 1.1 mmol) in 5 mL DMF and 1 mL of TMSCl. 2.4.2g was 
isolated as white solid (0.302 g, 69%), mp 275-277 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 3.46 (s, 3H, NMe), 3.60 (s, 3H, 
OMe), 6.87 (td, 1H, 
3
J = 8.0 Hz, 
4
J = 0.9 Hz, CHAr), 7.03 (dd, 1H, 
3
J = 
8.0 Hz, 
4
J = 0.9 Hz, CHAr), 7.30 (dd, 1H, 
3
J = 8.0 Hz, 
4
J = 1.6 Hz, 
CHAr), 7.55 (td, 1H, 
3
J = 8.0 Hz, 
4
J = 1.6 Hz, CHAr), 7.66-7.76 (m, 4H, C6H4), 7.88 (s, 1H, 
Py), 11.30 (s, 1H, OH).  
13
C NMR (75.5 MHz, DMSO-d6): δ = 27.5 (Me), 52.3 (OMe), 113.5, 117.6, 119.3 (CH), 
121.1, 127.1 (C), 128.2, 129.1 (CH), 131.8 (C), 132.1 (CH), 132.3, 133.0, 135.7 (C), 136.2 
(CH), 142.6, 152.8, 160.4, 164.9 (C), 198.6 (C=O). 
MS (EI, 70 eV): m/z (%) = 437 (M
+
, 3), 405 (24), 378 (M
+
-CO2Me, 100), 348 (11). 
HRMS (EI): Calcd for C22H16ClN3O5 (M
+
) 437.07730. Found 437.07733. 
IR (ATR, cm
-1
): 
~  = 1735 (s), 1713 (s), 1628 (s), 1499 (m), 1482 (s), 1450 (m), 1399 (m), 
1301 (m), 1245 (s), 1217 (s), 1190 (m), 1118 (m), 1086 (m), 1058 (w), 1015 (m), 961 (w), 
929 (s), 910 (m), 874 (w), 799 (w), 742 (s), 733 (s), 708 (m), 674 (m), 624 (w), 587 (s), 566 
(m). 
 
Methyl 5-(2-hydroxybenzoyl)-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-
carboxylate (2.4.2h). 
Starting from 3-methoxalylchromone 2.4.1 (0.232 g, 1 mmol) and and 4-
amino-1H-imidazole-2(3H)-thione E3 (0.190 g, 1.1 mmol) in 10 mL 
AcOH. 2.4.2h was isolated as light yellow solid (0.283 g, 73%), mp 179-
180 
o
C. 
1
H NMR (500 MHz, DMSO-d6): δ = 2.65 (s, 3H, Me), 3.72 (s, 3H, 
OMe), 6.93 (t, 1H, 
3
J = 7.8 Hz, CHAr), 7.01 (d, 1H, 
3
J = 8.0 Hz, CHAr), 7.37 (t, 1H, 
3
J = 7.4 
Hz, CHAr), 7.48 (dd, 1H, 
3
J = 8.2 Hz, 
4
J = 1.6 Hz, CHAr), 7.52-7.60 (m, 3H, CHAr), 8.23 (d, 
2H, 
3
J = 7.7 Hz, CHAr), 8.65 (s, 1H, Py), 10.94 (s, 1H, OH). 
13
C NMR (125.7 MHz, DMSO-d6): δ = 12.2 (Me), 52.8 (OMe), 116.9 (C), 117.4, 119.3, 120.4 
(CH), 122.1, 126.2 (C), 129.3, 129.6, 131.9, 132.2, 135.7 (CH), 138.5, 144.3, 147.0, 148.8, 
159.4, 165.5 (C), 196.8 (C=O). 
MS (GC, 70 eV): m/z (%) = 387 (M
+
, 5), 328 (M
+
-CO2Me, 100). 
HRMS (ESI): Calcd for C22H18N3O4 (M+H) 388.1292. Found 388.1297.  
N CO2Me
O
OH
N
N
Me
O
Cl  
OH
O
N CO2Me
N
N
Me
Ph  
 119 
 
IR (ATR, cm
-1
): 
~  = 3049 (w), 2925 (w), 1710 (m), 1625 (w), 1610 (w), 1595 (m), 1486 (m), 
1441 (m), 1330 (w), 1292 (m), 1266 (s), 1240 (s), 1166 (s), 1119 (m), 1102 (m), 1034 (w), 
1011 (w), 837 (w), 819 (w), 780 (m), 752 (s), 709 (m), 691 (s), 667 (s), 637 (s), 569 (m). 
 
Methyl 1-(4-methoxybenzyl)-5-(2-hydroxybenzoyl)-3-cyano-1H-pyrrolo[2,3-b]pyridine-
6-carboxylate (2.4.2i). 
Starting from 3-methoxalylchromone 2.4.1 (0.232 g, 1 mmol) and 1-(4-
methoxybenzyl)-5-amino-1H-pyrrole-3-carbonitrile E4a (0.250 g, 1.1 
mmol) in 10 mL AcOH. 2.4.2i was isolated as brown solid (0.344 g, 
78%), mp 186-187 
o
C. 
1
H NMR (250 MHz, DMSO-d6): δ = 3.72 (s, 6H, 2xOMe), 5.54 (s, 2H, 
CH2), 6.91-7.02 (m, 4H, CHAr), 7.34-7.55 (m, 4H, CHAr), 8.39 (s, 1H, Py), 
8.88 (s, 1H, pirrole), 11.06 (s, 1H, OH). 
13
C NMR (62.9 MHz, DMSO-d6): δ = 47.9 (CH2), 52.7, 55.1 (OMe), 84.3 (CN), 114.1 (CH), 
114.2 (C), 117.4, 119.3 (CH), 120.4, 121.8, 128.2 (C), 128.5, 129.4 (CH), 131.2 (C), 132.1, 
135.8, 141.6 (CH), 142.1, 145.1, 159.1, 159.8, 165.4 (C), 197.7 (C=O). 
MS (EI, 70 eV): m/z (%) = 441 (M
+
, 27), 121 (100), 91 (13), 77 (20). 
HRMS (ESI): Calcd for C25H20O5N3 (M+H) 442.1244. Found 442.1242. 
IR (ATR, cm
-1
): 
~  = 3056 (w), 2236 (w), 1645 (m), 1627 (m), 1600 (m), 1515 (m), 1481 (w), 
1458 (m), 1409 (m), 1360 (s), 1309 (m), 1291 (s), 1217 (m), 1209 (m), 1155 (w), 1114 (w), 
1084 (w), 1038 (w), 993 (w), 905 (m), 887 (w), 857 (w), 763 (s), 751 (s),741 (s), 675 (w), 575 
(w), 560 (m). 
 
Methyl 5-(2-hydroxybenzoyl)-3-cyano-1-cyclohexyl-1H-pyrrolo[2,3-b]pyridine-6-
carboxylate (2.4.2j). 
Starting from 3-methoxalylchromone 2.4.1 (0.232 g, 1 mmol) and 5-
amino-1-cyclohexyl-1H-pyrrole-3-carbonitrile E4b (0.208 g, 1.1 mmol) 
in 10 mL AcOH. 2.4.2j was isolated as brown solid (0.303 g, 75%), mp 
185–187 oC. 
1
H NMR (300 MHz, DMSO-d6): δ = 1.25-2.05 (m, 10H, cyclohexyl), 
3.71 (s, 3H, MeO), 4.79-4.81 (m, 1H, CHN), 6.90 (td, 1H, 
3
J = 8.0 Hz, 
4
J = 0.9 Hz, CHAr), 6.99 (d, 1H, 
3
J = 8.3 Hz, CHAr), 7.37 (dd, 1H, 
3
J = 7.7 Hz, 
4
J = 1.7 Hz, 
CHAr), 7.50-7.53 (m, 1H, CHAr), 8.36 (s, 1H, Py), 8.99 (s, 1H, pirrole), 11.05 (s, 1H, OH).  
13
C NMR (75.5 MHz, DMSO-d6): δ = 24.7, 25.1, 32.4 (CH2 cyclohexyl), 52.8 (OMe), 54.3 
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(CHN), 84.1 (CN), 114.5 (C), 117.4, 119.3 (CH), 120.4, 121.7 (C), 128.5 (CH), 131.0 (C), 
132.0, 135.8, 139.5 (CH), 141.9, 144.7, 160.0, 165.5 (C), 197.6 (C=O).  
MS (GC, 70 eV): m/z (%) = 403 (M
+
, 6), 371 (5), 344 (M
+
-CO2Me, 100), 289 (23), 262 (38). 
HRMS (ESI): Calcd for C23H22O4N3 (M+H) 404.1605. Found 404.1607.  
IR (ATR, cm
-1
): 
~  = 2933 (w), 2855 (w), 2226 (m), 1719 (m), 1636 (m), 1483 (w), 1448 (m), 
1374 (m), 1300 (m), 1263 (s), 1202 (s), 1147 (s), 1083 (m), 748 (s), 671 (m), 630 (m). 
 
Methyl 1-tert-butyl-5-(2-hydroxybenzoyl)-3-cyano-1H-pyrrolo[2,3-b]pyridine-6-
carboxylate (2.4.2k). 
Starting from 3-methoxalylchromone 2.4.1 (0.232 g, 1 mmol) and 1-
tert-butyl-5-amino-1H-pyrrole-3-carbonitrile E4c (0.179 g, 1.1 
mmol) in 10 mL AcOH. 2.4.2k was isolated as yellow solid (0.336 
g, 89%), mp 145-147 
o
C. 
1
H NMR (300 MHz, CDCl3): δ = 1.88 (s, 9H, t-Bu), 3.78 (s, 3H, 
OMe), 6.79 (td, 1H, 
3
J = 8.0 Hz, 
4
J = 0.9 Hz, CHAr), 7.06 (d, 1H, 
3
J 
= 8.0 Hz, CHAr), 7.16 (dd, 1H, 
3
J = 7.8 Hz, 
4
J = 1.5 Hz, CHAr), 7.45–7.51 (m, 1H, CHAr), 8.10 
(s, 1H, Py), 8.12 (s, 1H, pirrole), 11.82 (s, 1H, OH).  
13
C NMR (62.9 MHz, DMSO-d6): δ = 28.6 (t-Bu), 52.7 (OMe), 59.4 (Ct-Bu), 83.0 (CN), 
114.6 (C), 117.4, 119.3 (CH), 121.7, 121.8 (C), 127.9 (CH), 130.7 (C), 132.1, 135.8, 140.2 
(CH), 140.5, 145.3, 159.8, 165.4 (C), 197.8 (C=O). 
MS (GC, 70 eV): m/z (%) = 377 (M
+
, 4), 318 (49), 289 (35), 262 (100).  
HRMS (ESI): Calcd for C21H20O4N3 (M+H) 378.1448. Found 378.1448.  
IR (ATR, cm
-1
): 
~  = 2985 (w), 2224 (m), 1709 (m), 1628 (m), 1606 (m), 1519 (w), 1484 (w), 
1417 (m), 1377 (m), 1301 (m), 1264 (s), 1198 (s), 1163 (m), 1102 (m), 1031 (w), 947 (m), 
877 (m), 821 (m), 764 (m), 729 (s), 673 (m), 622 (m). 
 
Methyl 6-(2-hydroxybenzoyl)-2-(dimethylamino)thiazolo[4,5-b]pyridine-5-carboxylate 
(2.4.2l). 
Starting from 3-methoxalylchromone 2.4.1 (0.232 g, 1 mmol) and 
N
2
,N
2
-dimethylthiazole-2,4-diamine E5a (0.157 g, 1.1 mmol) in 10 
mL AcOH. 2.4.2l was isolated as yellow solid (0.243 g, 68%), mp 
190-192 
o
C. 
1
H NMR (250 MHz, DMSO-d6): δ = 3.23 (s, 6H, NMe2), 3.67 (s, 
3H, OMe), 6.90 (td, 1H, 
3
J = 8.0 Hz, 
4
J = 1.0 Hz, CHAr), 7.00 (dd, 1H, 
3
J = 8.0 Hz, 
4
J = 1.0 
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Hz, CHAr), 7.36 (dd, 1H, 
3
J = 7.8 Hz, 
4
J = 1.7 Hz, CHAr), 7.48–7.54 (m, 1H, CHAr), 8.40 (s, 
1H, Py), 11.00 (s, 1H, OH). 
 
13
C NMR (62.9 MHz, DMSO-d6): δ = 40.0 (NMe2), 52.3 (OMe), 117.4, 119.3 (CH), 122.1, 
127.5, 127.6 (C), 130.1, 131.7, 135.5 (CH), 144.8, 159.4, 164.5, 165.9, 171.9 (C), 197.3 
(C=O).  
MS (GC, 70 eV): m/z (%) = 357 (M
+
, 1), 298 (M
+
-CO2Me, 100). 
HRMS (ESI): Calcd for C17H16N3O4S (M+H) 358.0856. Found 358.0856.  
IR (ATR, cm
-1
): 
~  = 1712 (m), 1625 (w), 1562 (m), 1504 (w), 1483 (w), 1386 (w), 1352 (m), 
1286 (s), 1228 (s), 1151 (m), 943 (m), 927 (w), 832 (w), 811 (m), 771 (s), 760 (s), 725 (m), 
705 (w), 678 (m), 632 (w), 619 (m). 
 
Methyl 6-(2-hydroxybenzoyl)-2-morpholinothiazolo[4,5-b]pyridine-5-carboxylate 
(2.4.2m). 
Starting from 3-methoxalylchromone 2.4.1 (0.232 g, 1 mmol) and 
2-morpholinothiazol-4-amine E5b (0.204 g, 1.1 mmol) in 10 mL 
AcOH. 2.4.2m was isolated as brown solid (0.283 g, 71%), mp 
244-246 
o
C. 
1
H NMR (500 MHz, DMSO-d6): δ = 3.67 (s, 3H, OMe), 3.70–3.77 (m, 8H, morpholine), 6.90 
(td, 1H, 
3
J = 8.1 Hz, 
4
J = 1.0 Hz, CHAr), 7.00 (dd, 1H, 
3
J = 8.0 Hz, 
4
J = 1.0 Hz, CHAr), 7.36 
(dd, 1H, 
3
J = 8.0 Hz, 
4
J = 1.6 Hz, CHAr), 7.50-7.53 (m, 1H, CHAr), 8.44 (s, 1H, Py), 10.97 (s, 
1H, OH). 
 
13
C NMR (125.8 MHz, DMSO-d6): δ = 23.4, 24.9, 49.2 (CH2 morpholine), 52.3 (OMe), 
117.4, 119.3 (CH), 122.0, 127.2, 128.2 (C), 130.4, 131.7, 135.5 (CH), 144.7, 159.4, 164.1, 
165.8, 172.1 (C), 197.2 (C=O). 
MS (EI, 70 eV): m/z (%) = 399 (M
+
, 3), 367 (10), 340 (M
+
-CO2Me, 100), 282 (13), 69 (12). 
HRMS (ESI): Calcd for C19H18N3O5S (M+H) 400.0962. Found 400.0964. 
IR (ATR, cm
-1
): 
~  = 2922 (w), 1716 (m), 1623 (w), 1558 (s), 1507 (w), 1437 (m), 1389 (m), 
1280 (s), 1257 (s), 1146 (m), 1063 (s), 1024 (m), 957 (w), 862 (w), 829 (w), 757 (s), 743 (s), 
717 (m), 677 (m), 624 (m). 
 
Methyl 6-(2-hydroxybenzoyl)-2-(piperidin-1-yl)thiazolo[4,5-b]pyridine-5-carboxylate 
(2.4.2n). 
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Starting from 3-methoxalylchromone 2.4.1 (0.232 g, 1 mmol) and 
2-(piperidin-1-yl)thiazol-4-amine E5c (0.201 g, 1.1 mmol) in 10 
mL AcOH. 2.4.2n was isolated as orange solid (0.306 g, 77%), 
mp 166-168
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 1.66 (s, 6H, piperidine), 3.66 (s, 7H, piperidine, OMe), 
6.88-6.93 (m, 1H, CHAr), 7.00 (dd, 1H, 
3
J = 8.2 Hz, 
4
J = 0.8 Hz, CHAr), 7.35 (dd, 1H, 
3
J = 7.8 
Hz, 
4
J = 1.6 Hz, CHAr), 7.48–7.54 (m, 1H, CHAr), 8.38 (s, 1H, Py), 11.00 (s, 1H, OH).  
13
C NMR (62.9 MHz, DMSO-d6): δ = 23.4, 24.9, 49.2 (CH2 piperidine), 52.3 (OMe), 117.4, 
119.2 (CH), 122.0, 127.3, 127.7 (C), 130.0, 131.7, 135.5 (CH), 144.7, 159.5, 164.6, 165.9, 
171.3 (C), 197.3 (C=O).  
MS (EI, 70 eV): m/z (%) = 397 (M
+
, 14), 365 (48), 338 (M
+
-CO2Me, 100), 308 (24), 282 (38), 
269 (18), 121 (11), 69 (10), 41 (15). 
HRMS (ESI): Calcd for C20H20O4N3S (M+H) 398.1169. Found 398.1177. 
IR (ATR, cm
-1
): 
~  = 2938 (w), 2852 (w), 1711 (m), 1672 (m), 1547 (s), 1505 (m), 1439 (m), 
1428 (m), 1392 (m), 1324 (s), 1283 (s), 1215 (s), 1124 (s), 1008 (w), 941 (m), 883 (m), 855 
(m), 756 (s), 719 (s), 677 (m), 632 (s). 
 
Methyl 6-(2-hydroxybenzoyl)-1,2,3,4-tetrahydro-2,4-dioxopyrido[2,3-d]pyrimidine-7-
carboxylate (2.4.2o). 
Starting from 3-methoxalylchromone 2.4.1 (0.232 g, 1 mmol) and 6-
aminopyrimidine-2,4(1H,3H)-dione E6a (0.140 g, 1.1 mmol) in 10 
mL AcOH. 2.4.2o was isolated as white solid (0.218 g, 64%), mp 
262-264 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 3.73 (s, 3H, OMe), 6.92-7.00 (m, 
2H, CHAr), 7.43 (dd, 1H, 
3
J = 7.9 Hz, 
4
J = 1.6 Hz, CHAr), 7.48-7.54 (m, 1H, CHAr), 8.32 (s, 
1H, Py), 10.68 (s, 1H, OH), 11.73 (s, 1H, NH), 12.22 (s, 1H, NH). 
13
C NMR (62.9 MHz, DMSO-d6): δ = 52.9 (OMe), 111.0 (C), 117.2, 119.5 (CH), 122.7, 
129.1 (C), 131.3, 135.3, 138.4 (CH), 150.3, 152.3, 153.1, 158.3, 161.5, 165.2 (C), 194.3 
(C=O). 
MS (EI, 70 eV): m/z (%) = 341 (M
+
, 7), 282 (M
+
-CO2Me, 100), 238 (41), 210 (22), 121 (19), 
65 (10).  
HRMS (ESI): Calcd for C16H12N3O6 (M+H) 342.0721. Found 342.0726. 
IR (ATR, cm
-1
): 
~  = 3197 (w), 3095 (w), 1748 (w), 1731 (m), 1692 (m), 1636 (m), 1574 (m), 
1505 (w), 1484 (w), 1399 (w), 1360 (w), 1328 (m), 1270 (s), 1243 (m), 1147 (m), 1116 (w), 
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1053 (w), 1015 (w), 920 (w), 829 (m), 818 (m), 793 (w), 759 (s), 722 (m), 688 (m), 657 (m), 
627 (w). 
 
Methyl 6-(2-hydroxybenzoyl)-1,2,3,4-tetrahydro-1,3-dimethyl-2,4-dioxopyrido[2,3-
d]pyrimidine-7-carboxylate (2.4.2p). 
Starting from 3-methoxalylchromone 2.4.1 (0.232 g, 1 mmol) and 6-
amino-1,3-dimethylpyrimidine-2,4(1H,3H)-dione E6b (0.171 g, 1.1 
mmol) in 10 mL AcOH. 2.4.2p was isolated as white solid (0.203 g, 
55%), mp 203-204 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 3.31 (s, 3H, NMe), 3.59 (s, 3H, 
NMe), 3.74 (s, 3H, OMe), 6.93-7.00 (m, 2H, CHAr), 7.45 (dd, 1H, 
3
J = 7.4 Hz, 
4
J = 1.6 Hz, 
CHAr), 7.49-7.55 (m, 1H, CHAr), 8.44 (s, 1H, Py), 10.66 (s, 1H, OH). 
13
C NMR (75.5 MHz, DMSO-d6): δ = 28.3, 29.5 (Me), 52.9 (OMe), 111.3 (C), 117.2, 119.4 
(CH), 122.7, 129.3 (C), 131.2, 135.3, 138.7 (CH), 150.8, 151.1, 151.5, 158.2, 160.0, 165.1 
(C), 193.9 (C=O). 
MS (EI, 70 eV): m/z (%) = 369 (M
+
, 1), 337 (71), 309 (51), 280 (21), 225 (10), 197 (100), 140 
(9), 81 (10). 
HRMS (ESI): Calcd for C18H16O6N3 (M+H) 370.1034. Found 370.1034. 
IR (ATR, cm
-1
): 
~  = 1714 (m), 1660 (s), 1633 (s), 1603 (s), 1464 (m), 1409 (w), 1352 (m), 
1290 (s), 1264 (s), 1239 (s), 1214 (s), 1151 (m), 1081 (w), 1052 (w), 959 (w), 906 (m), 868 
(m), 812 (w), 788 (s), 751 (s), 713 (m), 689 (m), 663 (m). 
 
Methyl 6-(2-hydroxybenzoyl)-1,2,3,4-tetrahydro-1-methyl-2,4-dioxopyrido[2,3-
d]pyrimidine-7-carboxylate (2.4.2q). 
Starting from 3-methoxalylchromone 2.4.1 (0.232 g, 1 mmol) and 6-
amino-1-methylpyrimidine-2,4(1H,3H)-dione E6c (0.155 g, 1.1 mmol) 
in 10 mL AcOH. 2.4.2q was isolated as yellow solid (0.213 g, 60%), 
mp 243-245 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 3.51 (s, 3H, NMe), 3.74 (s, 3H, 
OMe), 6.93-7.00 (m, 2H, CHAr), 7.43-7.54 (m, 2H, CHAr), 8.38 (s, 1H, Py), 10.66 (s, 1H, 
OH), 12.00 (s, 1H, NH). 
13
C NMR (62.9 MHz, DMSO-d6): δ = 28.6 (Me), 52.9 (OMe), 112.1 (C), 117.2, 119.4 (CH), 
122.7, 128.9 (C), 131.2, 135.3, 138.4 (CH), 150.5, 151.6, 152.6, 158.2, 160.4, 165.2 (C), 
194.0 (C=O). 
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MS (EI, 70 eV): m/z (%) = 355 (M
+
, 2), 296 (100), 253 (29), 197 (33), 121 (12). 
HRMS (ESI): Calcd for C17H12N3O6 (M-H) 354.0732. Found 354.0737. 
IR (ATR, cm
-1
): 
~  = 3051 (w), 1724 (m), 1690 (s), 1630 (s), 1598 (s), 1449 (m), 1338 (m), 
1297 (m), 1241 (s), 1207 (s), 1144 (m), 1122 (m), 1024 (s), 896 (m), 854 (m), 828 (m), 785  
(s), 751 (s), 711 (s), 672 (s). 
 
Methyl 6-(2-hydroxybenzoyl)-1,2,3,4-tetrahydro-4-oxo-2-thioxopyrido[2,3-d]pyrimidine-
7-carboxylate (2.4.2r). 
Starting from 3-methoxalylchromone 2.4.1 (0.232 g, 1 mmol) and 6-
amino-2,3-dihydro-2-thioxopyrimidin-4(1H)-one E6d (0.157 g, 1.1 
mmol) in 10 mL AcOH. 2.4.2r was isolated as yellow solid (0.157 g, 
44%), mp 260-262 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 3.73 (s, 3H, OMe), 6.93-7.00 (m, 
2H, CHAr), 7.44-7.55 (m, 2H, CHAr), 8.33 (s, 1H, Py), 10.69 (s, 1H, OH), 12.83 (s, 1H, OH), 
13.54 (s, 1H, SH). 
13
C NMR (75.5 MHz, DMSO-d6): δ = 52.9 (OMe), 113.0 (C), 117.2, 119.4 (CH), 122.5, 
130.4 (C), 131.3, 135.4, 138.1 (CH), 151.9, 152.3, 158.3, 158.9, 164.9, 176.6 (C), 193.9 
(C=O). 
MS (EI, 70 eV): m/z (%) = 357 (M
+
, 15), 325 (13), 298 (M
+
-CO2Me, 100), 281 (15), 239 (58), 
210 (9), 121 (16), 78 (12), 63 (13).  
HRMS (ESI): Calcd for C16H12O5N3S (M+H) 358.0492. Found 358.0493. 
IR (ATR, cm
-1
): 
~  = 3090 (w), 1728 (m), 1682 (m), 1594 (s), 1551 (s), 1450 (m), 1340 (m), 
1317 (m), 1275 (s), 1227 (s), 1135 (s), 1052 (m), 921 (m), 799 (m), 783 (m), 760 (s), 733 (m), 
694 (m), 652 (m), 640 (m). 
 
A.2.7. General procedure for the synthesis of compounds 2.4.6a-d. 
 
The fused pyridine derivative 2.4.2 (1 equiv.) and potassium hydroxide (4 equiv.) were 
dissolved in methanol (10 mL/1 equiv. of 2.3.3) and heated under reflux for 2 h (under argon 
atmosphere). After completion of the reaction (TLC control), the reaction mixture was diluted 
with conc. HCl till slightly acidic pH (pH = 4-5). The precipitate was filtered, washed once 
with methanol and three times with distilled water, and dried in air. 
 
5-(2-hydroxybenzoyl)-2,3-dihydro-3-oxo-2-phenyl-1H-pyrazolo[3,4-b]pyridine-6-
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carboxylic acid (2.4.6a). 
Starting from 2.4.2a (0.150 g, 0.38 mmol) and potassium 
hydroxide (0.085 g, 1.52 mmol) in 10 mL methanol. 2.4.6a was 
isolated as white solid (0.114 g, 80%), mp 165-166 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 6.93-7.04 (m, 2H, CHAr), 
7.34 (t, 1H, 
3
J = 7.4 Hz, CHAr), 7.46-7.60 (m, 4H, CHAr), 7.91 (d, 
2H, 
3
J = 7.6 Hz, CHAr), 8.33 (s, 1H, Py), 10.99 (s, 1H, OH), 12.57 (s, 1H, NH), 13.85 (s, 1H, 
OH).  
13
C NMR (62.9 MHz, DMSO-d6): δ = 110.0 (C), 117.4, 119.3, 120.0 (CH), 122.2 (C), 125.9 
(CH), 128.1 (C), 129.2, 131.9, 135.1, 135.5 (CH), 136.5, 153.3, 157.3, 166.5 (C), 196.4 
(C=O). 
MS (EI, 70 eV): m/z (%) = 375 (M
+
, 14), 330 (100), 253 (37). 
HRMS (ESI): Calcd for C20H14O5N3 (M+H) 376.0928. Found 376.0924.  
IR (ATR, cm
-1
): 
~  = 3401 (w), 3046 (w), 1722 (m), 1653 (s), 1625 (m), 1596 (s), 1575 (m), 
1490 (s), 1446 (m), 1348 (m), 1304 (m), 1245 (s), 1156 (s), 951 (w), 925 (m), 824 (m), 762 
(s), 691 (s), 655 (s), 635 (s). 
 
5-(2-hydroxybenzoyl)-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine-6-carboxylic acid 
(2.4.6b). 
Starting from 2.4.2h (0.150 g, 0.38 mmol) and potassium hydroxide (0.085 
g, 1.52 mmol) in 10 mL methanol. 2.4.6b was isolated as white solid (0.116 
g, 82%), mp 128-130 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 2.65 (s, 3H, Me), 6.89-7.02 (m, 2H, 
CHAr), 7.35-7.63 (m, 5H, CHAr), 8.36 (d, 2H, 
3
J = 7.7 Hz, CHAr), 8.61 (s, 1H, Py), 11.19 (s, 
1H, OH), 13.71 (s, 1H, OH).  
13
C NMR (75.5 MHz, DMSO-d6): δ = 12.2 (Me), 116.8 (C), 117.5, 119.3, 120.3 (CH), 121.7 
(C), 126.1, 129.3 (CH), 129.7 (C), 131.5, 132.3, 135.9 (CH), 138.6, 144.1, 137.9, 148.8, 
160.1, 166.5 (C), 198.0 (C=O). 
MS (EI, 70 eV): m/z (%) = 373 (M
+
, 11), 328 (100), 251 (23), 236 (19). 
HRMS (ESI): Calcd for C21H16O4N3 (M+H) 374.1136. Found 374.1135.  
IR (ATR, cm
-1
): 
~  = 1706 (w), 1629 (s), 1595 (m), 1506 (w), 1444 (m), 1294 (s), 1152 (s), 
1142 (m), 1117 (m), 1103 (m), 945 (s), 909 (m), 787 (m), 760 (s), 746 (s), 687 (s), 668 (s), 
640 (s). 
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6-(2-hydroxybenzoyl)-2-(dimethylamino)thiazolo[4,5-b]pyridine-5-carboxylic acid 
(2.4.6c). 
Starting from 2.4.2l (0.150 g, 0.42 mmol) and potassium hydroxide 
(0.094 g, 1.68 mmol) in 10 mL methanol. 2.4.6c was isolated as white 
solid (0.114 g, 79%), mp 132-134 
o
C. 
1
H NMR (250 MHz, DMSO-d6): δ = 3.25 (s, 6H, NMe2), 6.89 (t, 1H, 
3
J = 7.7 Hz, CHAr), 6.99 (d, 1H, 
3
J = 8.1 Hz, CHAr), 7.31 (t, 1H, 
3
J = 7.8 Hz, 
4
J = 1.3 Hz, 
CHAr), 7.48-7.55 (m, 1H, CHAr), 8.36 (s, 1H, Py), 11.28 (s, 1H, OH), 14.01 (s, 1H, OH). 
13
C NMR (62.9 MHz, DMSO-d6): δ = 39.7 (NMe2), 117.5, 119.3 (CH), 121.5, 127.7, 127.9 
(C), 129.6, 132.1, 135.8 (CH), 145.0, 160.3, 164.2, 166.7, 171.7 (C), 198.7 (C=O). 
MS (EI, 70 eV): m/z (%) = 343 (M
+
, 9), 298 (100), 254 (23). 
HRMS (ESI): Calcd for C16H14O4N3S (M+H) 344.0689. Found 344.0690.  
IR (ATR, cm
-1
): 
~  = 2924 (w), 1706 (m), 1620 (m), 1597 (s), 1565 (s), 1519 (w), 1486 (w), 
1449 (w), 1403 (s), 1339 (s), 1286 (s), 1239 (s), 1215 (s), 1151 (m), 1106 (m), 945 (m), 914 
(w), 896 (m), 829 (w), 798 (w), 781 (w), 758 (s), 720 (s), 681 (m), 627 (m). 
 
6-(2-hydroxybenzoyl)-1,2,3,4-tetrahydro-1,3-dimethyl-2,4-dioxopyrido[2,3-d]pyrimidine-
7-carboxylic acid (2.4.6d). 
Starting from 2.4.2p (0.150 g, 0.41 mmol) and potassium hydroxide 
(0.092 g, 1.64 mmol) in 10 mL methanol. 2.4.6d was isolated as white 
solid (0.118 g, 81%), mp 254-256 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 3.31 (s, 3H, NMe), 3.62 (s, 3H, 
NMe), 6.91-7.00 (m, 2H, CHAr), 7.41-7.55 (m, 2H, CHAr), 8.41 (s, 
1H, Py), 10.84 (s, 1H, OH), 13.94 (s, 1H, OH). 
13
C NMR (62.9 MHz, DMSO-d6): δ = 28.3, 29.5 (NMe), 111.0 (C), 117.3, 119.3 (CH), 122.2, 
129.6 (C), 131.5, 135.6, 138.1 (CH), 150.8, 150.9, 152.3, 160.0, 161.1, 166.0 (C), 195.1 
(C=O). 
MS (EI, 70 eV): m/z (%) = 355 (M
+
, 7), 310 (100), 280 (15). 
HRMS (ESI): Calcd for C17H14O6N3 (M+H) 356.0877. Found 356.087.  
IR (ATR, cm
-1
): 
~  = 3052 (w), 1706 (m), 1650 (s), 1625 (s), 1598 (s), 1471 (m), 1449 (m), 
1358 (m), 1288 (m), 1262 (w), 1213 (s), 1152 (s), 1052 (m), 954 (w), 908 (m), 812 (w), 790 
(m), 763 (m), 751 (s), 704 (m), 663 (s). 
 
A.2.8. General procedure for the synthesis of 4-Hydroxy-3-nitrocoumarin. 
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To the suspension of 4-hydroxycoumarin (40.0 g, 250 mmol) and sodium nitrite (0.8 g, 12 
mmol) in acetic acid (120 mL) under stirring at room temperature was added 65% nitric acid 
(35 mL) in small portions. The reaction mixture was heated at 50-60 °C under intensive 
stirring for 15 min. The resulting solid was filtered and washed with water to give yellow 
crystals (44.6 g, 87%), mp 174-175 C (lit.98a mp 177 C). 
 
A.2.9. General procedure for the synthesis of 2'-Hydroxy-2-nitroacetophenone. 
 
4-Hydroxy-3-nitrocoumarin (12.6 g, 60 mmol) was dissolved in 5% water solution of 
potassium hydroxide (450 mL). The resulting reddish solution was heated at 55 °C for 1.5 h. 
After cooling to the reaction mixture an acetic acid was added dropwise under intensive 
stirring (till pH = 5). The precipitate was rapidly filtered and washed with water to afford a 
colorless solid (8.8 g, 81%), mp 106 C (lit.98a mp 106-107 C). 
 
A.2.10. General procedure for the synthesis of 3-Nitrochromone derivatives 2.5.1. 
 
To a solution of 2'-hydroxy-2-nitroacetophenone (1 equiv.) in appropriate orthoester (8 
equiv.) a concentrated sulfuric acid (0.5 equiv.) was added dropwise. Afterwards the reaction 
mixture was refluxed for 6 h and distilled to dryness.The formed solid was washed with water 
and recrystallized from methanol to give corresponding chromone 2.5.1a-e. 
 
2-Ethyl-3-Nitrochromone (2.5.1c) 
Starting from 2'-hydroxy-2-nitroacetophenone (5 g, 27.6 mmol), trimethyl 
orthopropionate (31 mL, 221 mmol) and sulfuric acid (1.35 g, 13.8 mmol). 
2.5.1c was isolated as colorless solid, mp 178–179 °C. 
1
H NMR (300 MHz, DMSO-d6): δ = 1.40 (t, 3H, 
3
J = 7.5 Hz, Me), 2.82 (q, 
2H, 
3
J = 7.5 Hz, CH2), 7.42-7.52 (m, 2H, CHAr), 7.71-7.76 (m, 1H, CHAr), 8.19 (dd, 1H, 
3
J = 
8.0 Hz, 
4
J = 1.5 Hz, CHAr).  
13
C NMR (62.9 MHz, DMSO-d6): δ = 11.0 (Me), 25.1 (CH2), 118.1 (CH), 122.5, 123.3 (C), 
126.3 (CH), 134.9 (C), 138.3, 155.2 (CH), 167.2, 168.2 (C). 
MS (EI, 70 eV): m/z (%) = 219 (M
+
, 100), 202 (46), 120 (37), 115 (52).  
HRMS (EI): Calcd for C11H9NO4 (M
+
) 219.0522. Found 219.0523.  
IR (ATR, cm
-1
): 
~  = 2993 (w), 1732 (w), 1654 (s), 1615 (m), 1568 (w), 1519 (s), 1456 (s), 
O
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1372 (s), 1326 (m), 1209 (w), 1140 (m), 1042 (m), 969 (w), 902 (m), 787 (s), 768 (s), 596 
(m). 
 
A.2.11. General procedure for the synthesis of compounds 2.5.3a-c, e-l in acetic acid. 
 
In a round-bottom flask the mixture of 3-nitrochromone 2.5.1a (1 equiv.) and appropriate 
aminoheterocycle E (1.1 equiv.) was dissolved in AcOH (10 mL/1.0 mmol of chromone 
2.5.1a) and heated under reflux in an inert atmosphere for 1-15 h (controlled by TLC). After 
completion of the reaction volatiles were evaporated under reduced pressure. The residue was 
treated with water, filtered, dried in air, and recrystallized from appropriate solvent or 
subjected to column chromatography (silica gel). 
 
A.2.12. General procedure for the synthesis of compounds 2.5.3d, m-p in TMSCl/DMF. 
 
The 3-nitrochromone 2.5.1a (1 equiv.) and 4-amino-1H-imidazole-2(3H)-thione E2b, E7-E9 
(1.1 equiv.) were placed in a pressure tube under the flow of dry argon and dissolved in dry 
DMF (5 mL/1 mmol of chromone 2.3.2) containing 1 mL of TMSCl. The mixture was heated 
at 100-140 °C for 2-12 h (controlled by TLC). After the reaction was completed volatiles 
were evaporated under reduced pressure. The residue was treated with water, filtered, dried in 
air, and recrystallized from appropriate solvent or subjected to column chromatography (silica 
gel). 
 
6-(2-Hydroxyphenyl)-5-nitro-2-phenyl-1,2-dihydropyrazolo[3,4-b]pyridin-3-one (2.5.3a). 
Starting from 3-nitrochromone 2.5.1a (0.191 g, 1 mmol) and 5-amino-
1,2-dihydro-2-phenylpyrazol-3-one E1a (0.193 g, 1.1 mmol) in 10 
mL AcOH. 2.5.3a was isolated as dark green solid (0.340 g, 98%), mp 
248-250 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 6.88 (d, 1H, 
3
J = 8.0 Hz, CHAr), 6.99 (t, 1H, 
3
J = 7.4 Hz, 
CHAr), 7.28-7.37 (m, 2H, CHAr), 7.51-7.56 (m, 3H, CHAr), 7.92 (d, 2H, 
3
J = 8.0 Hz, CHAr), 
8.75 (s, 1H, Py), 10.14 (s, 1H, OH), 12.0-13.5 (br s, 1H, NH).  
13
C NMR (62.9 MHz, DMSO-d6): δ = 107.9 (C), 115.3, 119.4, 119.9 (CH), 124.0 (C), 125.8, 
129.2, 130.2, 131.2, 131.4 (CH), 136.8, 140.3, 153.8, 154.7, 157.3 (C).  
MS (EI, 70 eV): m/z (%) = 348 (M
+
, 47), 318 (48), 303 (100), 289 (9), 274 (19), 183 (22), 156 
(12), 77 (42).  
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HRMS (ESI): Calcd for C18H13N4O4 (M+H) 349.0931. Found 349.0926.  
IR (ATR, cm
-1
): 
~  = 3055 (w), 1652 (w), 1605 (m), 1583 (m), 1527 (m), 1483 (w), 1407 (m), 
1339 (s), 1275 (m), 1240 (m), 1179 (m), 1157 (m), 1098 (w), 982 (w), 950 (w), 918 (w), 885 
(w), 843 (w), 791 (s), 746 (s), 702 (s), 679 (s), 639 (s), 611 (s). 
 
6-(2-Hydroxyphenyl)-2-methyl-5-nitro-1,2-dihydropyrazolo[3,4-b]pyridin-3-one (2.5.3b). 
Starting from 3-nitrochromone 2.5.1a (0.191 g, 1 mmol) and 5-amino-
1,2-dihydro-2-methylpyrazol-3-one E1b (0.124 g, 1.1 mmol) in 10 
mL AcOH. 2.5.3b was isolated as red solid (0.248 g, 87%), mp 295-
297 
o
C.  
1
H NMR (300 MHz, DMSO-d6): δ = 3.48 (s, 3H, Me), 6.85 (d, 1H, 
3
J = 8.1 Hz, CHAr), 6.95 
(td, 1H, 
3
J = 7.4 Hz, 
4
J = 0.7 Hz, CHAr), 7.30 (m, 1H, CHAr), 7.48 (dd, 1H, 
3
J = 7.6 Hz, 
4
J = 
1.6 Hz, CHAr), 8.65 (s, 1H, Py), 10.01 (s, 1H, OH), 12.5-13.0 (br s, 1H, NH).  
13
C NMR (62.9 MHz, DMSO-d6): δ = 30.6 (Me), 105.7 (C), 115.1, 119.3 (CH), 125.1 (C), 
130.1, 130.9 (CH), 140.8, 153.0, 154.4, 154.5, 157.1 (C).  
MS (EI, 70 eV): m/z (%) = 286 (M
+
, 32), 256 (79), 241 (37), 183 (23), 169 (23), 156 (16), 131 
(26), 119 (25), 105 (18), 77 (29), 69 (100).  
HRMS (ESI): Calcd for C13H11N4O4 (M+H) 287.07748. Found 287.07720.  
IR (ATR, cm
-1
): 
~  = 2929 (w), 1645 (m), 1621 (m), 1582 (m), 1532 (m), 1504 (m), 1447 (m), 
1318 (m), 1240 (m), 1116 (w), 1092 (w), 1033 (w), 999 (w), 961 (w), 939 (w), 861 (m), 793 
(s), 755 (s), 701 (s), 634 (s).  
 
6-(2-Hydroxyphenyl)-1-methyl-5-nitro-1,2-dihydropyrazolo[3,4-b]pyridin-3-one (2.5.3c). 
Starting from 3-nitrochromone 2.5.1a (0.191 g, 1 mmol) and 5-amino-
1,2-dihydro-2-methylpyrazol-3-one E1c (0.124 g, 1.1 mmol) in 10 mL 
AcOH. 2.5.3c was isolated as yellow solid (0.226 mg, 79%), mp 272-274 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 3.86 (s, 3H, Me), 6.83 (d, 1H, 
3
J = 8.1 Hz, CHAr), 6.97 
(td, 1H, 
3
J = 7.5 Hz, 
4
J = 0.8 Hz, CHAr), 7.29 (m, 1H, CHAr), 7.53 (dd, 1H, 
3
J = 7.6 Hz, 
4
J = 
1.5 Hz, CHAr), 8.77 (s, 1H, Py), 9.91 (s, 1H, OH), 11.63 (s, 1H, NH).  
13
C NMR (75.5 MHz, DMSO-d6): δ = 33.2 (Me), 102.0 (C), 115.0, 119.3 (CH), 125.7 (C), 
127.9, 130.2, 130.5 (CH), 140.5, 148.9, 151.2, 154.0, 154.5 (C).  
MS (EI, 70 eV): m/z (%) = 286 (M
+
, 52), 241 (100).  
HRMS (ESI): Calcd for C13H11N4O4 (M+H) 287.06789. Found 287.03788.  
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IR (ATR, cm
-1
): 
~  = 2256 (w), 1583 (m), 1488 (w), 1453 (w), 1404 (w), 1369 (w), 1349 (m), 
1288 (w), 1230 (m), 1160 (m), 1116 (w), 1015 (w), 933 (w), 920 (w), 844 (w), 820 (w), 796 
(m), 751 (s), 672 (m), 656 (m), 617 (m). 
 
5-(2-Hydroxyphenyl)-1-methyl-6-nitro-3-phenyl-1H-imidazo[4,5-b]pyridine-2(3H)-
thione (2.5.3d). 
Starting from 3-nitrochromone 2.5.1a (0.191 g, 1 mmol) and 4-amino-
1-methyl-3-phenyl-1H-imidazole-2(3H)-thione E2b (0.226 g, 1.1 
mmol) in 5 mL DMF and 1 mL of TMSCl. 2.5.3d was isolated as 
orange solid (0.359 g, 95%), mp 164-166 
o
C. 
1
H NMR (250 MHz, DMSO-d6): δ = 3.86 (s, 3H, Me), 6.79-6.92 (m, 2H, CHAr), 7.19-7.30 
(m, 2H, CHAr), 7.51-7.59 (m, 5H, CHAr), 7.93 (s, 1H, Py), 8.58 (s, 1H, OH).  
13
C NMR (75.5 MHz, DMSO-d6): δ = 31.6 (Me), 112.8, 117.9, 119.7 (CH), 120.5, 124.7 (C), 
127.7, 129.3, 129.7 (CH), 129.9, 131.9, 133.3, 142.1, 145.5, 145.8, 155.1, 174.5 (C).  
MS (EI, 70 eV): m/z (%) = 378 (M
+
, 100), 348 (60), 332 (90), 316 (12), 77 (14), 57 (10). 
HRMS (ESI): Calcd for C19H15N4O3S (M+H) 379.0859. Found 379.0860.  
IR (ATR, cm
-1
): 
~  = 1602 (w), 1534 (m), 1500 (m), 1466 (s), 1424 (s), 1376 (m), 1323 (s), 
1286 (s), 1245 (m), 1198 (s), 1158 (m), 1114 (m), 1079 (m), 904 (s), 806 (s), 782 (w), 766 (s), 
753 (s), 726 (s), 711 (s), 686 (s), 647 (s), 603 (m). 
 
2-(3-Methyl-5-nitro-1-phenyl-1H-pyrazolo[3,4-b]pyridin-6-yl)phenol (2.5.3e). 
Starting from 3-nitrochromone 2.5.1a (0.191 g, 1 mmol) and 4-amino-1H-
imidazole-2(3H)-thione E3 (0.190 g, 1.1 mmol) in 10 mL AcOH. 2.5.3e 
was isolated as yellow solid (0.336 g, 97%), mp 204-206 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 2.69 (s, 3H, Me), 6.87 (d, 1H, 
3
J = 
7.6 Hz, CHAr), 7.01 (t, 1H, 
3
J = 7.2 Hz, CHAr), 7.30-7.37 (m, 2H, CHAr), 7.55 (t, 2H, 
3
J = 7.6 
Hz, CHAr), 7.65 (m, 1H, CHAr), 8.22 (d, 2H, 
3
J = 7.6 Hz, CHAr), 9.09 (s, 1H, Py), 10.05 (s, 
1H, OH).  
13
C NMR (62.9 MHz, DMSO-d6): δ = 12.3 (Me), 114.5 (C), 115.1, 119.6, 120.5 (CH), 125.2 
(C), 126.3, 128.3, 129.3, 130.5, 130.9 (CH), 138.4, 142.3, 145.2, 149.3, 150.9, 154.7 (C).  
MS (EI, 70 eV): m/z (%) = 346 (M
+
, 100), 316 (10), 300 (63), 283 (30), 221 (10), 77 (18). 
HRMS (ESI): Calcd for C19H15N4O3 (M+H) 347.1136. Found 347.1141.  
IR (ATR, cm
-1
): 
~  = 3393 (m), 1592 (m), 1575 (m), 1495 (s), 1452 (m), 1421 (m), 1383 (w), 
1308 (s), 1286 (m), 1193 (m), 1118 (m), 982 (w), 916 (m), 845 (m), 807 (w), 780 (m), 752 (s), 
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691 (s), 682 (m), 672 (m), 639 (m), 632 (m). 
 
2-[2-(Dimethylamino)-6-nitrothiazolo[4,5-b]pyridin-5-yl]phenol (2.5.3f). 
Starting from 3-nitrochromone 2.5.1a (0.191 g, 1 mmol) and N
2
,N
2
-
dimethylthiazole-2,4-diamine E5a (0.157 g, 1.1 mmol) in 10 mL 
AcOH. 2.5.2f was isolated as brown solid (0.205 g, 65%), mp 266-
268 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 3.25 (s, 6H, NMe2), 6.82 (d, 1H, 
3
J = 8.0 Hz, CHAr), 
6.94 (t, 1H, 
3
J = 7.4 Hz, CHAr), 7.25 (t, 1H, 
3
J = 7.4 Hz, CHAr), 7.48 (d, 1H, 
3
J = 7.0 Hz, 
CHAr), 8.86 (s, 1H, Py), 9.81 (s, 1H, OH).  
13
C NMR (75.5 MHz, DMSO-d6): δ = 39.7 (NMe2), 114.9, 119.2 (CH), 123.2, 125.7 (C), 
126.3, 130.1, 130.2 (CH), 139.8, 149.0, 154.4, 166.0, 173.1 (C).  
MS (GC, 70 eV): m/z (%) = 316 (M
+
, 39), 270 (100), 254 (17), 227 (17), 207 (49).  
HRMS (ESI): Calcd for C14H13N4O3S (M+H) 317.0703. Found 317.0707.  
IR (ATR, cm
-1
): 
~  = 2921 (w), 2852 (w), 1601 (w), 1549 (s), 1497 (w), 1450 (w), 1408 (m), 
1307 (s), 1279 (s), 1181 (m), 1098 (s), 1079 (m), 972 (w), 901 (s), 861 (m), 827 (m), 781 (m), 
765 (s), 745 (s), 667 (s), 619 (m). 
 
2-(2-Morpholino-6-nitrothiazolo[4,5-b]pyridin-5-yl)phenol (2.5.3g). 
Starting from 3-nitrochromone 2.5.1a (0.191 g, 1 mmol) and 2-
morpholinothiazol-4-amine E5b (0.204 g, 1.1 mmol) in 10 mL 
AcOH. 2.5.3g was isolated as yellow solid (0.322 g, 90%), mp 
229-231 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 3.72-3.76 (m, 8H, morpholine), 6.82 (dd, 1H, 
3
J = 8.1 
Hz, 
4
J = 0.8 Hz, CHAr), 6.94 (td, 1H, 
3
J = 7.5 Hz, 
4
J = 1.0 Hz, CHAr), 7.26 (m, 1H, CHAr), 
7.49 (dd, 1H, 
3
J = 7.6 Hz, 
4
J = 1.7 Hz, CHAr), 8.89 (s, 1H, Py), 9.84 (s, 1H, OH).  
13
C NMR (62.9 MHz, DMSO-d6): δ = 48.1, 65.4 (CH2 morpholine), 114.9, 119.2 (C), 122.7, 
125.5 (C), 126.6, 130.2, 130.3 (CH), 140.2, 149.0, 154.4, 165.6, 173.2 (C).  
MS (GC, 70 eV): m/z (%) = 358 (M
+
, 34), 312 (100), 69 (13).  
HRMS (ESI): Calcd for C16H15N4O4S (M+H) 359.0809. Found 359.0805.  
IR (ATR, cm
-1
): 
~  = 3408 (w), 1599 (w), 1540 (s), 1492 (m), 1448 (w), 1409 (m), 1345 (m), 
1329 (s), 1311 (s), 1283 (s), 1238 (m), 1182 (w), 1112 (s), 1083 (w), 1028 (m), 896 (s), 864 
(w), 840 (w), 759 (s), 711 (w), 674 (w), 631 (m), 609 (m). 
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2-[6-Nitro-2-(piperidin-1-yl)thiazolo[4,5-b]pyridin-5-yl]phenol (2.5.3h). 
Starting from 3-nitrochromone 2.5.1a (0.191 g, 1 mmol) and 2-
(piperidin-1-yl)thiazol-4-amine E5c (0.201 g, 1.1 mmol) in 10 mL 
AcOH. 2.5.3h was isolated as yellow solid (0.253 g, 71%), mp 
109-110
o
C. 
1
H NMR (300 MHz, CDCl3): δ = 1.74 (s, 6H, piperidine), 3.72 (s, 4H, piperidine), 6.86 (m, 
1H), 7.02 (dd, 1H, 
3
J = 8.2 Hz, 
4
J = 1.0 Hz, CHAr), 7.22-7.31 (m, 3H, CHAr), 8.34 (s, 1H, Py), 
9.95 (br s, 1H, OH).  
13
C NMR (62.9 MHz, CDCl3): δ = 23.9, 25.4, 50.1 (CH2 piperidine), 118.1, 119.8 (CH), 
119.9, 123.0 (C), 126.5, 129.4, 131.6 (CH), 138.8, 149.8, 156.1, 164.8, 172.6 (C).  
MS (EI, 70 eV): m/z (%) = 356 (M
+
, 54), 310 (100).  
HRMS (EI): Calcd for C17H16N4O3S (M
+
) 356.09376. Found 356.09383.  
IR (ATR, cm
-1
): 
~  = 2937 (w), 1595 (w), 1537 (s), 1447 (m), 1416 (w), 1306 (s), 1251 (m), 
1118 (m), 1009 (m), 904 (w), 886 (m), 851 (m), 832 (w), 782 (m), 750 (s), 709 (m), 680 (w), 
629 (w). 
 
7-(2-Hydroxyphenyl)-6-nitropyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (2.5.3i). 
Starting from 3-nitrochromone 2.5.1a (0.191 g, 1 mmol) and 6-
aminopyrimidine-2,4(1H,3H)-dione E6a (0.140 g, 1.1 mmol) in 10 mL 
AcOH. 2.5.3i was isolated as yellow solid (0.252 g, 84%), mp 217-219 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 6.86 (d, 1H, 
3
J = 8.1 Hz, CHAr), 6.98 (t, 1H, 
3
J = 7.5 Hz, 
CHAr), 7.34 (m, 1H, CHAr), 7.50 (dd, 1H, 
3
J = 7.5 Hz, 
4
J = 1.0 Hz, CHAr), 8.64 (s, 1H, Py), 
10.19 (s, 1H, OH), 11.75 (s, 1H, NH), 12.24 (s, 1H, NH).  
13
C NMR (62.9 MHz, DMSO-d6): δ = 108.4 (C), 115.2, 119.3 (CH), 123.8 (C), 130.4, 131.6, 
132.8 (CH), 141.9, 150.3, 153.5, 154.8, 155.5, 161.2 (C).  
MS (EI, 70 eV): m/z (%) = 300 (M
+
, 96), 270 (100), 255 (40), 231 (13), 211 (35), 182 (11), 
168 (21), 156 (17), 128 (10).  
HRMS (ESI): Calcd for C13H9N4O5 (M+H) 301.05675. Found 301.05635.  
IR (ATR, cm
-1
): 
~  = 3306 (w), 3012 (w), 2824 (w), 1668 (m), 1599 (m), 1537 (m), 1494 (w), 
1348 (s), 1300 (m), 1203 (m), 1145 (w), 1114 (w), 1096 (w), 1017 (w), 978 (w), 884 (w), 841 
(w), 808 (w), 794 (w), 751 (s), 656 (m), 590 (m), 559 (m). 
 
7-(2-Hydroxyphenyl)-1,3-dimethyl-6-nitropyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione 
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(2.5.3j). 
Starting from 3-nitrochromone 2.5.1a (0.191 g, 1 mmol) and 6-amino-
1,3-dimethylpyrimidine-2,4(1H,3H)-dione E6b (0.171 g, 1.1 mmol) in 
10 mL AcOH. 2.5.3j was isolated as yellow solid (0.318 g, 97%), mp 
280-282 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 3.33 (s, 3H, Me), 3.61 (s, 3H, Me), 
6.87 (d, 1H, 
3
J = 7.9 Hz, CHAr), 7.01 (t, 1H, 
3
J = 7.3 Hz, CHAr), 7.36 (td, 1H, 
3
J = 8.0 Hz, 
4
J = 
1.6 Hz, CHAr), 7.64 (dd, 1H, 
3
J = 7.6 Hz, 
4
J = 1.5 Hz, CHAr), 8.73 (s, 1H, Py), 10.29 (s, 1H, 
OH).  
13
C NMR (62.9 MHz, DMSO-d6): δ = 28.3, 29.7 (Me), 108.5 (C), 115.2, 119.6 (CH), 123.8 
(C), 130.6, 131.9, 133.2 (CH), 141.8, 150.9, 151.3, 154.4, 155.0, 159.7 (C).  
MS (GC, 70 eV): m/z (%) = 328 (M
+
, 1), 281 (100), 253 (28), 196 (12), 169 (41).  
HRMS (ESI): Calcd for C15H13N4O5 (M+H) 329.0880. Found 329.0883.  
IR (ATR, cm
-1
): 
~  = 3256 (w), 1706 (m), 1650 (s), 1594 (s), 1537 (m), 1446 (m), 1419 (m), 
1353 (s), 1289 (m), 1197 (m), 1096 (m), 1067 (w), 1038 (w), 1010 (w), 949 (w), 844 (w), 795 
(m), 779 (m), 765 (s), 700 (s), 593 (m). 
 
7-(2-Hydroxyphenyl)-1-methyl-6-nitropyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione 
(2.5.3k). 
Starting from 3-nitrochromone 2.5.1a (0.191 g, 1 mmol) and 6-amino-
1-methylpyrimidine-2,4(1H,3H)-dione E6c (0.155 g, 1.1 mmol) in 10 
mL AcOH. 2.5.3k was isolated as yellow solid (0.229 g, 73%), mp 
230-232 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 3.53 (s, 3H, Me), 6.86 (d, 1H, 
3
J = 8.0 Hz, CHAr), 7.00 
(td, 1H, 
3
J = 7.4 Hz, 
4
J = 0.7 Hz, CHAr), 7.30-7.37 (m, 1H, CHAr), 7.63 (dd, 1H, 
3
J = 7.6 Hz, 
4
J = 1.6 Hz, CHAr), 8.67 (s, 1H, Py), 10.28 (s, 1H, OH), 12.01 (s, 1H, NH).  
13
C NMR (62.9 MHz, DMSO-d6): δ = 28.8 (Me), 109.3 (C), 115.3, 119.6 (CH), 123.9 (C), 
130.6, 131.9, 132.9 (CH), 141.6, 150.6, 152.7, 154.4, 155.0, 160.1 (C).  
MS (GC, 70 eV): m/z (%) = 314 (M
+
, 100), 281 (11), 267 (55), 225 (57), 207 (27), 195 (15), 
168 (63), 140 (17), 115 (13), 92 (13).  
HRMS (ESI): Calcd for C14H11N4O5 (M+H) 315.0724. Found 315.0725.  
IR (ATR, cm
-1
): 
~  = 3288 (w), 3153 (w), 2820 (w), 1707 (w), 1674 (m), 1602 (m), 1498 (w), 
1446 (m), 1426 (w), 1372 (m), 1343 (s), 1196 (m), 1155 (m), 1038 (w), 976 (m), 863 (m), 842 
(m), 815 (m), 765 (s), 749 (s), 737 (s), 659 (m). 
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7-(2-Hydroxyphenyl)-2-mercapto-6-nitropyrido[2,3-d]pyrimidin-4-ol (2.5.3l). 
Starting from 3-nitrochromone 2.5.1a (0.191 g, 1 mmol) and 6-amino-
2,3-dihydro-2-thioxopyrimidin-4(1H)-one E6d (0.157 g, 1.1 mmol) in 10 
mL AcOH. 2.5.3l was isolated as yellow solid (0.250 g, 79%), mp 307-
309 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 6.86 (d, 1H, 
3
J = 8.2 Hz, CHAr), 6.99 (td, 1H, 
3
J = 7.5 
Hz, 
4
J = 0.8 Hz, CHAr), 7.32-7.38 (m, 1H, CHAr), 7.52 (dd, 1H, 
3
J = 7.6 Hz, 
4
J = 1.7 Hz, 
CHAr), 8.64 (s, 1H, Py), 10.25 (s, 1H, OH), 12.86 (s, 1H, SH), 13.53 (s, 1H, OH).  
13
C NMR (62.9 MHz, DMSO-d6): δ = 110.5 (C), 115.2, 119.4 (CH), 123.5 (C), 130.5, 131.5, 
132.7 (CH), 142.5, 152.3, 154.8, 155.7, 158.7, 176.7 (C).  
MS (GC, 70 eV): m/z (%) = 316 (M
+
, 100), 286 (11), 270 (48), 253 (19).  
HRMS (ESI): Calcd for C13H9N4O4S (M+H) 317.0339. Found 317.0336.  
IR (ATR, cm
-1
): 
~  = 3188 (w), 1683 (m), 1605 (m), 1584 (m), 1520 (m), 1485 (w), 1417 (w), 
1352 (s), 1262 (m), 1194 (w), 1159 (m), 1131 (s), 948 (m), 805 (s), 744 (s), 692 (s), 659 (s), 
629 (s). 
 
2-(5,7-Dimethoxy-3-nitroquinolin-2-yl)phenol (2.5.3m). 
Starting from 3-nitrochromone 2.5.1a (0.191 g, 1 mmol) and 3,5-
dimethoxybenzenamine E7a (0.168 g, 1.1 mmol) in 10 mL AcOH. 
2.5.3m was isolated as yellow solid (0.202 g, 62%), mp 208-209 
o
C. 
1
H NMR (300 MHz, CDCl3): δ = 3.97 (s, 3H, OMe), 4.00 (s, 3H, 
OMe), 6.55 (br. s, 1H, CHAr), 6.86-6.94 (m, 2H, CHAr), 7.08 (dd, 1H, 
3
J = 8.3 Hz, 
4
J = 1.0 Hz, CHAr), 7.27 (dd, 1H, 
3
J = 8.0 Hz, 
4
J = 1.4 Hz, CHAr), 7.31-7.35 (m, 
1H, CHAr), 8.88 (s, 1H, Py), 11.70 (s, 1H, OH). 
13
C NMR (62.9 MHz, CDCl3): δ = 56.0, 56.1 (OMe), 98.8, 99.9 (CH), 113.5, 118.3 (C), 
118.5, 119.6, 129.1, 129.7, 132.3 (CH), 140.8, 148.5, 151.5, 156.8, 157.5, 165.0 (C).  
MS (GC, 70 eV): m/z (%) = 326 (M
+
, 73), 318 (48), 280 (100), 265 (27), 222 (20), 194 (12). 
HRMS (ESI): Calcd for C17H15N2O5 (M+H) 327.0975. Found 327.0976.  
IR (ATR, cm
-1
): 
~  = 1609 (m), 1582 (m), 1500 (m), 1452 (s), 1382 (m), 1346 (m), 1237 (s), 
1204 (m), 1160 (s), 1135 (s), 1039 (m), 970 (w), 939 (m), 831 (s), 797 (s), 774 (m), 751 (s), 
742 (s), 722 (m), 703 (m), 667 (m), 641 (s).  
 
2-(6,7-Dimethoxy-3-nitroquinolin-2-yl)phenol (2.5.3n). 
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Starting from 3-nitrochromone 2.5.1a (0.191 g, 1 mmol) and 3,4-
dimethoxybenzenamine E7c (0.168 g, 1.1 mmol) in 10 mL AcOH. 
2.5.3n was isolated as reddish solid (0.271 g, 83%), mp 202-204 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 3.94 (s, 3H, OMe), 4.01 (s, 3H, 
OMe), 6.79 (s, 1H, CHAr), 6.85 (d, 1H, 
3
J = 7.9 Hz, CHAr), 6.98 (t, 1H, 
3
J = 7.5 Hz, CHAr), 
7.09 (s, 1H, CHAr), 7.27-7.33 (m, 1H, CHAr), 7.59 (dd, 1H, 
3
J = 7.5 Hz, 
4
J = 1.3 Hz, CHAr), 
8.82 (s, 1H, Py), 9.95 (s, 1H, OH).  
13
C NMR (62.9 MHz, DMSO-d6): δ = 56.0, 56.5 (OMe), 99.7, 100.1 (CH), 112.8 (C), 114.9, 
119.3 (CH), 125.3 (C), 127.1, 130.3, 130.6 (CH), 141.9, 150.4, 150.8, 154.6, 156.5, 164.3 (C).  
MS (GC, 70 eV): m/z (%) = 326 (M
+
, 73), 280 (100), 265 (27), 236 (13), 222 (21), 194 (11). 
HRMS (ESI): Calcd for C17H15N2O5 (M+H) 327.09755. Found 327.09798.  
IR (ATR, cm
-1
): 
~  = 1591 (m), 1525 (m), 1499 (w), 1453 (m), 1382 (m), 1346 (s), 1237 (m), 
1204 (m), 1160 (s), 1134 (s), 1039 (m), 939 (m), 831 (s), 797 (m), 751 (s), 742 (s), 703 (m), 
667 (m), 641 (s).  
 
2-(7-(Dimethylamino)-3-nitroquinolin-2-yl)phenol (2.5.3o). 
Starting from 3-nitrochromone 2.5.1a (0.191 g, 1 mmol) and N
1
,N
1
-
dimethylbenzene-1,3-diamine E8 (0.152 g, 1.1 mmol) in 10 mL 
AcOH. 2.5.3o was isolated as dark red solid (0.281 g, 91%), mp 236-
238 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 3.18 (s, 6H, NMe2), 6.98-7.03 (m, 2H, CHAr), 7.19 (s, 
1H, CHAr), 7.38 (m, 1H, CHAr), 7.52 (m, 1H, CHAr), 7.59 (dd, 1H, 
3
J = 7.5 Hz, 
4
J = 1.2 Hz, 
CHAr), 8.11 (d, 1H, 
3
J = 9.5 Hz, CHAr), 9.13 (s, 1H, Py), 10.0-10.8 (br s, 1H, OH).  
13
C NMR (62.9 MHz, DMSO-d6): δ = 48.6 (NMe2), 100.3, 115.3 (CH), 118.2 (C), 118.8 
(CH), 119.2 (C), 121.8, 130.3, 131.0, 131.7, 135.5 (CH), 138.9, 146.1, 149.2, 154.4, 155.0 
(C).  
MS (GC, 70 eV): m/z (%) = 309 (M
+
, 45), 263 (100), 247 (35), 219 (15).  
HRMS (EI): Calcd for C17H15N3O3 (M
+
) 309.11079. Found 309.11112.  
IR (ATR, cm
-1
): 
~  = 3202 (w), 2914 (w), 1644 (w), 1603 (w), 1573 (m), 1515 (m), 1443 (w), 
1421 (w), 1331 (m), 1268 (m), 1216 (w), 1158 (m), 1101 (w), 1066 (w), 1017 (m), 956 (w), 
900 (m), 823 (m), 771 (m), 755 (s), 713 (m), 623 (m), 611 (m). 
 
2-(2,4-Diamino-6-nitropyrido[2,3-d]pyrimidin-7-yl)phenol (2.5.3p). 
NO2
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Starting from 3-nitrochromone 2.5.1a (0.191 g, 1 mmol) and 
pyrimidine-2,4,6-triamine E9 (0.138 g, 1.1 mmol) in 10 mL AcOH. 
2.5.3p was isolated as yellow solid (0.193 g, 65%), mp 285-287 
o
C. 
1
H NMR (250 MHz, DMSO-d6): δ = 6.91-7.03 (m, 2H, CHAr), 7.33-
7.39 (m, 1H, CHAr), 7.53-7.57 (m, 1H, CHAr), 8.08 (s, 1H, NH), 8.84 (s, 1H, NH), 9.31 (s, 1H, 
NH), 9.49 (s, 1H, Py), 9.62 (s, 1H, NH), 10.41 (s, 1H, OH). 
13
C NMR (62.9 MHz, DMSO-d6): δ = 103.6 (C), 115.3, 119.4 (CH), 123.4 (C), 130.3, 131.8, 
132.0 (CH), 142.6, 151.0, 155.0, 156.0, 156.7, 162.7 (C).  
MS (EI, 70 eV): m/z (%) = 298 (M
+
, 100), 282 (15), 266 (33), 220 (28).  
HRMS (ESI): Calcd for C13H11N6O3 (M+H) 299.08871. Found 299.08841.  
IR (ATR, cm
-1
): 
~  = 3119 (w), 1681 (w), 1645 (m), 1606 (m), 1515 (m), 1464 (w), 1450 (w), 
1425 (m), 1402 (m), 1358 (m), 1300 (m), 1200 (m), 1158 (m), 989 (w), 977 (w), 921 (w), 870 
(w), 795 (m), 755 (m), 650 (m). 
 
A.2.12. General procedure for the synthesis of compounds 2.5.5a-n. 
 
To a Schlenk flask equipped with a magnetic stir bar and filled with corresponding fused 
pyridine derivative 2.5.3 (1 equiv.) was added 10% Pd/C (0.1 equiv.). The flask was fitted 
with a rubber septum and then held under vacuum for 3 min, after that, it was filled with 
MeOH (25 ml for 0.5 g of fused pyridine derivative) and hydrogen. Holding under vacuum 
was repeated one more time, and after sequential filling with hydrogen, the reaction mixture 
was stirred for 2 days under H2 atmosphere. After the reaction was stopped, the mixture was 
filtered through a Celite pad, and the filtrate was evaporated to dryness or (if necessary) was 
purified by column chromatography typically using Heptane/Ethyl acetate mixtures or 
recrystallized from appropriate solvent to provide the desired product. 
 
5-Amino-6-(2-hydroxyphenyl)-2-phenyl-1,2-dihydropyrazolo[3,4-b]pyridin-3-one 
(2.5.5a). 
Starting from 3-nitrochromone 2.5.3a (0.150 g, 0.43 mmol). 2.5.5a 
was isolated as green solid (0.108 g, 78%), mp 195-196 
o
C. 
1
H NMR (250 MHz, DMSO-d6): δ = 4.52-5.51 (br. s, 2H, NH2), 6.93-
7.02 (m, 2H, CHAr), 7.23-7.54 (m, 6H, CHAr), 7.95 (br. s, 2H, CHAr), 
10.0-11.0 (br s, 1H, OH), 15.01 (br s, 1H, NH). 
13
C NMR (62.9 MHz, DMSO-d6): δ = 110.3 (C), 116.4, 117.0, 119.0, 119.3, 124.7 (CH), 
NO2
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125.6 (C), 128.9, 130.0, 131.1 (CH), 137.9, 138.6, 150.0, 151.5, 154.7, 159.4 (C).  
MS (EI, 70 eV): m/z (%) = 318 (M
+
, 100), 302 (28).  
HRMS (ESI): calcd for C18H15N4O2 (M+H) 319.1132. Found 319.1130.  
IR (ATR, cm
-1
): 
~  = 3301 (w), 1645 (m), 1593 (m), 1487 (m), 1422 (s), 1343 (w), 1292 (m), 
1274 (m), 1211 (m), 1150 (m), 1116 (w), 845 (w), 815 (w), 788 (w), 753 (s), 705 (m), 684 (s), 
664 (s), 603 (s).  
 
5-Amino-6-(2-hydroxyphenyl)-2-methyl-1,2-dihydropyrazolo[3,4-b]pyridin-3-one 
(2.5.5b). 
Starting from 3-nitrochromone2.5.3b (0.150 g, 0.52 mmol). 2.5.5b 
was isolated as red solid (0.128 g, 96%), mp 281-283 
o
C. 
1
H NMR (250 MHz, DMSO-d6): δ = 3.34 (s, 3H, Me), 4.51-5.33 (br s, 
2H, NH2), 6.91-7.00 (m, 2H, CHAr), 7.26-7.35 (m, 2H, CHAr), 7.46 (s, 
1H, Py), 9.71-10.71 (br. s, 1H, OH), 12.6 (br s, 1H, NH).  
13
C NMR (62.9 MHz, DMSO-d6): δ = 30.4 (Me), 109.9 (C), 116.4, 117.0, 119.3 (CH), 125.6 
(C), 129.8, 131.1 (CH), 138.0, 148.8, 151.1, 154.6, 159.8 (C).  
MS (EI, 70 eV): m/z (%) = 256 (M
+
, 100), 73 (21), 44 (29).  
HRMS (ESI): Calcd for C13H13N4O2 (M+H) 257.10330. Found 257.10293.  
IR (ATR, cm
-1
): 
~  = 3363 (w), 1569 (m), 1478 (m), 1449 (m), 1426 (m), 1325 (w), 1295 (w), 
1259 (m), 1234 (m), 1184 (m), 1161 (m), 1098 (w), 1055 (w), 1035 (w), 1018 (w), 959 (w), 
904 (w), 851 (w), 834 (w), 759 (s), 685 (s). 
 
5-Amino-6-(2-hydroxyphenyl)-1-methyl-1,2-dihydropyrazolo[3,4-b]pyridin-3-one 
(2.5.5c). 
Starting from 3-nitrochromone 2.5.3c (0.150 g, 0.52 mmol). 2.5.5c was 
isolated as red solid (0.122 g, 92%), mp 255-257 
o
C. 
1
H NMR (250 MHz, DMSO-d6): δ = 3.66 (s, 3H, Me), 4.05-6.01 (br. s, 
2H, NH2), 6.92-6.98 (m, 2H, CHAr), 7.26-7.32 (m, 2H, CHAr), 7.40 (dd, 
1H, 
3
J = 7.6 Hz, 
4
J = 1.6 Hz, CHAr), 7.44 (s, 1H, Py), 9.0–12.0 (br s, 1H, OH).  
13
C NMR (62.9 MHz, DMSO-d6): δ = 33.3 (Me), 104.4 (C), 114.1, 116.6 (CH), 126.5 (C), 
129.7, 131.4, 135.6 (CH), 147.2, 148.2, 152.0, 154.8 (C).  
MS (EI, 70 eV): m/z (%) = 256 (M
+
, 32), 240 (27), 201 (26), 183 (23), 152 (11), 77 (21). 
HRMS (ESI): Calcd for C13H13N4O2 (M+H) 257.10330. Found 257.10349.  
IR (ATR, cm
-1
): 
~  = 2931 (w), 2672 (w), 1605 (m), 1582 (m), 1550 (m), 1504 (w), 1475 (w), 
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1455 (w), 1425 (w), 1379 (w), 1299 (w), 1247 (m), 1229 (m), 1153 (m), 1112 (w), 1068 (w), 
1014 (w), 885 (w), 809 (m), 759 (s), 699 (m), 682 (m), 647 (s), 614 (m). 
 
2-(5-Amino-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridin-6-yl)phenol (2.5.5d). 
Starting from 3-nitrochromone 2.5.3e (0.150 g, 0.43 mmol). 2.5.5d was 
isolated as brown solid (0.118 g, 87%), mp 160-162 
o
C. 
1
H NMR (250 MHz, DMSO-d6): δ = 2.55 (s, 3H, Me), 4.02-6.04 (br s, 
2H, NH2), 6.94-7.03 (m, 2H, CHAr), 7.19 (tt, 1H, 
3
J = 7.4 Hz, 
4
J = 1.0 Hz, 
CHAr), 7.30-.35 (m, 1H, CHAr), 7.41 (dd, 1H, 
3
J = 7.6 Hz, 
4
J = 1.6 Hz, CHAr), 7.44-7.49 (m, 
2H, CHAr), 7.52 (s, 1H, Py), 8.28-8.31 (m, 2H, CHAr), 9.5-10.5 (br s, 1H, OH). 
13
C NMR (62.9 MHz, DMSO-d6): δ = 12.3 (Me), 112.8, 116.5 (CH), 116.5 (C), 118.7, 119.9, 
124.2 (CH), 126.5 (C), 129.0, 129.8, 131.5 (CH), 138.0, 139.8, 140.8, 145.1, 147.2, 155.0 (C) 
162.3 (CH).  
MS (EI, 70 eV): m/z (%) = 316 (M
+
, 100), 300 (10). 
HRMS (ESI): Calcd for C19H17N4O (M+H) 317.13969. Found 317.13947.  
IR (ATR, cm
-1
): 
~  = 3354 (w), 1667 (w), 1597 (m), 1505 (m), 1395 (s), 1288 (m), 1236 (m), 
1201 (m), 1141 (m), 1075 (m), 996 (m), 900 (w), 803 (w), 746 (s), 665 (m). 
 
2-[6-Amino-2-(dimethylamino)thiazolo[4,5-b]pyridin-5-yl]phenol (2.5.5e). 
Starting from 3-nitrochromone 2.5.3f (0.150 g, 0.47 mmol). 2.5.5e 
was isolated as yellow solid (0.064 g, 48%), mp 158-160 
o
C. 
1
H NMR (250 MHz, DMSO-d6): δ = 3.14 (s, 6H, NMe2), 4.85 (s, 2H, 
NH2), 6.88-6.95 (m, 2H, CHAr), 7.20-7.26 (m, 1H, CHAr), 7.54 (dd, 
1H, 
3
J = 7.8 Hz, 
4
J = 1.6 Hz, CHAr), 7.61 (s, 1H, Py), 10.75 (br s, 1H, OH).  
13
C NMR (62.9 MHz, DMSO-d6): δ = 39.4 (NMe2), 116.6, 117.5, 119.0 (CH), 124.5, 125.2 
(C), 129.0, 130.5 (CH), 136.1, 140.4, 155.0, 156.3, 167.0 (C).  
MS (EI, 70 eV): m/z (%) = 286 (M
+
, 90), 270 (25).  
HRMS (EI): Calcd for C14H14N4OS (M
+
) 286.08046. Found 286.08045.  
IR (ATR, cm
-1
): 
~  = 3324 (w), 2923 (w), 1583 (s), 1537 (s), 1487 (w), 1435 (m), 1403 (s), 
1351 (m), 1274 (m), 1233 (m), 1204 (m), 1121 (m), 1073 (m), 1039 (w), 975 (w), 920 (w), 
859 (m), 826 (m), 755 (s), 729 (s), 615 (m). 
 
2-(6-Amino-2-morpholinothiazolo[4,5-b]pyridin-5-yl)phenol (2.5.5f). 
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Starting from 3-nitrochromone 2.5.3g (0.150 g, 0.418 mmol). 
2.5.5f was isolated as brown solid (0.091 g, 66%), mp 148-150 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 3.72-3.75 (m, 8H, 
morpholine), 4.87-4.91 (br s, 2H, NH2), 6.82 (d, 1H, 
3
J = 8.6 Hz, CHAr), 6.94 (t, 1H, 
3
J = 7.2 
Hz, CHAr), 7.21-7.25 (m, 1H, CHAr), 7.50 (dd, 1H, 
3
J = 7.7 Hz, 
4
J = 1.6 Hz, CHAr), 8.89 (s, 
1H, Py), 9.83 (s, 1H, OH).  
13
C NMR (75.5 MHz, DMSO-d6): δ = 47.8, 65.5 (CH2 morpholine), 116.5, 117.2, 119.1 (CH), 
124.0, 125.3, 129.1, 130.7 (C), 136.9 (CH), 140.8, 154.9, 155.5, 167.4 (C).  
MS (EI, 70 eV): m/z (%) = 328 (M
+
, 100), 312 (14), 91 (17).  
HRMS (ESI): Calcd for C16H17N4O2S (M+H) 329.10667. Found 329.10649.  
IR (ATR, cm
-1
): 
~  = 2961 (w), 2850 (w), 1525 (s), 1486 (w), 1422 (s), 1339 (m), 1234 (s), 
1211 (m), 1182 (m), 1111 (s), 1073 (m), 1025 (m), 937 (w), 896 (m), 860 (m), 755 (s), 679 
(m), 646 (s), 597 (m).  
 
2-[6-Amino-2-(piperidin-1-yl)thiazolo[4,5-b]pyridin-5-yl]phenol (2.5.5g). 
Starting from 3-nitrochromone 2.5.3h (0.150 g, 0.42 mmol). 2.5.5g 
was isolated as yellow solid (0.096 g, 70%), mp 126-128 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 1.63 (s, 6H, piperidine), 3.55 
(s, 4H, piperidine), 4.86 (br s, 2H, NH2), 6.88-6.95 (m, 2H, CHAr), 7.22 (t, 1H, 
3
J = 7.05 Hz, 
CHAr), 7.52 (d, 1H, 
3
J = 8.05 Hz, CHAr), 7.59 (s, 1H, Py), 10.3-11.0 (br s, 1H, OH).  
13
C NMR (75.5 MHz, DMSO-d6): δ = 23.6, 24.8, 48.8 (CH2 piperidine), 116.6, 117.4, 119.0 
(CH), 124.2, 125.3, 129.1, 130.6 (C), 136.4 (CH), 140.4, 155.0, 156.0, 166.8 (C).  
MS (EI, 70 eV): m/z (%) = 326 (M
+
, 100), 310 (41), 257 (13).  
HRMS (ESI): Calcd for C17H19N4OS (M+H) 327.12013. Found 327.12830.  
IR (ATR, cm
-1
): 
~  = 2935 (w), 2852 (w), 1558 (m), 1531 (s), 1418 (s), 1307 (s), 1246 (s), 
1195 (m), 1155 (m), 1120 (m), 1074 (m), 1010 (m), 885 (m), 851 (m), 749 (s), 679 (m), 629 
(m), 586 (s). 
 
6-Amino-7-(2-hydroxyphenyl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (2.5.5h). 
Starting from 3-nitrochromone 2.5.3i (0.150 g, 0.50 mmol). 2.5.5h was 
isolated as brown solid (0.131 g, 97%), mp 309-311 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 4.2-5.8 (br s, 2H, NH2), 6.91 (t, 
1H, 
3
J = 7.4 Hz, CHAr), 6.99 (d, 1H, 
3
J = 7.8 Hz, CHAr), 7.25-7.31 (m, 
1H, CHAr), 7.35 (dd, 1H, 
3
J = 7.8 Hz, 
4
J = 1.5 Hz, CHAr), 7.68 (s, 1H, Py), 10.0-12.0 (br s, 
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3H, OH, NH).  
13
C NMR (75.5 MHz, DMSO-d6): δ = 109.0 (C), 116.4, 119.0, 120.7 (CH), 124.6 (C), 130.2, 
130.9 (CH), 139.0, 143.4, 149.1, 150.2, 154.9, 162.6 (C).  
MS (EI, 70 eV): m/z (%) = 270 (M
+
, 96), 224 (16), 160 (17), 128 (100), 97 (31).  
HRMS (ESI): Calcd for C13H11N4O3 (M+H) 271.08257. Found 271.08298.  
IR (ATR, cm
-1
): 
~  = 3246 (w), 3043 (w), 1682 (m), 1608 (m), 1487 (w), 1416 (m), 1385 (m), 
1299 (w), 1275 (w), 1239 (w), 1215 (w), 1101 (w), 1043 (w), 888 (w), 851 (m), 813 (w), 749 
(m), 677 (w), 624 (m), 574 (s).  
 
6-Amino-7-(2-hydroxyphenyl)-1,3-dimethylpyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione 
(2.5.5i). 
Starting from 3-nitrochromone 2.5.3j (0.150 g, 0.46 mmol). 2.5.5i was 
isolated as green solid (0.090 g, 66%), mp 299-301 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 3.30 (s, 3H, Me), 3.50 (s, 3H, Me), 
4.5-5.7 (br s, 2H, NH2), 6.91-7.02 (m, 2H, CHAr), 7.28-7.41 (m, 2H, 
CHAr), 7.80 (s, 1H, Py), 9.4-11.0 (br s, 1H, OH).  
13
C NMR (75.5 MHz, DMSO-d6): δ = 28.0, 28.9 (Me), 109.4 (C), 116.3, 119.3, 121.5 (CH), 
125.2 (C), 130.2, 131.4 (CH), 139.1, 141.8, 148.3, 150.6, 154.7, 161.0 (C).  
MS (EI, 70 eV): m/z (%) = 298 (M
+
, 100), 281 (18), 207 (19).  
HRMS (ESI): Calcd for C15H15N4O3 (M+H) 299.1139. Found 299.1138.  
IR (ATR, cm
-1
): 
~  = 3427 (w), 3349 (w), 3271 (w), 1694 (m), 1634 (s), 1604 (s), 1470 (m), 
1447 (s), 1356 (s), 1300 (s), 1105 (m), 1066 (m), 1018 (m), 981 (m), 911 (m), 834 (w), 804 
(w), 781 (m), 738 (s), 692 (m), 675 (m), 638 (m).  
 
6-Amino-7-(2-hydroxyphenyl)-1-methylpyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione 
(2.5.5j). 
Starting from 3-nitrochromone 2.5.3k (0.150 g, 0.48 mmol). 2.5.5j was 
isolated as brown solid (0.120 g, 88%), mp 290-292 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 3.44 (s, 3H, Me), 4.5-5.7 (br s, 
2H, NH2), 6.92-7.01 (m, 2H, CHAr), 7.28-7.38 (m, 1H, CHAr), 7.40 (dd, 
1H, 
3
J = 7.6 Hz, 
4
J = 1.5 Hz, CHAr), 7.76 (s, 1H, Py), 10.0–12.0 (br s, 2H, OH, NH).  
13
C NMR (75.5 MHz, DMSO-d6): δ = 28.0 (Me), 110.2 (C), 116.4, 119.3, 121.4 (CH), 125.2 
(C), 130.2, 131.2 (CH), 138.9, 143.1, 148.1, 150.4, 154.7, 161.5 (C).  
MS (EI, 70 eV): m/z (%) = 284 (M
+
, 100), 240 (14), 78 (15).  
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HRMS (ESI): Calcd for C14H13N4O3 (M+H) 285.09822. Found 285.09838.  
IR (ATR, cm
-1
): 
~  = 3341 (w), 3152 (w), 3041 (w), 2844 (w), 1681 (s), 1610 (m), 1586 (m), 
1468 (m), 1451 (m), 1411 (s), 1379 (m), 1286 (m), 1229 (m), 1149 (w), 1103 (w), 1077 (w), 
998 (w), 943 (m), 813 (m), 788 (m), 765 (w), 734 (s), 723 (s), 687 (m), 665 (w), 636 (m). 
 
2-(3-Amino-5,7-dimethoxyquinolin-2-yl)phenol (2.5.5k). 
Starting from 3-nitrochromone 2.5.3m (0.150 g, 0.46 mmol). 2.5.5k 
was isolated as brown solid (0.109 g, 80%), mp 166-168 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 3.84 (s, 3H, OMe), 3.94 (s, 3H, 
OMe), 5.04 (br. s, 2H, NH2), 6.56 (s, 1H, CHAr), 6.84 (s, 1H, CHAr), 
6.91-7.02 (m, 2H, CHAr), 7.27-7.32 (m, 1H, CHAr), 7.57 (d, 1H, 
3
J = 7.5 Hz, CHAr), 7.70 (s, 
1H, Py), 10.5-11.5 (br. s, 1H, OH).  
13
C NMR (75.5 MHz, DMSO-d6): δ = 55.2, 55.8 (OMe), 98.0, 98.9, 112.2 (CH), 116.3 (C), 
116.4, 119.0 (CH), 124.8 (C), 129.8, 130.5 (CH), 138.5, 142.1, 149.1, 154.0, 155.5, 157.5 (C). 
MS (GC, 70 eV): m/z (%) = 296 (M
+
, 92), 280 (35).  
HRMS (ESI): Calcd for C17H17N2O3 (M+H) 297.12337. Found 297.12324.  
IR (ATR, cm
-1
): 
~  = 1582 (m), 1446 (m), 1422 (w), 1396 (m), 1347 (w), 1331 (w), 1273 (m), 
1204 (s), 1156 (s), 1104 (m), 975 (w), 950 (w), 935 (w), 911 (m), 827 (m), 753 (s), 700 (s), 
642 (m), 626 (s). 
 
2-(3-Amino-6,7-dimethoxyquinolin-2-yl)phenol (2.5.5l). 
Starting from 3-nitrochromone 2.5.3n (0.150 g, 0.46 mmol). 2.5.5l was 
isolated as brown solid (0.127 g, 93%), mp 177-179 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 3.84 (s, 3H, OMe), 3.94 (s, 3H, 
OMe), 5.16 (br s, 2H, NH2), 6.56 (s, 1H, CHAr), 6.85 (s, 1H, CHAr), 
6.89-7.01 (m, 2H, CHAr), 7.26-7.28 (m, 1H, CHAr), 7.56 (d, 1H, 
3
J = 7.6 Hz, CHAr), 7.69 (s, 
1H, Py), 10.93 (s, 1H, OH).  
13
C NMR (75.5 MHz, DMSO-d6): δ = 55.2, 55.8 (OMe), 97.9, 98.9, 112.2 (CH), 116.4 (C), 
116.5, 118.8 (CH), 125.0 (C), 129.8, 130.6 (CH), 138.6, 142.2, 149.3, 154.0, 155.8, 157.5 (C). 
MS (GC, 70 eV): m/z (%) = 296 (M
+
, 76), 295 (100), 280 (27).  
HRMS (ESI): Calcd for C17H16N2O3 (M
+
) 296.11554. Found 296.115439.  
IR (ATR, cm
-1
): 
~  = 1582 (m), 1504 (w), 1445 (m), 1396 (w), 1348 (w), 1330 (w), 1272 (m), 
1204 (s), 1155 (m), 1126 (m), 1104 (m), 1046 (m), 935 (w), 911 (m), 826 (m), 751 (s), 700 
(m), 642 (m), 626 (m). 
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2-(3-Amino-7-(dimethylamino)quinolin-2-yl)phenol (2.5.5m). 
Starting from 3-nitrochromone 2.5.3o (0.150 g, 0.49 mmol). 2.5.5m 
was isolated as brown solid (0.127 g, 94%), mp 240-242 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 2.98 (s, 6H, NMe2), 4.91 (br s, 
2H, NH2), 6.91-6.99 (m, 3H, CHAr), 7.18-7.31 (m, 2H, CHAr), 7.41 (s, 
1H, CHAr), 7.55 (d, 1H, 
3
J = 8.5 Hz, CHAr), 7.68 (dd, 1H, 
3
J = 7.5 Hz, 
4
J = 1.4 Hz, CHAr), 
11.0-11.8 (br s, 1H, OH).  
13
C NMR (75.5 MHz, DMSO-d6): δ = 40.4 (NMe2), 106.3, 116.6, 117.3, 117.8, 118.9 (CH), 
121.2, 124.6 (C), 125.8, 130.0, 130.2 (CH), 137.5, 142.3, 148.7, 148.8, 155.9 (C).  
MS (GC, 70 eV): m/z (%) = 279 (M
+
, 94), 278 (100), 262 (37).  
HRMS (ESI): Calcd for C17H18N3O (M+H) 280.14444. Found 280.14436.  
IR (ATR, cm
-1
): 
~  = 3392 (w), 3324 (w), 2919 (w), 1623 (m), 1602 (w), 1573 (w), 1553 (w), 
1505 (m), 1428 (m), 1280 (m), 1244 (m), 1223 (m), 1184 (m), 1148 (m), 1008 (m), 971 (w), 
936 (w), 918 (w), 884 (w), 823 (m), 793 (m), 757 (s), 725 (m), 693 (s).  
 
2-(2,4,7-Triaminopyrido[3,2-d]pyrimidin-6-yl)phenol (2.5.5n). 
Starting from 3-nitrochromone 2.5.3p (0.150 g, 0.5 mmol). 2.5.5n 
was isolated as green solid (0.133 g, 93%), mp 169-171 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 5.04 (br s, 2H, NH2), 6.91-6.96 
(m, 1H, CHAr), 7.07 (d, 1H, 
3
J = 8.0 Hz, CHAr), 7.21-7.34 (m, 2H, 
CHAr), 7.94 (s, 1H, Py), 8.84 (s, 1H, NH2), 9.10 (s, 1H, NH2), 10.33 (br. s, 1H, OH), 12.50 
(br. s, 2H, NH2).  
13
C NMR (75.5 MHz, DMSO-d6): δ = 104.5 (C), 116.3, 119.3 (CH), 124.2 (C), 130.5, 130.9 
(CH), 140.5, 141.2, 151.4, 154.7, 155.1, 162.3, 162.9 (C).  
MS (GC, 70 eV): m/z (%) = 268 (M
+
, 100), 252 (22), 207 (15), 84 (17).  
HRMS (ESI): Calcd for C13H13N6O (M+H) 269.11454. Found 269.11528.  
IR (ATR, cm
-1
): 
~  = 3306 (w), 1514 (w), 1434 (m), 1409 (m), 1384 (m), 1352 (m), 1293 (m), 
1241 (m), 1154 (w), 1100 (w), 1007 (w), 831 (w), 753 (m), 701 (m).  
 
A.2.13. General procedure for the synthesis of compounds 2.6.2a-h. 
 
In a pressure tube under the flow of argon to the DMF (10 mL/2 mmol of 2.6.1) solution of 
corresponding 2.6.1 (1 equiv.) was added TMSCl (1 mL/2 mmol of 2.6.1). The reaction 
NH2
NN
HO
Me
Me
 
NH2
N
N
NH2N
HO
NH2
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mixture was heated at 100 
o
C for 3h (TLC control). After the formation of chromone was 
completed the solution was evaporated under reduced pressure, the residue was treated with 
water, filtered and dried on the air and recrystallized from appropriate solvent. 
 
All prepared chromones were previously synthesised and could be find in the literature.
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A.2.14. General procedure for the synthesis of compounds 2.6.3-2.6.12. 
 
Corresponding chromone 2.6.2a-e or enaminone 2.6.1a-e (1 equiv.) and appropriate amine E 
(1.1 equiv.) were placed in a pressure tube under the flow of dry argon and dissolved in dry 
DMF (5 mL/1 mmol of chromone 2.6.2) containing 1 mL of TMSCl. The mixture was heated 
at 100-120 °C for 1-5 h (controlled by TLC). After the reaction was completed volatiles were 
evaporated under reduced pressure. The residue was treated with water, filtered, dried in air, 
and recrystallized from appropriate solvent or subjected to column chromatography (silica 
gel). (Notice: Calculations for each compound are presented starting from chromone 2.6.2) 
 
1,2-dihydro-6-(2-hydroxy-5-methylphenyl)-2-phenylpyrazolo[3,4-b]pyridin-3-one 
(2.6.3a). 
Starting from chromone 2.6.2b (0.160 g, 1 mmol) and 5-amino-
1,2-dihydro-2-phenylpyrazol-3-one E1a (0.193 g, 1.1 mmol) in 5 
mL DMF and 1 mL of TMSCl. 2.6.3a was isolated as brown 
solid (0.190 g, 60%), mp 238-240 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 2.30 (s, 3H, Me), 6.94 (d, 1H, 
3
J = 8.3 Hz, CHAr), 7.18 
(dd, 1H, 
3
J = 8.3 Hz, 
4
J = 1.7 Hz, CHAr), 7.25-7.30 (m, 1H, CHAr), 7.49-7.55 (m, 2H, CHAr), 
7.85-7.97 (m, 4H, CHAr), 8.32 (d, 1H, 
3
J = 8.3 Hz, CHAr), 9.02 (br. s, 1H, OH), 11.04 (br. s, 
1H, NH).  
13
C NMR (62.9 MHz, DMSO-d6): δ = 34.0 (Me), 108.5 (C), 114.7, 117.7, 119.3 (CH), 119.7 
(C), 125.2 (CH), 127.9 (C), 128.7, 129.1, 132.9, 134.4 (CH), 137.2, 154.9, 156.2, 158.1, 160.0 
(C).  
MS (EI, 70 eV): m/z (%) = 317 (M
+
, 100), 288 (19), 77 (14). 
HRMS (EI): Calcd for C19H15N3O2 (M
+
) 317.11588. Found 317.115490. 
IR (ATR, cm
-1
): 
~  = 2967 (w), 2766 (w), 2456 (w), 1665 (w), 1593 (m), 1486 (m), 1447 (m), 
1392 (w), 1295 (m), 1231 (m), 1124 (m), 1076 (w), 1026 (w), 884 (w), 809 (m), 746 (s), 684 
(s), 603 (m). 
N
HO
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1,2-dihydro-6-(2-hydroxyphenyl)-2-phenylpyrazolo[3,4-b]pyridin-3-one (2.6.3b) 
Starting from chromone 2.6.2a (0.146 g, 1 mmol) and 5-amino-1,2-
dihydro-2-phenylpyrazol-3-one E1a (0.193 g, 1.1 mmol) in 5 mL 
DMF and 1 mL of TMSCl. 2.6.3b was isolated as orange solid (0.233 
g, 77%), mp 180-182 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 6.95-7.02 (m, 2H, CHAr), 7.25-7.30 (m, 1H, CHAr), 7.35-
7.41 (m, 1H, CHAr), 7.50-7.55 (m, 2H, CHAr), 7.93 (d, 3H, 
3
J = 7.6 Hz, CHAr), 8.05 (d, 1H, 
3
J 
= 7.7 Hz, CHAr), 8.33 (d, 1H, 
3
J = 8.3 Hz, CHAr), 11.80 (br. s, 1H, OH), 12.67 (br. s, 1H, NH).  
13
C NMR (62.9 MHz, DMSO-d6): δ = 108.6, 114.8 (C), 117.8, 119.3, 119.4 (CH), 120.0 (C), 
125.2, 128.7, 129.1, 132.3, 134.8 (CH), 137.1, 155.0, 158.0, 158.4, 160.0 (C).  
MS (EI, 70eV): m/z (%) = 302 (M
+
, 100), 274 (22), 77 (43). 
HRMS (EI): Calcd for C18H13N3O2 (M
+
) 303.10023. Found 303.100464. 
IR (ATR, cm
-1
): 
~  = 3024 (w), 1661 (m), 1600 (m), 1484 (m), 1445 (m), 1414 (m), 1295 (w), 
1273 (m), 1239 (m), 1187 (w), 1154 (w), 1033 (w), 935 (w), 903 (w), 815 (m), 752 (s), 689 
(m), 603 (m). 
 
6-(5-chloro-2-hydroxyphenyl)-1,2-dihydro-2-phenylpyrazolo[3,4-b]pyridin-3-one 
(2.6.3c). 
Starting from chromone 2.6.2d (0.181 g, 1 mmol) and 5-amino-1,2-
dihydro-2-phenylpyrazol-3-one E1a (0.193 g, 1.1 mmol) in 5 mL 
DMF and 1 mL of TMSCl. 2.6.3c was isolated as brown solid 
(0.310 g, 92%), mp 301-303 
o
C. 
1
H NMR (250 MHz, DMSO-d6): δ = 7.07 (d, 1H, 
3
J = 8.7 Hz, CHAr), 7.27 (t, 1H, 
3
J = 7.5 Hz, 
CHAr), 7.39 (dd, 1H, 
3
J = 8.7 Hz, 
3
J = 2.7 Hz, CHAr), 7.49-7.55 (m, 2H, CHAr), 7.92-8.06 (m, 
4H, CHAr), 8.31 (d, 1H, 
3
J = 8.3 Hz, CHAr), 11.92 (br. s, 1H, OH), 12.39 (br. s, 1H, NH).  
13
C NMR (62.9 MHz, DMSO-d6): δ = 109.0, 115.9 (C), 119.4, 119.5 (CH), 122.5, 123.0 (C), 
125.3, 128.3, 129.1, 131.4, 134.7 (CH), 155.3, 155.4, 156.8, 158.0, 178.9 (C).  
MS (EI, 70eV): m/z (%) = 337 (M
+
, 100), 308 (13). 
HRMS (ESI): Calcd for C18H13N3O2Cl (M+H) 338.79255. Found 338.79257. 
IR (ATR, cm
-1
): 
~  = 3391 (w), 2991 (w), 2771 (w), 2450 (w), 1661 (m), 1591 (m), 1486 (m), 
1447 (m), 1389 (m), 1336 (w), 1292 (m), 1245 (m), 1207 (w), 1175 (m), 1126 (w), 1099 (w), 
1075 (w), 1023 (w), 944 (w), 868 (w), 828 (m), 810 (m), 757 (s), 719 (s), 686 (m). 
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5-(2-hydroxy-5-methylphenyl)-1-methyl-3-phenyl-1H-imidazo[4,5-b]pyridine-2(3H)-
thione (2.6.4a). 
Starting from chromone 2.6.2b (0.160 g, 1 mmol) and 4-amino-1-
methyl-3-phenyl-1H-imidazole-2(3H)-thione E2b (0.225 g, 1.1 
mmol) in 5 mL DMF and 1 mL of TMSCl. 2.6.4a was isolated as 
brown solid (0.312 g, 90%), mp 224-225 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 2.25 (s, 3H, Me), 3.80 (s, 3H, NMe), 6.70 (d, 1H, , 
3
J = 
8.2 Hz, CHAr), 7.01 (dd, 1H, 
3
J = 8.2 Hz,
 4
J = 1.5 Hz, CHAr), 7.48-7.66 (m, 5H, CHAr), 7.70 
(s, 1H, CHAr), 7.99-8.05 (m, 2H, CHAr), 11.76 (s, 1H, OH). 
13
C NMR (62.9 MHz, DMSO-d6): δ = 20.2, 31.2 (Me), 115.6, 117.4, 118.7 (CH), 119.4, 124.8 
(C), 127.3 (CH), 127.6 (C), 128.1, 129.0, 129.2, 131.2 (CH), 134.2, 142.7, 150.0, 154.9, 170.6 
(C).  
MS (GC, 70eV): m/z (%) = 347 (M
+
, 100), 332 (15). 
HRMS (ESI): Calcd for C20H18N3OS (M+H) 348.2558. Found 348.2559. 
IR (ATR, cm
-1
): 
~  = 2912 (w), 1496 (w), 1464 (m), 1434 (m), 1381 (m), 1329 (m), 1282 (s), 
1249 (s), 1215 (m), 1183 (m), 1135 (m), 1189 (m), 1024 (w), 911 (w), 815 (s), 793 (s), 773 
(m), 758 (s), 733 (m), 686 (s), 648 (m). 
 
5-(2-hydroxyphenyl)-1-methyl-3-phenyl-1H-imidazo[4,5-b]pyridine-2(3H)-thione 
(2.6.4b). 
Starting from chromone 2.6.2a (0.146 g, 1 mmol) and 4-amino-1-
methyl-3-phenyl-1H-imidazole-2(3H)-thione E2b (0.225 g, 1.1 mmol) 
in 5 mL DMF and 1 mL of TMSCl. 2.6.4b was isolated as white solid 
(0.300 g, 90%), mp 220-222 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 3.82 (s, 3H, Me), 6.81-6.91 (m, 2H, CHAr), 7.19-7.25 
(m, 1H, CHAr), 7.54-7.67 (m, 5H, CHAr), 7.91 (dd, 1H, 
3
J = 8.1 Hz,
 4
J = 1.4 Hz, CHAr), 8.03-
8.10 (m, 2H, CHAr), 11.90 (s, 1H, OH). 
13
C NMR (62.9 MHz, DMSO-d6): δ = 31.2 (Me), 116.0, 117.5, 118.7, 119.2 (CH), 120.2, 
125.0 (C), 127.5, 128.2, 129.0, 129.3, 130.5 (CH), 134.2, 142.9, 149.9, 157.0, 170.7 (C). 
MS (GC, 70eV): m/z (%) = 333 (M
+
, 100), 318 (19). 
HRMS (EI): Calcd for C19H15N3OS (M
+
) 333.08521. Found 333.092105. 
IR (ATR, cm
-1
): 
~  = 3051 (w), 1615 (w), 1593 (w), 1499 (w), 1466 (m), 1427 (m), 1332 (s), 
1296 (m), 1281 (m), 1248 (m), 1227 (m), 1203 (m), 1164 (m), 1041 (m), 1090 (m), 1022 (w), 
963 (w), 932 (w), 812 (s), 753 (s), 734 (m), 706 (s), 689 (s), 636 (s). 
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5-(5-bromo-2-hydroxyphenyl)-1-methyl-3-phenyl-1H-imidazo[4,5-b]pyridine-2(3H)-
thione (2.6.4c). 
Starting from chromone 2.6.2c (0.225 g, 1 mmol) and 4-amino-1-methyl-
3-phenyl-1H-imidazole-2(3H)-thione E2b (0.225 g, 1.1 mmol) in 5 mL 
DMF and 1 mL of TMSCl. 2.6.4c was isolated as brown solid (0.313 g, 
76%), mp 248-250 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 3.58 (s, 3H, Me), 6.57 (d, 1H, 
3
J = 8.9 Hz, CHAr), 7.11 
(dd, 1H, 
3
J = 8.7 Hz, 
4
J = 2.2 Hz, CHAr), 7.29-7.42 (m, 5H, CHAr), 7.79-7.80 (m, 2H, CHAr), 
7.83 (s, 1H, CHAr), 11.64 (s, 1H, OH). 
13
C NMR (62.9 MHz, DMSO-d6): δ = 31.2 (Me), 110.5 (C), 116.9, 118.5, 119.7 (CH), 123.0, 
125.5 (C), 128.2, 129.0, 129.2, 129.9, 132.8 (CH), 134.2, 141.2, 143.2, 148.1, 156.0, 171.0 
(C).  
MS (GC, 70eV): m/z (%) = 412 (M
+
, 100), 166 (12). 
HRMS (ESI): Calcd for C19H15N3OSBr (M+H) 413.11258. Found 413.11261. 
IR (ATR, cm
-1
): 
~  = 2913 (w), 1499 (w), 1463 (m), 1431 (w), 1384 (m), 1329 (m), 1280 (s), 
1247 (m), 1200 (m), 1148 (m), 1090 (w), 969 (w), 934 (w), 864 (w), 819 (s), 714 (w), 687 (s), 
640 (m), 582 (w). 
 
5-(5-chloro-2-hydroxyphenyl)-1-methyl-3-phenyl-1H-imidazo[4,5-b]pyridine-2(3H)-
thione (2.6.4d). 
Starting from chromone 2.6.2d (0.181 g, 1 mmol) and 4-amino-1-
methyl-3-phenyl-1H-imidazole-2(3H)-thione E2b (0.225 g, 1.1 
mmol) in 5 mL DMF and 1 mL of TMSCl. 2.6.4d was isolated as 
yellow solid (0.224 g, 61%), mp 252-254 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 3.83 (s, 3H, Me), 6.87 (d, 1H, 
3
J = 8.7 Hz, CHAr), 7.23 (s, 1H, CHAr), 7.62 (s, 5H, CHAr), 7.92 (s, 1H, CHAr), 8.05-8.18 (m, 
2H, CHAr), 11.90 (br. s, 1H, OH). 
13
C NMR Due to bed solubility it was not possible to measure.  
MS (GC, 70eV): m/z (%) = 367 (M
+
, 100), 352 (11). 
HRMS (ESI): Calcd for C19H15N3OSCl (M+H) 368.06189. Found 368.06207. 
IR (ATR, cm
-1
): 
~  = 2915 (w), 1618 (w), 1498 (m), 1462 (s), 1434 (m), 1383 (m), 1330 (s), 
1297 (s), 1279 (s), 1247 (m), 1189 (m), 1150 (m), 1086 (m), 1026 (w), 971 (w), 935 (w), 904 
(w), 865 (w), 819 (s), 754 (m), 722 (m), 687 (s), 658 (m), 584 (m). 
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3-cyclohexyl-5-(2-hydroxyphenyl)-1-methyl-1H-imidazo[4,5-b]pyridine-2(3H)-thione 
(2.6.4e). 
Starting from chromone 2.6.2a (0.146 g, 1 mmol) and 4-amino-3-
cyclohexyl-1-methyl-1H-imidazole-2(3H)-thione E2c (0.232 g, 1.1 
mmol) in 5 mL DMF and 1 mL of TMSCl. 2.6.4e was isolated as yellow 
solid (0.231 g, 68%), mp 250-251 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 1.16-1.49 (m, 3H, cyclohexyl), 
1.75-1.93 (m, 5H, cyclohexyl), 2.35-2.43 (m, 2H, cyclohexyl), 3.75 (s, 3H, Me), 5.07-5.15 
(m, 1H, NCH), 6.93-7.00 (m, 2H, CHAr), 7.26-7.33 (m, 1H, CHAr), 7.96-8.08  (m, 3H, CHAr), 
12.02 (s, 1H, OH). 
13
C NMR (62.9 MHz, DMSO-d6): δ = 25.0, 25.5, 29.0, 31.4 (CH2 cyclohexyl), 56.1 (NCH), 
115.9, 117.4, 118.3, 119.5 (CH), 121.3, 124.8 (C), 128.1, 130.4 (CH), 142.2, 149.0, 156.8, 
169.8 (C).  
MS (GC, 70eV): m/z (%) = 339 (M
+
, 48), 257 (100).  
HRMS (EI): Calcd for C19H21ON3S (M
+
) 339.13998. Found 339.139863. 
IR (ATR, cm
-1
): 
~  = 2918 (w), 2858 (w), 1614 (w), 1504 (w), 1465 (m), 1428 (m), 1382 (m), 
1325 (m), 1282 (m), 1238 (m), 1167 (m), 1139 (m), 1044 (m), 894 (w), 808 (s), 738 (s), 685 
(m), 657 (m), 620 (m). 
 
5-(5-chloro-2-hydroxyphenyl)-3-cyclohexyl-1-methyl-1H-imidazo[4,5-b]pyridine-2(3H)-
thione (2.6.4f). 
Starting from chromone 2.6.2d (0.181 g, 1 mmol) and 4-amino-3-
cyclohexyl-1-methyl-1H-imidazole-2(3H)-thione E2c (0.232 g, 1.1 
mmol) in 5 mL DMF and 1 mL of TMSCl. 2.6.4f was isolated as 
yellow solid (0.220 g, 59%), mp 185-187 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 1.16-1.48 (m, 3H, cyclohexyl), 1.61-1.99 (m, 5H, 
cyclohexyl), 2.36-2.44 (m, 2H, cyclohexyl), 3.75 (s, 3H, Me), 5.05-5.13 (m, 1H, NCH), 7.02 
(d, 1H, 
3
J = 8.5 Hz, CHAr), 7.30 (dd, 1H, 
3
J = 8.8 Hz, 
4
J = 2.5 Hz, CHAr), 7.95-8.02  (m, 2H, 
CHAr), 8.14 (d, 1H, 
3
J = 8.8 Hz, CHAr), 11.91 (s, 1H, OH). 
13
C NMR (62.9 MHz, DMSO-d6): δ = 25.0, 25.5, 29.0 (CH2 cyclohexyl), 31.4 (Me), 56.2 
(NCH), 116.7, 118.0, 119.1 (CH), 123.1, 123.4, 125.2 (C), 127.6, 129.7 (CH), 142.5, 147.2, 
155.4, 170.0 (C).  
MS (GC, 70eV): m/z (%) = 373 (M
+
, 42), 291 (100).  
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HRMS (ESI): Calcd for C19H21ON3SCl (M+H) 374.10884. Found 374.10876. 
IR (ATR, cm
-1
): 
~  = 2934 (w), 2854 (w), 1615 (w), 1468 (m), 1434 (m), 1383 (m), 1338 (m), 
1323 (m), 1295 (m), 1279 (s), 1244 (m), 1213 (w), 1170 (m), 1141 (m), 1092 (w), 933 (w), 
864 (w), 825 (m), 806 (s), 718 (m), 655 (m), 625 (w), 582 (m). 
 
3-cyclohexyl-5-(2,5-dihydroxyphenyl)-1-methyl-1H-imidazo[4,5-b]pyridine-2(3H)-thione 
(2.6.4g). 
Starting from chromone 2.6.2f (0.176 g, 1 mmol) and 4-amino-3-
cyclohexyl-1-methyl-1H-imidazole-2(3H)-thione E2c (0.232 g, 1.1 
mmol) in 5 mL DMF and 1 mL of TMSCl. 2.6.4g was isolated as 
yellow solid (0.228 g, 68%), mp 307-309 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 1.21-1.53 (m, 3H, cyclohexyl), 
1.62-2.11 (m, 5H, cyclohexyl), 2.29-2.40 (m, 2H, cyclohexyl), 3.73 (s, 3H, Me), 5.06-5.14 
(m, 1H, NCH), 6.36-6.41 (m, 2H, CHAr), 7.82 (d, 1H, 
3
J = 8.7 Hz, CHAr), 7.88-7.95 (m, 2H, 
CHAr),  9.77 (s, 1H, OH), 12.44 (s, 1H, OH). 
13
C NMR (62.9 MHz, DMSO-d6): δ = 25.0, 25.6, 29.0 (CH2 cyclohexyl), 31.4 (Me), 56.0 
(NCH), 103.4, 107.8 (CH), 112.2 (C), 114.2, 118.7 (CH), 123.9 (C), 128.8 (CH), 141.6, 
150.0, 158.7, 160.0, 169.2 (C).  
MS (EI, 70eV): m/z (%) = 355 (M
+
, 74), 273 (100), 168 (10).  
HRMS (EI): Calcd for C19H21O2N3S (M
+
) 355.13490. Found 355.134366. 
IR (ATR, cm
-1
): 
~  = 3305 (w), 3139 (w), 2929 (m), 2862 (w), 1610 (m), 1465 (s), 1437 (s), 
1385 (m), 1323 (s), 1298 (s), 1250 (s), 1221 (m), 1169 (s), 1140 (s), 1122 (m), 1046 (m), 976 
(m), 946 (m), 840 (w), 791 (s), 721 (m), 652 (m), 611 (m). 
 
5-(5-chloro-2-hydroxyphenyl)-3-ethyl-1-methyl-1H-imidazo[4,5-b]pyridine-2(3H)-thione 
(2.6.4h). 
Starting from chromone 2.6.2d (0.181 g, 1 mmol) and 4-amino-3-
ethyl-1-methyl-1H-imidazole-2(3H)-thione E2d (0.173 g, 1.1 
mmol) in 5 mL DMF and 1 mL of TMSCl. 2.6.4h was isolated as 
green solid (0.185 g, 58%), mp 204-206 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 1.33 (t, 3H, 
3
J = 7.1 Hz, Me), 3.73 (s, 3H, NMe), 4.34 
(q, 2H, 
3
J = 7.1 Hz, CH2), 6.96 (d, 1H, 
3
J = 8.5 Hz, CHAr), 7.26 (dd, 1H, 
3
J = 8.7 Hz, 
4
J = 2.7 
Hz, CHAr), 7.89-7.93 (m, 2H, CHAr), 8.05 (d, 1H, 
3
J = 8.5 Hz, CHAr), 11.64 (br. s, 1H, OH). 
13
C NMR (62.9 MHz, DMSO-d6): δ = 12.7 (Me), 30.9 (NMe), 38.1 (CH2), 117.2, 117.7, 
N
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118.9 (CH), 123.0, 123.7, 125.0 (C), 127.7, 129.8 (CH), 142.5, 147.8, 155.2, 169.9 (C).  
MS (GC, 70eV): m/z (%) = 319 (M
+
, 100), 291 (50). 
HRMS (ESI): Calcd for C15H15N3OSCl (M+H) 320.06189, Found 320.06194. 
IR (ATR, cm
-1
): 
~  = 2938 (w), 1469 (m), 1436, 1383 (s), 1341 (m), 1316 (m), 1278 (s), 1244 
(m), 1187 (m), 1148 (w), 1122 (s), 1089 (m), 1028 (w), 957 (w), 867 (w), 858 (w), 846 (w), 
829 (m), 802 (s), 774 (w), 753 (w), 718 (m), 673 (w), 652 (m). 
 
4-methyl-2-(3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridin-6-yl)phenol (2.6.5a). 
Starting from chromone 2.6.2b (0.160 g, 1 mmol) and 3-methyl-1-
phenyl-1H-pyrazol-5-amine E3 (0.190 g, 1.1 mmol) in 5 mL DMF 
and 1 mL of TMSCl. 2.6.5a was isolated as yellow solid (0.306 g, 
97%), mp 139-140 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 2.30 (s, 3H, Me), 2.60 (s, 3H, Me), 6.88 (d, 1H, 
3
J = 8.8 
Hz, CHAr), 7.14 (dd, 1H, 
3
J = 8.3 Hz, 
3
J = 1.9 Hz, CHAr), 7.38 (t, 1H, 
3
J = 7.8 Hz, CHAr), 7.59 
(t, 2H, 
3
J = 7.8 Hz, CHAr), 7.86 (s, 1H, CHAr), 7.97-8.04 (m, 3H, CHAr), 8.42 (d, 1H, 
3
J = 8.8 
Hz, CHAr),  12.43 (s, 1H, OH).  
13
C NMR (62.9 MHz, DMSO-d6): δ = 12.1, 20.2 (Me), 114.8 (CH), 115.1 (C), 117.5 (CH), 
120.2 (C), 121.2, 126.2 (CH), 127.8 (C), 128.7, 129.4, 131.8, 132.3 (CH), 138.5, 143.2, 147.7, 
155.9, 156.3 (C). 
MS (GC, 70eV): m/z (%) = 315 (M
+
, 100), 286 (20). 
HRMS (EI): Calcd for C20H17N3O (M
+
) 315.13661. Found 315.136368. 
IR (ATR, cm
-1
): 
~  = 3380 (m), 2984 (m), 2770 (m), 2447 (w), 1580 (m), 1468 (s), 1439 (m), 
1403 (m), 1307 (w), 1284 (m), 1245 (m), 1193 (m), 1163 (m), 1130 (m), 1081 (m), 1022 (m), 
961 (w), 888 (w), 813 (s), 765 (m), 748 (s), 729 (s), 686 (s), 666 (s), 636 (s).  
 
4-bromo-2-(3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridin-6-yl)phenol (2.6.5b) 
Starting from chromone 2.6.2c (0.225 g, 1 mmol) and 3-methyl-1-
phenyl-1H-pyrazol-5-amine E3 (0.190 g, 1.1 mmol) in 5 mL DMF 
and 1 mL of TMSCl. 2.6.5b was isolated as yellow solid (0.349 g, 
92%), mp 180-181 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 2.62 (s, 3H, Me), 6.94 (d, 1H, 
3
J = 8.8 Hz, CHAr), 7.38 
(t, 1H, 
3
J = 7.7 Hz, CHAr), 7.47 (dd, 1H, 
3
J = 8.8 Hz, 
4
J = 2.2 Hz, CHAr), 7.86 (t, 2H, 
3
J = 7.7 
Hz, CHAr), 8.00-8.09 (m, 3H, CHAr), 8.18 (s, 1H, CHAr), 8.44 (d, 1H, 
3
J = 8.8 Hz, CHAr), 
12.44 (s, 1H, OH).  
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13
C NMR (62.9 MHz, DMSO-d6): δ = 12.1 (Me), 110.5 (C), 115.5, 115.6, 119.7, 121.1 (CH), 
123.4 (C), 126.2, 129.3, 131.1, 131.9, 133.8 (CH), 138.5, 143.2, 147.9, 154.5, 156.9 (C). 
MS (GC, 70eV): m/z (%) = 381 (99), 379 (M
+
, 100). 
HRMS (ESI): Calcd for C19H15N3OBr (M+H) 380.0393. Found 380.03927. 
IR (ATR, cm
-1
): 
~  = 3061 (m), 1593 (s), 1578 (m), 1510 (m), 1474 (m), 1430 (m), 1398 (m), 
1362 (m), 1286 (s), 1240 (m), 1206 (s), 1192 (m), 1171 (m), 1092 (m), 1013 (w), 954 (w), 
852 (w), 814 (s), 779 (m), 747 (s), 701 (m), 687 (s), 665 (s), 633 (s), 596 (m). 
 
4-chloro-2-(3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridin-6-yl)phenol (2.6.5c). 
Starting from chromone 2.6.2d (0.181 g, 1 mmol) and 3-methyl-1-
phenyl-1H-pyrazol-5-amine E3 (0.190 g, 1.1 mmol) in 5 mL DMF 
and 1 mL of TMSCl. 2.6.5c was isolated as yellow solid (0.252 g, 
75%), mp 186-188 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 3.31 (s, 3H, Me), 6.93-7.60 (m, 5H, CHAr), 8.08 (s, 4H, 
CHAr), 8.33-8.64 (m, 1H, CHAr), 12.42 (s, 1H, OH).  
13
C NMR (62.9 MHz, DMSO-d6): δ = 12.1 (Me), 112.2, 115.6, 119.3, 121.1 (CH), 123.0 (C), 
123.9 (CH), 125.3 (C), 126.2, 128.3 (CH), 129.4 (C), 131.0, 132.0, 134.1 (CH), 138.5, 143.2, 
156.5, 157.3 (C). 
MS (GC, 70eV): m/z (%) = 335 (M
+
, 100). 
HRMS (EI): Calcd for C19H14N3OCl (M
+
) 335.08199. Found 335.081761. 
IR (ATR, cm
-1
): 
~  = 3063 (m), 1641 (w), 1596 (m), 1579 (m), 1513 (m), 1480 (m), 1466 (m), 
1434 (m), 1398 (m), 1364 (m), 1331 (w), 1286 (s), 1241 (m), 1207 (m), 1194 (m), 1133 (w), 
1104 (m), 1081 (m), 1024 (w), 901 (w), 834 (w), 812 (s), 779 (m), 746 (s), 713 (m), 687 (s), 
653 (m), 633 (m).   
 
1-cyclohexyl-6-(2-hydroxy-5-methylphenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile 
(2.6.6a). 
Starting from chromone 2.6.2b (0.160 g, 1 mmol) and 5-amino-1-
cyclohexyl-1H-pyrrole-3-carbonitrile E4b (0.208 g, 1.1 mmol) in 5 mL 
DMF and 1 mL of TMSCl. 2.6.6a was isolated as yellow solid (0.258 g, 
78%), mp 168-170 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 1.24-1.54 (m, 4H, cyclhexyl), 1.72-2.08 (m, 6H, 
cyclhexyl), 2.30 (s, 3H, Me), 4.53-4.61 (m, 1H, NCH), 6.86 (d, 1H, 
3
J = 8.4 Hz, CHAr), 7.11 
(d, 1H, 
3
J = 7.9 Hz, CHAr), 7.81 (s, 1H, CHAr), 8.05 (d, 1H, 
3
J = 8.4 Hz, CHAr), 8.25 (d, 1H, 
3
J 
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= 8.7 Hz, CHAr), 8.61 (s, 1H, CHAr), 12.37 (s, 1H, OH). 
13
C NMR (62.9 MHz, DMSO-d6): δ = 20.2, 24.8, 25.2 (CH2 cyclohexyl), 32.1 (Me), 55.0 
(NCH), 83.1 (CN), 115.2 (C), 115.6, 117.4 (CH), 118.2, 120.3, 127.8 (C), 128.2, 129.5 (CH), 
131.6, 135.6, 143.2, 152.1, 155.4 (C).  
MS (GC, 70eV): m/z (%) = 331 (M
+
, 77), 246 (100), 220 (13). 
HRMS (EI): Calcd for C21H21ON3 (M
+
) 331.16791. Found 331.167627. 
IR (ATR, cm
-1
): 
~  = 3114 (w), 2922 (m), 2857 (m), 2219 (s), 1604 (w), 1579 (m), 1521 (m), 
1490 (m), 1443 (s), 1403 (m), 1361 (m), 1282 (s), 1245 (m), 1222 (s), 1209 (s), 1184 (s), 
1152 (m), 1028 (m), 862 (w), 819 (s), 791 (s), 764 (m), 732 (m), 673 (m), 648 (s), 615 (m). 
 
6-(5-chloro-2-hydroxyphenyl)-1-cyclohexyl-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile 
(2.6.6b). 
Starting from chromone 2.6.2d (0.181 g, 1 mmol) and 5-amino-1-
cyclohexyl-1H-pyrrole-3-carbonitrile E4b (0.208 g, 1.1 mmol) in 5 mL 
DMF and 1 mL of TMSCl. 2.6.6b was isolated as yellow solid (0.218 
g, 62%), mp 208-210 
o
C. 
1
H NMR (300 MHz, CDCl3): δ = 1.23-1.86 (m, 6H, cyclohexyl), 1.97-2.02 (m, 2H, 
cyclohexyl), 2.16-2.23 (m, 2H, cyclohexyl), 4.52-4.63 (m, 1H, NCH), 6.98 (d, 1H, 
3
J = 8.9 
Hz, CHAr), 7.25 (dd, 1H, 
3
J = 8.5 Hz, 
3
J = 2.5 Hz, CHAr), 7.79-7.83  (m, 3H, CHAr), 8.19 (d, 
1H, 
3
J = 8.5 Hz, CHAr), 13.34 (s, 1H, OH). 
13
C NMR (62.9 MHz, CDCl3): δ = 25.2, 25.5, 29.7 (CH2 cyclohexyl), 33.1 (Me), 55.6 (NCH), 
85.3 (CN), 114.3 (CH), 114.6, 119.3, 120.6, 124.2 (C), 126.5, 130.3, 131.1, 132.8 (CH), 
143.8, 143.0, 152.0, 157.4 (C).  
MS (GC, 70eV): m/z (%) = 351 (M
+
, 100).  
HRMS (EI): Calcd for C20H18ON3Cl (M
+
) 351.11329. Found 351.113058. 
IR (ATR, cm
-1
): 
~  = 3113 (w), 922 (w), 2219 (w), 1639 (w), 1580 (w), 1539 (w), 1474 (m), 
1446 (m), 1399 (m), 1357 (w), 1278 (m), 1215 (m), 1185 (m), 1027 (w), 891 (w), 817 (s), 795 
(m), 727 (m), 680 (m), 648 (s), 615 (m). 
 
4-chloro-2-(2-(dimethylamino)thiazolo[4,5-b]pyridin-5-yl)phenol (2.6.7a). 
Starting from chromone 2.6.2d (0.181 g, 1 mmol) and N
2
,N
2
-
dimethylthiazole-2,4-diamine E5a (0.157 g, 1.1 mmol) in 5 mL 
DMF and 1 mL of TMSCl. 2.6.7a was isolated as brown solid 
(0.186 g, 61%), mp 255-256 
o
C. 
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1
H NMR (300 MHz, DMSO-d6): δ = 3.23 (s, 6H, NMe2), 6.94 (d, 1H, 
3
J = 8.1 Hz, CHAr), 
7.30 (d, 1H, 
3
J = 7.0 Hz, CHAr), 7.89 (d, 1H, 
3
J = 7.6 Hz, CHAr), 8.06 (s, 1H, CHAr), 8.36 (d, 
1H, 
3
J = 7.6 Hz, CHAr), 14.21 (s, 1H, OH).  
13
C NMR (62.9 MHz, DMSO-d6): δ = 26.1 (NMe2), 112.1, 119.6 (CH), 120.9, 122.5, 124.0 
(C), 126.4, 130.3, 131.6 (CH), 134.0, 152.1, 157.6, 161.2 (C). 
MS (GC, 70eV): m/z (%) = 305 (M
+
, 100), 290 (12), 276 (12).  
HRMS (ESI): Calcd for C14H13ON3SCl (M+H) 306.04624. Found 306.04684. 
IR (ATR, cm
-1
): 
~  = 1598 (w), 1579 (w), 1538 (m), 1488 (w), 1404 (w), 1348 (m), 1278 (m), 
1218 (m), 1173 (m), 1140  (m), 1100 (w), 1083 (m), 961 (w), 914 (m), 877 (m), 817 (s), 747 
(m), 731 (m), 709 (m), 660 (s). 
 
4-chloro-2-(2-morpholinothiazolo[4,5-b]pyridin-5-yl)phenol (2.6.7b). 
Starting from chromone 2.6.2d (0.181 g, 1 mmol) and 2-
morpholinothiazol-4-amine E5b (0.204 g, 1.1 mmol) in 5 
mL DMF and 1 mL of TMSCl. 2.6.7b was isolated as red-
brown solid (0.209 g, 60%), mp 257-259 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 3.74 (s, 8H, morpholine), 6.96 (s, 1H, CHAr), 7.30 (s, 
1H, CHAr), 7.95-8.07 (m, 2H, CHAr), 8.40 (s, 1H, CHAr), 14.05 (s, 1H, OH).  
13
C NMR (62.9 MHz, DMSO-d6): δ =47.9, 65.4 (CH2 morpholine), 112.8, 119.6 (CH), 120.9, 
122.6, 123.4 (C), 126.5, 130.3, 131.9 (CH), 152.3, 157.5, 160.8, 171.2 (C). 
MS (EI, 70eV): m/z (%) = 347 (M
+
, 62), 269 (100), 206 (12).  
HRMS (EI): Calcd for C16H14O2N3SCl (M
+
) 347.04898. Found 347.048741. 
 IR (ATR, cm
-1
): 
~  = 1575 (w), 1529 (s), 1478 (m), 1426 (m), 1371 (m), 1330 (m), 1280 (s), 
1230 (s), 1217 (m), 1189 (m), 1115 (s), 1030 (m), 965 (w), 896 (m), 872 (m), 825 (s), 730 
(m), 621 (m).  
 
4-bromo-2-(2-(piperidin-1-yl)thiazolo[4,5-b]pyridin-5-yl)phenol (2.6.7c). 
Starting from chromone 2.6.2c (0.225 g, 1 mmol) and 2-
(piperidin-1-yl)thiazol-4-amine E5c (0.201 g, 1.1 mmol) in 5 
mL DMF and 1 mL of TMSCl. 2.6.7c was isolated as red-
brown solid (0.242 g, 62%), mp 194-196 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 1.66 (s, 6H, piperidine), 3.67 (s, 4H, piperidine), 6.87-
6.90 (m, 1H, CHAr), 7.42 (s, 1H, CHAr), 7.89 (s, 1H, CHAr), 8.16 (s, 1H, CHAr), 8.33-8.35 (s, 
1H, CHAr), 14.15 (s, 1H, OH). 
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13
C NMR due to bed solubility was not possible to measure 
MS (EI, 70eV): m/z (%) = 389 (M
+
, 100). 
HRMS (ESI): Calcd for C17H17N3OSBr (M+H) 390.02702. Found 390.02783. 
 IR (ATR, cm
-1
): 
~  = 2925 (w), 1573 (m), 1523 (s), 1485 (m), 1423 (m), 1365 (m), 1328 (m), 
1281 (s), 1272 (s), 1249 (s), 1213 (s), 1123 (m), 1086 (m), 1009 (m), 909 (m), 872 (m), 823 
(s), 811 (s), 747 (m), 696 (w), 655 (m), 622 (m). 
 
4-chloro-2-(2-(piperidin-1-yl)thiazolo[4,5-b]pyridin-5-yl)phenol (2.6.7d). 
Starting from chromone 2.6.2d (0.181 g, 1 mmol) and 2-
(piperidin-1-yl)thiazol-4-amine E5c (0.201 g, 1.1 mmol) in 5 
mL DMF and 1 mL of TMSCl. 2.6.7d was isolated as red-
brown solid (0.190 g, 55%), mp 194-196 
o
C. 
1
H NMR (300 MHz, CDCl3): δ = 1.72 (s, 6H, piperidine), 3.66 (s, 4H, piperidine), 6.97 (d, 
1H, 
3
J = 8.5 Hz, CHAr), 7.18 (dd, 1H, 
3
J = 8.7 Hz, 
4
J = 1.8 Hz, CHAr), 7.42 (d, 1H, 
3
J = 8.2 
Hz, CHAr), 7.69 (d, 1H, 
3
J = 2.2 Hz, CHAr), 7.91 (d, 1H, 
3
J = 8.2 Hz, CHAr), 13.77 (s, 1H, 
OH).  
13
C NMR (62.9 MHz, CDCl3): δ = 24.0, 25.3, 49.6 (CH2 piperidine), 111.3 (CH), 119.9 (C), 
120.4 (CH), 123.3, 123.4 (C), 125.9, 130.3, 130.5 (CH), 153.0, 158.0, 161.4, 170.6 (C).  
MS (GC, 70eV): m/z (%) = 345 (M
+
, 100), 316 (21), 289 (16), 227 (15), 207 (11), 172 (11), 
155 (16).  
HRMS (ESI): Calcd for C17H17ON3SCl (M+H) 346.07754. Found 346.07691. 
 IR (ATR, cm
-1
): 
~  = 2925 (w), 1573 (w), 1519 (m), 1487 (m), 1423 (m), 1360 (m), 1326 
(m), 1269 (s), 1214 (s), 1122 (m), 1009 (w), 957 (w), 901 (m), 857 (m), 824 (s), 811 (s), 747 
(m), 730 (m), 698 (w), 666 (s), 623 (m). 
 
7-(2-hydroxyphenyl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (2.6.8a) 
Starting from chromone 2.6.2a (0.146 g, 1 mmol) and 6-
aminopyrimidine-2,4(1H,3H)-dione E6a (0.140 g, 1.1 mmol) in 5 mL 
DMF and 1 mL of TMSCl. 2.6.8a was isolated as white solid (0.200 g, 
89%), mp more then 375 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 6.92-7.00 (m, 2H, CHAr), 7.35-
7.41 (m, 1H, CHAr), 7.96 (d, 1H, 
3
J = 8.4 Hz, CHAr), 8.04 (dd, 1H, 
3
J = 8.0 Hz,
 4
J = 1.4 Hz, 
CHAr), 8.33 (d, 1H, 
3
J = 8.4 Hz, CHAr), 11.51 (s, 1H, OH), 12.03 (s, 1H, NH), 12.52 (s, 1H, 
NH).  
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13
C NMR (62.9 MHz, DMSO-d6): δ = 107.9 (C), 114.9, 118.2 (CH), 118.7, 119.2 (C), 128.4, 
132.7, 137.5 (CH), 150.4, 150.7, 158.9, 160.8, 161.8 (C).  
MS (EI, 70eV): m/z (%) = 255 (M
+
, 12), 184 (20).  
HRMS (EI): Calcd for C13H9N3O3 (M
+
) 256.07167. Found 256.07177. 
IR (ATR, cm
-1
): 
~  = 3152 (w), 2984 (w), 2765 (m), 2456 (w), 1710 (m), 1667 (m), 1592 (m), 
1475 (m), 1414 (m), 1277 (m), 1220 (m), 1151 (m), 1007 (w), 942 (w), 859 (m), 803 (m), 749 
(s), 680 (m), 643 (m). 
 
7-(2-hydroxy-5-methylphenyl)pyrido[2,3-d]pyrimidine-2,4-diol (2.6.8b). 
Starting from chromone 2.6.2b (0.160 g, 1 mmol) and 6-
aminopyrimidine-2,4(1H,3H)-dione E6a (0.140 g, 1.1 mmol) in 5 
mL DMF and 1 mL of TMSCl. 2.6.8b was isolated as green solid 
(0.237 g, 88%), mp more then 375 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 2.28 (s, 3H, Me), 6.86 (d, 1H, 
3
J = 8.2 Hz, CHAr), 7.17 
(dd, 1H, 
3
J = 8.4 Hz, 
4
J = 1.7 Hz, CHAr), 7.83 (s, 1H, CHAr), 7.93 (d, 1H, 
3
J = 8.4 Hz, CHAr), 
8.30 (d, 1H, 
3
J = 8.4 Hz, CHAr), 8.93 (s, 1H, OH), 11.45 (s, 1H, OH), 12.00 (s, 1H, OH).  
13
C NMR (62.9 MHz, DMSO-d6): δ = 34.9 (Me), 107.7 (C), 114.8, 118.1 (CH), 118.2, 127.8 
(C), 128.2, 133.5, 137.4 (CH), 150.4, 150.7, 156.8, 160.9, 161.8 (C). 
MS (GC, 70eV): m/z (%) = 269 (M
+
, 100), 198 (16). 
HRMS (EI): Calcd for C14H11O3N3 (M
+
) 269.07949. Found 269.079464. 
IR (ATR, cm
-1
): 
~  = 3426 (w), 2981 (w), 2764 (m), 2457 (w), 1709 (m), 1661 (s), 1591 (s), 
1472 (m), 1409 (s), 1365 (m), 1266 (m), 1241 (m), 1203 (m), 1115 (w), 1054 (w), 1025 (m), 
950 (w), 878 (w), 800 (s), 767 (s), 706 (m), 678 (m), 651 (m), 588 (m). 
 
7-(5-chloro-2-hydroxyphenyl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (2.6.8c). 
Starting from chromone 2.6.2d (0.181 g, 1 mmol) and 6-
aminopyrimidine-2,4(1H,3H)-dione E6a (0.140 g, 1.1 mmol) in 5 
mL DMF and 1 mL of TMSCl. 2.6.8c was isolated as orange solid 
(0.246 g, 85%), mp more then 375 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 6.99 (d, 1H, 
3
J = 8.8 Hz, 
CHAr), 7.38 (dd, 1H, 
3
J = 8.8 Hz, 
4
J = 2.5 Hz, CHAr), 8.00-8.07 (m, 2H, CHAr), 8.31 (d, 1H, 
3
J 
= 8.4 Hz, CHAr), 11.52 (s, 1H, OH), 11.99 (s, 1H, NH), 12.40 (s, 1H, NH).  
13
C NMR (62.9 MHz, DMSO-d6): δ = 108.5 (C), 115.7, 120.0 (CH), 120.6, 123.0 (C), 127.8, 
132.1, 137.6 (CH), 150.3, 150.8, 157.4, 159.1, 161.8 (C).  
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MS (EI, 70eV): m/z (%) = 289 (M
+
, 100), 218 (27).  
HRMS (ESI): Calcd for C13H9O3N3Cl (M+H) 290.0327. Found 290.0331. 
IR (ATR, cm
-1
): 
~  = 3167 (w), 3043 (w), 1716 (m), 1659 (m), 1586 (m), 1467 (m), 1403 (m), 
1344 (m), 1265 (m), 1241 (m), 1171 (m), 1100 (w), 1045 (w), 946 (w), 829 (m), 799 (s), 773 
(m), 730 (m), 693 (s), 646 (m). 
 
7-(2-hydroxy-5-methylphenyl)-1-methylpyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione 
(2.6.8d). 
Starting from chromone 2.6.2b (0.160 g, 1 mmol) and 6-amino-1-
methylpyrimidine-2,4(1H,3H)-dione E6c (0.155 g, 1.1 mmol) in 5 
mL DMF and 1 mL of TMSCl. 2.6.8d was isolated as white solid 
(0.255 g, 90%), mp 332-333 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 2.29 (s, 3H, Me), 3.54 (s, 3H, NMe), 6.91 (d, 1H, 
3
J = 
8.6 Hz, CHAr), 7.16 (dd, 1H, 
3
J = 8.2 Hz,
 4
J = 2.0 Hz, CHAr), 7.81 (s, 1H, CHAr), 7.98 (d, 1H, 
3
J = 8.2 Hz, CHAr), 8.35 (d, 1H, 
3
J = 8.2 Hz, CHAr), 11.46 (br. s, 2H, OH).  
13
C NMR due to bed solubility was not possible to measure 
MS (EI, 70eV): m/z (%) = 283 (M
+
, 100), 254 (33), 185 (20).  
HRMS (EI): Calcd for C15H13N3O3 (M
+
) 283.09514. Found 283.094282. 
IR (ATR, cm
-1
): 
~  = 3182 (w), 2764 (m), 2457 (w), 1714 (m), 1682 (s), 1595 (s), 1470 (m), 
1404 (m), 1365 (m), 1277 (m), 1225 (m), 1159 (w), 1131 (w), 1078 (w), 1027 (w), 831 (m), 
804 (m), 774 (m), 734 (m), 690 (m), 669 (m), 611 (w). 
 
7-(5-chloro-2-hydroxyphenyl)-1-methylpyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione 
(2.6.8e) 
Starting from chromone 2.6.2d (0.181 g, 1 mmol) and 6-amino-1-
methylpyrimidine-2,4(1H,3H)-dione E6c (0.155 g, 1.1 mmol) in 5 
mL DMF and 1 mL of TMSCl. 2.6.8e was isolated as yellow solid 
(0.197 g, 65%), mp 148-150 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 3.54 (s, 3H, Me), 7.04 (d, 1H, 
3
J = 7.8 Hz, CHAr), 7.40 
(d, 1H, 
3
J = 8.0 Hz, CHAr), 8.07-8.11 (m, 2H, CHAr), 8.39 (d, 1H, 
3
J = 7.3 Hz, CHAr), 11.76 (s, 
2H, OH, NH).  
13
C NMR due to bed solubility was not possible to measure  
MS (EI, 70eV): m/z (%) = 303 (M
+
, 100), 274 (23), 205 (27), 168 (20), 99 (11), 78 (36). 
HRMS (EI): Calcd for C14H10O3N3Cl (M
+
) 303.04052. Found 303.040878. 
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 IR (ATR, cm
-1
): 
~  = 1709 (m), 1594 (s), 1484 (m), 1406 (s), 1365 (m), 1285 (s), 1239 (w), 
1162 (w), 1102 (w), 1074 (w), 1025 (w), 979 (w), 838 (m), 806 (m), 734 (w), 719 (s), 697 
(m), 686 (m), 651 (w). 
 
7-(2-hydroxy-5-methylphenyl)-1,3-dimethylpyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione 
(2.6.8f). 
Starting from chromone 2.6.2b (0.160 g, 1 mmol) and 6-amino-
1,3-dimethylpyrimidine-2,4(1H,3H)-dione E6b (0.170 g, 1.1 
mmol) in 5 mL DMF and 1 mL of TMSCl. 2.6.8f was isolated as 
white solid (0.193 g, 65%), mp 304-306
o
C. 
1
H NMR (300 MHz, CDCl3): δ = 2.35 (s, 3H, Me), 3.50 (s, 3H, NMe), 3.75 (s, 3H, NMe), 
6.95 (d, 1H, 
3
J = 8.4 Hz, CHAr), 7.22 (dd, 2H, 
3
J = 8.4 Hz,
 4
J = 1.4 Hz, CHAr), 7.65 (s, 1H, 
CHAr), 8.53 (d, 1H, 
3
J = 8.4 Hz, CHAr), 12.94 (br. s, 1H, OH).  
13
C NMR (62.9 MHz, CDCl3): δ = 20.7, 28.6, 29.8 (Me), 105.8 (C), 108.3, 114.2 (CH), 118.6 
(C), 127.5 (CH), 128.8 (C), 134.5, 138.7 (CH), 143.1, 149.4, 151.3, 155.0, 162.1 (C).  
MS (GC, 70eV): m/z (%) = 297 (M
+
, 100), 268 (25), 185 (14).  
HRMS (EI): Calcd for C16H15N3O3N3 (M
+
) 297.11079. Found 297.110626. 
IR (ATR, cm
-1
): 
~  = 1712 (w), 1652 (s), 1599 (s), 1478 (m), 1424 (s), 1358 (s), 1280 (s), 
1233 (m), 1221 (s), 1130 (m), 1103 (m), 1063 (w), 1018 (m), 831 (m), 798 (s), 776 (m), 747 
(s), 734 (m), 712 (s), 665 (m), 646 (m). 
 
7-(5-chloro-2-hydroxyphenyl)-1,3-dimethylpyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione 
(2.6.8g). 
Starting from chromone 2.6.2d (0.181 g, 1 mmol) and 6-amino-
1,3-dimethylpyrimidine-2,4(1H,3H)-dione E6b (0.170 g, 1.1 
mmol) in 5 mL DMF and 1 mL of TMSCl. 2.6.8g was isolated as 
yellow solid (0.308 g, 97%), mp 252-253
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 3.32 (s, 3H, NMe), 3.62 (s, 
3H, NCH3), 7.11 (d, 1H, 
3
J = 8.7 Hz, CHAr), 6.39 (dd, 1H, 
3
J = 9.0 Hz,
 4
J = 3.0 Hz, CHAr), 
8.05 (d, 1H, 
3
J = 2.7 Hz, CHAr), 8.12 (d, 1H, 
3
J = 8.3 Hz, CHAr), 8.43 (d, 1H, 
3
J = 8.3 Hz, 
CHAr), 11.70 (s, 1H, OH).  
13
C NMR (75.5 MHz, DMSO-d6): δ = 28.1, 29.2 (Me), 108.8 (C), 117.9, 119.2 (CH), 123.1, 
123.4 (C), 128.8, 131.5, 137.7 (CH), 149.8, 151.0, 156.3, 158.0, 160.4 (C). 
MS (GC, 70eV): m/z (%) = 317 (M
+
, 100), 288 (21), 205 (19).  
N
HO
Me
N
NO
O
Me
Me
 
N
HO
Cl
N
NO
O
Me
Me
 
 157 
 
HRMS (EI): Calcd for C15H12N3O3Cl (M
+
) 317.05617. Found 317.05629. 
IR (ATR, cm
-1
): 
~  = 3362 (w), 2962 (w), 2767 (m), 2452 (w), 1708 (m), 1658 (s), 1598 (s), 
1468 (s), 1424 (s), 1354 (m), 1284 (m), 1096 (m), 1052 (w), 1022 (m), 847 (m), 804 (s), 747 
(m), 711 (m), 691 (m), 651 (m). 
 
7-(2-hydroxy-5-methylphenyl)-2-mercaptopyrido[2,3-d]pyrimidin-4-ol (2.6.8h). 
Starting from chromone 2.6.2b (0.160 g, 1 mmol) and 6-amino-2,3-
dihydro-2-thioxopyrimidin-4(1H)-one E6d (0.157 g, 1.1 mmol) in 5 
mL DMF and 1 mL of TMSCl. 2.6.8h was isolated as green solid 
(0.254 g, 89%), mp 371-374 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 2.29 (s, 3H, Me), 6.87 (d, 1H, 
3
J = 8.4 Hz, CHAr), 7.20 
(dd, 1H, 
3
J = 8.4 Hz, 
4
J = 1.7 Hz, CHAr), 7.87 (s, 1H, CHAr), 8.04 (d, 1H, 
3
J = 8.7 Hz, CHAr), 
8.33 (d, 1H, 
3
J = 8.7 Hz, CHAr), 12.08 (s, 1H, OH), 12.65 (s, 1H, OH), 13.47 (s, 1H, SH). 
13
C NMR (62.9 MHz, DMSO-d6): δ = 34.1 (Me), 109.8 (C), 116.3 (CH), 118.0 (C), 118.3 
(CH), 127.9 (C), 128.3, 133.8, 137.2 (CH), 149.8, 156.9, 159.2, 161.2, 175.9 (C). 
MS (EI, 70eV): m/z (%) = 285 (M
+
, 100), 168 (26), 99 (14). 
HRMS (EI): Calcd for C14H11O2N3S (M
+
) 285.05665. Found 285.056686. 
IR (ATR, cm
-1
): 
~  = 3134 (w), 2768 (w), 1683 (m), 1609 (s), 1545 (s), 1481 (s), 1417 (m), 
1282 (m), 1239 (s), 1200 (s), 1161 (s), 1133 (s), 812 (s), 777 (s), 692 (m), 660 (m), 610 (w), 
578 (s), 543 (s).  
 
7-(5-bromo-2-hydroxyphenyl)-4-mercaptopyrido[2,3-d]pyrimidin-2-ol (2.6.8i). 
Starting from chromone 2.6.2c (0.225 g, 1 mmol) and 6-amino-2,3-
dihydro-2-thioxopyrimidin-4(1H)-one E6d (0.157 g, 1.1 mmol) in 5 
mL DMF and 1 mL of TMSCl. 2.6.8i was isolated as brown solid 
(0.277g, 79%), mp more then 375 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 7.00 (d, 1H, 
3
J = 8.8 Hz, 
CHAr), 7.52 (dd, 1H, 
3
J = 8.8 Hz, 
4
J = 2.5 Hz, CHAr), 8.14 (d, 1H, 
3
J = 8.6 Hz, CHAr), 8.23  (s, 
1H, CHAr), 8.34 (d, 1H, 
3
J = 8.6 Hz, CHAr), 12.20 (s, 1H, OH), 12.67 (s, 1H, OH), 13.44 (s, 
1H, SH).  
13
C NMR (62.9 MHz, DMSO-d6): δ = 110.4, 110.5 (C), 117.5, 120.5 (CH), 121.2 (C), 130.9, 
135.1, 137.3 (CH), 150.0, 157.8, 159.2, 159.4, 175.9 (C). 
MS (EI, 70eV): m/z (%) = 348 (M
+
, 100), 207 (16). 
HRMS (EI): Calcd for C13H8O2N3SBr (M
+
) 348.95151. Found 348.950828. 
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IR (ATR, cm
-1
): 
~  = 3184 (w), 2932 (w), 2758 (m), 2456 (w), 1665 (s), 1621 (m), 1586 (s), 
1470 (s), 1413 (m), 1356 (s), 1272 (s), 1236 (s), 1205 (s), 1175 (s), 1087 (w), 1026 (w), 838 
(m), 814 (m), 787 (s), 723 (m), 664 (m). 
 
7-(5-chloro-2-hydroxyphenyl)-2-mercaptopyrido[2,3-d]pyrimidin-4-ol (2.6.8j). 
Starting from chromone 2.6.2d (0.181 g, 1 mmol) and 6-amino-2,3-
dihydro-2-thioxopyrimidin-4(1H)-one E6d (0.157 g, 1.1 mmol) in 5 
mL DMF and 1 mL of TMSCl. 2.6.8j was isolated as yellow solid 
(0.241 g, 79%), mp more then 375 
o
C. 
1
H NMR (250 MHz, DMSO-d6): δ = 7.01 (d, 1H, 
3
J = 8.4 Hz, 
CHAr), 7.41 (td, 1H, 
3
J = 8.8 Hz, 
4
J = 2.5 Hz, CHAr), 8.11-8.15  (m, 2H, CHAr), 8.35 (d, 1H, 
3
J 
= 8.4 Hz, CHAr), 12.24 (s, 1H, OH), 12.69 (s, 1H, OH), 13.47 (s, 1H, SH). 
13
C NMR (62.9 MHz, DMSO-d6): δ = 110.5 (C), 117.1, 120.2 (CH), 120.3, 123.1 (C), 127.8, 
132.4, 137.4 (CH), 149.9, 157.6, 159.2, 159.5, 176.0 (C). 
MS (GC, 70eV): m/z (%) = 305 (M
+
, 100), 277 (12), 218 (12), 168 (28), 99 (16). 
HRMS (EI): Calcd for C13H8O2N3SCl (M
+
) 305.00203. Found 305.001007. 
IR (ATR, cm
-1
): 
~  = 3186 (w), 1665 (m), 1606 (m), 1587 (s), 1558 (m), 1470 (m), 1414 (m), 
1356 (m), 1271 (m), 1236 (m), 1192 (m), 1136 (m), 1098 (w), 1051 (w), 941 (w), 838 (m), 
815 (m), 785 (s), 735 (m), 699 (w), 667 (m), 575 (m), 540 (m). 
 
2-(2,4-diaminopyrido[2,3-d]pyrimidin-7-yl)-4-methylphenol (2.6.9a). 
Starting from chromone 2.6.2b (0.160 g, 1 mmol) and 
pyrimidine-2,4,6-triamine E9 (0.138 g, 1.1 mmol) in 5 mL DMF 
and 1 mL of TMSCl. 2.6.9a was isolated as yellow solid (0.160 
g, 60%), mp 152-154
o
C. 
1
H NMR (250 MHz, DMSO-d6): δ = 2.28 (s, 3H, Me), 6.90 (d, 1H, 
3
J = 8.2 Hz, CHAr), 7.19 
(d, 1H, 
3
J = 8.0 Hz, CHAr), 7.88 (br. s, 2H, NH2), 8.17 (d, 1H, 
3
J = 8.5 Hz, CHAr), 8.50 (br. s, 
1H, NH2), 8.87 (d, 1H, 
3
J = 8.5 Hz, CHAr), 9.04 (br. s, 1H, NH2), 11.94 (br. s, 1H, NH2), 
13.20 (s, 1H, OH).  
13
C NMR (62.9 MHz, DMSO-d6): δ = 30.6 (Me), 103.1 (C), 117.5, 117.8 (CH), 118.9, 128.0 
(C), 128.9, 133.8, 135.5 (CH), 148.7, 156.0, 156.6, 161.6, 162.7 (C). 
MS (GC, 70eV): m/z (%) = 267 (M
+
, 100). 
HRMS (EI): Calcd for C14H13ON5 (M
+
) 267.11146. Found 267.111500. 
IR (ATR, cm
-1
): 
~  = 3412 (w), 3131 (w), 1645 (m), 1608 (m), 1524 (w), 1480 (m), 1460 (m), 
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1370 (m), 1344 (m), 1291 (m), 1242 (m), 1214 (m), 1184 (m), 1147 (m), 1043 (m), 1004 (m), 
874 (w), 835 (m), 800 (s), 770 (m), 742 (s), 701 (s), 674 (s), 646 (s). 
 
2-(2,4-diaminopyrido[2,3-d]pyrimidin-7-yl)-4-chlorophenol (2.6.9b). 
Starting from chromone 2.6.2d (0.181 g, 1 mmol) and pyrimidine-
2,4,6-triamine E9 (0.138 g, 1.1 mmol) in 5 mL DMF and 1 mL of 
TMSCl. 2.6.9b was isolated as yellow solid (0.201 g, 70%), mp 
more than 375 
o
C. 
1
H NMR (250 MHz, DMSO-d6): δ = 7.08 (d, 1H, 
3
J = 8.9 Hz, 
CHAr), 7.40 (td, 1H, 
3
J = 8.9 Hz, 
4
J = 2.5 Hz, CHAr), 7.81 (br. s, 1H, NH2), 8.08 (d, 1H, 
3
J = 
2.5 Hz, CHAr), 8.23 (d, 1H, 
3
J = 8.9 Hz, CHAr), 8.52 (br. s, 1H, NH2), 8.88 (d, 1H, 
3
J = 8.5 Hz, 
CHAr), 9.07 (br. s, 1H, NH2), 9.41 (br. s, 1H, NH2), 12.04 (s, 1H, OH).  
13
C NMR (62.9 MHz, DMSO-d6): δ = 103.4 (C), 118.5, 119.7 (CH), 121.6, 123.1 (C), 128.4, 
132.1, 135.6 (CH), 148.9, 156.1, 157.0, 159.7, 162.7 (C). 
MS (GC, 70eV): m/z (%) = 287 (M
+
, 100), 122 (16), 105 (36), 77 (16). 
HRMS (ESI): Calcd for C13H11N5OCl (M+H) 288.06466. Found 288.06522. 
IR (ATR, cm
-1
): 
~  = 3307 (w), 3140 (w), 2586 (w), 1682 (w), 1645 (s), 1605 (s), 1525 (w), 
1453 (s), 1400 (w), 1285 (m), 1235 (m), 1192 (m), 1145 (w), 1041 (w), 981 (w), 802 (s), 738 
(m), 695 (m). 
 
5-(1-hydroxynaphthalen-2-yl)-1-methyl-3-phenyl-1H-imidazo[4,5-b]pyridine-2(3H)-
thione (2.6.10) 
Starting from chromone 2.6.2e (0.196 g, 1 mmol) and 4-amino-1-
methyl-3-phenyl-1H-imidazole-2(3H)-thione E2b (0.225 g, 1.1 
mmol) in 5 mL DMF and 1 mL of TMSCl. 2.6.10 was isolated as 
green solid (0.276 g, 72%), mp 305-306 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 3.85 (s, 3H, Me), 7.42-7.54 (m, 
3H, CHAr), 7.64-7.73 (m, 5H, CHAr), 7.82 (s, 1H, CHAr), 8.09-8.24 (m, 4H, CHAr), 13.61 (br. 
s, 1H, OH). 
13
C NMR due to bed solubility was not possible to measure  
MS (GC, 70eV): m/z (%) = 383 (M
+
, 100), 207 (13). 
HRMS (EI): Calcd for C23H17N3OS (M
+
) 383.10868. Found 383.107368. 
IR (ATR, cm
-1
): 
~  = 3049 (w), 1614 (w), 1569 (w), 1499 (w), 1462 (s), 1438 (m), 1402 (m), 
1337 (s), 1295 (s), 1223 (m), 1203 (m), 1139 (m), 1063 (w), 1027 (w), 977 (w), 853 (w), 795 
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(s), 769 (m), 723 (m), 704 (m), 622 (m). 
 
2-(3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridin-6-yl)naphthalen-1-ol (2.6.11). 
Starting from chromone 2.6.2e (0.196 g, 1 mmol) and 3-methyl-1-
phenyl-1H-pyrazol-5-amine E3 (0.190 g, 1.1 mmol) in 5 mL DMF and 
1 mL of TMSCl. 2.6.11 was isolated as white solid (0.295 g, 84%), mp 
186-187 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 2.65 (s, 3H, Me), 7.46-7.71 (m, 
6H, CHAr), 7.88-7.97 (m, 3H, CHAr), 8.20-8.25 (m, 2H, CHAr), 8.33 (d, 1H, 
3
J = 8.0 Hz, 
CHAr), 8.57 (d, 1H, 
3
J = 8.5 Hz, CHAr), 14.88 (s, 1H, OH). 
13
C NMR (62.9 MHz, DMSO-d6): δ = 34.0 (Me), 112.0, 113.8, 115.2 (C), 118.6, 121.9, 123.0, 
124.3, 125.3, 125.6, 126.8 (CH), 127.3 (C), 128.1, 129.6 (CH), 132.9, 134.9, 138.2, 143.5, 
146.8, 156.2, 156.7 (C). 
MS (GC, 70eV): m/z (%) = 351 (M
+
, 100). 
HRMS (ESI): Calcd for C23H18N3O (M+H) 352.1444. Found 352.14452. 
IR (ATR, cm
-1
): 
~  = 3400 (w), 2980 (m), 2763 (s), 2456 (w), 1582 (s), 1508 (m), 1480 (m), 
1431 (m), 1389 (s), 1349 (m), 1304 (m), 1231 (m), 1176 (m), 1119 (w), 1057 (m), 1023 (m), 
850 (m), 804 (m), 790 (s), 772 (s), 753 (s), 722 (m), 691 (s), 648 (s), 608 (m), 570 (m).  
 
7-(1-hydroxynaphthalen-2-yl)-4-mercaptopyrido[2,3-d]pyrimidin-2-ol (2.6.12) 
Starting from chromone 2.6.2e (0.196 g, 1 mmol) and 6-amino-2,3-
dihydro-2-thioxopyrimidin-4(1H)-one E6d (0.157 g, 1.1 mmol) in 5 
mL DMF and 1 mL of TMSCl. 2.6.12 was isolated as white solid 
(0.270 g, 84%), mp 278-280 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 7.41 (d, 1H, 
3
J = 8.8 Hz, 
CHAr), 7.51-7.62 (m, 2H, CHAr), 7.83 (d, 1H, 
3
J = 7.5 Hz, CHAr), 8.03-8.06 (m, 2H, CHAr), 
8.30-8.35 (m, 2H, CHAr), 12.65 (s, 1H, OH), 13.56 (s, 1H, OH), 13.99 (s, 1H, SH). 
13
C NMR (62.9 MHz, DMSO-d6): δ = 109.4, 110.8 (C), 115.8, 118.6, 123.3, 123.8 (CH), 
125.4 (C), 125.8, 127.3, 128.6 (CH), 135.4 (C), 137.3 (CH), 149.5, 157.2, 159.1, 161.2, 175.9 
(C). 
MS (GC, 70eV): m/z (%) = 321 (M
+
, 100), 234 (12), 78 (12). 
HRMS (EI): Calcd for C17H11O2N3S (M
+
) 321.05665. Found 321.056049. 
IR (ATR, cm
-1
): 
~  = 3284 (w), 1702 (w), 1672 (m), 1611 (m), 1581 (m), 1512 (m), 1472 (m), 
1396 (s), 1344 (m), 1273 (m), 1242 (m), 1178 (s), 1148 (m), 1126 (s), 1108 (m), 949 (w), 868 
N
HO
N
N
Me
Ph
 
N
HO
N
NHS
OH
 
 161 
 
(s), 808 (m), 786 (s), 764 (s), 723 (m), 650 (m). 
 
A.2.15. General procedure for the synthesis of compounds 2.6.15-2.6.19. 
 
Corresponding enaminone 2.6.14a-e (1 equiv.) and appropriate amine E (1.1 equiv.) were 
placed in a pressure tube under the flow of dry argon and dissolved in dry DMF (5 mL/1 
mmol of chromone 2.6.14) containing 1 mL of TMSCl. The mixture was heated at 100-120 
°C for 1-6 h (controlled by TLC). After the reaction was completed volatiles were evaporated 
under reduced pressure. The residue was treated with water, filtered, dried in air, and 
recrystallized from appropriate solvent or subjected to column chromatography (silica gel). 
 
6-(3-(trifluoromethyl)phenyl)-1,2-dihydro-2-phenylpyrazolo[3,4-b]pyridin-3-one 
(2.6.15a). 
Starting from chromone 2.6.14a (0.243 g, 1 mmol) and 5-amino-
1,2-dihydro-2-phenylpyrazol-3-one E1a (0.193 g, 1.1 mmol) in 5 
mL DMF and 1 mL of TMSCl. 2.6.15a was isolated as yellow 
solid (0.249g, 70%), mp 161-162 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 7.26-7.31 (m, 1H, CHAr), 
7.45-7.55 (m, 2H, CHAr), 7.90-7.95 (m, 5H, CHAr), 8.34-8.40 (m, 3H, CHAr), 11.80 (br.s, 1H, 
NH). 
19
F NMR (282 MHz, DMSO-d6): δ = -61.2 (CF3). 
13
C NMR Due to bed solubility it was not possible to measure. 
MS (GC, 70eV): m/z (%) = 355 (M
+
, 100), 286 (37). 
HRMS (EI): Calcd for C20H14N3F3 (M
+
) 355.09221. Found 355.09222. 
IR (ATR, cm
-1
): 
~  = 3382 (w), 3013 (m), 2773 (m), 2448 (w), 1651 (m), 1620 (m), 1594 (m), 
1501 (m), 1441 (m), 1403 (m), 1325 (m), 1301 (m), 1158 (m), 1120 (s), 1067 (s), 1017 (s), 
935 (w), 857 (m), 825 (s), 792 (s), 746 (s), 711 (s), 682 (s). 
 
1,2-dihydro-6-(4-methoxyphenyl)-2-phenylpyrazolo[3,4-b]pyridin-3-one (2.6.15b). 
Starting from chromone 2.6.14b (0.205 g, 1 mmol) and 5-
amino-1,2-dihydro-2-phenylpyrazol-3-one E1a (0.193 g, 1.1 
mmol) in 5 mL DMF and 1 mL of TMSCl. 2.6.15b was isolated 
as orange solid (0.228 g, 72%), mp 173-174 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 3.88 (s, 3H, OMe), 7.11 (d, 2H, 
3
J = 8.9 Hz, CHAr), 
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7.24-7.29 (m, 1H, CHAr), 7.49-7.55 (m, 2H, CHAr), 7.75 (d, 1H,
 3
J = 8.3 Hz,  CHAr), 7.93-7.96 
(m, 2H, CHAr), 8.16 (d, 2H, 
3
J = 8.9 Hz, CHAr), 8.23 (d, 1H, 
3
J = 8.1 Hz, CHAr), 10.31 (br s, 
1H, NH). 
13
C NMR (75.5 MHz, DMSO-d6): δ = 55.4 (OMe), 108.5 (CH), 113.9, 114.4, 118.8, 119.3, 
125.0, 128.9 (CH), 129.0 (C), 129.9 (CH), 134.2 (C), 135.7 (CH), 137.4, 157.4, 158.7, 159.6, 
161.1 (C). 
MS (EI, 70eV): m/z (%) = 317 (M
+
, 100), 288 (20). 
HRMS (EI): Calcd for C19H15N3O2 (M
+
) 317.11588. Found 317.115965. 
IR (ATR, cm
-1
): 
~  = 2936 (w), 2761 (m), 2456 (m), 1594 (m), 1576 (m), 1479 (m), 1356 (m), 
1319 (m), 1299 (m), 1257 (s), 1221 (m), 1182 (m), 1064 (m), 1025 (m), 809 (m), 783 (m), 
769 (m), 754 (m), 721 (w), 693 (m), 670 (w). 
 
6-(2-fluorophenyl)-1,2-dihydro-2-phenylpyrazolo[3,4-b]pyridin-3-one (2.6.15c). 
Starting from chromone 2.6.14c (0.193 g, 1 mmol) and 5-amino-1,2-
dihydro-2-phenylpyrazol-3-one E1a (0.193 g, 1.1 mmol) in 5 mL 
DMF and 1 mL of TMSCl. 2.6.15c was isolated as brown solid (0.241 
g, 78%), mp 241-243 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 7.25-7.30 (m, 1H, CHAr), 7.36-
7.42 (m, 2H, CHAr), 7.49-7.60 (m, 4H, CHAr), 7.92-8.00 (m, 3H, CHAr), 8.32 (d, 1H, 
3
J = 8.3 
Hz, CHAr), 11.65 (br s, 1H, NH).  
19
F NMR (282 MHz, DMSO-d6): δ = -115.9 (CF). 
13
C NMR: Due to bed solubility it was not possible to measure.  
MS (GC, 70eV): m/z (%) = 315 (M
+
, 100), 276 (41), 207 (15), 77 (17). 
HRMS (ESI): Calcd for C18H13FN3O (M+H) 316.10372. Found 316.10335. 
IR (ATR, cm
-1
): 
~  = 1643 (m), 1593 (m), 1497 (m), 1441 (m), 1415 (m), 1335 (w), 1302 (m), 
1280 (m), 1203 (m), 1128 (w), 1085 (w), 1026 (w), 937 (w), 893 (w), 789 (w), 760 (s), 740 
(s), 712 (w), 661 (s). 
 
1,2-dihydro-2-phenyl-6-(pyridin-3-yl)pyrazolo[3,4-b]pyridin-3-one (2.6.15d). 
Starting from chromone 2.6.14d (0.176 g, 1 mmol) and 5-amino-1,2-
dihydro-2-phenylpyrazol-3-one E1a (0.193 g, 1.1 mmol) in 5 mL 
DMF and 1 mL of TMSCl. 2.6.15d was isolated as yellow solid 
(0.202 g, 70%), mp 268-270 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 7.25-7.31 (m, 1H, CHAr), 7.50-7.55 (m, 2H, CHAr), 7.91-
N
N
N
H
O
Ph
F  
N
N
N
H
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7.94 (m, 2H, CHAr), 8.01-8.10 (m, 2H, CHAr), 8.42 (d, 1H, 
3
J = 8.1 Hz, CHAr), 8.96 (d, 1H, 
3
J 
= 5.2 Hz, CHAr), 9.09 (d, 1H, 
3
J = 8.7 Hz, CHAr), 9.53 (s, 1H, CHAr), 11.90 (br s, 1H, NH).  
13
C NMR (62.9 MHz, DMSO-d6): δ = 110.6 (C), 115.4, 119.6, 125.4, 126.6, 129.1, 135.1 
(CH), 135.7, 136.9 (CH), 141.2, 142.5, 144.4 (CH), 154.9, 157.1, 158.0 (C). 
MS (EI, 70eV): m/z (%) = 288 (M
+
, 100), 259 (50), 77 (28).  
HRMS (EI): Calcd for C17H12N4O (M
+
) 288.10056. Found 288.100698. 
IR (ATR, cm
-1
): 
~  = 3052 (w), 2442 (m), 2062 (w), 1651 (s), 1607 (m), 1538 (m), 1495 (m), 
1445 (m), 1422 (m), 1345 (m), 1304 (s), 1280 (m), 1034 (w), 1016 (w), 941 (w), 814 (m), 789 
(m), 770 (s), 724 (m), 680 (s), 623 (m), 602 (m).  
 
1,2-dihydro-2-phenyl-6-(pyridin-4-yl)pyrazolo[3,4-b]pyridin-3-one (2.6.15e). 
Starting from chromone 2.6.14e (0.176 g, 1 mmol) and 5-amino-
1,2-dihydro-2-phenylpyrazol-3-one E1a (0.193 g, 1.1 mmol) in 5 
mL DMF and 1 mL of TMSCl. 2.6.15e was isolated as yellow solid 
(0.236 g, 82%), mp 272-274 
o
C. 
1
H NMR (300 MHz, CF3COOD/DMSO-d6): δ = 7.20-7.25 (m, 3H, 
CHAr), 7.38-7.41 (m, 2H, CHAr), 7.69 (d, 1H, 
3
J = 8.2 Hz, CHAr), 8.37-8.42 (m, 3H, CHAr), 
8.60-8.62 (m, 2H, CHAr), 11.94 (s, 1H, NH). 
13
C NMR (75.5MHz, CF3COOD/DMSO-d6): δ = 110.8, 115.2, 117.6, (C), 119.5 (CH), 122.1 
(C), 125.7, 127.5, 131.5, 131.9 (CH), 135.0 (C) 139.3, 143.7 (CH), 154.9, 156.5, 158.6 (C). 
MS (EI, 70eV): m/z (%) = 288 (M
+
, 100), 259 (39). 
HRMS (ESI): Calcd for C17H13N4O (M+H) 289.10839. Found 289.10874. 
IR (ATR, cm
-1
): 
~  = 3059 (w), 2397 (m), 2068 (w), 1652 (m), 1630 (m), 1591 (m), 1496 (m), 
1417 (m), 1343 (w), 1300 (m), 1279 (m), 1128 (w), 1083 (w), 1001 (w), 942 (w), 814 (m), 
786 (m), 767 (s), 718 (m), 689 (m), 634 (m), 601 (m). 
 
6-(3-(trifluoromethyl)phenyl)-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine (2.6.16a). 
Starting from chromone 2.6.14a (0.243 g, 1 mmol) and 3-methyl-1-
phenyl-1H-pyrazol-5-amine E3 (0.190 g, 1.1 mmol) in 5 mL DMF 
and 1 mL of TMSCl. 2.6.16a was isolated as yellow solid (0.247g, 
70%), mp 151-152 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 2.62 (s, 3H, Me), 7.29-7.34 (m, 1H, CHAr), 7.54-7.59 
(m, 2H, CHAr), 7.89 (d, 2H, 
3
J = 8.5 Hz, CHAr), 7.97 (d, 1H, 
3
J = 8.5 Hz, CHAr), 8.32-8.44 (m, 
5H, CHAr). 
N
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19
F NMR (282 MHz, DMSO-d6): δ = -61.0 (CF3). 
13
C NMR (62.9 MHz, DMSO-d6): δ = 12.3 (Me), 115.1 (CH), 116.3 (C), 119.9 (CH), 124.2 
(q, 
1
J = 272 Hz, CF3), 125.3 (CH), 125.7, 125.8 (q, 
3
J = 4 Hz, CHCCF3), 128.0, 129.2 (CH), 
129.6 (q, 
2
J = 32 Hz, CCF3), 131.9 (CH), 139.2, 142.2, 143.0, 150.2, 150.9, 154.2, 165.5 (C).  
MS (GC, 70eV): m/z (%) = 353 (M
+
, 100), 338 (17). 
HRMS (ESI): Calcd for C20H15N3F3 (M+H) 354.12126. Found 354.12094. 
IR (ATR, cm
-1
): 
~  = 1592 (m), 1504 (s), 1394 (m), 1315 (s), 1283 (m), 1164 (s), 1124 (s), 
1081 (m), 1068 (s), 1013 (m), 956 (w), 908 (w), 856 (w), 838 (w), 815 (s), 749 (s), 690 (s), 
665 (s), 593 (m). 
 
6-(2-fluorophenyl)-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine (2.6.16b). 
Starting from chromone 2.6.14c (0.193 g, 1 mmol) and 3-methyl-1-
phenyl-1H-pyrazol-5-amine E3 (0.190 g, 1.1 mmol) in 5 mL DMF and 1 
mL of TMSCl. 2.6.16b was isolated as yellow solid (0.236 g, 78%), mp 
110-111 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 2.62 (s, 3H, Me), 7.26-7.31 (m, 1H, CHAr), 7.35-7.42 
(m, 2H, CHAr), 7.51-7.58 (m, 3H, CHAr), 7.70 (dd, 1H, 
3
J = 8.4 Hz, 
4
J = 2.2 Hz, CHAr), 8.01 
(dt, 1H, 
3
J = 8.4 Hz, 
3
J = 2.0 Hz, CHAr), 8.30-8.33 (m, 2H, CHAr), 8.41 (d, 1H, 
3
J = 7.8 Hz, 
CHAr). 
19
F NMR (282 MHz, DMSO-d6): δ = -116.6 (CF). 
13
C NMR (62.9 MHz, DMSO-d6): δ = 12.2 (Me), 113.2 (d, 
1
J = 240 Hz, CF), 115.6 (C), 116.4 
(d, 
2
J = 22.7 Hz, CH), 118.0 (d, 
3
J = 8.0 Hz, CH), 119.8 (CH), 125.0 (d, 
4
J = 3.5 Hz, CH), 
125.3 (CH), 126.9 (d, 
3
J = 11.4 Hz, C) , 129.1, 131.0, 131.3 (CH), 142.9, 150.1, 152.4 (d, 
4
J = 
2.8 Hz, C), 160.0 (d, 
1
J = 249.1 Hz, CF). 
MS (GC, 70eV): m/z (%) = 303 (M
+
, 100), 288 (21). 
HRMS (EI): Calcd for C19H14N3F (M
+
) 303.11663. Found 303.116564. 
IR (ATR, cm
-1
): 
~  = 1596 (m), 1504 (m), 1461 (m), 1392 (s), 1309 (m), 1286 (m), 1205 (m), 
1161 (m), 1107 (m), 1088 (m), 1030 (m), 957 (w), 901 (w), 820 (m), 797 (m), 742 (s), 682 (s), 
658 (s), 631 (m). 
 
3-methyl-1-phenyl-6-(pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine (2.6.16c). 
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Starting from chromone 2.6.14d (0.176 g, 1 mmol) and 3-methyl-1-
phenyl-1H-pyrazol-5-amine E3 (0.190 g, 1.1 mmol) in 5 mL DMF and 1 
mL of TMSCl. 2.6.15c was isolated as yellow solid (0.186 g, 65%), mp 
196-198 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 2.63 (s, 3H, Me), 7.30-7.35 (m, 1H, CHAr), 7.54-7.59 
(m, 2H, CHAr), 8.07-8.13 (m, 2H, CHAr), 8.28-8.31 (m, 2H,  CHAr), 8.52 (d, 1H, 
3
J = 8.3 Hz, 
CHAr), 8.94 (dd, 1H, 
3
J = 5.4 Hz, 
4
J = 1.0 Hz, CHAr), 9.16 (dt, 1H, 
3
J = 8.3 Hz, 
4
J = 1.8 Hz, 
CHAr),  9.59 (s, 1H, CHAr). 
13
C NMR (62.9 MHz, DMSO-d6): δ = 12.2 (Me), 115.1 (CH), 116.8, 120.0, 125.5, 126.7, 
129.2, 132.2 (CH), 136.4, 138.9 (C), 141.5, 142.2, 143.1 (CH), 143.8, 149.9, 150.6 (C). 
MS (GC, 70eV): m/z (%) = 286 (M
+
, 100), 271 (16). 
HRMS (ESI): Calcd for C18H15N4 (M+H) 287.12912. Found 287.12936. 
IR (ATR, cm
-1
): 
~  = 3343 (w), 2451 (m), 2072 (w), 1591 (m), 1556 (m), 1486 (m), 1395 (m), 
1360 (m), 1283 (w), 1199 (m), 1161 (m), 1113 (w), 1085 (w), 1013 (w), 910 (w), 833 (w), 
803 (m), 775 (m), 754 (s), 708 (m), 681 (m), 669 (s), 630 (s). 
 
3-methyl-1-phenyl-6-(pyridin-4-yl)-1H-pyrazolo[3,4-b]pyridine (2.6.16d). 
Starting from chromone 2.6.14e (0.176 g, 1 mmol) and 3-methyl-1-
phenyl-1H-pyrazol-5-amine E3 (0.190 g, 1.1 mmol) in 5 mL DMF and 
1 mL of TMSCl. 2.6.16d was isolated as yellow solid (0.223 g, 78%), 
mp 123-125 
o
C. 
1
H NMR (300 MHz, CF3COOD/DMSO-d6): δ = 1.42 (s, 3H, CH3), 6.10-6.22 (m, 3H, CHAr), 
6.49-6.51 (m, 2H, CHAr), 6.75 (d, 1H, 
3
J = 8.1 Hz, CHAr), 7.18 (d, 1H, 
3
J = 8.1 Hz, CHAr), 
7.36-7.38 (m, 2H, CHAr), 7.59 (m, 1H, CHAr). 
3
C NMR (62.9 MHz, CF3COOD/DMSO-d6): δ = 13.3 (Me), 118.1 (C), 119.2, 125.5, 127.0, 
130.7, 131.3, 135.8 (CH), 137.0 (C), 143.5 (CH), 146.4, 151.2, 155.2, 157.2 (C). 
MS (GC, 70eV): m/z (%) = 286 (M
+
, 100), 271 (18). 
HRMS (ESI): Calcd for C18H15N4 (M+H) 287.2256. Found 287.2255. 
IR (ATR, cm
-1
): 
~  = 2317 (w), 2064 (w), 1630 (m), 1588 (m), 1498 (m), 1445 (m), 1324 (w), 
1247 (m), 1164 (m), 1097 (m), 1082 (m), 997 (m), 833 (m), 803 (s), 763 (s), 692 (m), 661 
(m), 594 (m). 
 
1-cyclohexyl-6-(4-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile (2.6.17). 
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Starting from chromone 2.6.14b (0.205 g, 1 mmol) and 5-amino-1-
cyclohexyl-1H-pyrrole-3-carbonitrile E4b (0.208 g, 1.1 mmol) in 5 
mL DMF and 1 mL of TMSCl. 2.6.17 was isolated as yellow solid 
(0.248 g, 75%), mp 150-152 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 1.20-1.57 (m, 3H, cyclohexyl), 1.72-1.93 (m, 5H, 
cyclohexyl), 2.01-2.04 (m, 2H, cyclohexyl), 3.83 (s, 3H, OMe), 4.76-4.84 (m, 1H, NCH), 7.07 
(d, 2H, 
3
J = 8.9 Hz, CHAr), 7.84 (d, 1H, 
3
J = 8.5 Hz, CHAr), 8.10-8.14  (m, 3H, CHAr), 8.58 (s, 
1H, CHAr). 
13
C NMR (62.9 MHz, DMSO-d6): δ = 24.9, 25.2, 32.4 (cyclohexyl), 54.0 (NCH), 55.2 (OMe), 
82.5 (CN), 114.2, 114.6 (CH), 115.6, 117.8 (C), 128.0, 128.4 (CH), 131.0 (C), 135.3 (CH), 
145.6, 151.5, 160.1 (C). 
MS (GC, 70eV): m/z (%) = 331 (M
+
, 46), 249 (100), 234 (11), 206 (13). 
HRMS (EI): Calcd for C21H21ON3 (M
+
) 331.4112. Found 331.41121. 
IR (ATR, cm
-1
): 
~  = 2922 (m), 2851 (m), 2221 (m), 1698 (w), 1600 (m), 1581 (m), 1513 (m), 
1467 (m), 1427 (m), 1396 (m), 1304 (w), 1279 (m), 1251 (s), 1222 (m), 1179 (s), 1106 (m), 
1027 (m), 891 (w), 838 (m), 798 (s), 779 (s), 641 (m), 611 (s). 
 
5-(3-(trifluoromethyl)phenyl)-2-(piperidin-1-yl)thiazolo[4,5-b]pyridine (2.6.18a). 
Starting from chromone 2.6.14a (0.243 g, 1 mmol) and 2-
(piperidin-1-yl)thiazol-4-amine E5c (0.190 g, 1.1 mmol) in 
5 mL DMF and 1 mL of TMSCl. 2.6.18a was isolated as 
yellow solid (0.229 g, 63%), mp 187-188 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 1.66 (s, 6H, piperidine), 3.65 (s, 4H, piperidine), 7.71 (d, 
1H, 
3
J = 8.2 Hz, CHAr), 7.83 (d, 2H, 
3
J = 8.2 Hz, CHAr), 8.26-8.33 (m, 3H, CHAr). 
19
F NMR (282 MHz, DMSO-d6): δ = -60.9 (CF3). 
13
C NMR (62.9 MHz, DMSO-d6): δ = 23.6, 24.9, 48.9 (CH2 piperidine), 109.0 (C), 110.3, 
113.3 (CH), 120.3 (q, 
1
J = 230 Hz, CF3), 124.6, 125.5 (C), 127.1 (CH), 128.7 (q, 
2
J = 31 Hz, 
CCF3), 130.4 (CH), 142.8, 151.4, 164.4, 169.7 (C).  
MS (GC, 70eV): m/z (%) = 363 (M
+
, 100), 334 (55), 230 (18), 307 (47), 295 (24). 
HRMS (EI): Calcd for C18H16N3SF3 (M
+
) 363.4115. Found 363.4116. 
IR (ATR, cm
-1
): 
~  = 2944 (w), 1614 (w), 1582 (w), 1559 (w), 1531 (m), 1444 (w), 1396 (w), 
1322 (m), 1263 (m), 1217 (w), 1153 (m), 1105 (s), 1063 (m), 1008 (m), 909 (w), 882 (w), 837 
(m), 812 (s), 769 (m), 738 (m), 703 (w). 
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5-(4-methoxyphenyl)-2-(piperidin-1-yl)thiazolo[4,5-b]pyridine (2.6.18b). 
Starting from chromone 2.6.14b (0.205 g, 1 mmol) and 2-
(piperidin-1-yl)thiazol-4-amine E5c (0.190 g, 1.1 mmol) in 
5 mL DMF and 1 mL of TMSCl. 2.6.18a was isolated as 
brown solid (0.189 g, 58%), mp 173-175 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 1.66 (s, 6H, piperidine), 3.64 (s, 4H, piperidine), 3.81 (s, 
3H, OMe), 7.01-7.04 (m, 2H, CHAr), 7.54 (d, 1H, 
3
J = 8.1 Hz, CHAr), 8.02-8.05 (m, 2H, 
CHAr), 8.16 (d, 1H, 
3
J = 8.1 Hz, CHAr). 
13
C NMR (62.9 MHz, DMSO-d6):δ = 23.6, 24.9, 48.9 (CH2 piperidine), 55.2 (OMe), 112.0, 
114.0 (CH), 122.3 (C), 127.7, 130.1 (CH), 131.4, 145.6, 153.0, 159.9, 164.1, 169.5 (C). 
MS (GC, 70eV): m/z (%) = 325 (M
+
, 100), 296 (28), 289 (16), 282 (15), 269 (31), 242 (19).  
HRMS (EI): Calcd for C18H19ON3S (M
+
) 325.12433, Found 325.124003. 
 IR (ATR, cm
-1
): 
~  = 2934 (w), 1597 (m), 1537 (m), 1507 (m), 1446 (m), 1393 (m), 1359 
(m), 1337 (m), 1284 (m), 1245 (s), 1208 (m), 1176 (m), 1028 (m), 1005 (m), 881 (m), 803 (s), 
767 (m), 729 (m), 613 (m). 
 
7-(3-(trifluoromethyl)phenyl)-1,3-dimethylpyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione 
(2.6.19a). 
Starting from chromone 2.6.14a (0.243 g, 1 mmol) and 6-amino-
1,3-dimethylpyrimidine-2,4(1H,3H)-dione E6b (0.170 g, 1.1 
mmol) in 5 mL DMF and 1 mL of TMSCl. 2.6.19a was isolated as 
yellow solid (0.275 g, 82%), mp 173-175 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 3.32 (s, 3H, Me), 3.66 (s, 3H, 
Me), 7.85 (d, 2H, 
3
J = 8.3 Hz, CHAr), 7.93 (d, 1H, 
3
J = 8.3 Hz, CHAr), 8.36 (d, 2H, 
3
J = 8.0 
Hz, CHAr), 8.43 (d, 1H, 
3
J = 8.5 Hz, CHAr). 
19
F NMR (282 MHz, DMSO-d6): δ = -61.4 (CF3). 
13
C NMR Due to bed solubility it was not possible to measure.  
MS (GC, 70eV): m/z (%) = 335 (M
+
, 100), 307 (43), 223 (53). 
HRMS (ESI): Calcd for C16H13N3O2F3 (M+H) 336.09544. Found 336.09613. 
IR (ATR, cm
-1
): 
~  = 3362 (m), 2964 (m), 2766 (m), 2457 (w), 1709 (m), 1657 (s), 1595 (s), 
1574 (m), 1470 (m), 1424 (m), 1314 (s), 1289 (m), 1170 (m), 1154 (m), 1112 (s), 1072 (s), 
1001 (m), 889 (w), 835 (m), 791 (s), 744 (m), 705 (w), 664 (w), 589 (w). 
 
1,3-dimethyl-7-(pyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (2.6.19b). 
 
N
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Starting from chromone 2.6.14d (0.176 g, 1 mmol) and 6-amino-1,3-
dimethylpyrimidine-2,4(1H,3H)-dione E6b (0.170 g, 1.1 mmol) in 5 
mL DMF and 1 mL of TMSCl. 2.6.19b was isolated as yellow solid 
(0.220 g, 77%), mp 216-217 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 3.32 (s, 3H, Me), 3.68 (s, 3H, Me), 7.95-7.99 (m, 1H, 
CHAr), 8.11 (d, 1H, 
3
J = 8.1 Hz, CHAr), 8.51 (d, 1H, 
3
J = 8.1 Hz, CHAr), 8.91 (dd, 1H, 
3
J = 5.3 
Hz, 
4
J = 1.4 Hz, CHAr), 9.03 (d, 1H, 
3
J = 8.3 Hz, 
4
J = 1.8 Hz, CHAr), 9.56 (d, 1H, 
3
J = 1.8 Hz, 
CHAr).  
13
C NMR (75.5 MHz, DMSO-d6): δ = 28.1, 29.2 (Me), 110.3 (C), 115.8, 125.8 (CH), 134.2 
(C), 138.6, 139.3, 144.6, 146.9 (CH), 150.6, 151.0, 155.6, 160.5 (C). 
MS (EI, 70eV): m/z (%) = 268 (M
+
, 100). 
HRMS (EI): Calcd for C14H12N4O2 (M
+
) 268.1022. Found 268.10233. 
 IR (ATR, cm
-1
): 
~  = 3043 (w), 2351 (w), 2109 (w), 1996 (w), 1705 (m), 1651 (s), 1594 (s), 
1553 (m), 1478 (m), 1423 (s), 1373 (m), 1346 (s), 1291 (s), 1226 (m), 1101 (m), 1062 (m), 
937 (w), 869 (w), 829 (m), 791 (s), 748 (s), 685 (s), 622 (s). 
 
7-(4-methoxyphenyl)-1-methylpyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (2.6.19c). 
Starting from chromone 2.6.14b (0.205 g, 1 mmol) and 6-amino-1-
methylpyrimidine-2,4(1H,3H)-dione E6c (0.155 g, 1.1 mmol) in 5 
mL DMF and 1 mL of TMSCl. 2.6.19c was isolated as yellow solid 
(0.189 g, 80%), mp 236-238 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 3.58 (s, 3H, Me), 3.86 (s, 3H, 
OMe), 7.09 (d, 2H, 
3
J = 9.0 Hz, CHAr), 7.80 (d, 1H, 
3
J = 8.0 Hz, CHAr), 8.18 (d, 2H, 
3
J = 9.0 
Hz, CHAr), 8.29 (d, 1H, 
3
J = 8.0 Hz, CHAr), 11.64 (s, 1H, NH).  
13
C NMR (62.9 MHz, DMSO-d6): δ = 28.0 (Me), 55.3 (OMe), 108.8 (C), 113.9, 114.3, 128.9 
(CH), 129.4 (C), 137.4 (CH), 150.8, 151.7, 159.5, 161.1, 161.4 (C). 
MS (EI, 70eV): m/z (%) = 283 (M
+
, 100), 254 (34), 185 (26), 170 (13). 
HRMS (EI): Calcd for C15H13O3N3 (M
+
) 283.2865, Found 283.2866. 
 IR (ATR, cm
-1
): 
~  = 3167 (w), 3036 (w), 2835 (w), 1692 (s), 1585 (s), 1521 (m), 1454 (m), 
1404 (s), 1338 (m), 1299 (m), 1251 (s), 1205 (m), 1177 (m), 1080 (m), 1020 (m), 974 (w), 
860 (m), 833 (m), 790 (s), 749 (m), 694 (m), 636 (s). 
 
6-(3-(trifluoromethyl)phenyl)-4-mercaptopyrido[3,2-d]pyrimidin-2-ol (2.6.19d). 
N
N
N
O
O
Me
Me
N  
N
HN
N
O
O
Me
OMe  
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Starting from chromone 2.6.14a (0.243 g, 1 mmol) and 6-amino-2,3-
dihydro-2-thioxopyrimidin-4(1H)-one E6d (0.157 g, 1.1 mmol) in 5 
mL DMF and 1 mL of TMSCl. 2.6.19d was isolated as green solid 
(0.274 g, 85%), mp 172-174 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 7.92-7.98 (m, 2H, CHAr), 8.03 
(d, 1H, 
3
J = 8.0 Hz, CHAr), 8.37-8.41 (m, 3H, CHAr), 12.64 (s, 1H, OH), 13.22 (s, 1H, SH). 
13
C NMR (62.9 MHz, DMSO-d6): δ = 111.5 (C), 117.4 (CH), 124.1 (q, 
1
J = 272 Hz, CF3), 
125.8, 125.9, 128.1 (CH), 130.5 (q, 
2
J = 32 Hz, CCF3), 137.7 (CH), 140.5, 151.5, 159.0, 
159.4, 162.3, 176.1 (C).  
MS (GC, 70eV): m/z (%) = 323 (M
+
, 100), 280 (18), 265 (13), 236 (12). 
HRMS (ESI): Calcd for C14H9ON3SF3 (M+H) 324.04129. Found 324.04038. 
IR (ATR, cm
-1
): 
~  = 2938 (w), 2762 (s), 2457 (w), 1682 (m), 1611 (s), 1574 (m), 1476 (m), 
1412 (m), 1322 (s), 1276 (m), 1238 (m), 1159 (s), 1110 (s), 1070 (s), 1027 (m), 887 (w), 831 
(s), 791 (s), 762 (m), 654 (w). 
 
A.2.16. General procedure for the synthesis of compounds 3.2.2. 
 
To a Schlenk flask equipped with a magnetic stir bar PdCl2(PPh3)2 (0.02 equiv.) and CuI (0.04 
equiv.) were added. The flask was fitted with a rubber septum and then held under vacuum 
and back filled with argon. Afterwards THF (40 mL/10 mmol of 3.2.1), fluorinated benzoyl 
chloride (1 equiv.) and triethylamine (1.5 equiv.) were added successively. Afterwards the 
holding under vacuum and back filling with argon was repeated three times. At the end 
corresponding acetylene was added (1.3 equiv.) and the reaction was stirred at room 
temperature for 15 h. After the reaction was completed (TLC control) to the reaction mixture 
was added distilled water and extracted with DCM. The organic layers were collected, dried 
with Na2SO4 and evaporated to crude mass. The residue was purified by column 
chromatography over silica gel (Heptane : Ethyl acetate - 30:1). 
 
1-(2-fluorophenyl)-3-phenylprop-2-yn-1-one (3.2.2a). 
Starting from 2-fluorobenzoyl chloride 3.2.1a (1.585 g, 10 mmol), 1-
ethynylbenzene (1.326 g, 13 mmol) and TEA (1.515 g, 15 mmol) in 40 
mL THF. 3.2.2a was isolated as yellow oil (1.97 g, 88%). 
1
H NMR (300 MHz, CDCl3): δ = 6.97-7.03 (m, 1H, CHAr), 7.08-7.14 (m, 
1H, CHAr), 7.20-7.32 (m, 3H, CHAr), 7.37-7.50 (m, 3H, CHAr), 7.95 (dt, 1H, 
3
J = 7.6 Hz, 
4
J = 
N
HN
N
H
O
S
CF3  
F
O
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1.7 Hz, CHAr). 
19
F NMR (282 MHz, CDCl3): δ = -111.3 (CF).  
13
C NMR (62.9 MHz, CDCl3): δ = 88.1 (C), 92.5 (t, 
4
J = 3.1 Hz, C), 116.7 (d, 
2
J = 22.2 Hz, 
CHAr), 119.5 (C), 123.8 (d, 
4
J = 4.0 Hz, CH), 125.1 (d, 
3
J = 7.5 Hz, C), 128.3, 130.6, 131.4, 
132.7 (CH), 135.3 (d, 
3
J = 8.8 Hz, CH), 161.6 (d, 
1
J = 260.0 Hz, CF), 173.5 (C). 
MS (GC, 70eV): m/z (%) = 224 (M
+
, 58), 196 (100), 129 (72). 
HRMS (EI): Calcd for C15H9FO (M
+
) 224.06319. Found 224.063269. 
IR (ATR, cm
-1
): 
~  = 3063 (w), 2195 (s), 1627 (s), 1606 (s), 1482 (s), 1453 (s), 1306 (s), 1228 
(m), 1203 (s), 1154 (m), 1101 (m), 1026 (m), 1010 (s), 994 (s), 839 (m), 778 (m), 747 (s), 686 
(s), 617 (s). 
 
3-(4-tert-butylphenyl)-1-(2-fluorophenyl)prop-2-yn-1-one (3.2.2b). 
Starting from 2-fluorobenzoyl chloride 3.2.1a (1.585 g, 10 mmol), 
1-tert-butyl-4-ethynylbenzene (2.054 g, 13 mmol) and TEA (1.515 
g, 15 mmol) in 40 mL THF. 3.2.2b was isolated as yellow oil (1.62 
g, 78%). 
1
H NMR (300 MHz, CDCl3): δ = 1.33 (s, 9H, t-Bu), 7.14-7.21 (m, 1H, CHAr), 7.24-7.29 (m, 
1H, CHAr), 7.43 (dt, 2H, 
3
J = 8.6 Hz, 
4
J = 1.9 Hz, CHAr), 7.53-7.58 (m, 1H, CHAr), 7.60 (dt, 
2H, 
3
J = 8.6 Hz, 
4
J = 1.9 Hz, CHAr), 8.10 (dt, 1H, 
3
J = 7.6 Hz, 
4
J = 1.9 Hz, CHAr). 
19
F NMR (282 MHz, CDCl3): δ = -111.0 (CF).  
13
C NMR (62.9 MHz, CDCl3): δ = 31.0 (t-Bu), 35.1 (C), 88.4 (C), 93.8 (d, 
4
J = 3.2 Hz, C), 
117.0 (C),  117.1 (d, 
2
J = 21.9 Hz, CHAr), 124.1 (d, 
4
J = 3.8 Hz, CH), 125.7, 131.8, 133.1 
(CH), 135.4 (d, 
3
J = 8.7 Hz, CH), 154.7 (C), 162.1 (d, 
1
J = 262.0 Hz, CF), 174.3 (C).  
MS (GC, 70eV): m/z (%) = 280 (M
+
, 30), 265 (100), 123 (17). 
HRMS (EI): Calcd for C19H17FO (M
+
) 280.12579. Found 280.126387. 
IR (ATR, cm
-1
): 
~  = 2162 (w), 2193 (s), 1629 (s), 1606 (s), 1504 (w), 1481 (m), 1453 (s), 
1364 (w), 1305 (s), 1267 (m), 1207 (s), 1187 (m), 1154 (m), 1100 (m), 1006 (s), 834 (s), 776 
(m), 749 (s), 679 (m), 637 (s), 564 (s). 
 
3-(4-tert-butylphenyl)-1-(2,5-difluorophenyl)prop-2-yn-1-one (3.2.2c). 
Starting from 2,5-difluorobenzoyl chloride 3.2.1b (1.765 g, 10 
mmol), 1-tert-butyl-4-ethynylbenzene (2.054 g, 13 mmol) and 
TEA (1.515 g, 15 mmol) in 40 mL THF. 3.2.2c was isolated as 
yellow oil (2.503 g, 84%). 
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1
H NMR (300 MHz, CDCl3): δ = 1.22 (s, 9H, t-Bu), 7.01-7.08 (m, 1H, CHAr), 7.11-7.19 (m, 
1H, CHAr), 7.33 (d, 2H, 
3
J = 8.7 Hz, CHAr), 7.50 (d, 2H, 
3
J = 8.7 Hz, CHAr), 7.62-7.68 (m, 1H, 
CHAr). 
19
F NMR (282 MHz, CDCl3): δ = -117.3 (d, J = 18.2 Hz, CF), -117.0 (d, J = 18.2 Hz, CF).  
13
C NMR (62.9 MHz, CDCl3): δ = 30.9 (Me), 35.1, 88.1 (C), 94.6 (d, 
4
J = 3.4 Hz, C), 116.7 
(C), 117.4 (dd, 
2
J = 24.9 Hz, 
4
J = 1.2 Hz, CH), 118.5 (dd, 
2
J = 24.9 Hz, 
3
J = 8.6 Hz, CH), 
121.5 (dd, 
2
J = 24.3 Hz, 
3
J = 9.8 Hz, CH), 125.7 (CH), 126.5 (dd, 
3
J = 10.0 Hz, 
4
J = 6.6 Hz, 
C), 133.2 (CH), 155.0 (C), 158.0 (d, 
1
J = 256.6 Hz, CF), 158.2 (d, 
1
J = 253.6 Hz, CF), 172.7 
(C). 
MS (GC, 70eV): m/z (%) = 298 (M
+
, 26), 283 (100), 141 (19). 
HRMS (EI): Calcd for C19H16F2O (M
+
) 298.11637. Found 298.116143. 
IR (ATR, cm
-1
): 
~  = 2962 (w), 2186 (s), 1634 (m), 1589 (m), 1487 (s), 1419 (s), 1364 (s), 
1312 (m), 1291 (m), 1252 (s), 1190 (m), 1154 (s), 1101 (m), 1037 (m), 1010 (m), 914 (m), 
884 (w), 823 (s), 778 (m), 753 (s), 702 (m), 654 (m), 564 (s). 
 
1-(2,5-difluorophenyl)-3-p-tolylprop-2-yn-1-one (3.2.2d). 
Starting from 2,5-difluorobenzoyl chloride 3.2.1b (1.765 g, 10 
mmol), 1-ethynyl-4-methylbenzene (2.054 g, 13 mmol) and TEA 
(1.508 g, 15 mmol) in 40 mL THF. 3.2.2d was isolated as yellow 
oil (2.150 g, 84%). 
1
H NMR (300 MHz, CDCl3): δ = 2.39 (s, 3H, Me), 7.11-7.29 (m, 4H, CHAr), 7.54-7.57 (m, 
2H, CHAr), 7.72-7.78 (m, 1H, CHAr). 
19
F NMR (282 MHz, CDCl3): δ = -117.3 (d, J = 18.3 Hz, CF), -117.1 (d, J = 18.3 Hz, CF).  
13
C NMR (62.9 MHz, CDCl3): δ = 21.8 (Me), 88.2 (C), 94.7 (d, 
4
J = 3.5 Hz, C), 116.7 (C), 
117.4 (dd, 
2
J = 24.2 Hz, 
4
J = 1.7 Hz, CH), 118.5 (dd, 
2
J = 25.0 Hz, 
3
J = 8.4 Hz, CH), 122.1 
(dd, 
2
J = 23,9 Hz, 
3
J = 9.5 Hz, CH), 126.5-126.7 (C), 129.5, 133.4 (CH), 142.0 (C), 158.1 (d, 
1
J = 256.6 Hz, CF), 158.2 (d, 
1
J = 253.6 Hz, CF), 172.8 (C). 
MS (GC, 70eV): m/z (%) = 256 (M
+
, 67), 228 (48), 207 (13), 143 (100), 63 (22). 
HRMS (ESI): Calcd for C16H11F2O (M+H) 257.07725. Found 257.07736. 
IR (ATR, cm
-1
): 
~  = 2922 (w), 2187 (s), 1615 (m), 1582 (m), 1483 (m), 1420 (s), 1316 (m), 
1925 (m), 1246 (s), 1191 (m), 1150 (s), 1108 (m), 1039 (m), 911 (m), 895 (m), 812 (s), 768 
(m), 737 (s), 658 (m). 
 
1-(2,4-difluorophenyl)-3-p-tolylprop-2-yn-1-one (3.2.2e). 
O
F
Me
F
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Starting from 2,4-difluorobenzoyl chlorideloride 3.2.1c (1.765 g, 10 
mmol), 1-ethynyl-4-methylbenzene (2.054 g, 13 mmol) and TEA 
(1.508 g, 15 mmol) in 40 mL THF. 3.2.2e was isolated as yellow 
oil (2.483 g, 97%). 
1
H NMR (300 MHz, CDCl3): δ = 2.39 (s, 3H, Me), 7.11-7.29 (m, 4H, CHAr), 7.54-7.57 (m, 
2H, CHAr), 7.72-7.78 (m, 1H, CHAr). 
19
F NMR (282 MHz, CDCl3): δ = -106.0 (d, J = 13.1 Hz, CF), -99.7 (d, J = 13.1 Hz, CF).  
13
C NMR (62.9 MHz, CDCl3): δ = 21.7 (Me), 88.2 (C), 94.0 (d, 
4
J = 3.5 Hz, C), 105.2 (t, 
2
J = 
22.6 Hz, CH), 111.86 (dd, 
2
J = 22.0 Hz, 
4
J = 3.9 Hz, CH), 116.8 (C), 122.5 (dd, 
3
J = 7.6 Hz, 
4
J = 3.6 Hz, C), 129.5, 133.2 (CH), 133.7 (dd, 
3
J = 11.2 Hz, 
4
J = 1.8 Hz, CH), 141.8 (C), 
163.0 (dd, 
1
J = 264.7 Hz, 
4
J = 12.6 Hz, CF), 166.2 (d, 
1
J = 258.2 Hz, 
4
J = 11.7 Hz, CF), 172.7 
(C). 
MS (GC, 70eV): m/z (%) = 256 (M
+
, 93), 228 (95), 207 (16), 143 (100), 113 (23), 63 (28). 
HRMS (ESI): Calcd for C16H11F2O (M+H) 257.07725. Found 257.07696. 
IR (ATR, cm
-1
): 
~  = 2198 (s), 1629 (m), 1601 (s), 1495 (m), 1426 (m), 1307 (s), 1267 (s), 
1231 (m), 1198 (m), 1179 (m), 1104 (s), 1028 (m), 967 (m), 852 (s), 811 (s), 746 (s), 666 (m), 
594 (s).  
 
1-(2,6-difluorophenyl)-3-phenylprop-2-yn-1-one (3.2.2f). 
Starting from 2,6-difluorobenzoyl chlorideloride 3.2.1d (1.765 g, 10 
mmol), 1-ethynylbenzene (1.326 g, 13 mmol) and TEA (1.508 g, 15 
mmol) in 40 mL THF. 3.2.2f was isolated as yellow oil (1.694 g, 70%). 
1
H NMR (300 MHz, CDCl3): δ = 6.79-6.84 (m, 2H, CHAr), 7.18-7.33 
(m, 4H, CHAr), 7.41-7.44 (m, 2H, CHAr). 
19
F NMR (282 MHz, CDCl3): δ = -111.0 (CF).  
13
C NMR (62.9 MHz, CDCl3): δ = 89.2 (C), 93.4 (C), 112.3 (dd, 
2
J = 22.4 Hz, 
4
J = 3.4 Hz, 
2xCH), 116.0, 117.6 (C), 128.7 (CH), 131.1 (C), 133.3 (CH), 133.7 (t, 
3
J = 11.3 Hz, CH), 
161.0 (d, 
1
J = 259.8 Hz, 
4
J = 5.9 Hz, CF), 171.3 (C). 
MS (GC, 70eV): m/z (%) = 242 (M
+
, 44), 214 (100), 129 (59). 
HRMS (EI): Calcd for C15H8F2O (M
+
) 242.05377. Found 242.053779. 
IR (ATR, cm
-1
): 
~  = 3060 (w), 2193 (s), 1641 (s), 1619 (s), 1489 (w), 1464 (s), 1302 (m), 
1288 (m), 1236 (m), 1202 (m), 1068 (w), 1031 (m), 1002 (s), 990 (s), 818 (w), 793 (s), 754 
(s), 685 (s), 591 (w), 571 (s), 535 (m). 
 
O
F
Me
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1-(2,6-difluorophenyl)-3-p-tolylprop-2-yn-1-one (3.2.2g). 
Starting from 2,6-difluorobenzoyl chlorideloride 3.2.1d (1.765 g, 
10 mmol), 1-ethynyl-4-methylbenzene (2.054 g, 13 mmol) and 
TEA (1.508 g, 15 mmol) in 40 mL THF. 3.2.2g was isolated as 
yellow oil (1.868 g, 73%). 
1
H NMR (300 MHz, CDCl3): δ = 2.18 (s, 3H, Me), 6.75-6.80 (m, 2H, CHAr), 6.97-7.05 (m, 
2H, CHAr), 7.20-7.32 (m, 3H, CHAr). 
19
F NMR (282 MHz, CDCl3): δ = -111.0 (CF).  
13
C NMR (62.9 MHz, CDCl3): δ = 21.8 (Me), 89.2 (C), 94.2 (d, 
4
J = 2.9 Hz, C), 112.1-112.5 
(m, 2xCH), 116.7 (C), 117.7 (t, J = 15.0 Hz, C), 129.4 (CH), 132.0 (d, 
2
J = 42.2 Hz, C), 133.4 
(CH), 133.6 (d, 
3
J = 10.7 Hz, CH), 142.0 (C), 160.8 (dd, 
1
J = 258.4 Hz, 
4
J = 5.9 Hz, CF), 
171.3 (C). 
MS (GC, 70eV): m/z (%) = 256 (M
+
, 81), 228 (88), 143 (100). 
HRMS (ESI): Calcd for C16H11F2O (M+H) 257.07725. Found 257.07721. 
IR (ATR, cm
-1
): 
~  = 3032 (w), 2189 (s), 1643 (s), 1619 (s), 1508 (m), 1302(s), 1236 (s), 1202 
(m), 1177 (m), 1067 (w), 1027 (m), 994 (s), 815 (s), 793 (s), 755 (w), 725 (m), 687 (w), 572 
(m). 
 
3-(4-tert-butylphenyl)-1-(2,6-difluorophenyl)prop-2-yn-1-one (3.2.2h). 
Starting from 2,6-difluorobenzoyl chlorideloride 3.2.1d (1.765 g, 10 
mmol), 1-tert-butyl-4-ethynylbenzene (2.054 g, 13 mmol) and TEA 
(1.508 g, 15 mmol) in 40 mL THF. 3.2.2h was isolated as yellow oil 
(2.384 g, 80%). 
1
H NMR (300 MHz, CDCl3): δ = 1.31 (s, 9H, t-Bu), 6.95-7.01 (m, 2H, CHAr), 7.39-7.48 (m, 
3H, CHAr), 7.54-7.58 (m, 2H, CHAr). 
19
F NMR (282 MHz, CDCl3): δ = -111.0 (CF). 
13
C NMR (62.9 MHz, CDCl3): δ = 31.0 (t-Bu), 35.1, 89.2, 94.2 (C), 112.1-112.5 (m, 2xCH), 
116.7 (C), 125.7, 133.2 (CH), 133.5 (d, J = 12.6 Hz, CH), 155.0 (C), 160.9 (d, 
1
J = 258.5 Hz, 
4
J = 5.7 Hz, CF), 171.4 (C). 
MS (GC, 70eV): m/z (%) = 298 (M
+
, 30), 283 (100), 227(12), 141 (23). 
HRMS (EI): Calcd for C19H16FO (M
+
) 298.11637. Found 298.116627. 
IR (ATR, cm
-1
): 
~  = 2962 (w), 2191 (s), 1644 (s), 1619 (s), 1504 (w), 1465 (s), 1364 (w), 
1302 (s), 1237 (s), 1205 (m), 1109 (w), 1067 (w), 1026 (s), 994 (s), 835 (s), 793 (s), 688 (m), 
564 (s). 
O
F
F
Me  
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1-(2,6-difluorophenyl)oct-2-yn-1-one (3.2.2i). 
Starting from 2,6-difluorobenzoyl chlorideloride 3.2.1d (1.765 g, 10 
mmol), hept-1-yne (1.248 g, 13 mmol) and TEA (1.508 g, 15 mmol) in 40 
mL THF. 3.2.2i was isolated as yellow oil (1.652 g, 70%). 
1
H NMR (300 MHz, CDCl3): δ = 0.90 (t, 3H, 
3
J = 7.2 Hz, CH3CH2), 1.28-
1.45 (m, 4H, 2xCH2), 1.56-1.66 (m, 2H, CH2), 2.42 (t, 2H, 
3
J = 7.1 Hz, CCH2), 6.94 (t, 2H, 
3
J 
= 8.4 Hz, CHAr), 7.37-7.44 (m, 1H, CHAr). 
19
F NMR (282 MHz, CDCl3): δ = -111.4 (CF).  
13
C NMR (62.9 MHz, CDCl3): δ = 12.9 (CH3), 20.9, 27.5, 28.1, 47.1 (CH2), 89.2, 94.2, 116.7 
(C), 117.7 (t, 
3
J = 15.0 Hz, C), 132.0 (d, 
4
J = 3.1 Hz, C), 133.4 (CH), 142.0 (C), 161.0 (d, 
1
J = 
258.9 Hz, 
4
J = 5.7 Hz, CF), 171.3 (C). 
MS (GC, 70eV): m/z (%) = 236 (M
+
, 1), 180 (17), 151 (21), 141 (100), 113 (17). 
HRMS (EI): Calcd for C14H14F2O (M
+
) 236.10127. Found 236.10129. 
IR (ATR, cm
-1
): 
~  = 2932 (w), 2862 (s), 2206 (m), 1650 (s), 1619 (s), 1466 (s), 1280 (m), 
1252 (s), 1233 (s), 1121 (w), 1009 (s), 915 (w), 870 (w), 794 (s), 758 (w), 690 (w), 570 (m). 
 
3-(4-tert-butylphenyl)-1-(perfluorophenyl)prop-2-yn-1-one (3.2.2j). 
Starting from 2,3,4,5,6-pentafluorobenzoyl chlorideloride 3.2.1e (2.305 
g, 10 mmol), 1-tert-butyl-4-ethynylbenzene (2.054 g, 13 mmol) and 
TEA (1.508 g, 15 mmol) in 40 mL THF. 3.2.2j was isolated as yellow 
solid (2.640 g, 75%), mp 127-129 
o
C. 
1
H NMR (300 MHz, CDCl3): δ = 1.33 (s, 9H, t-Bu), 7.33-7.52 (m, 4H, CHAr). 
19
F NMR (282 MHz, CDCl3): δ = -162.1 (CF), -153.3 (t, 
3
J = 19.5 Hz, CF), -136.3 (CF), -
136.2 (CF).  
13
C NMR (62.9 MHz, CDCl3):δ = 31.1 (t-Bu), 34.9 (d, 
4
J = 2.8 Hz, C), 73.5, 81.5 (C), 118.7 
(d, 
3
J = 19.7 Hz, CF), 125.5 (d, 
4
J = 5.0 Hz, CH), 131.9 (d, 
3
J = 35.8 Hz, CH), 152.9 (d, 
3
J = 
36.6 Hz, C). 
MS (GC, 70eV): m/z (%) = 352 (M
+
, 100). 
HRMS (EI): Calcd for C19H13F5O (M
+
) 352.08866. Found 352.08870. 
IR (ATR, cm
-1
): 
~  = 2961 (w), 1524 (m), 1498 (s), 1392 (w), 1363 (m), 1267 (w), 1116 (m), 
1060 (m), 1017 (w), 987 (s), 964 (s), 835 (s), 771 (w), 736 (w), 651 (w), 561 (s). 
 
A.2.17. General procedure for the synthesis of compounds 3.2.3-3.2.7. 
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The 1-(2-fluorophenyl)prop-2-yn-1-one derivative 3.2.2a-i (1 equiv.), corresponding amine (2 
equiv.) and Li2CO3 (2 equiv.) were placed in a pressure tube or in the Schlenk flask under the 
flow of dry argon and dissolved in dry DMA (7 mL/1 mmol of 3.2.2). The mixture was heated 
at 160 C for 24-30 h (controlled by TLC). After the reaction was completed volatiles were 
evaporated under reduced pressure. The residue was purified by column chromatography over 
silica gel (Heptane : Ethyl acetate - 3:1). Preparation of compounds 3.2.10a-d were performed 
according this procedure. 
 
2-phenyl-1-(3-phenylpropyl)quinolin-4(1H)-one (3.2.3a). 
Starting from 1-(2-fluorophenyl)-3-phenylprop-2-yn-1-one 3.2.3a (0.224 g, 1 
mmol), 2-phenylethanamine (0.242 g, 2 mmol) and Li2CO3 (0.148 g, 2 mmol) 
in 7 mL DMA. 3.2.3a was isolated as yellow solid (0.289 g, 89%), mp 145-
146 
o
C. 
1
H NMR (300 MHz, CDCl3): δ = 2.92 (t, 2H, 
3
J = 7.6 Hz, (CH2)2), 4.28 (t, 2H, 
3
J = 7.6 Hz, (CH2)2), 6.25 (s, 1H, CHAr), 6.72-6.76 (m, 2H, CHAr), 7.15-7.20 (m, 5H, CHAr), 
7.41-7.51 (m, 4H, CHAr),  7.66-7.79 (m, 2H, CHAr), 8.55 (dd, 1H, 
3
J = 8.0 Hz,
 4
J = 1.2 Hz, 
CHAr). 
13
C NMR (62.9 MHz, CDCl3):δ = 34.8, 49.4 (CH2), 112.8, 116.2, 123.8, 127.0, 128.3, 128.5, 
128.7, 128.8, 129.4, 132.5 (CH), 135.7, 136.8, 140.4, 154.9, 177.1 (C). 
MS (GC, 70eV): m/z (%) = 325 (M
+
, 31), 234 (100), 132 (18). 
HRMS (EI): Calcd for C23H19NO (M
+
) 325.14612. Found 325.14617. 
IR (ATR, cm
-1
): 
~  = 1616 (m), 1589 (s), 1553 (s), 1483 (m), 1416 (m), 1368 (w), 1311 (m), 
1268 (m), 1174 (m), 1143 (m), 1074 (w), 1003 (w), 862 (w), 776 (m), 755 (s), 704 (s), 669 
(m), 557 (m). 
 
2-phenyl-1-(3-phenylpropyl)quinolin-4(1H)-one (3.2.3b). 
Starting from 1-(2-fluorophenyl)-3-phenylprop-2-yn-1-one 3.2.3a (0.224 g, 1 
mmol), 3-phenylpropan-1-amine (0.270 g, 2 mmol) and Li2CO3 (0.148 g, 2 
mmol) in 7 mL DMA. 3.2.3b was isolated as yellow viscous oil (0.292 g, 86%). 
1
H NMR (300 MHz, CDCl3): δ = 1.93-2.03 (m, 2H, (CH2)3), 2.46 (t, 2H, 
3
J = 
7.6 Hz, (CH2)3), 3.96-4.01 (m, 2H, (CH2)3), 6.23 (s, 1H, CHAr), 6.97-7.00 (m, 
2H, CHAr), 7.14-7.48 (m, 10H, CHAr), 7.56-7.62 (m, 1H, CHAr),  8.49 (dd, 1H, 
3
J = 8.0 Hz,
 4
J 
= 1.5 Hz, CHAr). 
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13
C NMR (62.9 MHz, CDCl3): δ = 29.8, 32.6, 47.5 (CH2), 112.8, 116.1, 123.7, 126.3, 127.0, 
128.1, 128.2, 128.5, 128.8, 129.5, 132.3 (CH), 135.8, 139.8, 140.5, 154.6, 177.0 (C). 
MS (GC, 70eV): m/z (%) = 339 (M
+
, 35), 375 (41), 361 (100), 243 (42), 91 (41). 
HRMS (ESI): Calcd for C24H21NO (M
+
) 339.16177. Found 339.16188. 
IR (ATR, cm
-1
): 
~  = 2937 (w), 1625 (s), 1594 (s), 1484 (m), 1463 (m), 1417 (s), 1299 (m), 
1265 (m), 1212 (w), 1172 (m), 1078  (w), 1029 (w), 912 (w), 835 (s), 778 (m), 759 (s), 697 
(s), 672 (s), 623 (m), 547 (m). 
 
1-(4-methoxybenzyl)-2-phenylquinolin-4(1H)-one (3.2.3c). 
Starting from 1-(2-fluorophenyl)-3-phenylprop-2-yn-1-one 3.2.3a (0.224 
g, 1 mmol), (4-methoxyphenyl)methanamine (0.274 g, 2 mmol) and 
Li2CO3 (0.148 g, 2 mmol) in 7 mL DMA. 3.2.3c was isolated as yellow 
solid (0.292 g, 86%), mp 209-210 
o
C. 
1
H NMR (300 MHz, CDCl3): δ = 3.74 (s, 3H, OMe), 5.20 (s, 2H, CH2), 
6.33 (s, 1H, CHAr), 6.78-6.81 (m, 2H, CHAr), 6.87-6.90 (m, 2H, CHAr), 7.30-7.42 (m, 7H, 
CHAr),  7.48-7.54 (m, 1H, CHAr), 8.50 (dd, 1H, 
3
J = 8.7 Hz,
 4
J = 1.5 Hz, CHAr). 
13
C NMR (62.9 MHz, CDCl3): δ = 51.7 (OMe), 55.2 (CH2), 113.0, 114.4, 117.4, 123.7, 126.6, 
126.7 (CH), 127.2 (C), 128.1, 128.6, 129.6, 132.3 (CH), 135.6, 141.1, 155.1, 159.0, 177.5 (C). 
MS (GC, 70eV): m/z (%) = 341 (M
+
, 7), 121 (100). 
HRMS (EI): Calcd for C23H19NO2 (M
+
) 341.14103. Found 341.14099. 
IR (ATR, cm
-1
): 
~  = 1623 (m), 1598 (s), 1514 (s), 1487 (s), 1429 (m), 1361 (w), 1313 (m), 
1251 (s), 1176 (s), 1143 (m), 1034 (m), 960 (m), 833 (s), 806 (m), 760 (s), 703 (s). 
 
1-pentyl-2-phenylquinolin-4(1H)-one (3.2.3d). 
Starting from 1-(2-fluorophenyl)-3-phenylprop-2-yn-1-one 3.2.3a (0.224 g, 1 
mmol), pentyl amine (0.170 g, 2 mmol) and Li2CO3 (0.148 g, 2 mmol) in 7 mL 
DMA. 3.2.3d was isolated as yellow oil (0.244 g, 84%). 
1
H NMR (300 MHz, CDCl3): δ = 0.73 (t, 3H, 
3
J = 7.0 Hz, Me(CH2)3CH2), 1.03-
1.13 (m, 4H, Me(CH2)3CH2), 1.57-1.67 (m, 2H, Me(CH2)3CH2), 3.95 (t, 2H, 
3
J = 
8.0 Hz, Me(CH2)3CH2), 6.19 (s, 1H, CHAr), 7.31-7.36 (m, 3H, CHAr), 7.43-7.51 (m, 4H, 
CHAr), 7.61-7.67 (m, 1H, CHAr), 8.46 (dd, 1H, 
3
J = 8.0 Hz,
 4
J = 1.6 Hz, CHAr). 
13
C NMR (75.5 MHz, CDCl3):δ = 12.9 (Me), 20.9, 27.5, 28.1, 47.1 (CH2), 111.7, 115.3, 
122.5, 125.9 (CH), 126.3 (C), 127.2, 127.7 (CH), 128.1 (C), 128.4, 131.2 (CH), 135.0, 139.6, 
153.5, 176.3 (C).  
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MS (GC, 70eV): m/z (%) = 291 (M
+
, 50), 234 (100), 132 (17). 
HRMS (EI): Calcd for C20H21NO (M
+
) 291.16177. Found 291.16171. 
IR (ATR, cm
-1
): 
~  = 2927 (m), 2863 (m), 1618 (s), 1595 (s), 1480 (s), 1422 (m), 1308 (m), 
1267 (m), 1177 (m), 1080 (m), 963 (w), 835 (s), 756 (s), 703 (s), 668 (m). 
 
1-hexyl-2-phenylquinolin-4(1H)-one (3.2.3e). 
Starting from 1-(2-fluorophenyl)-3-phenylprop-2-yn-1-one 3.2.3a (0.224 g, 1 
mmol), hexyl amine (0.198 g, 2 mmol) and Li2CO3 (0.148 g, 2 mmol) in 7 mL 
DMA. 3.2.3e was isolated as yellow oil (0.271 g, 89%). 
1
H NMR (300 MHz, CDCl3): δ = 0.79 (t, 3H, 
3
J = 7.2 Hz, Me(CH2)4CH2), 1.06-
1.20 (m, 6H, Me(CH2)4 CH2), 1.60-1.68 (m, 2H, Me(CH2)4CH2), 4.00 (t, 2H, 
3
J 
= 8.0 Hz, Me(CH2)4CH2), 6.27 (s, 1H, CHAr), 7.36-7.42 (m, 3H, CHAr), 7.46-7.54 (m, 4H, 
CHAr), 7.66-7.71 (m, 1H, CHAr), 8.51 (dd, 1H, 
3
J = 8.0 Hz,
 4
J = 1.6 Hz, CHAr).  
13
C NMR (75.5 MHz, CDCl3): δ = 13.8 (CH3), 22.2, 26.0, 28.6, 30.9, 48.2 (CH2), 112.7, 
116.2, 123.6, 127.0 (CH), 127.2 (C), 128.3, 128.7, 129.4, 132.2 (CH), 136.0, 140.5, 154.7, 
177.0 (C). 
MS (GC, 70eV): m/z (%) = 305 (M
+
, 56), 234 (100), 132 (17). 
HRMS (EI): Calcd for C21H23NO (M
+
) 305.17742. Found 305.17731. 
IR (ATR, cm
-1
): 
~  = 3044 (w), 2927 (m), 1617 (m), 1594 (s), 1570 (m), 1479 (s), 1421 (m), 
1306 (m), 1266 (m), 1177 (m), 1138 (m), 1035 (w), 923 (w), 835 (s), 758 (s), 703 (s), 668 
(m), 550 (m). 
 
1-(3,5-dimethoxyphenyl)-2-phenylquinolin-4(1H)-one (3.2.3f). 
Starting from 1-(2-fluorophenyl)-3-phenylprop-2-yn-1-one 3.2.3a (0.224 g, 1 
mmol), 3,5-dimethoxybenzenamine (0.306 g, 2 mmol) and Li2CO3 (0.148 g, 2 
mmol) in 7 mL DMA. 3.2.3f was isolated as yellow solid (0.264 g, 74%), mp 
216-218 
o
C. 
1
H NMR (300 MHz, CDCl3): δ = 3.66 (s, 6H, 2xOMe), 6.10 (s, 1H, CHAr), 
6.47 (t, 1H, 
4
J = 2.1 Hz, CHAr), 6.64 (d, 2H, 
4
J = 2.4 Hz, CHAr), 6.99 (d, 1H, 
3
J = 8.6 Hz, 
CHAr), 7.25-7.29 (m, 3H, CHAr), 7.38-7.43 (m, 3H, CHAr), 7.58-7.64 (m, 1H, CHAr), 8.25 (dd, 
1H, 
3
J = 7.8 Hz, 
4
J = 1.4 Hz, CHAr). 
13
C NMR (62.9 MHz, DMSO-d6): δ = 55.5 (OMe), 100.8, 108.6, 111.2, 118.3, 123.6, 125.1 
(CH), 125.4 (C), 127.6, 128.6, 129.0, 132.2 (CH), 133.0, 135.5, 140.3, 142.1, 153.8, 160.7, 
176.0 (C). 
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MS (GC, 70eV): m/z (%) = 357 (M
+
, 100), 329 (42). 
HRMS (EI): Calcd for C23H19NO3 (M
+
) 357.13594. Found 357.136003. 
IR (ATR, cm
-1
): 
~  = 3035 (w), 2197 (w), 1628 (m), 1590 (s), 1462 (s), 1417 (s), 1359 (m), 
1314 (m), 1264 (m), 1205 (s), 1150 (s), 1053 (s), 927 (m), 891 (w), 830 (m9, 773 (m), 754 (s), 
712 (s), 639 (w). 
 
2-(4-tert-butylphenyl)-1-(4-chlorophenyl)quinolin-4(1H)-one (5g). 
Starting from 3-(4-tert-butylphenyl)-1-(2-fluorophenyl)prop-2-yn-1-
one 3.2.3b (0.280 g, 1 mmol), 4-chlorobenzenamine (0.254 g, 2 
mmol) and Li2CO3 (0.148 g, 2 mmol) in 7 mL DMA. 3.2.3g was 
isolated as yellow oil (0.291 g, 75%). 
1
H NMR (300 MHz, CDCl3): δ = 1.25 (s, 9H, t-Bu), 6.42 (s, 1H, 
CHAr), 6.87 (d, 1H, 
3
J = 8.6 Hz, CHAr), 7.04-7.11 (m, 4H, CHAr), 
7.20-7.22 (m, 2H, CHAr), 7.32-7.50 (m, 4H, CHAr), 8.50 (dd, 1H, 
3
J = 8.1 Hz, 
4
J = 1.3 Hz, 
CHAr). 
13
C NMR (62.9 MHz, CDCl3):δ = 31.1 (t-Bu), 34.6 (C), 112.8, 117.7, 123.9, 125.0, 126.4, 
128.9, 129.8, 131.3, 131.9 (CH), 132.4, 134.8, 137.8, 142.5, 152.1, 153.9, 178.1 (C). 
MS (GC, 70eV): m/z (%) = 387 (M
+
, 100), 372 (46), 344 (20). 
HRMS (EI): Calcd for C25H22ClNO (M
+
) 387.13844. Found 387.138553. 
IR (ATR, cm
-1
): 
~  = 2962 (w), 1631 (s), 1603 (s), 1557 (w), 1505 (m), 1489 (s), 1408 (m), 
1318 (m), 1269 (m), 1137 (w), 1081 (m), 1023 (m), 970 (w), 833 (s), 742 (s), 666 (m), 638 
(m), 548 (m). 
 
2-(4-tert-butylphenyl)-1-(4-bromophenyl)quinolin-4(1H)-one (3.2.3h). 
Starting from 3-(4-tert-butylphenyl)-1-(2-fluorophenyl)prop-2-yn-1-
one 3.2.3b (0.280 g, 1 mmol), 4-bromobenzenamine (0.344 g, 2 
mmol) and Li2CO3 (0.148 g, 2 mmol) in 7 mL DMA. 3.2.3h was 
isolated as brown solid (0.315 g, 73%), mp 245-246 
o
C. 
1
H NMR (300 MHz, CDCl3): δ = 1.25 (s, 9H, t-Bu), 6.49 (s, 1H, 
CHAr), 6.88 (d, 1H, 
3
J = 8.9 Hz, CHAr), 7.02-7.07 (m, 4H, CHAr), 
7.20-7.23 (m, 2H, CHAr), 7.35-7.51 (m, 4H, CHAr), 8.50 (dd, 1H, 
3
J = 7.9 Hz, 
4
J = 1.2 Hz, 
CHAr). 
13
C NMR (62.9 MHz, CDCl3): δ = 31.1 (t-Bu), 34.6 (C), 112.7, 117.7 (CH), 122.9 (C), 124.1, 
125.0, 126.4, 128.9, 131.6, 132.1, 132.8 (CH), 138.3, 152.2, 154.2, 172.7, 177.6, 186.6 (C). 
N
O
Cl
Me
Me
Me
 
N
O
Br
Me
Me
Me
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MS (GC, 70eV): m/z (%) = 433 (M
+
, 100), 431 (99), 416 (36), 388 (17), 309 (11), 207 (15). 
HRMS (EI): Calcd for C25H22BrNO (M
+
) 431.08793. Found 431.087506. 
IR (ATR, cm
-1
): 
~  = 2962 (w), 1630 (s), 1602 (s), 1505 (w), 1486 (s), 1469 (m), 1408 (m), 
1363 (w), 1318 (m), 1269 (m), 1137 (w), 1068 (w), 1020 (m), 670 (w), 876 (w), 832 (s), 744 
(s), 730 (m), 637 (m). 
 
6-fluoro-1-hexyl-2-p-tolylquinolin-4(1H)-one (3.2.4a). 
Starting from 1-(2,5-difluorophenyl)-3-p-tolylprop-2-yn-1-one 3.2.3d 
(0.256 g, 1 mmol), pentyl amine (0.170 g, 2 mmol) and Li2CO3 
(0.148 g, 2 mmol) in 7 mL DMA. 3.2.4a was isolated as white solid 
(0.286 g, 85%), mp 181-182 
o
C. 
1
H NMR (300 MHz, CDCl3): δ = 0.77 (t, 3H, 
3
J = 7.3 Hz, 
Me(CH2)4CH2), 1.07-1.18 (m, 6H, Me(CH2)4CH2), 1.59-1.64 (m, 2H, Me(CH2)4CH2), 2.42 (s, 
3H, Me), 3.99 (t, 2H, 
3
J = 8.2 Hz, Me(CH2)4CH2), 6.16 (s, 1H, CHAr), 7.22-7.29 (m, 4H, 
CHAr), 7.74-7.41 (m, 1H, CHAr), 7.49-7.53 (m, 1H, CHAr), 8.10 (dd, 1H, 
3
J = 9.0 Hz,
 4
J = 3.0 
Hz,CHAr).  
19
F NMR (282 MHz, CDCl3): δ = -118.8 (CF). 
13
C NMR (75.5 MHz, CDCl3): δ = 13.8, 21.3 (Me), 22.3, 26.9, 28.6, 29.6, 48.4 (CH2), 111.4 
(d, 
2
J = 22.5 Hz, CH), 112.2 (CH), 118.6 (d, 
3
J = 8.1 Hz, CH), 120.5 (d, 
2
J = 27 Hz, CH), 
128.1 (CH), 128.8 (d, 
3
J = 7.0 Hz, C), 129.4 (CH), 132.9, 137.1, 139.6, 154.8 (C), 158.9 (d, 
1
J 
= 244.3 Hz, CF), 176.3 (C). 
MS (GC, 70eV): m/z (%) = 337 (M
+
, 52), 266 (100), 150 (18). 
HRMS (EI): Calcd for C22H24FNO (M
+
) 337.18419. Found 337.18421. 
IR (ATR, cm
-1
): 
~  = 3470 (m), 2928 (m), 1597 (s), 1564 (s), 1510 (m), 1471 (s), 1397 (m), 
1299 (m), 1255 (w), 1205 (w), 1160 (m), 1115 (w), 1007 (w), 936 (m), 892 (m), 846 (s), 821 
(s), 710 (m), 617 (m). 
 
6-fluoro-1-phenethyl-2-p-tolylquinolin-4(1H)-one (3.2.4b). 
Starting from 1-(2,5-difluorophenyl)-3-p-tolylprop-2-yn-1-one 3.2.3d 
(0.256 g, 1 mmol), 2-phenylethanamine (0.242 g, 2 mmol) and Li2CO3 
(0.148 g, 2 mmol) in 7 mL DMA. 3.2.4b was isolated as yellow oil 
(0.314 g, 88%). 
1
H NMR (300 MHz, CDCl3): δ = 2.43 (s, 3H, Me), 2.90 (t, 2H, 
3
J = 7.5 Hz, (CH2)2), 4.28 (t, 
2H, 
3
J = 7.5 Hz, (CH2)2), 6.16 (s, 1H, CHAr), 6.73-6.76 (m, 2H, CHAr), 7.03-7.06 (m, 2H, 
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CHAr), 7.15-7.22 (m, 5H, CHAr), 7.43-7.49 (m, 1H, CHAr), 7.62-7.67 (m, 1H, CHAr), 8.18 (dd, 
1H, 
3
J = 8.9 Hz,
 4
J = 3.1 Hz, CHAr). 
19
F NMR (282 MHz, CDCl3): δ = -117.8 (CF). 
13
C NMR (62.9 MHz, CDCl3):δ = 21.4 (Me), 34.5, 49.5 (CH2), 111.8 (d, 
2
J = 21.4 Hz, CH), 
112.3 (CH), 118.5 (d, 
3
J = 7.6 Hz, CH), 120.8 (d, 
2
J = 25.5 Hz, CH), 127.0, 128.1, 128.5, 
128.8 (CH), 129.0 (d, 
2
J = 40 Hz, C), 132.7, 136.7, 137.0, 139.6, 155.0 (C), 159.0 (d, 
1
J = 
247.9 Hz, CF), 176.3 (C). 
MS (GC, 70eV): m/z (%) = 357 (M
+
, 1), 234 (100). 
HRMS (EI): Calcd for C24H20FNO (M
+
) 357.15289. Found 357.15290. 
IR (ATR, cm
-1
): 
~  = 1633 (m), 1613 (s), 1510 (m), 1479 (s), 1396 (m), 1350 (w), 1295 (m), 
1203 (w), 1155 (m), 1063 (w), 1002 (w), 930 (m), 898 (m), 832 (s), 806 (m), 779 (m), 746 
(m), 729 (m), 698 (m). 
 
6-fluoro-1-(3-phenylpropyl)-2-p-tolylquinolin-4(1H)-one (3.2.4c). 
Starting from 1-(2,5-difluorophenyl)-3-p-tolylprop-2-yn-1-one 3.2.3d 
(0.256 g, 1 mmol), 3-phenylpropan-1-amine (0.270 g, 2 mmol) and 
Li2CO3 (0.148 g, 2 mmol) in 7 mL DMA. 3.2.4c was isolated as 
white solid (0.308 g, 83%), mp 163-165 
o
C. 
H NMR (300 MHz, CDCl3): δ = 1.84-1.92 (m, 2H, (CH2)3), 2.35-2.41 
(m, 5H, Me, (CH2)3), 3.88-3.94 (m, 2H, (CH2)3), 6.08 (s, 1H, CHAr), 6.89-6.92 (m, 2H, CHAr), 
7.07-7.21 (m, 8H, CHAr), 7.56-7.62 (m, 1H, CHAr),  8.02 (dd, 1H, 
3
J = 9.0 Hz,
 4
J = 2.6 Hz, 
CHAr). 
19
F NMR (282 MHz, CDCl3): δ = -118.1 (CF). 
13
C NMR (62.9 MHz, CDCl3): δ = 20.4 (Me), 29.9, 31.5, 46.6 (CH2), 110.4 (d, 
2
J = 23.1 Hz, 
CH), 111.2 (CH), 117.4 (d, 
4
J = 7.2 Hz, CH), 119.1 (d, 
2
J = 25.4 Hz, CH), 125.3, 127.0, 
127.2, 127.5  (CH), 127.8 (d, 
2
J = 27.5 Hz, C), 128.4 (CH), 131.7, 136.0 (C), 138.7 (d, 
3
J = 
13.1 Hz, CH), 153.7 (C), 157.9 (d, 
1
J = 247.8 Hz, CF), 175.3 (C). 
MS (GC, 70eV): m/z (%) = 371 (M
+
, 77), 266 (100), 253 (19), 150 (20), 91 (27). 
HRMS (EI): Calcd for C25H22FNO (M
+
) 371.16854. Found 371.16856. 
IR (ATR, cm
-1
): 
~  = 2919 (w), 1634 (s), 1604 (s), 1576 (m), 1510 (m), 1470 (s), 1394 (m), 
1295 (m), 1244 (w), 1201 (m), 1145 (s), 1055 (w), 975 (w), 930 (m), 888 (s), 833 (s), 822 (s), 
746 (s), 700 (s), 561 (m).  
 
7-((R)-1-phenylethylamino)-1-((R)-1-phenylethyl)-2-p-tolylquinolin-4(1H)-one (3.2.5). 
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Starting from 1-(2,4-difluorophenyl)-3-p-tolylprop-2-yn-1-one 
3.2.3e (0.256 g, 1 mmol), (R)-1-phenylethanamine (0.274 g, 2 
mmol) and Li2CO3 (0.148 g, 2 mmol) in 7 mL DMA. 3.2.5 
was isolated as yellow solid (0.151 g, 33%), mp 163-165 
o
C. 
1
H NMR (300 MHz, CDCl3): δ = 1.43 (t, 6H, 
3
J = 6.3 Hz, CHMe), 2.27 (s, 3H, Me), 4.38-
4.55 (m, 2H, CHMe), 5.63 (d, 1H, 
4
J = 1.7 Hz, CHAr), 5.99 (dd, 1H, 
3
J = 14.2 Hz, 
4
J = 2.2 Hz, 
CHAr), 6.26 (dd, 1H, 
3
J = 8.7 Hz, 
4
J = 2.2 Hz, CHAr), 7.04-7.24 (m, 14H, CHAr), 7.64 (t, 1H, 
3
J = 8.7 Hz, CHAr), 11.58 (d, 1H, 
3
J = 9.5 Hz, NH). 
13
C NMR (62.9 MHz, CDCl3): δ = 21.3, 24.5, 24.9 (Me), 53.2, 54.0 (CH), 98.0 (d, J = 10.0 
Hz, CH), 99.4 (d, J = 30.3 Hz, CH), 109.3 (C), 117.3 (d, J = 11.3 Hz, CH), 125.7, 126.7, 
127.2, 127.7, 128.5, 128.7, 128.8 (CH), 131.6 (d, J = 5.1 Hz, CH), 131.7 (d, J = 11.4 Hz, CH), 
133.2, 139.2, 144.0, 144.5 (C), 150.9 (d, J = 10.7 Hz, C), 160.4, 162.4 (d, J = 249.3 Hz, C), 
184.8 (C). 
MS (GC, 70eV): m/z (%) = 458 (M
+
, 19), 353 (100). 
HRMS (EI): Calcd for C32H30N2O (M
+
) 458.59341. Found 458.59344. 
IR (ATR, cm
-1
): 
~  = 3312 (w), 2969 (w), 1621 (w), 1575 (s), 1556 (s), 1488 (m), 1447 (m), 
1318 (s), 1238 (s), 1205 (m), 1106 (s), 975 (w), 908 (w), 823 (m), 783 (m), 759 (m), 696 (s). 
 
5-(3-phenylpropylamino)-2-(4-tert-butylphenyl)-1-(3-phenylpropyl)quinolin-4(1H)-one 
(3.2.6a). 
Starting from 3-(4-tert-butylphenyl)-1-(2,6-difluorophenyl)prop-2-
yn-1-one 3.2.3h (0.298 g, 1 mmol), 3-phenylpropan-1-amine (0.270 
g, 2 mmol) and Li2CO3 (0.148 g, 2 mmol) in 7 mL DMA. 3.2.6a 
was isolated as yellow solid (0.433 g, 82%), mp 215-216 
o
C. 
1
H NMR (300 MHz, CDCl3): δ = 1.39 (s, 9H, t-Bu), 1.97-2.12 (m, 
4H, CH2), 2.45 (t, 2H, 
3
J = 7.5 Hz, CH2), 2.81 (t, 2H, 
3
J = 7.5 Hz, 
CH2), 3.22 (t, 2H, 
3
J = 6.4 Hz, CH2), 3.91 (t, 2H, 
3
J = 8.0 Hz, CH2), 6.07 (s, 1H, CHAr), 6.29-
6.36 (m, 2H, CHAr), 7.00-7.02 (m, 2H, CHAr), 7.16-7.31 (m, 11H, CHAr), 7.44-7.47 (m, 2H, 
CHAr), 10.47 (s, 1H, NH). 
13
C NMR (62.9 MHz, CDCl3): δ = 29.3, 30.2 (CH2), 31.2 (t-Bu), 32.6, 33.3 (CH2), 34.7 (C), 
42.0, 48.0 (CH2), 100.2, 101.9, 112.5 (CH), 113.2 (C), 125.5, 125.7, 126.1, 127.9, 128.1, 
128.3, 128.4, 128.5 (CH), 132.9 (C), 133.3 (CH), 140.2, 141.7, 143.2, 152.1, 152.3, 153.0, 
180.8 (C). 
MS (GC, 70eV): m/z (%) = 528 (M
+
, 33), 437 (42), 423 (100), 305 (17), 91 (50). 
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HRMS (ESI): Calcd for C37H41N2O (M+H) 529.32134. Found 529.32191. 
IR (ATR, cm
-1
): 
~  = 2951 (w), 1617 (s), 1520 (m), 1450 (s), 1386 (w), 1264 (s), 1167 (s), 
1121 (w), 1015 (w), 909 (w), 840 (m), 740 (s), 697 (s), 563 (m). 
 
1-(4-methoxybenzyl)-5-(4-methoxybenzylamino)-2-(4-tert-butylphenyl)quinolin-4(1H)-
one (3.2.6b). 
Starting from 3-(4-tert-butylphenyl)-1-(2,6-difluorophenyl)prop-
2-yn-1-one 3.2.3h (0.298 g, 1 mmol), (4-
methoxyphenyl)methanamine (0.274 g, 2 mmol) and Li2CO3 
(0.148 g, 2 mmol) in 7 mL DMA. 3.2.6b was isolated as yellow 
solid (0.452 g, 85%), mp 192-193 
o
C. 
1
H NMR (300 MHz, CDCl3): δ = 1.31 (s, 9H, t-Bu), 3.76 (s, 3H, 
OMe), 3.78 (s, 3H, OMe), 4.40 (s, 2H, CH2), 5.12 (s, 2H, CH2), 
6.23-6.38 (m, 3H, CHAr), 6.79-6.93 (m, 6H, CHAr), 7.15-7.25 
(m, 3H, CHAr), 7.30-7.37 (m, 4H, CHAr), 10.76 (s, 1H, NH). 
13
C NMR (62.9 MHz, CDCl3): δ = 31.2 (t-Bu), 34.8 (C), 46.6, 52.4 (CH2), 55.2, 55.3 (OMe), 
102.4, 103.1 (CH), 112.6 (C), 113.2, 114.0, 114.2 (CH), 125.5, 126.8, 127.9, 128.3 (CH), 
128.6, 130.9, 132.6 (C), 133.4 (CH), 143.6, 151.5, 152.7, 154.0, 158.6, 158.8, 180.8 (C). 
MS (GC, 70eV): m/z (%) = 532 (M
+
, 8), 411 (47), 121 (100). 
HRMS (EI): Calcd for C35H36N2O3 (M
+
) 532.27204. Found 532.272902. 
IR (ATR, cm
-1
): 
~  = 2955 (w), 1614 (s), 1504 (s), 1447 (s), 1360 (w), 1244 (s), 1170 (s), 
1110 (m), 1030 (m), 925 (w), 814 (m), 740 (m), 676 (m), 561 (m). 
 
2-(4-tert-butylphenyl)-1-phenethyl-5-(phenethylamino)quinolin-4(1H)-one (3.2.6c). 
Starting from 3-(4-tert-butylphenyl)-1-(2,6-difluorophenyl)prop-2-
yn-1-one 3.2.3h (0.298 g, 1 mmol), 2-phenylethanamine (0.242 g, 
2 mmol) and Li2CO3 (0.148 g, 2 mmol) in 7 mL DMA. 3.2.6c was 
isolated as yellow solid (0.465 g, 93%), mp 185-187 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 1.35 (s, 9H, t-Bu), 2.49-2.51 
(m, 2H, CH2), 2.80-2.85 (m, 2H, CH2), 2.94 (t, 2H, 
3
J = 7.0 Hz, 
CH2), 3.37-3.46 (m, 2H, CH2), 4.07 (t, 2H, 
3
J = 8.1 Hz, CH2), 6.47 
(d, 1H, 
3
J = 8.5 Hz, CHAr), 6.71-6.74 (m, 2H, CHAr), 6.90 (d, 1H, 
3
J = 8.5 Hz, CHAr), 7.14-
7.36 (m, 11H, CHAr), 7.47-7.54 (m, 4H, CHAr), 10.4 (t, 1H, 
3
J = 5.1 Hz, NH). 
13
C NMR due to bed solubility it was not possible to measure.  
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MS (GC, 70eV): m/z (%) = 500 (M
+
, 3), 409 (100), 289 (14), 105 (35). 
HRMS (ESI): Calcd for C35H37N2O (M+H) 501.29004. Found 501.29016. 
IR (ATR, cm
-1
): 
~  = 2962 (w), 1635 (m), 1614 (m), 1585 (m), 1464 (m), 1401 (m), 1328 (w), 
1257 (w), 1197 (m), 1153 (s), 1122 (m), 1057 (m), 837 (s), 794 (w), 752 (m), 711 (m), 664 
(m), 583 (m). 
 
1-(3,4-dimethoxyphenethyl)-5-(3,4-dimethoxyphenethylamino)-2-p-tolylquinolin-4(1H)-
one (3.2.6d). 
Starting from 1-(2,6-difluorophenyl)-3-p-tolylprop-2-yn-1-one 
3.2.3h (0.256 g, 1 mmol), 2-(3,4-dimethoxyphenyl)ethanamine 
(0.362 g, 2 mmol) and Li2CO3 (0.148 g, 2 mmol) in 7 mL DMA. 
3.2.6d was isolated as yellow solid (0.491 g, 85%), mp 85-87 
o
C. 
1
H NMR (300 MHz, CDCl3): δ = 2.37 (s, 3H, Me), 2.81 (t, 2H, 
3
J 
= 7.4 Hz, CH2), 2.95-2.99 (m, 2H, CH2), 3.40-3.46 (m, 2H, CH2), 
3.65 (s, 3H, OMe), 3.80 (s, 3H, OMe), 3.83 (s, 3H, OMe), 3.87 
(s, 3H, OMe), 4.11 (t, 2H, 
3
J = 7.4 Hz, CH2), 5.95 (s, 1H, CHAr), 
6.10 (d, 1H, 
4
J = 2.0 Hz, CHAr), 6.32 (dd, 1H, 
3
J = 8.2 Hz,
 4
J = 1.7 Hz, CHAr), 6.38  (d, 1H, 
3
J 
= 8.3 Hz, CHAr), 6.61-6.67 (m, 2H, CHAr), 6.79-6.87 (m, 3H, CHAr), 6.98 (d, 2H, 
3
J = 8.3 Hz, 
CHAr), 7.19 (d, 2H, 
3
J = 7.4 Hz, CHAr), 7.42 (t, 1H, 
3
J = 8.3 Hz, CHAr), 10.51 (s, 1H, NH). 
13
C NMR (62.9 MHz, CDCl3): δ = 21.1 (Me), 33.6, 34.9, 44.9, 49.7 (CH2), 55.4, 55.6, 55.7, 
55.8 (OMe), 110.3, 101.9, 111.1, 111.2, 111.4, 112.0 (CH), 112.5 (C), 113.0, 120.5, 128.2, 
128.9 (CH), 129.4, 132.2, 132.9 (C), 133.3 (CH), 138.8, 143.0, 147.4, 147.7, 148.7, 148.8, 
151.9, 152.9, 180.7 (C). 
MS (GC, 70eV): m/z (%) = 578 (M
+
, 3), 427 (100), 165 (85). 
HRMS (ESI): Calcd for C36H39N2O5 (M+H) 579.28535. Found 579.2862. 
IR (ATR, cm
-1
): 
~  = 2932 (w), 1616 (m), 1590 (m), 1505 (s), 1447 (m), 1257 (m), 1234 (s), 
1138 (s), 1025 (s), 910 (w), 827 (m), 806 (m), 763 (m), 726 (m), 637 (m). 
 
5-((R)-1-phenylethylamino)-1-((R)-1-phenylethyl)-2-p-tolylquinolin-4(1H)-one (3.2.6e). 
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Starting from 1-(2,6-difluorophenyl)-3-p-tolylprop-2-yn-1-one 
3.2.3h (0.256 g, 1 mmol), (R)-1-phenylethanamine (0.274 g, 2 
mmol) and Li2CO3 (0.148 g, 2 mmol) in 7 mL DMA. 3.2.6e was 
isolated as yellow solid (0.183 g, 40%), mp 123-125 
o
C. 
1
H NMR (300 MHz, CDCl3): δ = 1.54 (d, 3H, 
3
J = 6.7 Hz, 
CHMe), 1.78 (d, 3H, 
3
J = 6.7 Hz, CHMe), 2.30 (s, 3H, Me), 
4.43 (q, 1H, 
3
J = 6.7 Hz, CHMe), 5.68 (q, 1H, 
3
J = 6.7 Hz, CHMe), 5.94 (d, 1H, 
3
J = 8.5 Hz, 
CHAr), 6.07 (d, 1H, 
3
J = 8.5 Hz, CHAr), 6.11 (s, 1H, CHAr), 6.80 (t, 1H, 
3
J = 8.5 Hz, CHAr), 
7.07-7.34 (m, 14H, CHAr), 10.81 (s, 1H, NH). 
13
C NMR (62.9 MHz, CDCl3): δ = 17.3, 21.3, 25.0 (Me), 53.1, 58.9 (CH), 103.5, 105.3, 
113.5, 125.1, 126.0, 126.7, 127.0, 127.5, 128.5, 128.7, 129.5, 132.0 (CH), 133.6, 139.5, 
140.5, 141.8, 145.2, 150.9, 154.2, 181.0 (C). 
MS (GC, 70eV): m/z (%) = 458 (M
+
, 19), 443 (22), 353 (100), 207 (28), 105 (19). 
HRMS (EI): Calcd for C32H30N2O (M
+
) 458.23527. Found 458.235207. 
IR (ATR, cm
-1
): 
~  = 2966 (w), 1616 (s), 1519 (m), 1505 (s), 1445 (s), 1377 (m), 1339 (w), 
1267 (m), 1216 (m), 1159 (s), 1019 (w), 827 (m), 744 (m), 697 (s). 
 
2-pentyl-1-phenethyl-5-(phenethylamino)quinolin-4(1H)-one (3.2.6f). 
Starting from 1-(2,6-difluorophenyl)oct-2-yn-1-one 3.2.3i (0.236 g, 1 
mmol), 2-phenylethanamine (0.242 g, 2 mmol) and Li2CO3 (0.148 g, 2 
mmol) in 7 mL DMA. 3.2.6f was isolated as yellow oli (0.359 g, 82%). 
1
H NMR (300 MHz, CDCl3): δ = 0.78-0.83 (m, 3H, CH2(CH2)3Me), 
1.17-1.26 (m, 4H, CH2(CH2)3Me), 1.46-1.51 (m, 2H, CH2(CH2)3Me), 
2.29 (t, 2H, 
3
J = 6.5 Hz, CH2(CH2)3Me), 2.92-2.97 (m, 4H, CH2CH2), 
3.36 (t, 2H, 
3
J = 7.3 Hz, CH2CH2), 4.13 (t, 2H, 
3
J = 7.3 Hz, CH2CH2), 
5.92 (s, 1H, CHAr), 6.28 (d, 1H, 
3
J = 8.7 Hz, CHAr), 6.53 (d, 1H, 
3
J = 8.7 Hz, CHAr), 7.04-7.34 
(m, 11H, CHAr), 10.44 (s, 1H, NH). 
13
C NMR (62.9 MHz, CDCl3): δ = 13.8 (Me), 22.3, 28.2, 31.3, 33.3, 34.4, 35.4, 44.8, 47.5 
(CH2), 99.8, 101.7, 111.4 (CH), 112.2 (C), 126.2, 127.0, 128.4, 128.6, 128.7, 128.9, 133.2 
(CH), 137.5, 139.6, 143.4, 151.9, 152.6, 181.2 (C). 
MS (GC, 70eV): m/z (%) = 438 (M
+
, 4), 347 (100), 105 (42). 
HRMS (ESI): Calcd for C30H35N2O (M+H) 439.27439. Found 439.27482. 
IR (ATR, cm
-1
): 
~  = 2943 (w), 2865 (w), 1626 (s), 1596 (s), 1554 (m), 1516 (m), 1453 (w), 
1365 (w), 1264 (s), 1208 (w), 1172 (m), 1080 (w), 1029 (w), 854 (w), 828 (m), 750 (m), 738 
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(m), 696 (s), 628 (m). 
 
5-(3-phenylpropylamino)-2-pentyl-1-(3-phenylpropyl)quinolin-4(1H)-one (3.2.6g). 
Starting from 1-(2,6-difluorophenyl)oct-2-yn-1-one 3.2.3i (0.236 g, 1 
mmol), 3-phenylpropan-1-amine (0.270 g, 2 mmol) and Li2CO3 
(0.148 g, 2 mmol) in 7 mL DMA. 3.2.6g was isolated as yellow oli 
(0.350 g, 75%). 
1
H NMR (300 MHz, CDCl3): δ = 0.88-0.93 (m, 3H, CH2(CH2)3Me), 
1.26-1.29 (m, 4H, CH2(CH2)3Me), 1.49-1.59 (m, 2H, CH2(CH2)3Me), 
2.00-2.09 (m, 4H, CH2(CH2)3Me, (CH2)3), 2.38-2.43 (m, 2H, (CH2)3), 
2.74-2.83 (m, 4H, (CH2)3), 3.19 (t, 2H, 
3
J = 6.6 Hz, (CH2)3), 3.95 (m, 2H, (CH2)3), 6.03 (s, 
1H, CHAr), 6.25 (d, 1H, 
3
J = 8.2 Hz, CHAr), 6.33 (d, 1H, 
3
J = 8.6 Hz, CHAr), 7.16-7.37 (m, 
11H, CHAr), 10.47 (s, 1H, NH). 
13
C NMR (62.9 MHz, CDCl3): δ = 13.8 (Me), 22.3, 28.5, 29.4, 30.3, 31.3, 32.7, 33.2, 33.3, 
42.0, 45.6 (CH2), 99.5, 101.5, 111.3 (CH), 112.1 (C), 125.7, 126.5, 128.2, 128.3, 128.5, 128.6, 
133.0 (CH), 140.1, 141.7, 143.6, 152.0, 152.5, 181.2 (C). 
MS (GC, 70eV): m/z (%) = 466 (M
+
, 35), 375 (41), 361 (100), 243 (42), 91 (41). 
HRMS (ESI): Calcd for C32H39N2O (M+H) 467.30569. Found 467.30601. 
IR (ATR, cm
-1
): 
~  = 2927 (w), 2857 (w), 1616 (s), 1594 (s), 1557 (m), 1518 (s), 1451 (s), 
1370 (w), 1267 (s), 1170 (s), 1029 (w), 910 (w), 837 (w), 739 (s), 697 (s), 620 (m). 
 
2-(4-tert-butylphenyl)-6-fluoro-1-(3,5-dimethoxyphenyl)quinolin-4(1H)-one (3.2.7a). 
Starting from 3-(4-tert-butylphenyl)-1-(2,6-difluorophenyl)prop-2-
yn-1-one 3.2.3c (0.298 g, 1 mmol), 3,5-dimethoxybenzenamine 
(0.306 g, 2 mmol) and Li2CO3 (0.148 g, 2 mmol) in 7 mL DMA. 
3.2.7a was isolated as yellow solid (0.332 g, 77%), mp 121-122 
o
C. 
1
H NMR (300 MHz, CDCl3): δ = 1.24 (s, 9H, t-Bu), 3.67 (s, 6H, 2xOMe), 6.29 (q, 2H, 
4
J = 
2.3 Hz, CHAr), 6.38-6.40 (m, 2H, CHAr), 7.04-7.24 (m, 6H, CHAr), 8.10 (dd, 1H, 
3
J = 8.9 Hz, 
4
J = 3.0 Hz, CHAr). 
19
F NMR (282 MHz, CDCl3): δ = -117.8 (CF). 
13
C NMR (62.9 MHz, CDCl3): δ = 31.1 (t-Bu), 34.6 (C), 55.6 (2xOMe), 101.1, 108.3 (CH), 
110.3 (d, 
2
J = 22.4 Hz, CHAr), 111.8 (CHAr), 120.1-120.6 (m, CHAr), 124.8 (CHAr),  127.4 (d, 
4
J = 7.0 Hz, C), 128.6 (CHAr), 132.5, 138.8, 140.5, 152.0, 154.0, 159.2  (d, 
1
J = 245.7 Hz, 
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CF), 177.0 (C). 
MS (GC, 70eV): m/z (%) = 431 (M
+
, 100), 416 (42). 
HRMS (ESI): Calcd for C27H27FNO3 (M+H) 432.19695. Found 432.19788. 
IR (ATR, cm
-1
): 
~  = 2961 (w), 1611 (s), 1579 (s), 1506 (w), 1456 (s), 1427 (m), 1386 (m), 
1290 (m), 1252 (m), 1193 (m), 1152 (s), 1057 (m), 1012 (w), 930 (m), 834 (s), 700 (m), 603 
(m). 
 
2-(4-tert-butylphenyl)-6-fluoro-1-(4-methoxyphenyl)quinolin-4(1H)-one (3.2.7b). 
Starting from 3-(4-tert-butylphenyl)-1-(2,6-difluorophenyl)prop-2-
yn-1-one 3.2.3c (0.298 g, 1 mmol), 4-methoxybenzenamine (0.246 
g, 2 mmol) and Li2CO3 (0.148 g, 2 mmol) in 7 mL DMA. 3.2.7b 
was isolated as white solid (0.313 g, 78%), mp 185-186 
o
C. 
1
H NMR (300 MHz, CDCl3): δ = 1.23 (s, 9H, t-Bu), 3.78 (s, 3H, 
OMe), 6.42 (s, 1H, CHAr), 6.83-6.86 (m, 2H, CHAr), 6.90-6.95 (m, 
2H, CHAr), 7.01-7.08 (m, 4H, CHAr), 7.14-7.21 (m, 2H, CHAr), 8.10 (dd, 1H, 
3
J = 8.9 Hz, 
4
J = 
2.9 Hz, CHAr). 
19
F NMR (282 MHz, CDCl3): δ = -117.8 (CF). 
13
C NMR (62.9 MHz, CDCl3): δ = 31.1 (t-Bu), 34.6 (C), 55.5 (OMe), 110.6 (d, 
3
J = 19.8 Hz, 
CH), 114.7, 120.1 (CH), 120.5 (d, 
4
J = 7.4 Hz, CH), 124.8, 128.9, 130.8 (CH), 131.7, 132.5, 
139.5, 151.8, 154.7, 159.2 (d, 
1
J = 245.3 Hz, CF), 159.5, 176.9 (C). 
MS (GC, 70eV): m/z (%) = 401 (M
+
, 100), 386 (29), 358 (13). 
HRMS (EI): Calcd for C26H24FNO2 (M
+
) 401.17856. Found 401.179009. 
IR (ATR, cm
-1
): 
~  = 2958 (w), 1609 (s), 1580 (m), 1505 (s), 1480 (s), 1391 (m), 1361 (m), 
1294 (m), 1243 (s), 1173 (s), 1135 (m), 1084 (w), 1032 (m), 927 (m), 884 (m), 860 (w), 832 
(s), 795 (s), 713 (w), 631 (m), 540 (s). 
 
1-(4-tert-butylphenyl)-7-fluoro-2-p-tolylquinolin-4(1H)-one (3.2.7c). 
Starting from 3-(4-tert-butylphenyl)-1-(2,6-difluorophenyl)prop-2-yn-1-
one 3.2.3e (0.256 g, 1 mmol), 4-tert-butylbenzenamine (0.298 g, 2 mmol) 
and Li2CO3 (0.148 g, 2 mmol) in 7 mL DMA. 3.2.7c was isolated as 
yellow solid (0.289 g, 75%), mp 218-220 
o
C. 
1
H NMR (300 MHz, CDCl3): δ = 1.28 (s, 9H, t-Bu), 2.24 (s, 3H, Me), 6.43 
(s, 1H, CHAr), 6.59 (dd, 1H, 
3
J = 11.2 Hz, 
4
J = 2.2 Hz, CHAr), 6.94-7.10 (m, 7H, CHAr), 7.32-
7.37 (m, 2H, CHAr), 8.46-8.52 (m, 1H, CHAr). 
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19
F NMR (282 MHz, CDCl3): δ = -105.5 (CF). 
13
C NMR (62.9 MHz, CDCl3):δ = 21.1 (Me), 31.2 (t-Bu), 34.8 (C), 104.2 (d, 
2
J = 27.6 Hz, 
CH), 112.5 (d, 
2
J = 22.3 Hz, CH), 112.7 (CH), 122.7 (C), 126.6, 128.5, 129.0, 129.1, 129.2 
(CH), 132.5, 136.1, 138.7 (C), 144.2 (d, 
3
J = 11.5 Hz, C), 152.5, 154.9 (C), 164.7 (d, 
1
J = 
249.5 Hz, CF), 177.1 (C). 
MS (GC, 70eV): m/z (%) = 385 (M
+
, 100), 370 (59). 
HRMS (ESI): calcd for C26H25FNO (M+H) 386.19147, found 386.1918. 
IR (ATR, cm
-1
): 
~  = 2963 (w), 1639 (s), 1601 (s), 1510 (s), 1449 (s), 1392 (s), 1306 (s), 1263 
(m), 1175 (m), 1124 (w), 1083 (w), 1027 (w), 986 (w), 841 (s), 814 (s), 754 (w), 660 (w), 634 
(w), 571 (m). 
 
7-fluoro-1-(3,5-dimethylphenyl)-2-p-tolylquinolin-4(1H)-one (3.2.7d). 
Starting from 3-(4-tert-butylphenyl)-1-(2,6-difluorophenyl)prop-2-yn-
1-one 3.2.3e (0.256 g, 1 mmol), 3,5-dimethylbenzenamine (0.242 g, 2 
mmol) and Li2CO3 (0.148 g, 2 mmol) in 7 mL DMA. 3.2.7d was 
isolated as yellow solid (0.282 g, 79%), mp 271-273 
o
C. 
1
H NMR (300 MHz, CDCl3): δ = 2.24 (s, 6H, 2xMe), 2.25 (s, 3H, 
Me), 6.37 (s, 1H, CHAr), 6.57 (dd, 1H, 
3
J = 11.3 Hz, 
4
J = 2.4 Hz, CHAr), 6.73 (s, 2H, CHAr), 
6.94-7.08 (m, 6H, CHAr), 8.44-8.50 (m, 1H, CHAr). 
19
F NMR (282 MHz, CDCl3): δ = -105.7 (CF). 
13
C NMR (75.5 MHz, CDCl3): δ = 21.0, 21.2 (Me), 104.2 (d, 
2
J = 27.1 Hz, CH), 112.4 (d, 
2
J = 
23.2 Hz, CH), 112.6 (CH), 122.7 (C), 127.2, 128.5, 128.9 (CH), 129.1 (d, 
3
J = 10.6 Hz, CH), 
130.7 (CH), 132.6 (C), 138.6 (d, 
4
J = 2.6 Hz, C), 139.5 (C), 144.1 (d, 
3
J = 11.3 Hz, C), 154.7 
(C), 164.7 (d, 
1
J = 250.8 Hz, CF), 177.2 (C). 
MS (GC, 70eV): m/z (%) = 357 (M
+
, 100), 329 (91), 150 (13). 
HRMS (ESI): Calcd for C24H21FNO (M+H) 358.16017. Found 358.16006. 
IR (ATR, cm
-1
): 
~  = 2917 (w), 1633 (s), 1601 (s), 1511 (w), 1441 (s), 1386 (s), 1313 (m), 
1261 (m), 1166 (m), 1125 (m), 1080 (w), 1021 (w), 951 (w), 848 (s), 819 (s), 763 (m), 709 
(m), 640 (w), 596 (w). 
 
5-fluoro-1-(3,5-dimethylphenyl)-2-phenylquinolin-4(1H)-one (3.2.7e). 
NF
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Starting from 1-(2,6-difluorophenyl)-3-phenylprop-2-yn-1-one 3.2.3f (0.242 g, 
1 mmol), 3,5-dimethylbenzenamine (0.242 g, 2 mmol) and Li2CO3 (0.148 g, 2 
mmol) in 7 mL DMA. 3.2.7e was isolated as yellow solid (0.264 g, 77%), mp 
132-133 
o
C. 
1
H NMR (300 MHz, CDCl3) δ = 2.21 (s, 6H, 2xMe), 6.36 (s, 1H, CHAr), 6.69-
6.72 (m, 3H, CHAr), 6.91-6.98 (m, 2H, CHAr), 7.12-7.20 (m, 5H, CHAr), 7.30-7.37 (m, 1H, 
CHAr). 
19
F NMR (282 MHz, CDCl3): δ = -112.1 (CF). 
13
C NMR (62.9 MHz, DMSO-d6): δ = 21.0 (Me), 110.1 (d, 
2
J = 17.4 Hz, CH), 114.1 (CH), 
114.2 (d, 
4
J = 4.6 Hz, CH), 116.2 (d, 
3
J = 8.6 Hz, C), 127.3, 127.7, 128.6, 129.0, 130.5 (CH), 
131.7 (d, 
3
J = 10.3 Hz, C), 135.2, 138.9, 139.5 (C), 144.8 (d, 
4
J = 3.8 Hz, C), 153.4 (C), 161.7 
(d, 
1
J = 259.4 Hz, CF), 176.8 (C). 
MS (GC, 70eV): m/z (%) = 343 (M
+
, 97), 315 (100), 299 (14). 
HRMS (EI): Calcd for C23H18FNO (M
+
) 343.13669. Found 343.137067. 
IR (ATR, cm
-1
): 
~  = 3047 (w), 1614 (s), 1471 (s), 1403 (s), 1307 (m), 1198 (w), 1120 (w), 
1056 (m), 932 (w), 846 (M), 799 (m), 753 (s), 728 (m), 702 (s), 648 (m), 536 (m). 
 
5-fluoro-1-(3,5-dimethylphenyl)-2-p-tolylquinolin-4(1H)-one (3.2.7f). 
Starting from 1-(2,6-difluorophenyl)-3-p-tolylprop-2-yn-1-one 3.2.3g 
(0.256 g, 1 mmol), 3,5-dimethylbenzenamine (0.242 g, 2 mmol) and 
Li2CO3 (0.148 g, 2 mmol) in 7 mL DMA. 3.2.7f was isolated as yellow 
solid (0.253 g, 71%), mp 133-134 
o
C. 
1
H NMR (300 MHz, CDCl3): δ = 2.22 (s, 6H, 2xMe), 2.24 (s, 3H, Me), 
6.32 (s, 1H, CHAr), 6.67-6.72 (m, 3H, CHAr), 6.89-7.03 (m, 6H, CHAr), 7.27-7.35 (m, 1H, 
CHAr). 
19
F NMR (282 MHz, CDCl3): δ = -112.3 (CF). 
13
C NMR (62.9 MHz, CDCl3): δ = 21.0, 21.1 (Me), 109.9 (d, 
2
J = 21.5 Hz, CH), 114.2 (CH), 
116.1 (d, 
3
J = 7.2 Hz, CH), 127.3, 128.4, 128.9, 130.5 (CH), 131.5 (d, 
3
J = 10.8 Hz, CH), 
132.4, 138.5, 139.1, 139.4 (C), 144.8 (d, 
4
J = 3.8 Hz, C), 153.5 (C), 161.8 (d, 
1
J = 259.6 Hz, 
CF), 176.8 (C). 
MS (GC, 70eV): m/z (%) = 357 (M
+
, 79), 329 (100). 
HRMS (ESI): Calcd for C24H21FNO (M+H) 358.16017. Found 358.16034. 
IR (ATR, cm
-1
): 
~  = 2917 (w), 1633 (s), 1614 (s), 1510 (w), 1471 (s), 1398 (s), 1305 (m), 
1195 (w), 1116 (w), 1089 (w), 1056 (m), 933 (w), 830 (s), 795 (m), 752 (s), 726 (m), 666 (w), 
 
N
O
MeMe
Me
F
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602 (w). 
 
1-(4-ethylphenyl)-5-fluoro-2-p-tolylquinolin-4(1H)-one (3.2.7g). 
Starting from1-(2,6-difluorophenyl)-3-p-tolylprop-2-yn-1-one 3.2.3g 
(0.256 g, 1 mmol), 4-ethylbenzenamine (0.242 g, 2 mmol) and Li2CO3 
(0.148 g, 2 mmol) in 7 mL DMA. 3.2.7g was isolated as yellow solid 
(0.250 g, 70%), mp 250-251 
o
C. 
1
H NMR (300 MHz, CDCl3): δ = 1.20 (t, 3H, 
3
J = 7.7 Hz, CH2Me), 2.24 
(s, 3H, Me), 2.62 (q, 2H, 
3
J = 7.7 Hz, CH2Me), 6.33 (s, 1H, CHAr), 6.66 
(d, 1H, 
3
J = 8.8 Hz, CHAr), 6.90-7.02 (m, 7H, CHAr), 7.14-7.17 (m, 2H, CHAr), 7.27-7.35 (m, 
1H, CHAr).  
19
F NMR (282 MHz, CDCl3): δ = -111.5 (CF). 
13
C NMR (75.5 MHz, CDCl3): δ = 15.1 (CH2Me), 21.1 (Me), 28.4 (CH2Me), 110.0 (d, 
2
J = 
21.4 Hz, CH), 114.1 0 (d, 
4
J = 4.4 Hz, CH), 114.3, 128.5, 129.0, 129.6 (CH), 131.6 (d, 
3
J = 
11.8 Hz, CH), 132.4, 136.9, 138.5 (C), 145.0 (d, 
4
J = 3.8 Hz, C), 145.3, 153.6 (C), 161.8 (d, 
1
J 
= 262.1 Hz, CF), 176.9 (C).  
MS (GC, 70eV): m/z (%) = 357 (M
+
, 94), 329 (100), 314 (18). 
HRMS (ESI): Calcd for C24H21FNO (M+H) 358.16017. Found 358.16061. 
IR (ATR, cm
-1
): 
~  = 3057 (w), 2970 (w), 1633 (s), 1614 (s), 1511 (s), 1475 (s), 1407 (s), 
1306 (m), 1253 (m), 1190 (w), 1122 (w), 1104 (w), 1037 (m), 920 (w), 857 (m), 831 (s), 789 
(m), 747 (s), 650 (m), 598 (w). 
 
2-(4-tert-butylphenyl)-5-fluoro-1-(3,5-dimethoxyphenyl)quinolin-4(1H)-one (3.2.7h). 
Starting from 3-(4-tert-butylphenyl)-1-(2,6-difluorophenyl)prop-2-
yn-1-one 3.2.3h (0.298 g, 1 mmol), 3,5-dimethoxybenzenamine 
(0.306 g, 2 mmol) and Li2CO3 (0.148 g, 2 mmol) in 7 mL DMA. 
3.2.7h was isolated as yellow solid (0.315 g, 73%), mp 263-265 
o
C. 
1
H NMR (300 MHz, CDCl3): δ = 1.21 (s, 9H, t-Bu), 3.65 (s, 6H, 
2xOMe), 6.01 (s, 1H, CHAr), 6.47-6.48 (m, 1H, CHAr), 6.62-6.63 (m, 2H, CHAr), 6.78 (d, 1H, 
3
J = 9.1 Hz, CHAr), 7.06-7.12 (m, 1H, CHAr), 7.28 (br. s, 4H, CHAr), 7.50-7.57 (m, 1H, CHAr). 
19
F NMR (282 MHz, CDCl3): δ = -113.4. 
13
C NMR (62.9 MHz, CDCl3):δ = 28.9 (t-Bu), 32.3 (C), 52.9, 53.6 (OMe), 99.0, 106.5 (CH), 
107.7 (d, J = 21.4 Hz, CH), 111.1, 112.4 (CH), 113.4 (C), 122.4, 126-9, 130.3 (CH), 138.6 
(C), 142.3 (d, J = 4.4 Hz, C), 149.1, 151.0, 157.0, 158.0, 160.5, 173.0 (C). 
N
O
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MS (GC, 70eV): m/z (%) = 431 (M
+
, 100), 416 (20), 388 (19). 
HRMS (ESI): calcd for C27H27FNO3 (M+H) 432.19695, found 432.19743. 
IR (ATR, cm
-1
): 
~  = 3003 (w), 1621 (s), 1558 (m), 1517 (m), 1504 (m), 1447 (s), 1365 (m), 
1291 (m), 1257 (m), 1171 (m), 1122 (w), 1023 (w), 1000 (w), 842 (s), 742 (s), 660 (m), 565 
(s). 
 
5-fluoro-1-(4-methoxyphenyl)-2-pentylquinolin-4(1H)-one (3.2.7i). 
Starting from 1-(2,6-difluorophenyl)oct-2-yn-1-one 3.2.3i (0.236 g, 1 mmol), 
4-methoxybenzenamine (0.146 g, 2 mmol) and Li2CO3 (0.148 g, 2 mmol) in 7 
mL DMA. 3.2.7i was isolated as yellow oil (0.244 g, 72%). 
1
H NMR (300 MHz, CDCl3): δ = 0.80 (t, 3H, 
3
J = 6.7 Hz, CH2Me), 1.15-1.20 
(m, 4H, CH2), 1.47-1.53 (m, 2H, CH2), 2.24 (t, 2H, 
3
J = 7.2 Hz, CCH2), 3.91 
(s, 3H, OMe), 6.33 (s, 1H, CHAr), 6.46 (d, 1H, 
3
J = 8.5 Hz,CHAr), 6.87-6.93 
(m, 1H, CHAr), 7.07-7.18 (m, 4H, CHAr), 7.23-7.31 (m, 1H, CHAr).  
19
F NMR (282 MHz, CDCl3): δ = -112.2 (CF). 
13
C NMR (62.9 MHz, CDCl3): δ = 13.8 (CH2Me), 22.3, 27.9, 31.2, 33.5 (CH2), 55.7 (OMe), 
109.9 (d, 
2
J = 23 Hz,CH), 111.7 (CH), 113.8 (d, 
4
J = 5 Hz,CH), 115.5, 130.1 (CH), 131.2-
131.5 (m, CH), 145.5, 154.9, 159.7, 162.0 (d, 
1
J = 258.6 Hz,CH), 162.9, 176.9 (C). 
MS (GC, 70eV): m/z (%) = 339 (M
+
, 22), 296 (17), 283 (100), 268 (13), 121 (29). 
HRMS (EI): Calcd for C22H22FNO2 (M
+
) 339.16291. Found 339.162750. 
IR (ATR, cm
-1
): 
~  = 2923 (m), 1613 (s), 1507 (s), 1469 (s), 1408 (s), 1296 (m), 1235 (s), 
1170 (m), 1107 (m), 1038 (s), 826 (m), 798 (m), 551 (m). 
 
A.2.18. General procedure for the synthesis of compounds 3.2.8. 
 
Corresponding 1-(2-fluorophenyl)prop-2-yn-1-one derivative 3.2.2b,c (1 equiv.) and Li2CO3 
(2 equiv.) were placed in a pressure tube or in the Schlenk flask under the flow of dry argon 
and dissolved in dry DMA (7 mL/1 mmol of 3.2.2). The mixture was heated at 100 C for 15 
h (controlled by TLC). After the reaction was completed volatiles were evaporated under 
reduced pressure. The residue was purified by column chromatography over silica gel 
(Heptane : Ethyl acetate - 5:1). 
 
(Z)-3-(4-tert-butylphenyl)-1-(2,5-difluorophenyl)-3-(phenethylamino)prop-2-en-1-one 
(3.2.8a). 
N
O
C5H11
OMe
F
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Starting from 3-(4-tert-butylphenyl)-1-(2,5-
difluorophenyl)prop-2-yn-1-one 3.2.3c (0.298 g, 1 mmol) and 
Li2CO3 (0.148 g, 2 mmol) in 7 mL DMA. 3.2.8a was isolated 
as yellow oil (0.310 g, 74%). 
1
H NMR (300 MHz, CDCl3): δ = 1.32 (s, 9H, t-Bu), 2.85 (t, 2H, 
3
J = 6.9 Hz, CH2), 3.48 (m, 
2H, CH2), 5.66 (d, 1H, 
4
J = 2.0 Hz, CHC), 6.95-7.01 (m, 2H, CHAr), 7.07-7.09 (m, 2H, CHAr), 
7.16-7.25 (m, 5H, CHAr), 7.37-7.40 (m, 2H, CHAr), 7.49-7.54 (m, 1H, CHAr), 11.47 (s, 1H, 
NH). 
19
F NMR (282 MHz, CDCl3): δ = -118.8 (d, 
3
J = 18.6 Hz, CF), -118.1 (d, 
3
J = 18.6 Hz, CF).  
13
C NMR (62.9 MHz, CDCl3): δ = 31.2 (Me), 34.7 (C), 37.3, 46.5 (CH2), 97.5 (d, 
3
J = 9.9 Hz, 
CH), 116.4 (dd, 
2
J = 24.8 Hz, 
4
J = 3.5 Hz, CH), 117.3 (dd, 
2
J = 27.4 Hz, 
3
J = 8.2 Hz, CH), 
117.9 (dd, 
2
J = 24.5 Hz, 
3
J = 8.7 Hz, CH), 125.4, 126.6, 127.4, 128.5, 128.8 (CH), 130.3 (dd, 
3
J = 16.0 Hz, 
4
J = 6.5 Hz, C), 132.0, 138.1, 152.9, 156.2 (d, 
1
J = 244.6 Hz, CF), 158.6 (d, 
1
J = 
240.0 Hz, CF), 167.6 (C), 182.8 (d, 
4
J = 3.0 Hz, C). 
MS (GC, 70eV): m/z (%) = 419 (M
+
, 19), 328 (100), 272 (10), 141 (51). 
HRMS (EI): Calcd for C27H27F2ON (M
+
) 419.20552. Found 419.205681. 
IR (ATR, cm
-1
): 
~  = 2948 (w), 1568 (m), 1538 (m), 1484 (m), 1456 (m), 1412 (m), 1364 (w), 
1327 (m), 1288 (m), 1267 (m), 1246 (m), 1161 (m), 1143 (m), 1099 (m), 1065 (w), 1019 (w), 
990 (w), 908 (w), 844 (m), 814 (s), 794 (m), 776 (m), 743 (s), 697 (s), 632 (m). 
 
(Z)-3-(4-tert-butylphenyl)-1-(2-fluorophenyl)-3-(adeamantylamino)prop-2-en-1-one 
(3.2.8b). 
Starting from 3-(4-tert-butylphenyl)-1-(2-fluorophenyl)prop-2-yn-
1-one 3.2.3b (0.280 g, 1 mmol) and Li2CO3 (0.148 g, 2 mmol) in 7 
mL DMA. 3.2.8b was isolated as yellow solid (0.349 g, 81%), mp 
116-118 
o
C. 
1
H NMR (300 MHz, CDCl3): δ = 1.29 (s, 9H, t-Bu), 1.40-1.53 (m, 
6H, Adamantyl), 1.73-1.74 (m, 6H, Adamantyl), 1.20 (br. s, 3H, Adamantyl), 6.92-6.99 (m, 
1H, CHAr), 7.09 (dt, 1H, 
3
J = 7.6 Hz, 
4
J = 1.1 Hz, CHAr), 7.20-7.32 (m, 6H, CHAr), 7.76 (dt, 
1H, 
3
J = 7.7 Hz, 
4
J = 1.9 Hz, CHAr), 11.68 (s, 1H, NH). 
19
F NMR (282 MHz, CDCl3): δ = -112.3 (CF). 
13
C NMR (62.9 MHz, CDCl3): δ = 29.5 (CH), 31.3 (t-Bu), 34.7 (C), 35.9, 44.4 (CH2), 55.2 
(CH), 99.5 (C), 116.0 (d, 
2
J = 24.6 Hz, CH), 123.9 (d, 
4
J = 3.5 Hz, CH), 124.5, 127.8 (CH), 
129.1  (d, 
3
J = 13.7 Hz, C), 130.4 (d, 
4
J = 3.0 Hz, CH), 131.4 (d, 
3
J = 8.8 Hz, CH), 134.8, 
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152.2 (C), 160.3 (d, 
1
J = 252.1 Hz, C), 167.3 (C), 183.8 (d, 
4
J = 3.1 Hz, C). 
MS (GC, 70eV): m/z (%) = 431 (M
+
, 100), 374 (41), 336 (24), 308 (67), 252 (17), 123 (52). 
HRMS (ESI): Calcd for C29H34FNO (M+H) 432.26244. Found 432.27007. 
IR (ATR, cm
-1
): 
~  = 2904 (m), 1610 (m), 1583 (s), 1493 (m), 1477 (m), 1448 (m), 1398 (w), 
1338 (s), 1299 (s), 1208 (m), 1150 (m), 1098 (m), 1086 (m), 1028 (m), 880 (w), 839 (m), 760 
(s), 676 (w), 628 (w), 582 (m). 
 
A.2.19. General procedure for the synthesis of compounds 3.2.11a,b. 
 
Corresponding 1-(2-fluorophenyl)prop-2-yn-1-one derivative 3.2.2e,g (1 equiv.), appropriate 
amine (1 equiv.) and Li2CO3 (2 equiv.) were placed in a pressure tube under the flow of dry 
argon and dissolved in dry DMA (7 mL/1 mmol of 3.2.2). The mixture was heated at 160 C 
for 10 h (controlled by TLC). After the reaction was completed volatiles were evaporated 
under reduced pressure. The residue was purified by column chromatography over silica gel 
(Heptane : Ethyl acetate - 5:1). 
 
(Z)-3-(1-phenylethylamino)-1-(2-(1-phenylethylamino)-4-fluorophenyl)-3-p-tolylprop-2-
en-1-one (3.2.11a). 
Starting from 1-(2,4-difluorophenyl)-3-p-tolylprop-2-yn-1-one 
3.2.3e (0.256 g, 1 mmol), (R)-(+)-(1-phenethyl)amine (0.121 
g, 1 mmol) and Li2CO3 (0.148 g, 2 mmol) in 7 mL DMA. 
3.2.11a was isolated as yellow solid (0.306 g, 64%), mp 174-
176 
o
C. 
1
H NMR (300 MHz, CDCl3): δ = 1.48 (d, 3H, 
3
J = 6.8 Hz, CHMe), 1.54 (d, 3H, 
3
J = 6.8 Hz, 
CHMe), 2.28 (s, 3H, Me), 4.39-4.54 (m, 2H, 2xCHMe), 5.54 (s, 1H, CHAr), 5.95-6.08 (m, 2H, 
CHAr), 7.06 (s, 4H, CHAr), 7.09-7.32 (m, 10H, CHAr), 7.47-7.52 (m, 1H, CHAr), 9.22 (s, 1H, 
NH), 11.19 (d, 1H, J = 10.2 Hz, NH). 
19
F NMR (282 MHz, CDCl3): δ = -107.0 (CF). 
13
C NMR (62.9 MHz, CDCl3):δ = 21.3, 24.6, 25.1 (Me), 53.0, 54.0 (CH), 95.1 (CH), 99.0 (d, 
2
J = 25.0 Hz, CH), 101.5 (d, 
2
J = 25.0 Hz, CH), 117.5 (C), 125.7, 125.8, 126.8, 126.9, 127.6, 
128.6, 128.7, 128.9 (CH), 130.8 (d, J = 200.0 Hz, CH), 131.7 (d, J = 11.4 Hz, CH), 133.4, 
139.2 (C), 144.7 (d, 
3
J = 18.7 Hz, C), 151.4 (d, 
3
J = 11.4 Hz, C), 165.0 (C), 165.5 (d, 
1
J = 
251.6 Hz, CF), 191.4 (C). 
MS (GC, 70eV): m/z (%) = 478 (M
+
, 3), 373 (84), 355 (18), 240 (100), 105 (74). 
F
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HRMS (ESI): Calcd for C32H32N2O (M+H) 479.24932. Found 479.24955. 
IR (ATR, cm
-1
): 
~  = 3262 (w), 2968 (w), 1621 (w), 1594 (m), 1556 (s), 1507 (s), 1451 (s), 
1371 (w), 1338 (m), 1303 (m), 1279 (m), 1191 (s), 1138 (m), 1105 (s), 1017 (m), 908 (w), 
827 (m), 775 (s), 697 (s), 592 (m). 
 
(Z)-3-(1-phenylethylamino)-1-(2-(1-phenylethylamino)-6-fluorophenyl)-3-p-tolylprop-2-
en-1-one (3.2.11b). 
Starting from 1-(2,6-difluorophenyl)-3-p-tolylprop-2-yn-1-one 
3.2.3g (0.256 g, 1 mmol), (R)-(+)-(1-phenethyl)amine (0.121 g, 
1 mmol) and Li2CO3 (0.148 g, 2 mmol) in 7 mL DMA. 3.2.11b 
was isolated as yellow solid (0.330 g, 69%), mp 154-156 
o
C. 
1
H NMR (300 MHz, CDCl3): δ = 1.52 (d, 6H, 
3
J = 6.8 Hz, 2xCHMe), 2.30 (s, 3H, Me), 4.44-
4.46 (m, 1H, CHMe), 4.54-4.64 (m, 1H, CHMe), 5.57 (d, 1H, 
3
J = 4.6 Hz, NH), 6.07 (d, 1H, 
3
J = 8.8 Hz, CHAr), 6.12-6.19 (m, 1H, CHAr), 6.81-6.88 (m, 1H, CHAr), 7.07-7.42 (m, 14H, 
CHAr), 7.86-7.91 (m, 1H, CHAr), 11.49 (d, 1H, J = 10.2 Hz, NH). 
19
F NMR (282 MHz, CDCl3): δ = -108.9 (CF). 
13
C NMR (62.9 MHz, CDCl3): Due to bed solubility was not possible to measure. 
MS (GC, 70eV): m/z (%) = 478 (M
+
, 2), 373 (87), 355 (31), 240 (100), 105 (100). 
HRMS (ESI): Calcd for C32H32FN2O5 (M+H) 479.24932. Found 479.25022. 
IR (ATR, cm
-1
): 
~  = 3342 (w), 2976 (w), 1613 (m), 1557 (s), 1489 (s), 1449 (s), 1412 (m), 
1333 (s), 1267 (m), 1241 (m), 1205 (m), 1140 (m), 1085 (m), 1016 (m), 871 (w), 819 (m), 
800 (s), 752 (s), 697 (s), 670 (m), 576 (m). 
 
A.2.20. General procedure for the synthesis of compounds 3.2.12. 
 
Corresponding quinolone 3.2.3d,f,g (1 equiv.), appropriate amine (2 equiv.) and Li2CO3 (2 
equiv.) were placed in a pressure tube under the flow of dry argon and dissolved in dry DMA 
(7 mL/1 mmol of 3.2.3). The mixture was heated at 160 C for 26 h (controlled by TLC). 
After the reaction was completed volatiles were evaporated under reduced pressure. The 
residue was purified by column chromatography over silica gel (Heptane : Ethyl acetate - 
2:1). 
 
1-(3,5-dimethylphenyl)-5-(phenethylamino)-2-p-tolylquinolin-4(1H)-one (3.2.12a). 
NH
Me
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Starting from 3.2.7f (0.150 g, 0.42 mmol), phenethylamine (0.101 
g, 0.84 mmol) and Li2CO3 (0.062 g, 0.84 mmol) in 4 mL DMA. 
3.2.12a was isolated as yellow solid (0.187 g, 97%), mp 154 
o
C. 
1
H NMR (300 MHz, CDCl3): δ = 2.21 (s, 6H, 2xMe), 2.24 (s, 3H, 
Me), 3.05 (t, 2H, 
3
J = 7.5 Hz, CH2), 3.47 (t, 2H, 
3
J = 7.5 Hz, CH2), 
5.88 (d, 1H, 
3
J = 8.1 Hz, CHAr), 6.20 (s, 1H, CHAr), 6.33 (d, 1H, 
3
J 
= 8.1 Hz, CHAr), 6.70 (s, 2H, CHAr), 6.88-7.03 (m, 5H, CHAr), 
7.12-7.23 (m, 2 H, CHAr), 7.32-7.33 (m, 4H, CHAr), 10.38 (s, 1H, NH). 
13
C NMR (62.9 MHz, CDCl3): δ = 21.0, 21.2 (Me), 35.4, 44.9 (CH2), 101.8, 103.0 (CH), 
111.7 (C), 112.8, 126.3, 17.6, 128.3, 128.5, 128.8, 129.0, 130.0, 132.8, 132.9 (CH), 138.1, 
139.0, 139.7, 145.5, 151.2, 152.5, 181.5 (C). 
MS (GC, 70eV): m/z (%) = 458 (M
+
, 3), 367 (100). 
HRMS (ESI): Calcd for C32H31N2O (M+H) 459.24309. Found 459.24347. 
IR (ATR, cm
-1
): 
~  = 3207 (w), 2831 (w), 1619 (s), 1586 (m), 1519 (m), 1505 (s), 1441 (s), 
1382 (m), 1348 (m), 1307 (m), 1251 (s), 1182 (m), 1125 (s), 1024 (w), 839 (s), 746 (s), 697 
(s), 658 (m), 586 (m).  
 
1-(4-ethylphenyl)-5-(phenethylamino)-2-p-tolylquinolin-4(1H)-one (3.2.12b). 
Starting from 3.2.7f (0.150 g, 0.42 mmol), phenethylamine (0.101 g, 
0.84 mmol) and Li2CO3 (0.062 g, 0.84 mmol) in 4 mL DMA. 3.2.12b 
was isolated as yellow oil (0.162 g, 84%). 
1
H NMR (300 MHz, CDCl3): δ = 1.19 (t, 3H, 
3
J = 7.6 Hz, MeCH2), 
2.24 (s, 3H, Me), 2.61 (q, 2H, 
3
J = 7.6 Hz, MeCH2), 3.05 (t, 2H, 
3
J = 
7.3 Hz, CH2CH2), 3.47 (t, 2H, 
3
J = 7.3 Hz, CH2CH2), 5.87 (d, 1H, 
3
J = 
8.4 Hz, CHAr), 6.23 (s, 1H, CHAr), 6.34 (d, 1H, 
3
J = 8.0 Hz, CHAr), 
6.92-7.00 (m, 6H, CHAr), 7.11-7.23 (m, 4H, CHAr), 7.30-7.33 (m, 4H, CHAr), 10.39 (s, 1H, 
NH). 
13
C NMR (62.9 MHz, CDCl3): δ = 15.2 (MeCH2), 21.2 (Me), 28.4, 35.4, 44.9 (CH2), 102.0, 
103.0, 111.7 (CH), 112.8 (C), 126.3, 128.4, 128.5, 128.7, 128.8, 129.1, 129.7 (CH), 132.9, 
137.5, 138.2, 139.7, 144.7, 145.6, 151.2, 152.7, 181.4 (C). 
MS (GC, 70eV): m/z (%) = 458 (M
+
, 3), 367 (100). 
HRMS (ESI): Calcd for C32H31N2O (M+H) 459.24309. Found 459.24349. 
IR (ATR, cm
-1
): 
~  = 3214 (w), 2962 (w), 2865 (w), 1619 (m), 1504 (s), 1344 (w), 1267 (s), 
1183 (m), 1021 (m), 851 (m), 816 (m), 740 (m), 698 (s), 565 (m). 
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5,7-(hexylamino)-1-(3,5-dimethylphenyl)-2-p-tolylquinolin-4(1H)-one (3.2.12c). 
Starting from 3.2.7d (0.150 g, 0.42 mmol), hexyl amine (0.084 
g, 0.84 mmol) and Li2CO3 (0.062 g, 0.84 mmol) in 4 mL DMA. 
3.2.12c was isolated as yellow oil (0.146 g, 79%). 
1
H NMR (300 MHz, CDCl3): δ = 0.84-0.91 (m, 3H, 
Me(CH2)4CH2), 1.13-1.30 (m, 6H, Me(CH2)4CH2), 1.43-1.50 
(m, 2H, Me(CH2)4CH2), 2.23 (s, 6H, 2xMe), 2.24 (s, 3H, Me), 2.91-3.00 (m, 2H, 
Me(CH2)4CH2), 4.06 (br. s, 1H, NH), 5.80 (d, 1H, 
4
J = 2.0 Hz, CHAr), 6.27 (s, 1H, CHAr), 6.62 
(dd, 1H, 
3
J = 8.7 Hz, 
4
J = 2.0 Hz, CHAr), 6.74 (s, 2H, CHAr), 6.90-7.04 (m, 5H, CHAr), 8.25 (d, 
1H, 
3
J = 8.2 Hz, CHAr).  
13
C NMR (62.9 MHz, CDCl3): δ = 13.9, 20.9, 21.1 (Me), 22.5, 26.6, 28.9, 31.5, 43.2 (CH2), 
96.9, 111.7 (CH), 117.4 (C), 127.4, 127.5, 128.2, 129.0, 130.0 (CH), 133.3, 138.0, 138.9, 
139.3, 144.9, 151.2, 153.1 (C). 
MS (GC, 70eV): m/z (%) = 438 (M
+
, 54), 367 (100). 
HRMS (ESI): Calcd for C30H35N2O (M+H) 439.27439. Found 439.27378. 
IR (ATR, cm
-1
): 
~  = 3307 (w), 2922 (w), 1596 (s), 1556 (s), 1512 (m), 1441 (s), 1396 (m), 
1296 (m), 1220 (m), 1148 (m), 1017 (m), 848 (m), 815 (m), 706 (m), 636 (m). 
 
A.2.21. General procedure for the synthesis of compounds 3.2.13. 
 
Corresponding 1-(2-fluorophenyl)prop-2-yn-1-one derivative 3.2.2g,i (1 equiv.), appropriate 
amine (2 equiv.) and Li2CO3 (2 equiv.) were placed in a pressure tube under the flow of dry 
argon and dissolved in dry NMP (7 mL/1 mmol of 3.2.2). The mixture was heated at 185 C 
for 35 h (controlled by TLC). After the reaction was completed volatiles were evaporated 
under reduced pressure. The residue was purified by column chromatography over silica gel 
(Heptane : Ethyl acetate - 1:1). 
 
5-(4-ethylphenylamino)-1-(4-ethylphenyl)-2-p-tolylquinolin-4(1H)-one (3.2.13a). 
N
O
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Starting from 1-(2,6-difluorophenyl)-3-p-tolylprop-2-yn-1-one 
3.2.3h (0.256 g, 1 mmol), 4-ethylphenyl amine (0.240 g, 2 
mmol) and Li2CO3 (0.148 g, 2 mmol) in 7 mL N-methyl-2-
pyrrollidine. 3.2.13a was isolated as yellow solid (0.362 g, 
79%), mp 174-175 
o
C. 
1
H NMR (300 MHz, CDCl3): δ = 1.11-1.20 (m, 6H, 2xMeCH2), 
2.17 (s, 3H, Me), 2.51-2.61 (m, 4H, 2xMeCH2), 5.91 (dd, 1H, 
3
J 
= 8.4 Hz, 
4
J = 0.8 Hz, CHAr), 6.22 (s, 1H, CHAr), 6.84-6.95 (m, 7H, CHAr), 7.00-7.12 (m, 5H, 
CHAr), 7.18-7.21 (m, 2H, CHAr), 11.99 (s, 1H, NH). 
13
C NMR (75.5 MHz, CDCl3): δ = 15.2, 15.7 (2xMeCH2), 21.2 (Me), 28.3, 28.4 (2xMeCH2), 
104.5, 104.9 (CH), 112.7 (C), 128.5, 128.6, 128.8, 129.0, 129.7, 132.5 (CH), 132.7, 137.4, 
138.4, 138.7, 139.5, 144.9, 145.6, 148.9, 153.2, 181.4 (C). 
MS (GC, 70eV): m/z (%) = 458 (M
+
, 100), 443 (38). 
HRMS (ESI): Calcd for C32H31N2O (M+H) 459.24309. Found 459.24294. 
IR (ATR, cm
-1
): 
~  = 2960 (w), 1623 (m), 1591 (s), 1564 (m), 1504 (m), 1441 (s), 1376 (w), 
1342 (w), 1274 (s), 1176 (m), 1112 (w), 1038 (w), 1018 (w), 844 (s), 819 (s), 751 (m), 721 
(m), 636 (m). 
 
5-(4-methoxyphenylamino)-1-(4-methoxyphenyl)-2-pentylquinolin-4(1H)-one (3.2.13b). 
Starting from 1-(2,6-difluorophenyl)oct-2-yn-1-one 3.2.3i (0.236 g, 
1 mmol), 4-methoxyphenyl amine (0.244 g, 2 mmol) and Li2CO3 
(0.148 g, 2 mmol) in 7 mL N-methyl-2-pyrrollidine. 3.2.13b was 
isolated as yellow oil (0.338 g, 80%). 
1
H NMR (300 MHz, CDCl3): δ = 0.75 (t, 3H, 
3
J = 7.0 Hz, MeCH2), 
1.09-1.18 (m, 4H, CH2), 1.40-1.45 (m, 2H, CH2), 2.15 (t, 2H, 
3
J = 
7.7 Hz, CCH2), 3.73 (s, 3H, OMe), 3.83 (s, 3H, OMe), 5.67 (dd, 1H, 
3
J = 8.4 Hz,
 4
J = 0.8 Hz, CHAr), 6.13 (s, 1H, CHAr), 6.60 (dd, 1H, 
3
J = 8.3 Hz,
 4
J = 0.8 Hz, 
CHAr), 6.81-6.85 (m, 2H, CHAr), 6.92-7.01 (m, 3H, CHAr), 7.05-7.09 (m, 2H, CHAr), 7.15-7.16 
(m, 2H, CHAr), 11.80 (s, 1H, NH). 
13
C NMR (62.9 MHz, CDCl3): δ = 13.8 (MeCH2), 22.3, 27.9, 31.2, 33.55 (CH2), 55.5, 55.6 
(2xOMe), 103.7, 104.3, 110.2 (CH), 111.7 (C), 114.5, 115.3, 125.7, 130.2, 131.9, 132.2 (CH), 
134.0 (C), 146.1, 150.0, 154.0, 156.3, 159.9, 181.7 (C). 
MS (GC, 70eV): m/z (%) = 442 (M
+
, 100), 427 (90). 
HRMS (ESI): Calcd for C28H31N2O3 (M+H) 443.22564. Found 443.23317. 
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IR (ATR, cm
-1
): 
~  = 2928 (w), 1624 (s), 1601 (s), 1452 (s), 1263 (s), 1207 (s), 1123 (m), 
1109 (s), 883 (m), 867 (s), 787 (m), 704 (w), 661 (s). 
 
A.2.22. General procedure for the synthesis of compounds 3.2.14. 
 
Corresponding 1-(2-fluorophenyl)prop-2-yn-1-one derivative 3.2.2d (2 equiv.), appropriate 
amine (1 equiv.) and Li2CO3 (4 equiv.) were placed in a pressure tube under the flow of dry 
argon and dissolved in dry DMA (7 mL/1 mmol of 3.2.2). The mixture was heated at 160 C 
for 24-30 h (controlled by TLC). After the reaction was completed volatiles were evaporated 
under reduced pressure. The residue was purified by column chromatography over silica gel 
(Heptane : Ethyl acetate - 3:1). 
 
1,1'-(ethane-1,2diylbis(4,1-phenylene))bis(6-fluoro-2-(p-tolyl)quinolin-4(1H)-one) 
(3.2.14a). 
Starting from 1-(2,5-difluorophenyl)-3-p-tolylprop-2-yn-
1-one 3.2.3d (0.512 g, 2 mmol), 4-(4-
aminophenethyl)benzenamine (0.212 g, 1 mmol) and 
Li2CO3 (0.296 g, 4 mmol) in 7 mL DMA. 3.2.14a was 
isolated as yellow oil (0.335 g, 49%). 
1
H NMR (300 MHz, DMSO-d6): δ = 2.20 (br. s, 6H, 
2xMe), 2.85 (br. s, 4H, 2xCH2), 6.38 (s, 2H, CHAr), 6.82 
(dd, 2H, 
3
J = 9.4 Hz, 
3
J= 4.4 Hz, CHAr), 6.90-7.06 (m, 
16H, CHAr), 7.12-7.19 (m, 2H, CHAr), 8.11 (dd, 2H, 
3
J = 8.8 Hz, 
3
J = 3.0 Hz, CHAr). 
19
F NMR (282 MHz, CDCl3): δ = -117.6 (CF). 
13
C NMR (62.9 MHz, CDCl3): δ = 21.2 (Me), 37.3 (CH2), 110.8 (d, 
2
J = 22.3 Hz, CH), 112.0 
(CH), 120.1 (d, 
3
J = 8.8 Hz, CH), 128.4 (d, 
3
J = 8.8 Hz, CH), 127.5 (d, 
3
J = 6.7 Hz, C), 128.6, 
129.1, 129.6, 129.9 (CH), 132.7, 137.2, 138.6, 139.2, 141.9, 154.2 (C), 159.2 (d, 
1
J = 251.6 
Hz, CF), 176.9 (d, 
4
J = 2.5 Hz, C).  
MS (EI, 70eV): m/z (%) = 684 (M
+
, 100), 342 (44), 314 (10), 226 (43). 
HRMS (EI): Calcd for C46H34F2N2O2 (M
+
) 684.25829. Found 684.258764. 
IR (ATR, cm
-1
): 
~  = 3033 (w), 2920 (w), 1603 (s), 1510 (s), 1469 (s), 1384 (m), 1306 (s), 
1253 (w), 1180 (m), 1099 (w), 1021 (w), 927 (s), 854 (m), 817 (s), 725 (s), 632 (m), 596 (m), 
553 (s). 
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1,1'-(hexane-1,6diyl)bis(6-fluoro-2-(p-tolyl)quinolin-4(1H)-one) (3.2.14b). 
Starting from 1-(2,5-difluorophenyl)-3-p-tolylprop-2-yn-1-
one 3.2.3d (0.512 g, 2 mmol), hexane-1,6-diamine (0.116 
g, 1 mmol) and Li2CO3 (0.296 g, 4 mmol) in 7 mL DMA. 
3.2.14b was isolated as white solid (0.417 g, 71%), mp 
more than 350 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 0.80 (br. s, 4H, 
2xCH2), 1.41 (br. s, 4H, 2xCH2), 2.36 (s, 6H, Me), 3.96 (br. 
s, 4H, 2xCH2), 5.89 (s, 2H, CHAr), 7.28 (m, 8H, CHAr), 7.62-7.68 (m, 2H, CHAr), 7.84-7.90 
(m, 4H, CHAr). 
19
F NMR (282 MHz, CDCl3): δ = -117.6 (CF). 
13
C NMR Due to bed solubility it was not possible to measure.  
MS (GC, 70eV): m/z (%) = 588 (M
+
, 44), 266 (33), 207 (21), 150 (19). 
HRMS (ESI): Calcd for C38H35F2N2O2 (M+H) 589.26611. Found 589.26599. 
IR (ATR, cm
-1
): 
~  = 1613 (w), 1479 (s), 1417 (s), 1293 (w), 1154 (w), 1087 (w), 931 (w), 
859 (m), 828 (w), 740 (w). 
 
A.2.23. General procedure for the synthesis of 3-(2-halobenzoil)chromones 3.3.4: 
 
To a dry dichloromethane solution (10 mL/1 mmol 3.3.5) of corresponding enaminone 3.3.5 
(1 equiv.) was added dry pyridine (3 equiv.). The solution was set on stirring on ice bath. 
Afterwards corresponding halogenated benzoyl chloride 3.3.6 (1.1 equiv.) was added 
dropwise. The reaction mixture was stirred at room temperature for 8 h. After the reaction was 
completed volatiles were evaporated under reduced pressure. The residue was treated with 
water, filtered, dried in air, and purified by flash column chromatography. 
 
3-(2-bromobenzoil)-4H-chromen-4-one (3.3.4a).  
Starting from (E)-3-(dimethylamino)-1-(2-hydroxyphenyl)prop-2-en-1-
one 3.3.5a (1.911 g, 10 mmol), 2-bromobenzoyl chloride (2.387g, 11 
mmol) and pyridine (6.33 g, 30 mmol) in 100 mL DCM. 3.3.4a was 
isolated as white solid (2.67 g, 81%), mp 132-133 
o
C. 
1
H NMR (300 MHz, CDCl3): δ = 7.11-7.15 (m, 1H, CHAr), 7.26-7.30 (m, 1H, CHAr), 7.48-
7.58 (m, 3H, CHAr), 7.72-7.86 (m, 2H, CHAr), 8.25-8.32 (m, 1H, CHAr), 8.45 (s, 1H, CHAr). 
13
C NMR (75.5 MHz, DMSO-d6): δ = 118.7, 124.2, 124.5, 125.3 (CH), 126.1, 128.5 (C), 
N
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128.6, 129.4 (CH), 129.5 (C), 133.6, 134.8, 136.9 (CH), 155.8, 158.8, 174.3, 191.6 (C). 
 
3-(2-chlorobenzoil)-4H-chromen-4-one (3.3.4b).  
Starting from (E)-3-(dimethylamino)-1-(2-hydroxyphenyl)prop-2-en-1-
one 3.3.5a (1.911 g, 10 mmol), 2-bromobenzoyl chloride (1.925 g, 11 
mmol) and pyridine (6.33 g, 30 mmol) in 100 mL DCM. 3.3.4b was 
isolated as white solid (2.28 g, 80%), mp 130-131 
o
C. 
1
H NMR (300 MHz, CDCl3): δ = 7.08-7.10 (m, 1H, CHAr), 7.20-7.28 (m, 1H, CHAr), 7.50-
7.55 (m, 3H, CHAr), 7.80-7.90 (m, 2H, CHAr), 8.30-8.35 (m, 1H, CHAr), 8.41 (s, 1H, CHAr). 
13
C NMR (75.5 MHz, DMSO-d6): δ = 118.9, 124.4, 124.6, 125.1 (CH), 126.0, 128.8 (C), 
128.9, 129.3 (CH), 129.5 (C), 133.8, 135.0, 136.9 (CH), 155.9, 159.0, 174.5, 192.0 (C). 
 
3-(2-fluorobenzoil)-4H-chromen-4-one (3.3.4c).  
Starting from (E)-3-(dimethylamino)-1-(2-hydroxyphenyl)prop-2-en-1-
one 3.3.5a (1.911 g, 10 mmol), 2-fluorobenzoyl chloride (1.744 g, 11 
mmol) and pyridine (6.33 g, 30 mmol) in 100 mL DCM. 3.3.4c was 
isolated as white solid (2.09 g, 78%), mp 141-143 
o
C. 
1
H NMR (300 MHz, CDCl3): δ = 7.04-7.10 (m, 1H, CHAr), 7.25 (dt, 1H, 
3
J = 7.6 Hz, 
4
J = 1.1 
Hz, CHAr), 7.41-7.54 (m, 3H, CHAr), 7.68-7.76 (m, 2H, CHAr), 8.20 (dt, 1H, 
3
J = 7.8 Hz, 
4
J = 
1.7 Hz, CHAr), 8.43 (s, 1H, CHAr). 
19
F NMR (282 MHz, CDCl3): δ = -111.4. 
13
C NMR (75.5 MHz, CDCl3): δ = 115.7, 116.0, 118.3 (CH), 124.4 (d, J = 3.1 Hz, CH), 
125.0, 125.8 (C), 126.2, 126.4 (CH), 127.4 (d, 
3
J = 12.6 Hz, C), 130.5 (d, J = 2.4 Hz, CH), 
134.3 (CH), 156.0, 159.5 (CH), 162.1 (d, 
1
J = 253.5 Hz, CF), 174.5, 188.7 (C). 
MS (GC, 70eV): m/z (%) = 268 (M
+
, 1), 249 (100) 
HRMS (EI): Calcd for C16H9FO3 (M
+
) 268.05302. Found 268.05297. 
IR (ATR, cm
-1
): ~  = 2922 (w), 1664 (m), 1642 (s), 1608 (s), 1563 (s), 1460 (s), 1388 (m), 
1340 (m), 1300 (s), 1239 (m), 1207 (m), 1136 (m), 1099 (m), 973 (m), 864 (s), 757 (s), 706 
(m), 629 (m). 
 
6-methyl-3-(2-fluorobenzoil)-4H-chromen-4-one (3.3.4d).  
Starting from (E)-3-(dimethylamino)-1-(2-hydroxy-5-
methylphenyl)prop-2-en-1-one 3.3.5b (2.05 g, 10 mmol), 2-
fluorobenzoyl chloride (1.744 g, 11 mmol) and pyridine (6.33 g, 
O
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30 mmol) in 100 mL DCM. 3.3.4d was isolated as white solid (2.256 g, 80%), mp 97-99 
o
C. 
1
H NMR (300 MHz, CDCl3): δ = 2.27 (s, 3H, Me), 6.86-6.93 (m, 1H, CHAr), 7.06-7.11 (m, 
1H, CHAr), 7.22 (s, 1H, CHAr), 7.31-7.39 (m, 2H, CHAr), 7.56 (dt, 1H, 
3
J = 7 Hz, 
4
J = 2 Hz, 
CHAr), 7.81-7.82 (m, 1H, CHAr), 8.24 (s, 1H, CHAr). 
19
F NMR (282 MHz, CDCl3): δ = -111.4 (CF). 
13
C NMR (75.5 MHz, CDCl3): δ = 20.9 (Me), 100.6 (CH), 115.8 (d, 
2
J = 22.1 Hz, CH), 118.6 
(CH), 124.4 (d, J = 3.4 Hz, CH), 124.6, 125.3, 125.6 (C), 125.8 (CH), 127.4 (d, 
3
J = 12.7 Hz, 
C), 130.4 (d, J = 1.9 Hz, CH), 134.3 (d, 
3
J = 8.8 Hz, CH), 135.6 (CH), 136.4, 154.3 (C), 159.4 
(CH), 161.2 (d, 
1
J = 254.7 Hz, CF), 174.6, 188.9 (C). 
MS (GC, 70eV): m/z (%) = 282 (M
+
, 70), 263 (42), 253 (100), 235 (39), 187 (25), 135 (28), 
95 (38). 
HRMS (EI): Calcd for C17H11FO3 (M
+
) 282.06867. Found 282.06832. 
IR (ATR, cm
-1
): ~  = 1660 (m), 1612 (s), 1555 (m), 1478 (s), 1452 (m), 1372 (w), 1311 (S), 
1216 (m), 1154 (w), 1127 (w), 1103 (m), 978 (w), 941 (w), 908 (m), 863 (m), 820 (m), 802 
(m), 781 (s), 766 (s), 637 (s). 
 
7-methoxy-3-(2-fluorobenzoil)-4H-chromen-4-one (3.3.4e). 
Starting from (E)-3-(dimethylamino)-1-(2-hydroxy-4-
methoxyphenyl)prop-2-en-1-one 3.3.5c (2.211 g, 10 mmol), 2-
fluorobenzoyl chloride (1.744 g, 11 mmol) and pyridine (6.33 g, 
30 mmol) in 100 mL DCM. 3.3.4e was isolated as light brown 
solid (2.041 g, 88%), mp 154-155 
o
C. 
1
H NMR (300 MHz, CDCl3): δ = 3.90 (s, 3H, OMe), 6.89 (d, 1H, 
4
J = 2.4 Hz, CHAr), 6.97-
7.09 (m, 2H, CHAr), 7.22-7.27 (m, 1H, CHAr), 7.48-7.56 (m, 1H, CHAr), 7.72 (dt, 1H, 
3
J = 7.6 
Hz, 
4
J = 1.7 Hz,CHAr), 8.10 (d, 1H, 
3
J = 8.9 Hz, CHAr), 8.35 (s, 1H, CHAr). 
19
F NMR (282 MHz, CDCl3): δ = -111.4 (CF). 
13
C NMR (75.5 MHz, CDCl3):δ = 54.9 (OMe), 100.6 (CH), 115.4 (d, 
2
J = 22.3 Hz, CH), 
115.9 (CH), 118.4 (C), 124.2 (d, J = 3.2 Hz, CH), 125.7 (C), 127.4 (d, 
3
J = 13.5 Hz, C), 127.6 
(CH), 130.3 (d, J = 3.1 Hz, CH), 134.2 (d, 
3
J = 9.7 Hz, CH), 158.1 (CH), 160.2 (d, 
1
J = 254.1 
Hz, CF), 172.9, 187.9 (C). 
MS (GC, 70eV): m/z (%) = 298 (M
+
, 61), 279 (35), 269 (100), 251 (28), 151 (25). 
HRMS (EI): Calcd for C17H11FO4 (M
+
) 298.06359. Found 298.06287. 
IR (ATR, cm
-1
): ~  = 2852 (w), 1683 (m), 1569 (m), 1613 (s), 1454 (m), 1390 (w), 1356 (w), 
1313 (m), 1278 (s), 1203 (m), 1163 (m), 1135 (m), 1089 (m), 1024 (m), 867 (m), 844 (m), 
O
O O F
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777 (s), 749 (s), 649 (m), 572 (m). 
 
6-chloro-3-(2-fluorobenzoil)-4H-chromen-4-one (3.3.4f). 
Starting from (E)-1-(5-chloro-2-hydroxyphenyl)-3-
(dimethylamino)prop-2-en-1-one 3.3.5d (2.255 g, 10 mmol), 2-
fluorobenzoyl chloride (1.744 g, 11 mmol) and pyridine (6.33 g, 30 
mmol) in 100 mL DCM. 3.3.4f was isolated as yellow solid (2.148 
g, 71%), mp 97-99 
o
C. 
1
H NMR (300 MHz, CDCl3): δ = 7.07 (ddd, 1H, 
3
J = 10.7 Hz, 
4
J = 8.3 Hz, 
5
J = 0.9 Hz, CHAr), 
7.24-7.30 (m, 1H, CHAr), 7.48 (d, 1H, 
3
J = 8.9 Hz, CHAr), 7.50-7.58 (m, 1H, CHAr), 7.65 (dd, 
1H, 
3
J = 8.9 Hz, 
4
J = 2.6 Hz, CHAr), 7.72-7.77 (m, 1H, CHAr), 8.16 (d, 1H, 
4
J = 2.6 Hz, CHAr), 
8.41 (s, 1H, CHAr). 
19
F NMR (282 MHz, CDCl3): δ = -111.2 (CF). 
13
C NMR (75.5 MHz, CDCl3): δ = 115.9 (d, 
2
J = 21.8 Hz, CH), 120.0 (CH), 124.5 (d, J = 3.4 
Hz, CH), 125.8 (CH), 128.9 (C), 127.1 (d, 
3
J = 10.9 Hz, C), 130.5 (CH), 132.3 (C), 134.5, 
134.6 (CH), 154.3 (C), 159.4 (CH), 161.2 (d, 
1
J = 253.7 Hz, CF), 173.4, 188.1 (C). 
MS (GC, 70eV): m/z (%) = 302 (M
+
, 69), 273 (100), 255 (35), 207 (32), 155 (31), 123 (69), 
95 (51). 
HRMS (EI): Calcd for C16H8ClO2 (M
+
) 303.98664. Found 303.98572. 
IR (ATR, cm
-1
): ~  = 3056 (w), 1644 (s), 1608 (s), 1560 (m) 1482 (w), 1463 (s), 1436 (m), 
1335 (m), 1315 (s), 1260 (m), 1211 (m), 1140 (m), 1101 (m), 1037 (w), 985 (m), 951 (m), 
887 (m), 863 (m), 835 (m), 820 (s), 783 (s), 761 (s), 735 (m), 674 (m), 631 (s).  
 
3-(2-fluorobenzoil)-6-chloro-7-methyl-4H-chromen-4-one (3.3.4g). 
Starting from (E)-1-(5-chloro-2-hydroxy-4-methylphenyl)-3-
(dimethylamino)prop-2-en-1-one 3.3.5e (2.391 g, 10 mmol), 2-
fluorobenzoyl chloride (1.744 g, 11 mmol) and pyridine (6.33 g, 
30 mmol) in 100 mL DCM. 3.3.4g was isolated as yellow solid 
(1.836 g, 58%), mp 143-144 
o
C. 
1
H NMR (300 MHz, CDCl3): δ = 2.51 (s, 3H, Me), 7.03-7.10 (m, 1H, CHAr), 7.24-7.29 (m, 
1H, CHAr), 7.40 (s, 1H, CHAr), 7.50-7.58 (m, 1H, CHAr), 7.74 (dt, 1H, 
3
J = 7.5 Hz, 
4
J = 1.8 
Hz, CHAr), 8.15 (s, 1H, CHAr), 8.38 (s, 1H, CHAr). 
19
F NMR (282 MHz, CDCl3): δ = -117.3 (CF). 
13
C NMR (75.5 MHz, CDCl3): δ = 20.9 (Me), 100.6 (CH), 115.9 (d, 
2
J = 22.6 Hz, CH), 120.1 
O
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(CH), 124.0 (C), 124.4 (d, J = 2.8 Hz, CH), 125.7 (C), 126.1 (CH), 127.2 (d, 
3
J = 12.2 Hz, C), 
130.5 (d, J = 2.0 Hz, CH), 132.9 (C), 134.5 (d, 
3
J = 7.9 Hz, CH), 143.9, 154.3 (C), 161.2 (d, 
1
J = 253.6 Hz, CF), 173.3, 188.4 (C). 
MS (GC, 70eV): m/z (%) = 316 (M
+
, 65), 287 (100), 269 (34), 221 (21), 169 (25), 123 (36), 
95 (39). 
HRMS (EI): Calcd for C17H10O3FCl (M
+
) 316.02970. Found 316.02908. 
IR (ATR, cm
-1
): ~  = 3040 (w), 1651 (s), 1620 (s), 1547 (m), 1486 (w), 1452 (s), 1412 (m), 
1334 (m), 1308 (s), 1259 (m), 1226 (m), 1183 (m), 1145 (m), 1126 (m), 1104 (m), 1039 (w), 
1003 (m), 966 (m), 934 (w), 910 (m), 871 (s), 797 (m), 768 (s), 750 (s), 704 (w), 667 (m), 638 
(s). 
 
3-(2,4-fluorobenzoil)-4H-chromen-4-one (3.3.4h).  
Starting from (E)-3-(dimethylamino)-1-(2-hydroxyphenyl)prop-2-
en-1-one 3.3.5a (1.911 g, 10 mmol), 2,4-difluorobenzoyl chloride 
(1.942 g, 11 mmol) and pyridine (6.33 g, 30 mmol) in 100 mL 
DCM. 3.3.4h was isolated as brown solid (1.716 g, 60%), mp 138-
140 
o
C. 
1
H NMR (300 MHz, CDCl3): δ = 6.78-7.03 (m, 3H, CHAr), 7.43-7.55 (m, 1H, CHAr), 7.70-
7.82 (m, 1H, CHAr), 8.03-8.10 (m, 1H, CHAr), 8.20-8.23 (m, 1H, CHAr), 8.44 (s, 1H, CHAr). 
19
F NMR (282 MHz, CDCl3): δ = -106.0 (d, 
3
J = 13.1 Hz, CF), -102.0 (d, 
3
J = 13.1 Hz, CF).  
13
C NMR (75.5 MHz, CDCl3): δ = 104.3 (t, 
2
J = 25.9 Hz, CH), 112.0 (dd, 
2
J = 21.7 Hz, J = 
3.8 Hz, CH), 118.3 (CH), 124.0 (dd, 
3
J = 12.6 Hz, J = 3.8 Hz, C), 124.8, 125.7 (C), 126.2, 
126.3 (CH), 132.3 (dd, 
3
J = 10.6 Hz, J = 3.8 Hz, CH), 138.4 (CH), 156.0 (C), 159.5 (CH), 
161.9 (dd, 
1
J = 237.8 Hz, 
3
J = 12.6 Hz, CF), 165.9 (dd, 
1
J = 237.8 Hz, 
3
J = 12.6 Hz, CF), 
174.4 (d, J = 2.2 Hz, C=O), 187.3 (C=O). 
MS (GC, 70eV): m/z (%) = 286 (M
+
, 85), 267 (48), 257 (100), 239 (57), 173 (30), 141 (45). 
HRMS (EI): Calcd for C16H8F2O3 (M
+
) 286.04360. Found 286.04384. 
IR (ATR, cm
-1
): ~  = 3080 (w), 1640 (s), 1609 (s), 1487 (w), 1464 (s), 1426 (m), 1384 (m), 
1348 (m), 1294 (m), 1213 (m), 1138 (m), 1096 (s), 1028 (w), 977 (m), 855 (s), 802 (w), 757 
(s), 662 (m), 302 (m). 
 
3-(2,5-fluorobenzoil)-4H-chromen-4-one (3.3.4i).  
O
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Starting from (E)-3-(dimethylamino)-1-(2-hydroxyphenyl)prop-2-en-
1-one 3.3.5a (1.911 g, 10 mmol), 2,5-difluorobenzoyl chloride (1.942 
g, 11 mmol) and pyridine (6.33 g, 30 mmol) in 100 mL DCM. 3.3.4i 
was isolated as yellow solid (2.717 g, 95%), mp 138-140 
o
C. 
1
H NMR (300 MHz, CDCl3): δ = 7.00-7.08 (m, 1H, CHAr), 7.17-7.23 (m, 1H, CHAr), 7.38-
7.54 (m, 2H, CHAr), 7.70-7.75 (m, 2H, CHAr), 8.20 (dd, 1H, 
3
J = 8.0 Hz, 
4
J = 1.6 Hz, CHAr), 
8.45 (s, 1H, CHAr). 
19
F NMR (282 MHz, CDCl3): δ = -117.9 (d, J = 17.7 Hz, CF), -117.2 (d, J = 17.7 Hz, CF). 
13
C NMR (75.5 MHz, CDCl3): δ = 116.6 (dd, 
2
J = 25.5 Hz, J = 3.3 Hz, CH), 117.2 (dd, 
2
J = 
25.5 Hz, J = 8.2 Hz, CH), 118.3 (CH), 120.7 (dd, 
2
J = 25.5 Hz, J = 9.4 Hz, CH), 124.9, 125.3 
(C), 126.3 (d, J = 5.3 Hz, CH), 128.4 (dd, J = 16.7 Hz, J = 7.3 Hz, CH), 134.5 (CH), 156.0 
(C), 157.1 (d, 
1
J = 247.2 Hz, CF), 158.6 (d, J = 242.2 Hz, CF), 159.8 (CH), 174.4, 187.6 (C). 
 MS (GC, 70eV): m/z (%) = 286 (M
+
, 80), 267 (57), 257 (100), 239 (66), 173 (35), 141 (22), 
121 (39). 
HRMS (EI): Calcd for C16H8F2O3 (M
+
) 286.04360. Found 286.043440. 
IR (ATR, cm
-1
): ~  = 3068 (w), 1636 (s), 1614 (m), 1566 (m), 1483 (m), 1461 (s), 1422 (m), 
1392 (m), 1344 (m), 1316 (m), 1287 (w), 1260 (m), 1230 (m), 1186 (s), 1131 (m), 1000 (w), 
961 (w), 929 (w), 891 (m), 833 (s), 773 (s), 750 (s), 700 (m), 637 (m), 591 (w), 540 (m). 
 
3-(2,5-fluorobenzoil)-6-bromo-4H-chromen-4-one (3.3.4j). 
Starting from (E)-1-(5-bromo-2-hydroxyphenyl)-3-
(dimethylamino)prop-2-en-1-one 3.3.5f (2.700 g, 10 mmol), 2,5-
difluorobenzoyl chloride (1.942 g, 11 mmol) and pyridine (6.33 g, 
30 mmol) in 100 mL DCM. 3.3.4j was isolated as white solid 
(2.737 g, 675%), mp 153-155 
o
C. 
1
H NMR (300 MHz, CDCl3): δ = 7.00-7.08 (m, 1H, CHAr), 7.17-7.27 (m, 1H, CHAr), 7.38-
7.44 (m, 2H, CHAr), 7.80 (dd, 1H, 
3
J = 8.0 Hz, 
4
J = 2.5 Hz, CHAr), 8.31 (d, 1H, 
4
J = 3 Hz, 
CHAr), 8.42 (s, 1H, CHAr). 
19
F NMR (282 MHz, CDCl3): δ = -117.7 (d, J = 18 Hz, CF), -117.0 (d, J = 18 Hz, CF). 
13
C NMR (75.5 MHz, CDCl3): δ = 116.6 (dd, 
2
J = 25.6 Hz, J = 3.3 Hz, CH), 117.2 (dd, 
2
J = 
25.6 Hz, J = 8.7 Hz, CH), 119.9 (C), 120.2 (CH), 121.0 (dd, 
2
J = 25.6 Hz, J = 8.6 Hz, CH), 
125.4, 126.1 (C), 128.0 (dd, 
3
J = 14.3 Hz, J = 7.2 Hz, C), 129.0 (CH), 137.5 (CH), 154.8 (C), 
157.2 (d, 
1
J = 248.4 Hz, CF), 158.6 (d, 
1
J = 280.1 Hz, CF), 159.7 (CH), 173.1 (d, J = 2.3 Hz, 
C=O), 187.0 (C=O). 
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MS (GC, 70eV): m/z (%) = 366 (M
+
, 91), 365 (35), 347 (69), 346 (12), 337 (100), 336 (48), 
335 (95), 319 (68), 317 (64), 251 (36), 199 (32), 141 (50), 113 (62). 
HRMS (EI): Calcd for C16H7F2O3Br (M
+
) 363.95411. Found 363.954477. 
IR (ATR, cm
-1
): ~  = 3067 (w), 1645 (s), 1606 (m), 1557 (m), 1488 (m), 1459 (s), 1423 (m), 
1372 (w), 1329 (m), 1307 (m), 1278 (m), 1251 (m), 1192 (m), 1177 (s), 1126 (m), 1093 (m), 
1062 (w), 1005 (w), 932 (w), 893 (m), 878 (m), 824 (s), 804 (s), 769 (m), 750 (s), 676 (s), 640 
(m), 603 (m), 539 (m). 
 
3-(2,6-fluorobenzoil)-4H-chromen-4-one (3.3.4k).  
Starting from (E)-3-(dimethylamino)-1-(2-hydroxyphenyl)prop-2-en-
1-one 3.3.5a (1.911 g, 10 mmol), 2,6-difluorobenzoyl chloride (1.942 
g, 11 mmol) and pyridine (6.33 g, 30 mmol) in 100 mL DCM. 3.3.4k 
was isolated as white solid (1.888 g, 66%), mp 114-116 
o
C. 
1
H NMR (300 MHz, CDCl3): δ = 6.92-6.99 (m, 2H, CHAr), 7.37-7.48 (m, 2H, CHAr), 7.51-
7.54 (m, 1H, CHAr), 7.69-7.75 (m, 1H, CHAr), 8.19 (dd, 1H, 
3
J = 7.9 Hz, 
4
J = 1.5 Hz, CHAr), 
8.64 (s, 1H, CHAr). 
19
F NMR (282 MHz, CDCl3): δ = -113.1 (CF). 
13
C NMR (75.5 MHz, CDCl3): δ = 111.7 (dd, 
2
J = 22.8 Hz, J = 2.6 Hz, CH), 118.3 (CH), 
123.8, 125.1, 126.4 (CH), 132.4 (t, 
3
J = 10.4 Hz, CH), 134.5 (CH), 155.9 (C), 160.1 (dd, 
1
J = 
252.6 Hz, J = 6.5 Hz, CF), 161.6 (CH), 174.2, 185.1 (C). 
MS (GC, 70eV): m/z (%) = 286 (M
+
, 75), 267 (44), 257 (27), 239 (100), 173 (30), 141 (28), 
121 (28). 
HRMS (EI): Calcd for C16H8F2O3 (M
+
) 286.04361. Found 286.043442. 
IR (ATR, cm
-1
): ~  = 3074 (w), 1674 (m), 1656 (s), 1611 (m), 1552 (m), 1459 (s), 1384 (m), 
1307 (m), 1286 (m), 1265 (m), 1232 (m), 1206 (m), 1144 (m), 994 (s), 964 (s), 865 (m), 789 
(s), 760 (s), 717 (s), 680 (m), 591 (m). 
 
A.2.24. General procedure for the synthesis of compounds 3.3.7-3.3.13: 
 
Corresponding ortho-F-benzoyl chromone derivative 3.3.4 (1 equiv.), appropriate amine or 
aminoheterocycle (2 equiv.) and K2CO3 (2 equiv.) were placed in a pressure tube under the 
flow of dry argon and dissolved in dry DMF (7 mL/1 mmol of 3.3.4). The mixture was heated 
at 130 C for 24-30 h (controlled by TLC). After the reaction was completed volatiles were 
evaporated under reduced pressure. The residue was purified by column chromatography over 
O
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silica gel (Heptane : Ethyl acetate - 3:1) or by recrystalisation from appropriate solvant. 
 
1-tert-butyl-3-(2-hydroxy benzoyl)quinolin-4(1H)-one (3.3.7a). 
Starting from 3-(2-fluorobenzoil)-4H-chromen-4-one 3.3.4a (0.268 g, 1 
mmol), tert-buthyl amine (0.146 g, 2 mmol) and K2CO3 (0.276 g, 2 
mmol) in 7 mL DMF. 3.3.7a was isolated as colourless solid (0.177 g, 
55%), mp 230-231 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 1.15 (s, 9H, t-Bu), 6.34 (d, 1H, 
3
J = 
10.6 Hz, CHAr), 7.01 (d, 1H, 
3
J = 8.3 Hz, CHAr), 7.16 (t, 1H, 
3
J = 8.0 Hz, CHAr), 7.51 (t, 1H, 
3
J = 7.0 Hz, CHAr), 7.77-7.87 (m, 2H, CHAr), 7.97 (t, 1H, 
3
J = 8.1 Hz, CHAr), 8.06 (d, 1H, 
3
J = 
7.7 Hz, CHAr), 8.08 (d, 1H, 
3
J = 7.7 Hz, CHAr), 16.09 (br. s, 1H, OH). 
13
C NMR (62.9 MHz, DMSO-d6): δ = 30.1 (t-Bu), 49.6 (Ct-Bu), 80.1 (CH), 111.8, 115.8 (C), 
118.4, 118.6, 120.9, 123.6, 123.9, 125.0, 125.2, 133.3, 134.1 (CH), 154.4, 154.6, 155.1, 173.4 
(C).  
MS (GC, 70eV): m/z (%) = 321 (M
+
, 30), 264 (64), 249 (100). 
HRMS (EI): Calcd for C20H19NO3 (M
+
) 321.13594. Found 321.136189. 
IR (ATR, cm
-1
): ~  = 3303 (w), 2965 (w), 1638 (s), 1604 (m), 1561 (m), 1514 (w), 1465 (s), 
1419 (s), 1360 (w), 1327 (w), 1311 (w), 1258 (m), 1205 (m), 1142 (m), 1099 (m), 1023 (w), 
949 (w), 900 (w), 869 (m), 840 (m), 755 (s), 709 (s), 673 (m), 614 (m), 555 (m). 
 
1-cyclohexyl-3-((E)-(cyclohexylimino)(2-hydroxyphenyl)methyl)quinolin-4(1H)-one 
(3.3.8b). 
Starting from 3-(2-fluorobenzoil)-4H-chromen-4-one 3.3.4a (0.268 g, 1 
mmol), cyclohexyl amine (0.198 g, 2 mmol) and K2CO3 (0.276 g, 2 
mmol) in 7 mL DMF. 3.3.8b was isolated as yellow solid (0.197 g, 46%), 
mp 230-231 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 1.20-1.80 (m, 20H, cyclohexyl), 
3.30 (br. s, 1H, cyclohexyl), 4.73 (br. s, 1H, cyclohexyl), 6.64 (t, 1H, 
3
J = 
8.1 Hz, CHAr), 6.86 (d, 1H,
3
J = 8.1 Hz, CHAr), 6.86 (d, 1H, 
3
J = 8.1 Hz, 
CHAr), 7.25 (t, 1H, 
3
J = 7.1 Hz, CHAr), 7.47 (t, 1H, 
3
J = 7.1 Hz, CHAr), 7.83 (t, 1H, 
3
J = 8.1 
Hz, CHAr), 8.06 (d, 1H, 
3
J = 9.1 Hz, CHAr), 8.22-8.29 (m, 2H, CHAr), 16.09 (s, 1H, OH). 
13
C NMR (75.5 MHz, DMSO-d6): δ = 23.4, 24.6, 25.1, 25.2, 31.4, 31.6, 32.9, 33.4 (cyclohxyl 
CH2), 57.7, 58.8 (cyclohexyl CH), 113.9 (C), 116.4, 117.1, 117.5 (CH), 119.8 (C), 123.8, 
126.2 (CH), 128.2, 128.9 (C), 130.5, 131.9, 132.6, 138.9 (CH), 139.9, 163.1, 167.7, 172.9 (C). 
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 MS (GC, 70eV): m/z (%) = 428 (M
+
, 90), 411 (26), 345 (27), 332 (100), 250 (35). 220 (18), 
171 (14). 
HRMS (EI): Calcd for C28H32N2O2 (M
+
) 428.24638. Found 428.24655. 
IR (ATR, cm
-1
): ~  = 3307 (w), 2922 (m), 2848 (w), 1626 (m), 1582 (m), 1554 (m), 1486 (m), 
1445 (w), 1361 (m), 1309 (w), 1257 (w), 1216 (m), 1190 (w), 1150 (w), 1099 (w), 1002 (w), 
913 (w), 889 (m), 859 (w), 838 (w), 750 (s), 709 (m), 635 (w), 575 (w), 534 (w). 
 
1-cyclopropyl-3-((E)-(cyclopropylimino)(2-hydroxyphenyl)methyl)quinolin-4(1H)-one 
(3.3.8c). 
Starting from 3-(2-fluorobenzoil)-4H-chromen-4-one 3.3.4a (0.268 g, 1 
mmol), cyclopropyl amine (0.114 g, 2 mmol) and K2CO3 (0.276 g, 2 
mmol) in 7 mL DMF. 3.3.8c was isolated as yellowviscous oil (0.165 g, 
48%). 
1
H NMR (300 MHz, DMSO-d6): δ = 0.84-1.06 (m, 4H, cyclopropyl, 
CH2), 1.24-1.31 (m, 4H, cyclopropyl, CH2), 2.84-2.94 (m, 1H, 
cyclopropyl CH), 3.44-3.51 (m, 1H, cyclopropyl CH), 6.64 (t, 1H, 
3
J = 7.2 Hz, CHAr), 6.89 (d, 
1H, 
3
J = 7.7 Hz, CHAr), 7.04-7.07 (m, 1H, CHAr), 7.14-7.20 (m, 1H, CHAr), 7.71-7.78 (m, 2H, 
CHAr), 7.99 (d, 1H, 
3
J = 8.6 Hz, CHAr), 8.47 (d, 1H, 
3
J = 8.3 Hz, CHAr), 14.51 (s, 1H, OH). 
13
C NMR (62.9 MHz, DMSO-d6): δ = 7.8, 10.0 (cyclopropyl CH2), 33.9, 34.0 (C), 114.3 (C), 
116.8, 117.4, 117.1 (CH), 120.1 (C), 124.1, 125.8 (CH), 125.9 (C), 130.3, 131.3, 132.3 (CH), 
141.3 (C), 142.8 (CH), 161.0, 167.6, 173.4 (C). 
MS (GC, 70eV): m/z (%) = 344 (M
+
, 4), 238 (100), 221 (18), 147 (76), 121 (43). 
HRMS (ESI): Calcd for C22H21N2O2 (M+H) 345.15975. Found 345.16062. 
IR (ATR, cm
-1
): ~  = 2922 (w), 1620 (m), 1586 (s), 1480 (s), 1401 (w), 1339 (m), 1247 (m), 
1166 (m), 1113 (w), 1035 (w), 943 (w), 866 (w), 752 (s), 704 (m), 644 (m). 
 
3-((E)-(2-hydroxyphenyl)(phenethylimino)methyl)-1-phenethylquinolin-4(1H)-one 
(3.3.8d). 
Starting from 3-(2-fluorobenzoil)-4H-chromen-4-one 3.3.4a (0.268 g, 1 
mmol), phenethyl amine (0.242 g, 2 mmol) and K2CO3 (0.276 g, 2 mmol) 
in 7 mL DMF. 3.3.8d was isolated as yellow solid (0.349 g, 74%), mp 
172-174 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 2.85-2.90 (m, 2H, CH2), 3.10-3.14 
(m, 2H, CH2), 3.34-3.52 (m, 2H, CH2), 4.55-4.63 (m, 2H, CH2), 6.62 (t, 
N
O N OH
 
N
O
Ph
N
Ph
OH
 
 207 
 
1H, 
3
J = 7.5 Hz, CHAr), 6.76-6.83 (m, 2H, CHAr), 7.07-7.30 (m, 11H, CHAr), 7.50 (t, 1H, 
3
J = 
7.6 Hz, CHAr), 7.64 (s, 1H, CHAr), 7.84-8.00 (m, 2H, CHAr), 8.25 (d, 1H, 
3
J = 7.6 Hz, CHAr), 
15.4 (s, 1H, OH). 
13
C NMR (75.5 MHz, DMSO-d6): δ = 34.0, 36.1, 52.3, 53.4 (CH2), 113.1 (C), 117.1, 117.2, 
117.3 (CH), 119.4 (C), 124.1, 126.0, 126.2, 126.6, 128.3, 128.4, 128.7, 128.9, 130.6, 132.0, 
132.6 (CH), 137.2, 139.2, 139.7 (C), 143.5 (CH), 162.3, 169.6, 172.9. 
MS (GC, 70eV): m/z (%) = 472 (M
+
, 100), 455 (20), 381 (18), 367 (35), 354 (98), 262 (26), 
105 (97). 
HRMS (ESI): Calcd for C32H29N2O2 (M+H) 473.22336. Found 473.22235. 
IR (ATR, cm
-1
): ~  = 3027 (w), 1712 (w), 1660 (w), 1623 (m), 1605 (m), 1598 (m), 1553 1486 
(m), 1451 (m), 1375 (m), 1338 (m), 1307 (m), 1229 (m), 1183 (m), 1149 (m), 1082 (m), 1000 
(m), 926 (m), 855 (m), 742 (s), 694 (s), 627 (m), 559 (m). 
 
1-hexyl-3-((E)-(hexylimino)(2-hydroxyphenyl)methyl)quinolin-4(1H)-one (3.3.8e). 
Starting from 3-(2-fluorobenzoil)-4H-chromen-4-one 3.3.4a (0.268 g, 1 
mmol), hexyl amine (0.202 g, 2 mmol) and K2CO3 (0.276 g, 2 mmol) in 
7 mL DMF. 3.3.8e was isolated as yellow viscous oil (0.281 g, 65%). 
1
H NMR (300 MHz, CDCl3): δ = 0.53-0.60 (m, 6H, hexyl), 0.94-1.12 (m, 
12H, hexyl), 1.37-1.63 (m, 4H, hexyl), 3.19 (br.s, 2H, CH2 hexyl), 3.88 (t, 2H, 
3
J = 7.1 Hz, 
CH2), 6.30-6.35 (m, 1H, CHAr), 6.70 (d, 1H, 
3
J = 8.3 Hz, CHAr), 6.83 (dd, 1H, 
3
J = 8.0 Hz, 
4
J 
= 1.7 Hz, CHAr), 6.92-6.97 (m, 1H, CHAr), 7.16-7.26 (m, 3H, CHAr), 7.44-7.50 (m, 1H, CHAr), 
8.23 (dd, 1H, 
3
J = 8.1 Hz, 
4
J = 1.5 Hz, CHAr), 15.6 (s, 1H, OH). 
13
C NMR (75.5 MHz, CDCl3): δ = 13.8, 14.0 (Me), 22.4, 22.5, 26.4, 27.1, 28.8, 30.5, 31.2, 
31.5, 51.2, 53.7 (CH2), 114.8 (C), 115.6, 116.8, 118.5 (CH), 119.6 (C), 124.4 (CH), 127.1 (C), 
127.7, 130.4, 132.3, 132.6 (CH), 139.3 (C), 142.6 (CH), 164.6, 168.2, 174.0 (C). 
MS (GC, 70eV): m/z (%) = 432 (M
+
, 74), 375 (100), 334 (72), 248 (28). 
HRMS (EI): Calcd for C28H36N2O2 (M
+
) 432.27713. Found 432.27756. 
IR (ATR, cm
-1
): ~  = 3038 (w), 2924 (s), 2854 (m), 1621 (s), 1603 (s), 1577 (s), 1552 (s), 
1489 (s), 1451 (m), 1413 (m), 1389 (m), 1345 (m), 1311 (m), 1269 (m), 1232 (s), 1176 (m), 
1152 (m), 1055 (w), 966 (w), 864 (w), 824 w), 786 (w), 753 (s), 706 (m), 660 (w), 625 (w), 
529 (w). 
 
1-cyclopentyl-3-((Z)-(cyclopentylimino)(2-hydroxy-4-methoxyphenyl)methyl)quinolin-
4(1H)-one (3.3.8f). 
N
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Starting from 7-methoxy-3-(2-fluorobenzoil)-4H-chromen-4-one 
3.3.4e (0.298 g, 1 mmol), cyclopentyl amine (0.170 g, 2 mmol) and 
K2CO3 (0.276 g, 2 mmol) in 7 mL DMF. 3.3.8f was isolated as 
yellow solid (0.237 g, 55%), mp 220-222 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 1.56-2.03 (m, 14H, 
cyclopentyl), 2.27-2.36 (m, 2H, cyclopentyl), 3.76 (s, 3h, OMe), 
3.83-3.90 (m, 1H, NCH), 4.97-5.04 (m, 1H, NCH), 6.09 (dd, 1H, 
3
J 
= 8.8 Hz, 
4
J = 2.4 Hz, CHAr), 6.35 (d, 1H, 
4
J = 2.6 Hz, CHAr), 6.88 (d, 1H, 
3
J = 9.0 Hz, CHAr), 
7.43-7.49 (m, 1H, CHAr), 7.59 (s, 1H, CHAr), 7.68-7.79 (m, 2H, CHAr), 8.52-8.56 (m, 1H, 
CHAr), 12.71 (br. s, 1H, OH). 
13
C NMR (75.5 MHz, DMSO-d6): δ = 23.8, 24.2, 24.3, 32.2, 32.3, 32.4, 34.2, 35.1 
(cyclopentyl CH2), 55.2 (OMe), 60.2, 61.0 (cyclopentyl CH), 102.3, 105.5 (CH), 112.6, 114.6 
(C), 115.6, 124.4 (CH), 127.3 (C), 127.9, 131.8, 132.6, 138.1 (CH), 140.4, 164.2, 166.4, 
171.6, 173.8 (C). 
MS (GC, 70eV): m/z (%) = 430 (M
+
, 67), 413 (35), 399 (23), 361 (21), 348 (100), 293 (35). 
251 (23), 168 (35). 
HRMS (EI): Calcd for C27H30N2O3 (M
+
) 430.22509. Found 430.22451. 
IR (ATR, cm
-1
): ~  = 2952 (w), 2859 (w), 1581 (s), 1552 (m), 1514 (w), 1485 (m), 1444 (m), 
1412 (w), 1345 (m), 1281 (w), 1208 (s), 1169 (m), 1119 (m), 1100 (m), 1035 (m), 957 (m), 
856 (w), 831 (m), 796 (m), 752 (s), 708 (m), 645 (w). 
 
3-((E)-(3-phenylpropylimino)(5-chloro-2-hydroxyphenyl)methyl)-1-(3-
phenylpropyl)quinolin-4(1H)-one (3.3.8g). 
Starting from 6-chloro-3-(2-fluorobenzoil)-4H-chromen-4-on 3.3.4f 
(0.302 g, 1 mmol), 3-phenylpropan-1-amine (0.270 g, 2 mmol) and 
K2CO3 (0.276 g, 2 mmol) in 7 mL DMF. 3.3.8g was isolated as orange 
solid (0.283 g, 53%), mp 87-89 
o
C. 
1
H NMR (300 MHz, CDCl3): δ = 2.00-2.32 (m, 4H, 2xCH2), 2.71-2.77 
(m, 4H, 2xCH2), 3.30-3.41 (m, 1H, CH2), 3.58-3.71 (m, 1H, CH2), 4.07-
4.22 (m, 2H, CH2), 6.94 (d, 1H, 
3
J = 8.9 Hz, CHAr), 7.07-7.40 (m, 14H, 
CHAr), 7.45-7.51 (m, 1H, CHAr), 7.67-7.77 (m, 1H, CHAr), 8.51 (dd, 1H, 
3
J = 8.1 Hz, 
4
J = 1.6 
Hz, CHAr), 16.0 (br. s, 1H, OH). 
13
C NMR (75.5 MHz, CDCl3): δ = 30.0, 31.7, 32.5, 33.3, 50.5, 52.7 (CH2), 114.2 (C), 115.6, 
120.0 (CH), 120.3, 121.4 (C), 124.6, 125.7, 126.6 (CH), 127.0 (C), 127.7, 128.2, 128.4, 128.7, 
N
O N OH
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129.4, 132.2, 132.8 (CH), 139.3, 139.4, 141.3 (C), 142.2 (CH), 163.0, 167.9, 173.8 (C). 
MS (GC, 70eV): m/z (%) = 534 (M
+
, 13), 443 (100), 430 (14), 91 (47). 
HRMS (ESI): Calcd for C34H32N2O2Cl (M+H) 535.21468. Found 535.21473. 
IR (ATR, cm
-1
): ~  = 3025 (w), 2924 (w), 1623 (s), 1600 (s), 1576 (s), 1552 (m), 1487 (s), 
1415 (w), 1379 (m), 1328 (w), 1287 (m), 1226 (m), 1173 (m), 1087 (w), 1029 (w), 983 (w), 
883 (w), 822 (m), 745 (s), 697 (s), 647 (m), 529 (w). 
 
3-((E)-(5-chloro-2-hydroxy-4-methylphenyl)(hexylimino)methyl)-1-hexylquinolin-4(1H)-
one (3.3.8h). 
Starting from 3-(2-fluorobenzoil)-6-chloro-7-methyl-4H-chromen-4-
one 3.3.4g (0.316 g, 1 mmol), hexyl amine (0.202 g, 2 mmol)and 
K2CO3 (0.276 g, 2 mmol) in 7 mL DMF. 3.3.8h was isolated as yellow 
solid (0.336 g, 70%), mp 128-130 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 0.79-0.87 (m, 6H, hexyl CH3), 
1.20-1.37 (m, 12H, hexyl CH2), 1.61-1.72 (m, 2H, hexyl CH2), 1.87 (br.s, 2H, hexyl CH2), 
2.24 (s, 3H, Me), 3.22-3.33 (m, 1H, hexyl CH2), 3.51-3.62 (m, 1H, hexyl CH2), 4.16 (t, 2H, 
3
J 
= 7.0 Hz, hexyl CH2), 6.78 (s, 1H, CHAr), 7.02 (s, 1H, CHAr), 7.41-7.52 (m, 2H, CHAr), 7.70-
7.77 (m, 1H, CHAr), 8.46 (dd, 1H, 
3
J = 8.0 Hz, 
4
J = 1.5 Hz, CHAr), 15.8 (br. s, 1H, OH). 
13
C NMR (75.5 MHz, CDCl3): δ = 13.8, 13.9 (Me), 20.2, 22.3, 22.4, 26.3, 27.0, 28.8, 30.3, 
31.2, 31.5 (CH2), 114.0 (C), 115.7 (CH), 118.4 (C), 120.8, 121.7, 124.5 (CH), 127.1 (C), 
127.6, 129.7, 132.7 (CH), 139.3, 140.8 (C), 142.6 (CH), 163.7, 167.3, 173.9 (C). 
 MS (GC, 70eV): m/z (%) = 480 (M
+
, 69), 463 (23), 423 (100), 382 (63), 179 (16). 
HRMS (ESI): Calcd for C29H37N2O2Cl (M+H) 481.26163. Found 481.26226. 
IR (ATR, cm
-1
): ~  = 3041 (w), 2926 (m), 2855 (w), 1623 (m), 1599 (s), 1577 (s), 1552 (m), 
1490 (s), 1461 (m), 1384 (m), 1271 (w), 1231 (s), 1168 (s), 1135 (w), 1055 (w), 1008 (w), 
965 (w), 883 (w), 858 (m), 795 (w), 763 (s), 732 (w), 708 (m), 690 (m), 626 (w), 576 (w). 
 
3-((E)-(5-bromo-2-hydroxyphenyl)(phenethylimino)methyl)-1-phenethylquinolin-4(1H)-
one (3.3.8i). 
Starting from 3-(2,5-fluorobenzoil)-4H-chromen-4-one 3.3.4i (0.286 g, 
1 mmol), phenethyl amine (0.242 g, 2 mmol) and K2CO3 (0.276 g, 2 
mmol) in 7 mL DMF. 3.3.8i was isolated as brown viscous oil (0.382 g, 
78%). 
1
H NMR (300 MHz, CDCl3): δ = 2.99 (t, 2H, 
3
J = 6.9 Hz, CH2), 3.10 (t, 
N
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2H, 
3
J = 6.9 Hz, CH2), 3.56 (br. s, 1H, CH2), 3.66-3.76 (m, 1H, CH2), 4.26 (t, 2H, 
3
J = 6.4 Hz, 
CH2), 6.53-6.59 (m, 2H, CHAr), 6.70-6.73 (m, 1H, CHAr), 6.93-6.97 (m, 3H, CHAr), 7.12-7.27 
(m, 9H, CHAr), 7.47-7.59 (m, 2H, CHAr), 8.15 (dd, 1H, 
3
J = 8.7 Hz, 
4
J = 2.7 Hz, CHAr), 15.32 
(br. s, 1H, OH). 
19
F NMR (282 MHz, DMSO-d6): δ = -116.3 (CF). 
13
C NMR (75.5 MHz, DMSO-d6): δ = 34.8, 36.7, 53.2, 55.1 (CH2), 108.7 (C), 112.6 (d, 
2
J = 
23.4 Hz, CH), 114.0 (C), 117.4 (CH), 117.8 (d, 
3
J = 8 Hz, CH), 118.0 (CH), 119.5 (C), 121.3 
(d, 
2
J = 25.6 Hz, CH), 126.1, 127.5, 128.4 (d, 
3
J = 11.3 Hz, CH), 129.1 (d, J = 3.0 Hz, CH), 
130.3, 132.2 (CH), 135.6, 136.1, 139.9 (C), 142.3 (CH), 159.4 (d, 
1
J = 247.7 Hz, CF), 163.3, 
168.1, 173.2 (C). 
MS (GC, 70eV): m/z (%) = 490 (M
+
, 33), 385 (13), 372 (32), 315 (19), 283 (18), 105 (28), 73 
(100). 
HRMS (EI): Calcd for C32H27N2O2F (M
+
) 491.21293. Found 491.21309. 
IR (ATR, cm
-1
): ~  = 3388 (w), 3025 (w), 2927 (w), 1602 (m), 1560 (m), 1490 (s), 1453 (m), 
1380 (m), 1335 (m), 1281 (m), 1224 (m), 1175 (m), 1151 (m), 1083 (w), 1030 (w), 895 (m), 
815 (m), 748 (s), 697 (s). 
 
3-((E)-(5-bromo-2-hydroxyphenyl)(phenethylimino)methyl)-6-fluoro-1-
phenethylquinolin-4(1H)-one (3.3.8j). 
Starting from 3-(2,5-fluorobenzoil)-6-bromo-4H-chromen-4-one 3.3.4g 
(0.363 g, 1 mmol), phenethyl amine (0.242 g, 2 mmol)and K2CO3 
(0.276 g, 2 mmol) in 7 mL DMF. 3.3.8j was isolated as yellow solid 
(0.224 g, 40%), mp 200-202 
o
C. 
1
HNMR (300 MHz, DMSO-d6): δ = 2.93-3.11 (m, 4H, 2xCH2), 3.26-
3.37 (m, 1H, CH2), 3.66-3.76 (m, 1H, CH2), 4.25 (t, 2H, 
3
J = 6.8 Hz, 
CH2), 6.49 (s, 1H, CHAr), 6.81 (d, 1H, 
3
J = 8.8 Hz, CHAr), 6.96-6.97 (m, 2H, CHAr), 6.98-6.99 
(m, 1H, CHAr), 7.11-7.28 (m, 9H, CHAr), 7.48-7.58 (m, 2H, CHAr), 8.11 (dd, 1H, 
3
J = 8.6 Hz, 
4
J = 2.6 Hz, CHAr), 15.57 (br. s, 1H, OH). 
19
F NMR (282 MHz, DMSO-d6): δ = -115.4. 
13
C NMR (75.5 MHz, DMSO-d6): δ = 34.9, 36.8, 53.2, 55.0 (CH2), 108.7 (C), 112.5 (d, 
2
J = 
23.3 Hz, CH), 113.2 (C), 117.9 (d, 
3
J = 8.1 Hz, CH), 120.2 (CH), 120.9 (C), 121.5 (d, 
2
J = 
26.3 Hz, CH), 126.3, 127.5, 128.4, 128.5, 129.1, 132.3, 135.0 (CH), 135.7, 136.1, 139.5 (C), 
142.0 (CH), 159.5 (d, J = 26 Hz, CF), 162.6, 167.5, 173.1 (C). 
MS (GC, 70eV): m/z (%) = 570 (M
+
, 30), 569 (14), 568 (32), 450 (31), 360 (32), 310 (35), 
N
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105 (100). 
HRMS (EI): Calcd for C32H26N2O2FBr
81
 (M
+
) 570.11357. Found 570.11322. 
IR (ATR, cm
-1
): ~  = 2919 (w), 1619 (m), 1581 (m), 1556 (m), 1489 (m), 1380 (m), 1332 (m), 
1281 (m), 1226 (m), 1169 (m), 1081 (w), 1056 (w), 999 (w), 925 (w), 895 (w), 818 (m), 786 
(w), 748 (m), 698 ), 565 (m). 
 
(E)-3-((2-hydroxyphenyl)(phenethylimino)methyl)-1-phenethyl-5-
(phenetylamino)quinolin-4(1H)-one (3.3.9). 
Starting from 3-(2,6-fluorobenzoil)-4H-chromen-4-one 3.3.4k (0.286 g, 1 
mmol), phenethyl amine (0.242 g, 2 mmol) and K2CO3 (0.276 g, 2 mmol) 
in 7 mL DMF. 3.3.9 was isolated as yellow viscous oil (0.242 g, 41%). 
1
H NMR (300 MHz, CDCl3): δ = 2.96-3.13 (m, 6H, 3xCH2), 3.37-3.46 (m, 
4H, 2xCH2), 4.09 (br. s, 2H, CH2), 4.55-4.63 (m, 2H, CH2), 6.28 (s, 1H, 
CHAr), 6.42 (d, 1H, 
3
J = 7.5 Hz, CHAr), 6.53-6.59 (m, 2H, CHAr), 6.78-6.81 
(m, 1H, CHAr), 6.90-7.00 (m, 3H, CHAr), 7.12-7.31 (s, 14H, CHAr), 7.46 (t, 1H, 
3
J = 8.4 Hz, 
CHAr), 10.32 (t, 1H, 
3
J = 4.6 Hz, NH), 15.57 (br. s, 1H, OH). 
13
C NMR (75.5 MHz, DMSO-d6): δ = 34.1, 35.3, 37.0, 44.9, 53.0, 55.5 (CH2), 99.5, 103.0 
(CH), 111.9, 114.7 (C), 117.2, 118.0 (CH), 119.6 (C), 126.1, 126.3, 127.2, 128.3, 128.4, 
128.6, 128.7, 129.0, 129.2, 130.5, 132.1, 133.9, 136.6 (CH), 139.4, 139.9 (C), 140.9 (CH), 
141.7, 152.3, 163.5, 168.7, 177.8 (C). 
MS (GC, 70eV): m/z (%) = 591 (M
+
, 16), 500 (15), 396 (18), 105 (15), 43 (100). 
HRMS (ESI): Calcd for C40H37N3O2 (M+H) 592.29585. Found 592.29622. 
IR (ATR, cm
-1
): ~  = 3207 (w), 3026 (w), 2922 (w), 2851 (w), 1631 (m), 1596 (m), 1570 (m), 
1513 (m), 1469 (m), 1452 (m), 1303 (m), 1268 (m), 1186 (m), 1152 (m), 1080 (w), 908 (w), 
850 (w), 796 (w), 746 (s), 697 (s). 
 
6-((4-fluoro phenyl)amino)chromeno[4,3-b]chromen-7(6H)-one (3.3.10a). 
Starting from 3-(2-fluorobenzoil)-4H-chromen-4-one 3.3.4a (0.268 g, 1 
mmol), p-fluoro aniline (0.222 g, 2 mmol) and K2CO3 (0.276 g, 2 
mmol) in 7 mL DMF. 3.3.10a was isolated as yellow solid (0.302 g, 
84%), mp 274-276 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 6.71 (d, 1H, 
3
J = 8.0 Hz, CHNH), 
6.86-6.91 (m, 2H, CHAr), 6.99-7.07 (m, 4H, CHNH, CHAr), 7.23 (t, 1H, 
3
J = 8.0 Hz, CHAr), 
7.48-7.58 (m, 2H, CHAr), 7.83-7.93 (m, 2H, CHAr), 8.03-8.12 (m, 2H, CHAr). 
N
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19
F NMR (282 MHz, DMSO-d6): δ = -126.5 (CF). 
13
C NMR (62.9 MHz, DMSO-d6): δ = 77.8 (CH), 110.3 (C), 114.4 (d, 
3
J = 8.0 Hz, CH), 115.3 
(CH), 115.5 (C), 115.6 (CH), 118.4 (d, 
3
J = 8.0 Hz, CH), 121.7 (CH), 123.7 (C), 123.8, 125.0, 
125.6, 133.8, 134.5 (CH), 140.1 (d, 
2
J = 50.8 Hz, C), 141.9, 154.5, 155.0, 155.2 (C), 155.6 (d, 
1
J = 232.8 Hz, CF), 173.5 (C=O). 
MS (GC, 70eV): m/z (%) = 359 (M
+
, 1), 249 (100). 
HRMS (ESI): Calcd for C22H15FNO3 (M+H) 360.10305. Found 360.1038. 
IR (ATR, cm
-1
): ~  = 3312 (m), 2958 (w), 1636 (s), 1603 (m), 1563 (w), 1530 (m), 1506 (s), 
1464 (s), 1426 (s), 1347 (w), 1306 (m), 1253 (w), 1207 (m), 1149 (m), 1130 (m), 1088 (m), 
1027 (w), 921 (s), 867 (m), 825 (s), 760 (s), 700 (m), 658 (m), 603 (m), 554 (m). 
 
6-((3-trifluoromethyl)phenyl)amino)chromeno[4,3-b]chromen-7(6H)-one (3.3.10b). 
Starting from 3-(2-fluorobenzoil)-4H-chromen-4-one 3.3.4a (0.268 g, 
1 mmol), m-trifluoromrthyl aniline (0.322 g, 2 mmol) and K2CO3 
(0.276 g, 2 mmol) in 7 mL DMF. 3.3.10b was isolated as yellow solid 
(0.303 g, 74%), mp 277-279 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 6.83 (d, 1H, 
3
J = 7.7 Hz, 
NHCH), 7.04-7.07 (m, 2H, NHCH, CHAr), 7.14-7.27 (m, 3H, CHAr), 7.40-7.45 (m, 1H, CHAr), 
7.49-7.58 (m, 3H, CHAr), 7.84-7.91 (m, 2H, CHAr), 8.05-8.13 (m, 2H, CHAr),  
19
F NMR (282 MHz, CDCl3): δ = -61.3 (CF3). 
13
C NMR (75.5 MHz, CDCl3): δ = 76.9 (CH), 109.4 (q, J = 4 Hz, CH), 110.0 (C), 114.5 (q, J 
= 4 Hz, CH), 115.4 (C), 117.0, 118.3, 118.5, 122.1 (CH), 123.6 (C), 123.9 (CH), 124.3 (q, 
1
J 
= 272 Hz, CF3), 125.0, 125.7 (CH), 129.9 (q, 
2
J = 31 Hz, CCF3), 130.2, 133.9, 134.6 (CH), 
145.9, 154.3, 155.1, 155.2, 173.5 (C). 
MS (GC, 70eV): m/z (%) = 409 (M
+
, 1), 249 (100). 
HRMS (ESI): Calcd for C23H14NNaO3F3 (M+Na) 432.0818. Found 432.08149. 
IR (ATR, cm
-1
): ~  = 3297 (w), 1634 (m), 1601 (m), 1563 (m), 1539 (m), 1489 (m), 1466 (m), 
1425 (s), 1342 (s), 1312 (m), 1263 (m), 1214 (m), 1166 (m), 1136 (m), 1089 (s), 1068 (s), 
1025 (m), 996 (w), 927 (m), 868 (m), 856 (m), 760 (s), 695 (s), 564 (m). 
 
2-chlorio-6-((3-trifluoromethyl)phenyl)amino)chromeno[4,3-b]chromen-7(6H)-one 
(3.3.10c). 
O
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Starting from 6-chloro-3-(2-fluorobenzoil)-4H-chromen-4-on 3.3.4f 
(0.302 g, 1 mmol), m-trifluoromrthyl aniline (0.322 g, 2 mmol) and 
K2CO3 (0.276 g, 2 mmol) in 7 mL DMF. 3.3.9c was isolated as 
yellow solid (0.222 g, 50%), mp 272-274 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 6.87 (d, 1H, 
3
J = 7.7 Hz, 
NHCH), 7.05-7.13 (m, 3H, NHCH, CHAr), 7.17-7.20 (m, 1H, CHAr), 
7.39-7.47 (m, 1H, CHAr), 7.50-7.59 (m, 3H, CHAr), 7.90-7.95 (m, 2H, OH, CHAr), 8.09-8.12 
(m, 2H, CHAr). 
19
F NMR (282 MHz, CDCl3): δ = -61.3 (CF3). 
13
C NMR Due to bed solubility it was not possible to measure. 
MS (GC, 70eV): m/z (%) = 443 (M
+
, 36), 441 (100), 145 (20). 
HRMS (ESI): Calcd for C23H13ClF3NNaO3 (M+Na) 466.04283. Found 466.04275. 
IR (ATR, cm
-1
): ~  = 3292 (w), 1620 (m), 1562 (m), 1465 (m), 1409 (s), 1376 (m), 1339 (w), 
1291 (m), 1248 (m), 1211 (m), 1168 (m), 1138 (m), 1090 (s), 1046 (m), 927 (m), 861 (m), 
821 (s), 782 (m), 761 (s), 693 (s), 659 (m), 612 (m), 598 (m). 
 
2-chloro-3-methyl-6-((3-trifluoromethyl)phenyl)amino)chromeno[4,3-b]chromen-7(6H)-
one (3.3.10d). 
 Starting from 3-(2-fluorobenzoil)-6-chloro-7-methyl-4H-chromen-4-
one 3.3.4g (0.316 g, 1 mmol), m-trifluoromrthyl aniline (0.322 g, 2 
mmol) and K2CO3 (0.276 g, 2 mmol) in 7 mL DMF. 3.3.10d was 
isolated as white solid (0.247 g, 54%), mp 297-299 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 2.33 (s, 3H, Me), 6.83 (d, 1H, 
3
J 
= 7.9 Hz, NHCH), 7.05-7.21 (m, 4H, NHCH, CHAr), 7.39-7.58 (m, 
3H, CHAr), 7.90-7.93 (m, 2H, CHAr), 8.04 (s, 1H, CHAr), 8.10 (m, 1H, CHAr). 
19
F NMR (282 MHz, DMSO-d6): δ = -61.2 (CF3). 
13
C NMR Due to bed solubility it was not possible to measure. 
MS (GC, 70eV): m/z (%) = 457 (M
+
, 1), 297 (100), 161 (26). 
HRMS (ESI): Calcd for C24H15NClF3NaO3 (M+Na) 480.05848. Found 480.05841. 
IR (ATR, cm
-1
): ~  = 3307 (w), 1614 (m), 1573 (w), 1540 (m), 1477 (m), 1427 (m), 1337 (s), 
1294 (w), 1270 (w), 1246 (w). 1165 (m), 1111 (s), 1068 (s), 1005 (w), 974 (w), 921 (m), 893 
(s), 876 (m), 856 (m), 838 (m), 783 (m), 764 (s), 695 (m), 675 (m), 554 (m). 
 
6-((3,5-dichlorophenyl)amino)-9-fluorochromeno[4,3-b]chromen-7(6H)-one (3.3.10e). 
O
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Starting from 3-(2,5-fluorobenzoil)-4H-chromen-4-one 3.3.4i (0.286 
g, 1 mmol), 3,5-dichloro aniline (0.324 g, 2 mmol) and K2CO3 
(0.276 g, 2 mmol) in 7 mL DMF. 3.3.10e was isolated as white solid 
(0.304 g, 71%), mp 285-286 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 6.83 (d, 1H, 
3
J = 7.6 Hz, 
NHCH), 6.90 (br. s, 3H, CHAr), 7.10 (d, 1H, 
3
J = 8.1 Hz, NHCH), 
7.25 (t, 1H, 
3
J = 7.2 Hz, CHAr), 7.51-7.60 (m, 2H, CHAr), 7.78-7.83 (m, 2H, CHAr), 7.96-8.00 
(m, 1H, CHAr), 8.06 (m, 1H, CHAr). 
19
F NMR (282 MHz, DMSO-d6): δ = -114.9 (CF). 
13
C NMR Due to bed solubility it was not possible to measure. 
MS (GC, 70eV): m/z (%) = 427 (M
+
, 1), 297 (100). 
HRMS (ESI): Calcd for C22H12NCl2FO3 (M+H) 428.01783. Found 428.01788. 
IR (ATR, cm
-1
): ~  = 3290 (m), 1626 (m), 1580 (s), 1556 (s), 1479 (m), 1446 (m), 1409 (m), 
1356 (m), 1272 (w), 1253 (m), 1209 (m), 1129 (m), 1105 (m), 1088 (m), 1014 (w), 989 (w), 
961 (m), 923 (m), 872 (m), 824 (m), 773 (m), 763 (s), 746 (m), 668 (m), 611 (m).  
 
6-((3,4,5-trimethoxyphenyl)amino)chromeno[4,3-b]chromen-7(6H)-one (3.3.10f). 
Starting from 3-(2-fluorobenzoil)-4H-chromen-4-one 3.3.4c (0.268 g, 1 
mmol), 3,4,5-trimethoxy aniline (0.366 g, 2 mmol) and K2CO3 (0.276 
g, 2 mmol) in 7 mL DMF. 3.3.10f was isolated as yellow solid (0.302 
g, 60%), mp 265-267 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 3.57 (s, 3H, OMe), 3.74 (s, 6H, 
2xOMe), 6.18 (s, 2H, CHAr), 6.74 (d, 1H, 
3
J = 7.4 Hz, NHCH), 6.95 (d, 1H, 
3
J = 7.4 Hz, 
CHAr), 7.08 (d, 1H, 
3
J = 8.2 Hz, NHCH), 7.22 (t, 1H, 
3
J = 7.4 Hz, CHAr), 7.50-7.57 (m, 2H, 
CHAr), 7.84-7.92 (m, 2H, CHAr), 8.03-8.12 (m, 2H, CHAr). 
13
C NMR Due to bed solubility it was not possible to measure.  
MS (GC, 70eV): m/z (%) = 431 (M
+
, 3), 249 (100). 
HRMS (ESI): Calcd for C25H22NO6 (M+H) 432.14416. Found 432.14418. 
IR (ATR, cm
-1
): ~  = 3322 (m), 2938 (w), 1638 (s), 1600 (s), 1563 (m), 1530 (m), 1509 (m), 
1456 (s), 1422 (s), 1348 (w), 1310 (w), 1236 (s), 1196 (s), 1121 (s), 1101 (s), 1010 (m), 912 
(m), 883 (m), 850 (m), 804 (m), 757 (s), 705 (m), 651 (m). 
 
6-((3,4-dimethoxyphenyl)amino)-2-methylchromeno[4,3-b]chromen-7(6H)-one (3.3.10g). 
O
O
O
HN Cl
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Starting from 6-methyl-3-(2-fluorobenzoil)-4H-chromen-4-one 3.3.4d 
(0.282 g, 1 mmol), 3,4-dimethoxy aniline (0.306 g, 2 mmol) and K2CO3 
(0.276 g, 2 mmol) in 7 mL DMF. 3.3.10g was isolated as yellowsolid 
(0.249 g, 60%), mp 258-260 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 2.38 (s, 3H, Me), 3.67 (s, 3H, 
OMe), 3.69 (s, 3H, OMe), 6.44-6.46 (m, 2H, CHAr), 6.64 (d, 1H, 
3
J = 
7.8 Hz, NHCH), 6.74 (d, 1H, 
3
J = 7.8 Hz, CHAr), 6.81 (d, 1H, 
3
J = 7.8 Hz, CHAr), 6.94 (d, 1H, 
3
J = 7.8 Hz, NHCH), 7.29-7.33 (m, 1H, CHAr), 7.51-7.56 (m, 1H, CHAr), 7.83-7.7.91 (m, 3H, 
CHAr), 8.09 (d, 1H, 
3
J = 7.4 Hz, CHAr). 
13
C NMR Due to bed solubility it was not possible to measure.  
MS (GC, 70eV): m/z (%) = 415 (M
+
, 3), 263 (100). 
HRMS (ESI): Calcd for C25H22NO5 (M+H) 416.14925. Found 416.14892. 
IR (ATR, cm
-1
): ~  = 3312 (m), 1635 (s), 101 (m), 1515 (m), 1463 (s), 1429 (s), 1355 (w), 
1318 (m), 1296 (w), 1257 (m), 1227 (s), 1202 (s), 1168 (m), 1134 (s), 1106 (s), 1028 (m), 928 
(m), 910 (m), 859 (m), 828 (s), 786 (m), 757 (s), 702 (m), 670 (m). 
 
6-((3,5-dimethoxyphenyl)amino)-2-methylchromeno[4,3-b]chromen-7(6H)-one (3.3.10c). 
Starting from 6-methyl-3-(2-fluorobenzoil)-4H-chromen-4-one 3.3.4d 
(0.282 g, 1 mmol), 3,5-dimethoxy aniline (0.306 g, 2 mmol) and K2CO3 
(0.276 g, 2 mmol) in 7 mL DMF. 3.3.10h was isolated as yellowsolid 
(0.228 g, 55%), mp 268-270 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 2.38 (s, 3H, Me), 3.68 (s, 6H, 
2xOMe), 5.92 (t, 1H, 
4
J = 2 Hz, CHAr), 6.04 (d, 2H, 
4
J = 2 Hz, CHAr), 
6.67 (d, 1H, 
3
J = 7.7 Hz, NHCH), 6.96 (d, 1H, 
3
J = 8.3 Hz, CHAr), 7.02 (d, 1H, 
3
J = 7.7 Hz, 
NHCH), 7.30-7.34 (m, 1H, CHAr), 7.51-7.57 (m, 1H, CHAr), 7.83-7.7.93 (m, 3H, CHAr), 8.10 
(d, 1H, 
3
J = 8.1 Hz, CHAr). 
13
C NMR (62.9 MHz, DMSO-d6): δ = 20.2 (Me), 54.8 (OMe), 77.1, 90.8, 92.2 (CH), 110.3, 
115.3 (C), 118.2, 118.4, 123.5 (CH), 123.7 (C), 125.0, 125.6 (CH), 130.9 (C), 134.5 (CH), 
147.2, 152.4, 155.2, 161.1, 173.5 (C). 
MS (GC, 70eV): m/z (%) = 415 (M
+
, 3), 263 (100). 
HRMS (ESI): Calcd for C25H22NO5 (M+H) 416.14925. Found 416.14974. 
IR (ATR, cm
-1
): 
~  = 3317 (m), 1634 (m), 1596 (s), 1564 (s), 1540 (m), 1465 (s), 1429 (s), 
1343 (w), 1296 (w), 1224 (w), 1195 (s), 1175 (m), 1144 (s), 1109 (s), 1059 (m), 1001 (m), 
928 (m), 910 (m), 860 (s), 812 (s), 786 (m), 758 (s), 705 (m), 677 (s), 621 (m), 560 (m). 
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6-((3,4-dimethoxyphenyl)amino)-2-methylchromeno[4,3-b]chromen-7(6H)-one (3.3.11g). 
Starting from 6-methyl-3-(2-fluorobenzoil)-4H-chromen-4-one 
3.3.4d (0.282 g, 1 mmol), 3,4-dimethoxy aniline (0.306 g, 2 mmol) 
and K2CO3 (0.276 g, 2 mmol) in 7 mL DMF. 3.3.12g was isolated as 
yellow solid (0.042 g, 10%), mp 173-174 
o
C. 
1
H NMR (300 MHz, CDCl3): δ = 2.08 (s, 3H, Me), 4.04 (s, 3H, 
OMe), 4.10 (s, 3H, OMe), 6.62-6.69 (m, 1H, CHAr), 6.92 (d, 1H, 
3
J = 8.4 Hz, NHCH), 7.00-
7.05 (m, 2H, CHAr), 7.11 (s, 1H, CHAr), 7.14-7.24 (m, 3H, CHAr), 7.42 (s, 1H, CHAr), 8.15 (s, 
1H, Py), 11.84 (s, 1H, OH), 12.72 (br. s, 1H, OH). 
13
C NMR (62.9 MHz, CDCl3): δ = 20.2 (Me), 56.3, 56.5 (OMe), 105.3, 106.5, 117.9, 118.2, 
119.0 (CH), 119.1, 120.1, 121.1, 128.4, 129.4 (C), 130.1, 131.2, 132.4, 136.9, 138.1 (CH), 
142.9, 150.9, 153.7, 154.6, 158.2, 161.3, 201.8 (C). 
MS (GC, 70eV): m/z (%) = 415 (M
+
, 3), 263 (100). 
HRMS (ESI): Calcd for C25H22NO5 (M+H) 416.14925. Found 416.14892. 
IR (ATR, cm
-1
): ~  = 3305 (s), 1619 (w), 1580 (w), 1499 (m), 1474 (m), 1372 (w), 1282 (w), 
1243 (m), 1195 (m), 1155 (m), 1009 (m), 953 (w), 910 (w), 886 (w), 851 (m), 827 (m), 777 
(m), 757 (m), 711 (m), 689 (m), 656 (m). 
 
3-(2-(benzyl(metyl)amino)benzyl)-4H-chromen-4-one (3.3.13). 
Starting from 3-(2-fluorobenzoil)-4H-chromen-4-one 3.3.4c 
(0.268 g, 1 mmol), N-methyl-1-phenylmethanamine (0.242 g, 2 
mmol) and K2CO3 (0.276 g, 2 mmol) in 7 mL DMF. 3.3.8g was 
isolated as white solid (0.336 g, 91%), mp 149-150 
o
C. 
1
H NMR (300 MHz, CDCl3): δ = 2.28 (s, 3H, Me), 3.90 (q, 2H, 
3
J = 9.7 Hz, CH2), 6.48 (s, 
1H, Chromone), 7.04-7.11 (m, 2H, CHAr), 7.15-7.33 (m, 5H, CHAr), 7.38-7.49 (m, 2H, CHAr), 
7.53-7.56 (m, 1H, CHAr), 7.65-7.72 (m, 1H, CHAr), 7.89 (dd, 1H, 
3
J = 8.2 Hz, 
4
J = 1.8 Hz, 
CHAr). 
13
C NMR (75.5 MHz, CDCl3): δ = 35.5 (Me), 56.6 (CH2), 88.4, 109.2, 114.8 (C), 116.36, 
117.9, 120.8, 123.6 (CH), 124.4 (C), 125.1, 126.0, 127.0, 128.2, 128.6, 133.6, 133.9 (CH), 
155.5, 156.5, 157.7, 175.1 (C). 
MS (GC, 70eV): m/z (%) = 369 (M
+
, 1), 249 (100), 120 (27). 
HRMS (ESI): Calcd for C24H20NO3 (M+H) 370.14377. Found 370.14384. 
IR (ATR, cm
-1
): ~  = 2997 (w), 1640 (m), 1601 (m), 1563 (m), 1485 (w), 1463 (m), 1416 (s), 
N
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1350 (m), 1330 ‘(m), 1258 (m), 1209 (m), 1164 (m), 1148 (m), 1107 (w), 1047 (s), 994 (w), 
964 (m), 906 (m), 882 (m), 840 (m)m 790 (w), 758 (s), 744 (s), 698 (s), 663 (m), 638 (m).  
 
6-Hydroxychromeno[4,3-b]chromen-7(6H)-one (3.3.14). 
3.3.14 was isolated as white solid, mp 240-241 
o
C. 
1
H NMR (300 MHz, DMSO): δ = 6.55 (s, 1H, CHOH), 7.16-7.27 (m, 2H, 
CHAr), 7.50-7.61 (m, 2H, CHAr), 7.64 (br. s, 1H, CHOH), 7.79-7.90 (m, 
2H, CHAr), 8.01-8.04 (m, 1H, CHAr), 8.09-8.12 (m, 1H, CHAr). 
13
C NMR (62.9 MHz, DMSO):
 δ = 87.3 (CHOH), 111.5, 114.6 (C), 117.9, 118.5, 122.0, 123.6 
(CH), 123.7 (C), 125.0, 125.6, 133.8, 134.5 (CH), 154.1, 154.6, 155.1, 173.8 (C). 
MS (GC, 70eV): m/z (%) = 266 (M
+
, 100). 
HRMS (EI): calcd for C16H10O4 (M
+
) 266.05791, found 266.05793. 
IR (ATR, cm
-1
): ~  = 3024 (w), 1641 (m), 1600 (m), 1557 (m), 1477 (w), 1416 (s), 1351 (m), 
1331 (m), 1258 (m), 1210 (m), 1164 (m), 1100 (w), 1051 (s), 994 (w), 906 (m), 882 (m), 840 
(m)m 790 (w), 758 (s), 698 (s), 650 (m). 
 
13-methyl-11-phenyldibenzo[2,3:7,8]oxocino[4,5-b]pyrazolo[4,3-e]pyridine-15(11H)-one 
(3.3.15). 
Starting from 3-(2-fluorobenzoil)-4H-chromen-4-one 3.3.4a (0.268 g, 
1 mmol), 4-amino-1H-imidazole-2(3H)-thione E3 (0.346 g, 2 mmol) 
and K2CO3 (0.276 g, 2 mmol) in 7 mL DMF. 3.3.13 was isolated as 
yellowsolid (0.286 g, 71%), mp 250-251 
o
C. 
1
H NMR (250 MHz, CDCl3): δ = 2.40 (s, 3H, Me), 6.07-7.10 (m, 1H, 
CHAr), 7.17-7.45 (m, 7H, CHAr), 7.51-7.57 (m, 1H, CHAr), 7.66 (dd, 1H, 
3
J = 7.4 Hz, 
3
J = 1.7 
Hz, CHAr), 7.98-8.01 (m, 2H, CHAr), 8.28-8.31 (m, 2H, CHAr). 
13
C NMR (62.9 MHz, CDCl3): δ = 12.5 (Me), 115.7 (C), 120.6, 121.7, 122.4, 125.0, 125.6, 
126.1, 129.0, 130.1, 130.6, 130.8, 130.9, 131.6 (CH), 132.8, 133.7 (C), 135.2 (CH), 139.4, 
143.3, 150.7, 151.1, 127.5, 161.1, 194.9 (C). 
MS (GC, 70eV): m/z (%) = 403 (M
+
, 100). 
HRMS (ESI): Calcd for C26H18N3O2 (M+H) 404.13935, found 404.1389. 
IR (ATR, cm
-1
): 
~  = 3064 (s), 1645 (w), 1594 (s), 1495 (m), 1446 (m), 1382 (m), 1340 (w), 
1308 (m), 1280 (s), 1210 (m), 1120 (m), 1102 (m), 1080 (m), 998 (w), 908 (w), 781 (m), 754 
(s), 711 (m), 689 (s), 661 (m), 626 (m), 607 (m). 
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A.2.25. General procedure for the synthesis of compound 3.3.14: 
 
Corresponding ortho-F-benzoyl chromone derivative 3.3.4 (2 equiv.), appropriate amine (1 
equiv.) and K2CO3 (4 equiv.) were placed in a pressure tube under the flow of dry argon and 
dissolved in dry DMF (7 mL/1 mmol of 3.3.4). The mixture was heated at 120 C for 30 h 
(controlled by TLC). After the reaction was completed volatiles were evaporated under 
reduced pressure. The residue was purified by column chromatography over silica gel 
(Heptane : Ethyl acetate - 1:1).  
 
1,1'-(methylenbis(4,1-phenylene))bis(3-(2-hydroxybenzoyl)quinolin-4(1H)-one (3.3.16). 
Starting from 3-(2-fluorobenzoil)-4H-chromen-4-one 
3.3.4a (0.536 g, 2 mmol), 4,4'-methylendiamine (0.198 
g, 1 mmol) and K2CO3 (0.552 g, 4 mmol) in 7 mL DMF. 
3.3.14 was isolated as yellowsolid (0.458 g, 66%), mp 
more than 375 
o
C. 
1
H NMR (300 MHz, DMSO-d6): δ = 3.72 (s, 2H, CH2), 6.71 (d, 2H, 
3
J = 8.0 Hz, CHAr), 6.82 
(d, 2H, 
3
J = 8.3 Hz, CHAr), 7.00-7.06  (m, 8H, CHAr), 7.19-7.24 (m, 2H, CHAr), 7.47-7.57 (m, 
6H, CHAr), 7.84-7.92 (m, 4H, OH, CHAr), 8.03-8.12 (m, 4H, CHAr). 
13
C NMR Due to bed solubility it was not possible to measure.  
MS (GC, 70eV): m/z (%) = 694 (M
+
, 100). 
HRMS (ESI): Calcd for C45H31N2O6 (M+H) 695.21766. Found 695.21771. 
IR (ATR, cm
-1
): 
~  = 3305 (m), 1626 (s), 1559 (s), 1517 (m), 1466 (m), 1427 (s), 1297 (m), 
1249 (m), 1212 (m), 1137 (m), 1095 (m), 915 (m), 849 (m), 812 (m), 754 (s), 701 (m), 663 
(m), 599 (m), 558 (m).  
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A3. Crystallographic data 
 
 
Crystal data and structure refinement for 2.3.3e 
 
Identification code sm305  
Empirical formula C21H15Cl2N3O2 
Formula weight 412.26 
Temperature 173 K 
Wavelength 0.71073 Å 
Crystal system, space group Monoclinic, P21/c 
Unit cell dimensions a = 12.5227 (3) Å α = 90o  
b = 14.4854 (3) Å β = 111.858 (1)o 
c = 11.1599 (2) Å γ = 90o 
Volume 1878.83 (3) Å
3
 
Z 4 
Calculated density 1.457 mg/m
3
 
Absorption coefficient 0.37 mm
-1
 
F(000) 848 
Crystal size 0.31 x 0.16 x 0.12 mm 
Θ range for data collection 4.8 to 59.7o 
Limiting indices: -16≤h≤17, -20≤k≤19, -15≤l≤15 
Reflections collected / unique 20936/ 5421 [R(Int) = 0.0305] 
Completeness to Θ 27.58o 
Absorption correction multi scan 
Refinement method Full-matrix least-squares on F
2
 
Data / restraints / parameters 5421 / 0 / 258 
Goodness-of-fit on F
2
 1.079 
Final R indices [I>2σ(I)] R1 = 0.0578, wR2 = 0.1057 
R indices (all data) R1 = 0.0394, wR2 = 0.0985 
Largest diff. peak and hole 0.372 and -0.390 e. Å
-3
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Crystal data and structure refinement for 2.4.1 
 
Identification code g104  
Empirical formula C12H8O5 
Formula weight 232.18 
Temperature 173 K 
Wavelength 0.71073 Å 
Crystal system, space group Monoclinic, P21/n 
Unit cell dimensions a = 10.4760 (8) Å α = 90o  
b = 6.7599 (5) Å β = 93.438 (1)o 
c = 14.5944 (10) Å γ = 90o 
Volume 1031.67 (13) Å
3
 
Z 4 
Calculated density 1.495 mg/m
3
 
Absorption coefficient 0.12 mm
-1
 
F(000) 480 
Crystal size 1.00 x 0.22 x 0.04 mm 
Θ range for data collection 4.9 to 53.6o 
Limiting indices: -14≤h≤13, -6≤k≤9, -20≤l≤20 
Reflections collected / unique 20936 / 5421 [R(Int) = 0.0355] 
Completeness to Θ 27.59o 
Absorption correction multi scan 
Refinement method Full-matrix least-squares on F
2
 
Data / restraints / parameters 2982 / 0 / 155 
Goodness-of-fit on F
2
 1.011 
Final R indices [I>2σ(I)] R1 = 0.0946, wR2 = 0.1368 
R indices (all data) R1 = 0.0494, wR2 = 0.1225 
Largest diff. peak and hole 0.321and -0.206 e. Å
-3
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Crystal data and structure refinement for 2.4.2i 
 
Identification code sm305 
Empirical formula C21H15Cl2N3O2 
Formula weight 412.26 
Temperature 173 K 
Wavelength 0.71073 Å 
Crystal system, space group Monoclinic, P21/c 
Unit cell dimensions a = 12.5227 (3) Å α = 90o  
b = 14.4854 (3) Å β = 111.858 (1)o 
c = 11.1599 (2) Å γ = 90o 
Volume 1878.83 (7) Å
3
 
Z 4 
Calculated density 1.457 mg/m
3
 
Absorption coefficient 0.37 mm
-1
 
F(000) 480 
Crystal size 0.37 x 0.16 x 0.12 mm 
Θ range for data collection 4.8 to 59.7o 
Limiting indices: -16≤h≤17, -20≤k≤19, -15≤l≤15 
Reflections collected / unique 20936/ 5421 [R(Int) = 0.0305] 
Completeness to Θ 27.58o 
Absorption correction multi scan 
Refinement method Full-matrix least-squares on F
2
 
Data / restraints / parameters 5421 / 0 / 258 
Goodness-of-fit on F
2
 1.079 
Final R indices [I>2σ(I)] R1 = 0.0578, wR2 = 0.1057 
R indices (all data) R1 = 0.0394, wR2 = 0.0985 
Largest diff. peak and hole 0.372 and -0.390 e. Å
-3
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Crystal data and structure refinement for 2.4.2l 
 
Identification code sm285 
Empirical formula C17H15N3O4S 
Formula weight 357.38 
Temperature 173 K 
Wavelength 0.71073 Å 
Crystal system, space group Monoclinic, P21/c 
Unit cell dimensions a = 15.5148 (4) Å α = 90o  
b = 8.3533 (2) Å β = 98.6393 (1)o 
c = 12.6393 (3) Å γ = 90o 
Volume 1619.37 (7) Å
3
 
Z 4 
Calculated density 1.466 mg/m
3
 
Absorption coefficient 0.23 mm
-1
 
F(000) 744 
Crystal size 0.44 x 0.42 x 0.08 mm 
Θ range for data collection 5.6 to 60.0o 
Limiting indices: -13≤h≤21, -8≤k≤11, -17≤l≤15 
Reflections collected / unique 17166 / 4697 [R(Int) = 0.0223] 
Completeness to Θ 27.34o 
Absorption correction multi scan 
Refinement method Full-matrix least-squares on F
2
 
Data / restraints / parameters 4697 / 0 / 233 
Goodness-of-fit on F
2
 1.059 
Final R indices [I>2σ(I)] R1 = 0.0480, wR2 = 0.1068 
R indices (all data) R1 = 0.0377, wR2 = 0.1017 
Largest diff. peak and hole 0.358 and -0.345 e. Å
-3
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Crystal data and structure refinement for 2.5.3d 
 
Identification code sm282 
Empirical formula C19H14N4O3S.CHCl3 
Formula weight 497.77 
Temperature 173 K 
Wavelength 0.71073 Å 
Crystal system, space group Monoclinic, P21/c 
Unit cell dimensions a = 14.2696 (9) Å α = 90o  
b = 5.9365 (4) Å β = 95.353 (2)o 
c = 25.2475 (16) Å γ = 90o 
Volume 2129.4 (2) Å
3
 
Z 4 
Calculated density 1.533 mg/m
3
 
Absorption coefficient 0.56 mm
-1
 
F(000) 744 
Crystal size 0.40 x 0.10 x 0.06 mm 
Θ range for data collection 5.7 to 49.7o 
Limiting indices: -13≤h≤21, -8≤k≤11, -17≤l≤15 
Reflections collected / unique 15941 / 4195 [R(Int) = 0.0493] 
Completeness to Θ 23.22o 
Absorption correction multi scan 
Refinement method Full-matrix least-squares on F
2
 
Data / restraints / parameters 4195 / 0 / 286 
Goodness-of-fit on F
2
 1.038 
Final R indices [I>2σ(I)] R1 = 0.1073, wR2 = 0.1161 
R indices (all data) R1 = 0.0498, wR2 = 0.1013 
Largest diff. peak and hole 1.196 and -0.678 e. Å
-3
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Crystal data and structure refinement for 2.5.3e 
 
Identification code ag045 
Empirical formula C19H14N4O3 
Formula weight 346.34 
Temperature 173 K 
Wavelength 0.71073 Å 
Crystal system, space group Monoclinic, P21/n 
Unit cell dimensions a = 11.1798 (3) Å α = 90o  
b = 8.3934 (5) Å β = 99.528 (2)o 
c = 17.7153 (5) Å γ = 90o 
Volume 1639.41 (9) Å
3
 
Z 4 
Calculated density 1.403 mg/m
3
 
Absorption coefficient 0.10 mm
-1
 
F(000) 720 
Crystal size 0.42 x 0.23 x 0.15 mm 
Θ range for data collection 4.7 to 61.4o 
Limiting indices: -15≤h≤12, -11≤k≤11, -24≤l≤24 
Reflections collected / unique 18031 / 4769 [R(Int) = 0.0332] 
Completeness to Θ 27.67o 
Absorption correction multi scan 
Refinement method Full-matrix least-squares on F
2
 
Data / restraints / parameters 4769 / 0 / 240 
Goodness-of-fit on F
2
 1.083 
Final R indices [I>2σ(I)] R1 = 0.0606, wR2 = 0.1182 
R indices (all data) R1 = 0.0429, wR2 = 0.1105 
Largest diff. peak and hole 0.316 and -0.259 e. Å
-3
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Crystal data and structure refinement for 2.5.3j 
 
Identification code ag050 
Empirical formula C15H12N4O5 
Formula weight 328.29 
Temperature 173 K 
Wavelength 0.71073 Å 
Crystal system, space group Monoclinic, P21/n 
Unit cell dimensions a = 8.2923 (3) Å α = 90o  
b = 16.8902 (5) Å β = 90.925 (2)o 
c = 17.7153 (5) Å γ = 90o 
Volume 1517.44 (8) Å
3
 
Z 4 
Calculated density 1.437 mg/m
3
 
Absorption coefficient 0.11 mm
-1
 
F(000) 680 
Crystal size 0.33 x 0.28 x 0.09 mm 
Θ range for data collection 4.8 to 60.9o 
Limiting indices: -11≤h≤11, -14≤k≤15, -23≤l≤23 
Reflections collected / unique 16871 / 4437 [R(Int) = 0.0294] 
Completeness to Θ 27.77o 
Absorption correction multi scan 
Refinement method Full-matrix least-squares on F
2
 
Data / restraints / parameters 4437 / 0 / 223 
Goodness-of-fit on F
2
 1.063 
Final R indices [I>2σ(I)] R1 = 0.0631, wR2 = 0.1231 
R indices (all data) R1 = 0.0420, wR2 = 0.1143 
Largest diff. peak and hole 0.329 and -0.266 e. Å
-3
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Crystal data and structure refinement for 2.5.3m 
 
Identification code sm319 
Empirical formula C17H14N2O5 
Formula weight 326.30 
Temperature 173 K 
Wavelength 0.71073 Å 
Crystal system, space group Orthorhombic Pca21 
Unit cell dimensions a = 15.2372 (17) Å α = 90o  
b = 13.6592 (15) Å β = 90o 
c = 14.0634 (14) Å γ = 90o 
Volume 2927.0 (5) Å
3
 
Z 8 
Calculated density 1.481 mg/m
3
 
Absorption coefficient 0.11 mm
-1
 
F(000) 1360 
Crystal size 0.51 x 0.25 x 0.14 mm 
Θ range for data collection 4.9 to 59.7o 
Limiting indices: -19≤h≤20, -18≤k≤18, -19≤l≤19 
Reflections collected / unique 26058 / 7741 [R(Int) = 0.0258] 
Completeness to Θ 27.51o 
Absorption correction multi scan 
Refinement method Full-matrix least-squares on F
2
 
Data / restraints / parameters 7741 / 1 / 445 
Goodness-of-fit on F
2
 1.050 
Final R indices [I>2σ(I)] R1 = 0.0442, wR2 = 0.0952 
R indices (all data) R1 = 0.0357, wR2 = 0.0911 
Largest diff. peak and hole 0.287 and -0.241 e. Å
-3
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Crystal data and structure refinement for 2.6.3a 
 
Identification code ag132 
Empirical formula C19H15N3O2 
Formula weight 317.34 
Temperature 173 K 
Wavelength 0.71073 Å 
Crystal system, space group Monoclinic, P21/c 
Unit cell dimensions a = 13.5332 (7) Å α = 90o  
b = 11.4883 (6) Å β = 111.013 (2)o 
c = 10.2680 (5) Å γ = 90o 
Volume 1490.24 (13) Å
3
 
Z 4 
Calculated density 1.414 mg/m
3
 
Absorption coefficient 0.09 mm
-1
 
F(000) 664 
Crystal size 0.30 x 0.28 x 0.08 mm 
Θ range for data collection 5.5 to 50.3o 
Limiting indices: -19≤h≤19, -16≤k≤12, -14≤l≤14 
Reflections collected / unique 17580 / 4342 [R(Int) = 0.0571] 
Completeness to Θ 27.6o 
Absorption correction multi scan 
Refinement method Full-matrix least-squares on F
2
 
Data / restraints / parameters 4342 / 0 / 226 
Goodness-of-fit on F
2
 1.022 
Final R indices [I>2σ(I)] R1 = 0.0947, wR2 = 0.1206 
R indices (all data) R1 = 0.0494, wR2 = 0.1064 
Largest diff. peak and hole 0.220 and -0.282 e. Å
-3
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Crystal data and structure refinement for 2.6.3b 
 
Identification code ag145 
Empirical formula C18H13N3O2 
Formula weight 303.31 
Temperature 173 K 
Wavelength 0.71073 Å 
Crystal system, space group Orthorhombic P212121 
Unit cell dimensions a = 6.1634 (6) Å α = 90o  
b = 11.2748 (10) Å β = 90o 
c = 19.9532 (5) Å γ = 90o 
Volume 1386.6 (2) Å
3
 
Z 4 
Calculated density 1.453 mg/m
3
 
Absorption coefficient 0.10 mm
-1
 
F(000) 632 
Crystal size 0.55 x 0.13 x 0.06 mm 
Θ range for data collection 5.5 to 43.1o 
Limiting indices: -7≤h≤8, -14≤k≤14, -25≤l≤25 
Reflections collected / unique 13573 / 3171 [R(Int) = 0.0593] 
Completeness to Θ 24.77o 
Absorption correction multi scan 
Refinement method Full-matrix least-squares on F
2
 
Data / restraints / parameters 3171 / 0 / 216 
Goodness-of-fit on F
2
 0.990 
Final R indices [I>2σ(I)] R1 = 0.0759, wR2 = 0.0939 
R indices (all data) R1 = 0.0446, wR2 = 0.0.848 
Largest diff. peak and hole 0.175 and -0.226 e. Å
-3
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Crystal data and structure refinement for 2.6.3c 
 
Identification code ag124 
Empirical formula C18H12ClN3O2 
Formula weight 337.76 
Temperature 173 K 
Wavelength 0.71073 Å 
Crystal system, space group Monoclinic, P21/c 
Unit cell dimensions a = 13.5897 (4) Å α = 90o  
b = 11.4742 (3) Å β = 110.969 (2)o 
c = 10.2062 (3) Å γ = 90o 
Volume 1486.07 (7) Å
3
 
Z 4 
Calculated density 1.510 mg/m
3
 
Absorption coefficient 0.27 mm
-1
 
F(000) 696 
Crystal size 0.33 x 0.26 x 0.14 mm 
Θ range for data collection 5.6 to 64.7o 
Limiting indices: -18≤h≤18, -15≤k≤15, -13≤l≤13 
Reflections collected / unique 17175 / 3944 [R(Int) = 0.0238] 
Completeness to Θ 26.22o 
Absorption correction multi scan 
Refinement method Full-matrix least-squares on F
2
 
Data / restraints / parameters 3944 / 0 / 225 
Goodness-of-fit on F
2
 1.060 
Final R indices [I>2σ(I)] R1 = 0.0454, wR2 = 0.0971 
R indices (all data) R1 = 0.0347, wR2 = 0.0.971 
Largest diff. peak and hole 0.325 and -0.239 e. Å
-3
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Crystal data and structure refinement for 2.6.5a 
 
Identification code ag140 
Empirical formula C20H17N3O 
Formula weight 315.37 
Temperature 173 K 
Wavelength 0.71073 Å 
Crystal system, space group Monoclinic, P21/c 
Unit cell dimensions a = 12.7467 (5) Å α = 90o  
b = 16.7588 (6) Å β = 105.053 (2)o 
c = 7.5184 (3) Å γ = 90o 
Volume 1550.96 (10) Å
3
 
Z 4 
Calculated density 1.351 mg/m
3
 
Absorption coefficient 0.09 mm
-1
 
F(000) 664 
Crystal size 0.70 x 0.21 x 0.07 mm 
Θ range for data collection 4.9 to 61.0o 
Limiting indices: -17≤h≤17, -22≤k≤22, -10≤l≤7 
Reflections collected / unique 17175 / 3944 [R(Int) = 0.0238] 
Completeness to Θ 26.05o 
Absorption correction multi scan 
Refinement method Full-matrix least-squares on F
2
 
Data / restraints / parameters 4114 / 0 / 223 
Goodness-of-fit on F
2
 1.097 
Final R indices [I>2σ(I)] R1 = 0.0612, wR2 = 0.1272 
R indices (all data) R1 = 0.0443, wR2 = 0.1195 
Largest diff. peak and hole 0.329 and -0.235 e. Å
-3
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Crystal data and structure refinement for 2.6.7d 
 
Identification code ag148 
Empirical formula C17H16ClN3OS 
Formula weight 345.84 
Temperature 173 K 
Wavelength 0.71073 Å 
Crystal system, space group Monoclinic, P21/n 
Unit cell dimensions a = 7.0888 (4) Å α = 90o  
b = 24.9100 (13) Å β = 101.728 (3)o 
c = 8.8454 (4) Å γ = 90o 
Volume 1529.33 (14) Å
3
 
Z 4 
Calculated density 1.502 mg/m
3
 
Absorption coefficient 0.39 mm
-1
 
F(000) 720 
Crystal size 0.39 x 0.27 x 0.07 mm 
Θ range for data collection 6.1 to 56.7o 
Limiting indices: -9≤h≤9, -35≤k≤35, -12≤l≤11 
Reflections collected / unique 170935 / 4447 [R(Int) = 0.0463] 
Completeness to Θ 27.51o 
Absorption correction multi scan 
Refinement method Full-matrix least-squares on F
2
 
Data / restraints / parameters 4447 / 0 / 212 
Goodness-of-fit on F
2
 1.047 
Final R indices [I>2σ(I)] R1 = 0.0673, wR2 = 0.0933 
R indices (all data) R1 = 0.0403, wR2 = 0.0855 
Largest diff. peak and hole 0.402 and -0.279 e. Å
-3
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Crystal data and structure refinement for 2.6.18b 
 
Identification code ag188 
Empirical formula C18H19N3OS 
Formula weight 325.42 
Temperature 173 K 
Wavelength 0.71073 Å 
Crystal system, space group Orthorhombic P212121 
Unit cell dimensions a = 6.3395 (2) Å α = 90o  
b = 7.8493 (3) Å β = 90o 
c = 31.3577 (10) Å γ = 90o 
Volume 1560.38 (10) Å
3
 
Z 4 
Calculated density 1.385 mg/m
3
 
Absorption coefficient 0.22 mm
-1
 
F(000) 688 
Crystal size 0.42 x 0.39 x 0.03 mm 
Θ range for data collection 5.2 to 60.9o 
Limiting indices: -8≤h≤7, -11≤k≤6, -43≤l≤44 
Reflections collected / unique 14344 / 4521 [R(Int) = 0.0322] 
Completeness to Θ 27.1o 
Absorption correction multi scan 
Refinement method Full-matrix least-squares on F
2
 
Data / restraints / parameters 4521 / 0 / 209 
Goodness-of-fit on F
2
 1.031 
Final R indices [I>2σ(I)] R1 = 0.0498, wR2 = 0.0824 
R indices (all data) R1 = 0.0365, wR2 = 0.0772 
Largest diff. peak and hole 0.264 and -0.255 e. Å
-3
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Crystal data and structure refinement for 3.2.2e 
 
Identification code sm537 
Empirical formula C16H10F2O 
Formula weight 256.24 
Temperature 173 K 
Wavelength 0.71073 Å 
Crystal system, space group Orthorhombic P212121 
Unit cell dimensions a = 3.8619 (2) Å α = 90o  
b = 11.3140 (4) Å β = 90o 
c = 28.0022 (8) Å γ = 90o 
Volume 1223.52 (8) Å
3
 
Z 4 
Calculated density 1.391 mg/m
3
 
Absorption coefficient 0.11 mm
-1
 
F(000) 528 
Crystal size 0.45 x 0.13 x 0.09 mm 
Θ range for data collection 4.6 to 47.0o 
Limiting indices: -5≤h≤5, -15≤k≤15, -38≤l≤35 
Reflections collected / unique 13135 / 3253 [R(Int) = 0.0446] 
Completeness to Θ 26.17o 
Absorption correction multi scan 
Refinement method Full-matrix least-squares on F
2
 
Data / restraints / parameters 3253 / 0 / 173 
Goodness-of-fit on F
2
 1.007 
Final R indices [I>2σ(I)] R1 = 0.0888, wR2 = 0.1198 
R indices (all data) R1 = 0.0463, wR2 = 0.1077 
Largest diff. peak and hole 0.474 and -0.220 e. Å
-3
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Crystal data and structure refinement for 3.2.3f 
 
Identification code sm500 
Empirical formula C23H19NO3 
Formula weight 357.39 
Temperature 173 K 
Wavelength 0.71073 Å 
Crystal system, space group Orthorhombic Pbca 
Unit cell dimensions a = 7.7611 (3) Å α = 90o  
b = 15.9902 (7) Å β = 90o 
c = 29.7957 (12) Å γ = 90o 
Volume 3697.7 (3) Å
3
 
Z 8 
Calculated density 1.284 mg/m
3
 
Absorption coefficient 0.09 mm
-1
 
F(000) 1504 
Crystal size 0.91 x 0.18 x 0.10 mm 
Θ range for data collection 5.9 to 59.5o 
Limiting indices: -10≤h≤9, -21≤k≤21, -41≤l≤41 
Reflections collected / unique 20523 / 5250 [R(Int) = 0.0269] 
Completeness to Θ 27.45o 
Absorption correction multi scan 
Refinement method Full-matrix least-squares on F
2
 
Data / restraints / parameters 5250 / 0 / 246 
Goodness-of-fit on F
2
 1.034 
Final R indices [I>2σ(I)] R1 = 0.0738, wR2 = 0.1228 
R indices (all data) R1 = 0.0512, wR2 = 0.1111 
Largest diff. peak and hole 0.247 and -0.245 e. Å
-3
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Crystal data and structure refinement for 3.2.6b 
 
Identification code sm515r 
Empirical formula C35H36N2O3 
Formula weight 532.66 
Temperature 173 K 
Wavelength 0.71073 Å 
Crystal system, space group Monoclinic, P21/n 
Unit cell dimensions a = 11.3533 (3) Å α = 90o  
b = 14.1741 (5) Å β = 103.552 (1)o 
c = 17.9575 (5) Å γ = 90o 
Volume 2809.31 (15) Å
3
 
Z 4 
Calculated density 1.259 mg/m
3
 
Absorption coefficient 0.08 mm
-1
 
F(000) 1136 
Crystal size 0.60 x 0.15 x 0.14 mm 
Θ range for data collection 4.7 to 56.4o 
Limiting indices: -15≤h≤11, -18≤k≤18, -24≤l≤24 
Reflections collected / unique 27727 / 7368 [R(Int) = 0.0297] 
Completeness to Θ 26.26o 
Absorption correction multi scan 
Refinement method Full-matrix least-squares on F
2
 
Data / restraints / parameters 7368 / 0 / 383 
Goodness-of-fit on F
2
 1.075 
Final R indices [I>2σ(I)] R1 = 0.0793, wR2 = 0.1199 
R indices (all data) R1 = 0.0455, wR2 = 0.1091 
Largest diff. peak and hole 0.270 and -0.213 e. Å
-3
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Crystal data and structure refinement for 3.2.7h 
 
Identification code sm515r 
Empirical formula C29H32FNO4S 
Formula weight 509.62 
Temperature 173 K 
Wavelength 0.71073 Å 
Crystal system, space group Triclinic P1 
Unit cell dimensions a = 9.6165 (5) Å α = 77.745 (3)o  
b = 11.5053 (6) Å β = 85.414 (3)o 
c = 12.1257 (6) Å γ = 85.328 (3)o 
Volume 1303.96 (12) Å
3
 
Z 2 
Calculated density 1.298 mg/m
3
 
Absorption coefficient 0.17 mm
-1
 
F(000) 540 
Crystal size 0.24 x 0.16 x 0.12 mm 
Θ range for data collection 5.3 to 58.5o 
Limiting indices: -13≤h≤13, -16≤k≤16, -17≤l≤17 
Reflections collected / unique 27764 / 13605 [R(Int) = 0.0307] 
Completeness to Θ 27.87o 
Absorption correction multi scan 
Refinement method Full-matrix least-squares on F
2
 
Data / restraints / parameters 13605 / 9 / 676 
Goodness-of-fit on F
2
 1.020 
Final R indices [I>2σ(I)] R1 = 0.0763, wR2 = 0.1118 
R indices (all data) R1 = 0.0499, wR2 = 0.1022 
Largest diff. peak and hole 0.279 and -0.360 e. Å
-3
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Crystal data and structure refinement for 3.2.8b 
 
Identification code sm504 
Empirical formula C29H34FNO 
Formula weight 431.57 
Temperature 173 K 
Wavelength 0.71073 Å 
Crystal system, space group Triclinic P1 
Unit cell dimensions a = 6.6652 (8) Å α = 80.328 (8)o  
b = 12.7975 (17) Å β = 87.550 (8)o 
c = 14.5555 (19) Å γ = 76.956 (8)o 
Volume 1192.5 (3) Å
3
 
Z 2 
Calculated density 1.202 mg/m
3
 
Absorption coefficient 0.08 mm
-1
 
F(000) 464 
Crystal size 0.61 x 0.13 x 0.09 mm 
Θ range for data collection 4.7 to 58.6o 
Limiting indices: -8≤h≤8, -16≤k≤16, -18≤l≤19 
Reflections collected / unique 22164 / 5750 [R(Int) = 0.0350] 
Completeness to Θ 25.65o 
Absorption correction multi scan 
Refinement method Full-matrix least-squares on F
2
 
Data / restraints / parameters 5750 / 0 / 296 
Goodness-of-fit on F
2
 1.058 
Final R indices [I>2σ(I)] R1 = 0.0777, wR2 = 0.1168 
R indices (all data) R1 = 0.0460, wR2 = 0.1066 
Largest diff. peak and hole 0.181 and -0.235 e. Å
-3
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Crystal data and structure refinement for 3.2.11b 
 
Identification code sm550_1 
Empirical formula C32H31FN2O 
Formula weight 478.59 
Temperature 173 K 
Wavelength 0.71073 Å 
Crystal system, space group Orthorhombic P212121 
Unit cell dimensions a = 7.9842 (2) Å α = 90o  
b = 14.5796 (3) Å β = 90o 
c = 22.5905 (5) Å γ = 90o 
Volume 2629.68 (10) Å
3
 
Z 4 
Calculated density 1.209 mg/m
3
 
Absorption coefficient 0.08 mm
-1
 
F(000) 1016 
Crystal size 0.69 x 0.22 x 0.18 mm 
Θ range for data collection 4.6 to 56.8o 
Limiting indices: -11≤h≤11, -21≤k≤19, -19≤l≤32 
Reflections collected / unique 31551 / 8396 [R(Int) = 0.0727] 
Completeness to Θ 28.29o 
Absorption correction multi scan 
Refinement method Full-matrix least-squares on F
2
 
Data / restraints / parameters 8396 / 0 / 336 
Goodness-of-fit on F
2
 1.048 
Final R indices [I>2σ(I)] R1 = 0.0625, wR2 = 0.1012 
R indices (all data) R1 = 0.0434, wR2 = 0.0957 
Largest diff. peak and hole 0.201 and -0.191 e. Å
-3
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Crystal data and structure refinement for 3.3.4e 
 
Identification code sm458 
Empirical formula C17H11FO4 
Formula weight 298.26 
Temperature 173 K 
Wavelength 0.71073 Å 
Crystal system, space group Monoclinic, P21/n 
Unit cell dimensions a = 7.7191 (2) Å α = 90o  
b = 13.9145 (3) Å β = 99.863 (1)o 
c = 12.5580 (3) Å γ = 90o 
Volume 1328.89 (5) Å
3
 
Z 4 
Calculated density 1.491 mg/m
3
 
Absorption coefficient 0.12 mm
-1
 
F(000) 616 
Crystal size 0.32 x 0.31 x 0.24 mm 
Θ range for data collection 6.1 to 62.0o 
Limiting indices: -10≤h≤8, -15≤k≤19, -16≤l≤17 
Reflections collected / unique 15570 / 3878 [R(Int) = 0.0174] 
Completeness to Θ 27.32o 
Absorption correction multi scan 
Refinement method Full-matrix least-squares on F
2
 
Data / restraints / parameters 3878 / 0 / 200 
Goodness-of-fit on F
2
 1.044 
Final R indices [I>2σ(I)] R1 = 0.0437, wR2 = 0.1081 
R indices (all data) R1 = 0.0379, wR2 = 0.1048 
Largest diff. peak and hole 0.415 and -0.200 e. Å
-3
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Crystal data and structure refinement for 3.3.8b 
 
Identification code sm406 
Empirical formula C28H32N2O4 
Formula weight 428.56 
Temperature 173 K 
Wavelength 0.71073 Å 
Crystal system, space group Monoclinic, C2/c 
Unit cell dimensions a = 23.8305 (13) Å α = 90o  
b = 9.8495 (5) Å β = 102.587 (3)o 
c = 19.7081 (11) Å γ = 90o 
Volume 4514.7 (4) Å
3
 
Z 8 
Calculated density 1.261 mg/m
3
 
Absorption coefficient 0.08 mm
-1
 
F(000) 1840 
Crystal size 0.63 x 0.05 x 0.04 mm 
Θ range for data collection 4.9 to 43.3o 
Limiting indices: -30≤h≤30, -12≤k≤12, -25≤l≤25 
Reflections collected / unique 24312 / 4929 [R(Int) = 0.1167] 
Completeness to Θ 24.05o 
Absorption correction multi scan 
Refinement method Full-matrix least-squares on F
2
 
Data / restraints / parameters 4929 / 0 / 293 
Goodness-of-fit on F
2
 0.980 
Final R indices [I>2σ(I)] R1 = 0.1595, wR2 = 0.1295 
R indices (all data) R1 = 0.0600, wR2 = 0.0979 
Largest diff. peak and hole 0.221 and -0.230 e. Å
-3
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Crystal data and structure refinement for 3.3.8d 
 
Identification code sm395 
Empirical formula C32H28N2O4 
Formula weight 472.56 
Temperature 173 K 
Wavelength 0.71073 Å 
Crystal system, space group Monoclinic, C2/c 
Unit cell dimensions a = 31.6167 (10) Å α = 90o  
b = 10.4048 (3) Å β = 114.191 (2)o 
c = 16.4565 (5) Å γ = 90o 
Volume 4938.2 (3) Å
3
 
Z 8 
Calculated density 1.271 mg/m
3
 
Absorption coefficient 0.08 mm
-1
 
F(000) 2000 
Crystal size 0.52 x 0.33 x 0.17 mm 
Θ range for data collection 5.0 to 50.0o 
Limiting indices: -44≤h≤45, -14≤k≤14, -23≤l≤23 
Reflections collected / unique 36127 / 7608 [R(Int) = 0.0487] 
Completeness to Θ 28.75o 
Absorption correction multi scan 
Refinement method Full-matrix least-squares on F
2
 
Data / restraints / parameters 7608 / 15 / 367 
Goodness-of-fit on F
2
 1.008 
Final R indices [I>2σ(I)] R1 = 0.0835, wR2 = 0.1282 
R indices (all data) R1 = 0.0481, wR2 = 0.1076 
Largest diff. peak and hole 0.265 and -0.215 e. Å
-3
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Crystal data and structure refinement for 3.3.8i 
 
Identification code sm805 
Empirical formula C32H26FN2O2 
Formula weight 569.46 
Temperature 173 K 
Wavelength 0.71073 Å 
Crystal system, space group Monoclinic, P21/n 
Unit cell dimensions a = 12.1385 (4) Å α = 90o  
b = 10.7741 (3) Å β = 94.598 (2)o 
c = 20.8967 (5) Å γ = 90o 
Volume 2724.10 (14) Å
3
 
Z 4 
Calculated density 1.389 mg/m
3
 
Absorption coefficient 1.55 mm
-1
 
F(000) 1168 
Crystal size 0.52 x 0.43 x 0.25 mm 
Θ range for data collection 2.5 to 30.0o 
Limiting indices: -17≤h≤17, -15≤k≤15, -30≤l≤30 
Reflections collected / unique 76363 / 8727 [R(Int) = 0.0501] 
Completeness to Θ 29.0o 
Absorption correction multi scan 
Refinement method Full-matrix least-squares on F
2
 
Data / restraints / parameters 8727 / 17 / 372 
Goodness-of-fit on F
2
 1.029 
Final R indices [I>2σ(I)] R1 = 0.0571, wR2 = 0.0879 
R indices (all data) R1 = 0.0358, wR2 = 0.0798 
Largest diff. peak and hole 0.484 and -0.559 e. Å
-3
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Crystal data and structure refinement for 3.3.11h 
 
Identification code sm447 
Empirical formula C25H21NO5 
Formula weight 415.43 
Temperature 173 K 
Wavelength 0.71073 Å 
Crystal system, space group Monoclinic, P21/n 
Unit cell dimensions a = 7.6454 (3) Å α = 90.303 (2)o  
b = 10.9083 (5) Å β = 99.563 (2)o 
c = 12.5017 (5) Å γ = 104.055 (3)o 
Volume 996.22 (7) Å
3
 
Z 2 
Calculated density 1.385 mg/m
3
 
Absorption coefficient 0.10 mm
-1
 
F(000) 436 
Crystal size 0.25 x 0.10 x 0.08 mm 
Θ range for data collection 5.0 to 60.8o 
Limiting indices: -10≤h≤10, -15≤k≤15, -17≤l≤17 
Reflections collected / unique 21491 / 5759 [R(Int) = 0.0331] 
Completeness to Θ 27.21o 
Absorption correction multi scan 
Refinement method Full-matrix least-squares on F
2
 
Data / restraints / parameters 5759 / 0 / 291 
Goodness-of-fit on F
2
 1.042 
Final R indices [I>2σ(I)] R1 = 0.0824, wR2 = 0.1242 
R indices (all data) R1 = 0.0478, wR2 = 0.1136 
Largest diff. peak and hole 0.325 and -0.228 e. Å
-3
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Crystal data and structure refinement for 3.3.13 
 
Identification code sm407 
Empirical formula C16H10O4 
Formula weight 266.24 
Temperature 173 K 
Wavelength 0.71073 Å 
Crystal system, space group Orthorhombic, Pbcn 
Unit cell dimensions a = 10.7720 (6) Å α = 90o  
b = 12.0538 (7) Å β = 90o 
c = 18.4416 (10) Å γ = 90o 
Volume 2394.5 (2) Å
3
 
Z 8 
Calculated density 1.477 mg/m
3
 
Absorption coefficient 0.11 mm
-1
 
F(000) 1104 
Crystal size 0.38 x 0.13 x 0.06 mm 
Θ range for data collection 5.5 to 60.4o 
Limiting indices: -14≤h≤12, -16≤k≤16, -25≤l≤25 
Reflections collected / unique 20244 / 3178 [R(Int) = 0.0365] 
Completeness to Θ 26.09o 
Absorption correction multi scan 
Refinement method Full-matrix least-squares on F
2
 
Data / restraints / parameters 3178 / 0 / 185 
Goodness-of-fit on F
2
 1.032 
Final R indices [I>2σ(I)] R1 = 0.0595, wR2 = 0.1107 
R indices (all data) R1 = 0.0446, wR2 = 0.1033 
Largest diff. peak and hole 0.288 and -0.201 e. Å
-3
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Crystal data and structure refinement for 3.3.14 
 
Identification code sm497 
Empirical formula C26H17N3O2 
Formula weight 403.42 
Temperature 173 K 
Wavelength 0.71073 Å 
Crystal system, space group Monoclinic, P21/c 
Unit cell dimensions a = 8.5696 (2) Å α = 90o  
b = 19.5048 (5) Å β = 106.200 (2)o 
c = 11.9606 (3) Å γ = 90o 
Volume 1919.86 (8) Å
3
 
Z 4 
Calculated density 1.396 mg/m
3
 
Absorption coefficient 0.09 mm
-1
 
F(000) 840 
Crystal size 0.22 x 0.17 x 0.14 mm 
Θ range for data collection 2.7 to 26.0o 
Limiting indices: -12≤h≤11, -25≤k≤28, -16≤l≤17 
Reflections collected / unique 30523 / 6102 [R(Int) = 0.0659] 
Completeness to Θ 28.19o 
Absorption correction multi scan 
Refinement method Full-matrix least-squares on F
2
 
Data / restraints / parameters 6102 / 0 / 281 
Goodness-of-fit on F
2
 1.033 
Final R indices [I>2σ(I)] R1 = 0.1384, wR2 = 0.1281 
R indices (all data) R1 = 0.0571, wR2 = 0.0983 
Largest diff. peak and hole 0.245 and -0.271 e. Å
-3
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A.4. List of Abbreviation. 
  
Ac Acyl 
ADA Adenosine deaminase 
Alk Alkyl 
Ar Aryl 
Ar Argon (under the arrow) 
AIDS Acquired immunodeficiency syndrom 
CN Nitril 
Bu Butyl 
t-Bu tert-Butyl 
br. Broad (NMR)  
d Doublet (NMR) 
dd Double doublet (NMR) 
ddd Double double doublet (NMR) 
DDQ 2,3-dichloro-5,6-dicyano-1,4-benzoquinone 
DMA N,N-dimethylacetamide 
DMF N,N-dimethylformamide 
DMFDMA N,N-dimethylformamide dimethyl acetal 
DNA Deoxyribonucleic acid 
dt Double triplet (NMR) 
EDG Electron donating group 
EI Electronic ionization (HRMS) 
ESI Electrospray ionization (HRMS) 
Et Ethyl 
equiv. Equivalent  
EWG Electron withdrawing group 
GMP Guanosine-5´-monophosphate 
GC-MS Gass chromatography-mass spectrometry 
h hour 
HIV Human immunodeficiency virus   
HMBC Heteronuclear multiple bond correlation spectroscopy 
HPLC High-performance liquid chromatography 
HRMS High-resolution mass spectrometry 
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HSQC Heteronuclear single quantum correlation spectroscopy 
IMP Inosine-5´-monophosphate 
IMPDH Inosine-5´-monophosphate dehydrogenase 
IR Infrared spectrometry 
m Multiplet (NMR) 
m Medium (IR) 
Me Methyl 
NAD Nicotinamide adenine dinucleotide 
NADP Nicotinamide adenine dinucleotide phosphate 
NMP N-Methyl-2-pyrrolidone 
NMR Nuclear magnetic resonance spectroscopy 
NOESY Nuclear overhauser effect spectroscopy 
Nu Nucleophile 
Ph Phenyl 
ppm Parts per million 
i-Pr Isopropyl 
Py Pyridine 
q Quartet (NMR) 
Rf Retardation factor 
RF Polifluoroalkyl group 
RM Reaction mixture 
RNA Ribonucleic acid 
r.t. Room temperature  
SCID Severe combined immunodeficiency  
SEM 2-(trimethylsilyl)ethoxy)-methyl 
t triplet 
td Triple doublet (NMR) 
TFA Trifluoroacetic acid 
THP Tetrahydropyranyl ether 
TLC Thin layer chromatography 
TMSCl Trimethylsilyl chloride 
TMSOTf Trimethylsilyl trifluoromethansulfonate 
Tol Toluene 
tt Triple triplet 
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ttt Triple triple triplet 
w Week (IR) 
XMP Xantosine-5´-monophosphate 
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